field_name_1,ticker,title,description,author,url,source,timestamp,published_at,sentiment
755854,ABBV,"With Solid Fourth Quarter Results, AbbVie Shows That Its Growth Days Are Far From Over","Despite Humira's declining international sales, AbbVie is still worth considering.",newsfeedback@fool.com (Prosper Junior Bakiny),https://www.fool.com/investing/2020/02/11/with-solid-fourth-quarter-results-abbvie-shows-tha.aspx,Fool.com,,2020-02-11T15:41:34Z,0.62
755855,ABBV,AbbVie to Present at the SVB Leerink 9th Annual Global Healthcare Conference,"AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the SVB Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25. Michael Severino, M.D., vice chairman and president and Robert A. Michael, executive v…",PR Newswire,https://news.yahoo.com/abbvie-present-svb-leerink-9th-130000313.html,Yahoo.com,,2020-02-11T13:00:00Z,0
755856,ABBV,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) ...",,https://finance.yahoo.com/news/daily-biotech-pulse-logicbio-slapped-122306131.html,Yahoo.com,,2020-02-11T12:23:06Z,0.34
756177,LLY,"Lilly's Taltz OK'd in Canada for arthritis of the spine","<ul><li>Health Canada has <a href=""https://seekingalpha.com/pr/17774824-health-canada-approved-taltz-ixekizumab-for-treatment-of-active-ankylosing-spondylitis"" target=""_blank"">approved </a>Eli Lilly's (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title=…",Douglas W. House,https://seekingalpha.com/news/3540423-lillys-taltz-okd-in-canada-for-arthritis-of-spine,Seekingalpha.com,,2020-02-11T12:19:34Z,0
755544,LLY,BRIEF-Health Canada Has Approved Taltz For The Treatment Of Active Ankylosing Spondylitis,Eli Lilly and Co:,Reuters Editorial,https://uk.reuters.com/article/brief-health-canada-has-approved-taltz-f-idUKFWN2AB0FF,Reuters,,2020-02-11T11:54:25Z,0.67
753668,ABBV,"How Allergan Beat Estimates in What's Likely Its Last Quarterly Update",The drugmaker delivered solid top- and bottom-line improvement as it awaited the closing of its acquisition by AbbVie.,newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2020/02/10/how-allergan-beat-estimates-in-whats-likely-its-la.aspx,Fool.com,,2020-02-10T18:00:00Z,0.65
753669,ABBV,Allergan Reports Fourth-Quarter 2019 Results That Plow Past Expectations,The maker of Botox appears to be on an upswing just ahead of its megamerger with AbbVie.,newsfeedback@fool.com (Cory Renauer),https://www.fool.com/investing/2020/02/10/allergan-reports-fourth-quarter-2019-results-that.aspx,Fool.com,,2020-02-10T17:24:00Z,0
753814,BMY,Bristol-Myers Squibb Stock Is Too Cheap to Ignore,The acquisition of Celgene is working wonders so far.,newsfeedback@fool.com (Prosper Junior Bakiny),https://www.fool.com/investing/2020/02/10/bristol-myers-squibb-stock-is-too-cheap-to-ignore.aspx,Fool.com,,2020-02-10T17:17:25Z,0
754060,LLY,"Eli Lilly, Roche Drugs Fail to Move Needle in Genetically-Driven Alzheimer’s","<p>Two experimental drugs from Eli Lilly and Roche have failed a clinical trial testing them as treatments for a form of Alzheimer’s disease caused by certain genetic mutations, the companies reported Monday. The study, sponsored by Washington University, tes…",Frank Vinluan,https://xconomy.com/national/2020/02/10/eli-lilly-roche-drugs-fail-to-move-needle-in-genetically-driven-alzheimers/,Xconomy.com,,2020-02-10T15:14:26Z,-0.69
754061,LLY,"Roche, Lilly drugs fail to halt gene-driven Alzheimer's disease","Experimental drugs from Roche and Eli Lilly failed to halt Alzheimer's disease in their latest test, the companies said on Monday, in a blow to people whose genes make them particularly vulnerable to the illness.",John Miller,https://in.reuters.com/article/roche-alzheimers-idINKBN2041G3,Reuters,,2020-02-10T14:55:23Z,-0.89
754062,LLY,"Thinking about buying stock in L Brands, Eli Lilly, Netflix, Tesla, or Xylem?","NEW YORK, Feb. 10, 2020 InvestorsObserver issues critical PriceWatch Alerts for LB, LLY, NFLX, TSLA, and XYL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the correspo…",,https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-l-brands-eli-lilly-netflix-tesla-or-xylem-301001898.html,Prnewswire.com,,2020-02-10T14:31:00Z,-0.03
753670,ABBV,"Top Analyst Upgrades and Downgrades: AbbVie, Apple, Arch Coal, FedEx, Ford, GM, Nvidia, Skyworks, Stitch Fix, WWE and More","Monday's top analyst upgrades, downgrades and initiations included AbbVie, Apple, Arch Coal, FedEx, Ford, General Motors, Nvidia, Skyworks Solutions, Stitch Fix and World Wrestling Entertainment.",Jon C. Ogg,https://247wallst.com/investing/2020/02/10/top-analyst-upgrades-and-downgrades-abbvie-apple-arch-coal-fedex-ford-gm-nvidia-skyworks-stitch-fix-wwe-and-more/,247wallst.com,,2020-02-10T14:00:31Z,0.73
754258,PRGO,Perrigo: Hold Until Certainty Returns,"With reported sales expanding in 2019, after back-to-back declines, Perrigo is rallying this year.However, the outlook remains uncertain amid the ongoing tax disputes and stagnant organic sales growth.The consumer-focused transformation looks unclear with no …",Dulan Lokuwithana,https://seekingalpha.com/article/4322763-perrigo-hold-until-certainty-returns,Seekingalpha.com,,2020-02-10T13:59:17Z,-0.67
754719,ZTS,Zoetis to Participate in the Bank of America Merrill Lynch Animal Health Summit,"PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. will present at the Bank of America Merrill Lynch Animal Health Summit on Feb 24th.",,https://www.businesswire.com/news/home/20200210005108/en/Zoetis-Participate-Bank-America-Merrill-Lynch-Animal,Businesswire.com,,2020-02-10T13:38:30Z,0
754064,LLY,"Lilly's stock falls on failed Alzheimer's study","Shares of Eli Lilly and Co. fell 4% in premarket trading on Monday after solanezumab, the experimental therapy it was testing in people with a form of Alzheimer's disease caused by a rare gene mutation, failed in a Phase 2/3 clinical study. Lilly said it does…",Jaimy Lee,https://www.marketwatch.com/story/lillys-stock-falls-on-failed-alzheimers-study-2020-02-10,Marketwatch.com,,2020-02-10T13:01:08Z,-0.77
754065,LLY,"Stocks making the biggest moves in the premarket: Allergan, Taubman Centers, Eli Lilly & more","The stocks making the biggest moves in premarket trading include Allergan, Taubman Centers, Eli Lilly, and more.",Peter Schacknow,https://www.cnbc.com/2020/02/10/stocks-making-the-biggest-moves-in-the-premarket-allergan-taubman-centers-eli-lilly-more.html,CNBC,,2020-02-10T12:46:59Z,0
753370,LLY,Lilly and Roche’s antibodies fail late-phase Alzheimer’s test,"Anti-amyloid beta antibodies in development at Eli Lilly and Roche have failed to improve outcomes in a phase 2/3 Alzheimer’s disease trial. Despite the setback, Roche is continuing two phase 3 trials of its asset in a broader population of Alzheimer’s patien…",Nick Paul,https://www.fiercebiotech.com/biotech/lilly-and-roche-s-antibodies-fail-late-phase-alzheimer-s-test,Fiercebiotech.com,,2020-02-10T11:53:09Z,-0.34
753371,LLY,"Lilly's solanezumab flunks latest Alzheimer's study; shares down 4% premarket","<ul><li>Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) slips <font color=""red"">4%</font> premarket on light volume in reaction to its <a href=""https://seekingalpha.com/pr/17773268-lilly-announces-topline-r…",Douglas W. House,https://seekingalpha.com/news/3539933-lillys-solanezumab-flunks-latest-alzheimers-study-shares-down-4-premarket,Seekingalpha.com,,2020-02-10T11:36:38Z,-0.15
753373,LLY,Eli Lilly AI automates adverse reaction reporting,"Assembling information about adverse reactions to drugs vexes pharmaceutical companies, which are required to produce reports on any incidents to federal regulators. The far-flung data arrives in different languages and formats, making it hard to manage. To r…","Clint Boulton, Clint Boulton",https://www.cio.com/article/3521010/eli-lilly-ai-automates-adverse-reaction-reporting.html,Cio.com,,2020-02-10T11:00:00Z,-0.66
753288,BMY,"Bristol-Myers Squibb Company Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next Year","It's been a good week for Bristol-Myers Squibb Company (NYSE:BMY) shareholders, because the company has just released...",Simply Wall St,https://finance.yahoo.com/news/bristol-myers-squibb-company-annual-104154475.html,Yahoo.com,,2020-02-10T10:41:54Z,0.44
753374,LLY,Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study,"INDIANAPOLIS, Feb. 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the analysis performed by Washington University School of Medicine in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study showed that solanez…",,https://prnmedia.prnewswire.com:443/news-releases/lilly-announces-topline-results-for-solanezumab-from-the-dominantly-inherited-alzheimer-network-trials-unit-dian-tu-study-301001653.html,Prnewswire.com,,2020-02-10T06:00:00Z,0.1
752892,MRK,"Merck & Co., Inc. Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?","The yearly results for Merck & Co., Inc. (NYSE:MRK) were released last week, making it a good time to revisit its...",Simply Wall St,https://finance.yahoo.com/news/merck-co-inc-just-reported-143844033.html,Yahoo.com,,2020-02-09T14:38:44Z,0.44
752885,LLY,"Eli Lilly and Company (NYSE:LLY)'s Could Be A Buy For Its Upcoming Dividend","Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Eli Lilly...",Simply Wall St,https://finance.yahoo.com/news/eli-lilly-company-nyse-lly-130024164.html,Yahoo.com,,2020-02-09T13:00:24Z,0.81
752352,ZTS,"Zoetis Acquires Ethos Diagnostic Science, a Veterinary Reference Lab Business, to Further Expand its Comprehensive Diagnostics Capabilities","PARSIPPANY, N.J. & WOBURN, Mass.--(BUSINESS WIRE)---- $ZTS #acquistion--Zoetis acquires Ethos Diagnostic Science, a veterinary reference lab business, to further expand its comprehensive diagnostics capabilities.",,https://www.businesswire.com/news/home/20200207005449/en/Zoetis-Acquires-Ethos-Diagnostic-Science-Veterinary-Reference,Businesswire.com,,2020-02-07T21:52:15Z,0.77
751910,ABBV,"Uber, AbbVie rise; Wynn, Myrian Genetics fall on Wall Street","NEW YORK (AP) — Stocks that moved heavily or traded substantially on Friday: Uber Technologies Inc., up $3.54 to $40.63 The ride-hailing company reported a big jump in revenue and says it expects to reach profitability earlier than forecast. Ford Motor Co., d…",The Associated Press,https://www.seattletimes.com/business/uber-abbvie-rise-wynn-myrian-genetics-fall-on-wall-street/,Seattletimes.com,,2020-02-07T21:16:46Z,0.3
751912,ABBV,AbbVie Inc (ABBV) Q4 2019 Earnings Call Transcript,"ABBV earnings call for the period ending December 31, 2019.",newsfeedback@fool.com (Motley Fool Transcribers),https://www.fool.com/earnings/call-transcripts/2020/02/07/abbvie-inc-abbv-q4-2019-earnings-call-transcript.aspx,Fool.com,,2020-02-07T20:31:08Z,0
751180,BMY,"Sell-siders on board with Bristol-Myers Squibb's Q4 & outlook","<ul><li>Takeaways from Bristol-Myers Squibb's (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color=""red"">-1.5%</font>) <a href=""https://seekingalpha.com/news/3539183-bristol-myersplus-3-premarket-on-q4-beat"" …",Douglas W. House,https://seekingalpha.com/news/3539775-sell-siders-on-board-bristol-myers-squibbs-q4-outlook,Seekingalpha.com,,2020-02-07T17:50:31Z,0
751347,JNJ,Johnson & Johnson Hit with $750M Punitive Damages Verdict for Failing to Warn about Cancer-Causing Asbestos in Talc Products,"NEW BRUNSWICK, N.J., Feb. 7, 2020 /PRNewswire/ -- A New Jersey jury has ordered Johnson & Johnson (NYSE:JNJ) to pay $750 million in punitive damages to four cancer victims who charged that the company's iconic Johnson's Baby Powder contained cancer-causing as…",,https://prnmedia.prnewswire.com:443/news-releases/johnson--johnson-hit-with-750m-punitive-damages-verdict-for-failing-to-warn-about-cancer-causing-asbestos-in-talc-products-301001036.html,Prnewswire.com,,2020-02-07T17:34:00Z,-0.97
751082,ABBV,"AbbVie Stock: AbbVie Earnings Top, Guidance Solid - Investor's Business Daily","AbbVie stock flirted with a breakout Friday after the pharma giant topped Wall Street's fourth-quarter earnings expectations and delivered in-line sales.","Investor's Business Daily",https://www.investors.com/news/technology/abbvie-stock-abbvie-earnings-q4-2019/,Investors.com,,2020-02-07T16:02:00Z,0.3
751083,ABBV,AbbVie Wows Again With Q4 Results,AbbVie released better than expected fourth-quarter financial results before the markets opened on Friday.,247chrislange,https://247wallst.com/healthcare-business/2020/02/07/abbvie-wows-again-with-q4-results/,247wallst.com,,2020-02-07T15:20:09Z,0.71
751084,ABBV,"Thinking about trading options or stock in AbbVie, Gilead Sciences, Microsoft, NVIDIA, or Shopify?","NEW YORK, Feb. 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABBV, GILD, MSFT, NVDA, and SHOP. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade id…",,https://www.prnewswire.com/news-releases/thinking-about-trading-options-or-stock-in-abbvie-gilead-sciences-microsoft-nvidia-or-shopify-301000944.html,Prnewswire.com,,2020-02-07T14:31:00Z,0.27
751085,ABBV,AbbVie +4% premarket on Q4 and guidance beat,"<ul><li>AbbVie (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) <a href=""https://seekingalpha.com/pr/17772660-abbvie-reports-full-year-and-fourth-quarter-2019-financial-results"" target=""_blank"">Q4 results</a>:</li><li>Revenues: $8…",Mamta Mayani,https://seekingalpha.com/news/3539677-abbvieplus-4-premarket-on-q4-and-guidance-beat,Seekingalpha.com,,2020-02-07T13:40:17Z,0
751086,ABBV,"AbbVie's stock rises on strong earnings","Shares of AbbVie Inc. climbed 2% in premarket trading on Friday although the drugmaker beat earnings expectations for the quarter. The company reported earnings of $2.8 billion, or $1.88 per share, in the fourth quarter of 2019, compared with a loss of $1.8 b…",Jaimy Lee,https://www.marketwatch.com/story/abbvies-stock-rises-on-strong-earnings-2020-02-07,Marketwatch.com,,2020-02-07T13:10:43Z,0.49
751540,PRGO,Perrigo Announces Consumer Self-Care Americas Segment Leadership Transition,"Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of Quality, Affordable Self-Care Products™, today announced the future retirement of Jeff Needham, Executive Vice President and President, Consumer Self-Care Americas (CSCA). Rich Sorota, curre…",PR Newswire,https://news.yahoo.com/perrigo-announces-consumer-self-care-131000444.html,Yahoo.com,,2020-02-07T13:10:00Z,0.56
751087,ABBV,AbbVie: 4Q Earnings Snapshot,"NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported fourth-quarter earnings of $2.8 billion.",,https://www.stltoday.com/business/national-and-international/abbvie-q-earnings-snapshot/article_bb97c8c5-358e-5a25-87bc-145637247215.html,Stltoday.com,,2020-02-07T12:54:12Z,-0.82
751088,ABBV,AbbVie leans on new treatments to forecast upbeat 2020 profit,AbbVie Inc  on Friday forecast 2020 earnings above Wall Street estimates as the drugmaker expects growth to be powered by its new treatments for psoriasis and rheumatoid arthritis at a time when sales of its blockbuster drug Humira slow.,CNA,https://www.channelnewsasia.com/news/business/abbvie-leans-on-new-treatments-to-forecast-upbeat-2020-profit-12406766,Channelnewsasia.com,,2020-02-07T12:50:32Z,0.76
751089,ABBV,"AbbVie EPS beats by $0.02, beats on revenue","<ul><li>AbbVie (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>): Q4 Non-GAAP EPS of $2.21 <font color=""green"">beats by $0.02</font>; GAAP EPS of $1.88 <font color=""green"">beats by $0.05</font>.</li><li>Revenue of $8.7B (+4.7%…",Mamta Mayani,https://seekingalpha.com/news/3539653-abbvie-eps-beats-0_02-beats-on-revenue,Seekingalpha.com,,2020-02-07T12:46:50Z,0
751090,ABBV,AbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results,"NORTH CHICAGO, Ill., Feb. 7, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2019. ""Our strong performance this quarter completes another excellent year for AbbVie,"" said Richard A. G…",,https://www.prnewswire.com/news-releases/abbvie-reports-full-year-and-fourth-quarter-2019-financial-results-301000918.html,Prnewswire.com,,2020-02-07T12:43:00Z,0.79
750676,ZTS,Responsible use of moxidectin in sheep,"SCOPS (sustainable control of parasites in sheep) and Zoetis held a joint workshop in September 2019 to discuss how to advise prescribers and sheep farmers on the use of moxidectin, and prioritising the 2 per cent injectable formulation. This was in response …","Hart, N.",https://veterinaryrecord.bmj.com/content/186/5/161.1,Bmj.com,,2020-02-07T00:05:30Z,0.32
749982,BMY,Bristol-Myers Squibb Smashes Earnings Predictions Following Celgene Acquisition,2019 marked a pivotal turning point for the pharmaceutical giant Continue reading...,GuruFocus.com,https://finance.yahoo.com/news/bristol-myers-squibb-smashes-earnings-212823920.html,Yahoo.com,,2020-02-06T21:28:23Z,0
748867,BMY,Bristol-Myers Squibb and Merck going opposite ways with PD-1 inhibitors,"<ul><li>Q4 results for Merck (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co., Inc.'>MRK</a> <font color=""red"">-0.3%</font>) and Bristol-Myers Squibb (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> …",Douglas W. House,https://seekingalpha.com/news/3539335-bristol-myers-squibb-and-merck-going-opposite-ways-pdminus-1-inhibitors,Seekingalpha.com,,2020-02-06T18:06:01Z,0
748868,BMY,Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q4 2019 Results - Earnings Call Transcript,,SA Transcripts,https://seekingalpha.com/article/4322044-bristol-myers-squibb-company-bmy-ceo-giovanni-caforio-on-q4-2019-results-earnings-call,Seekingalpha.com,,2020-02-06T17:44:34Z,0
748869,BMY,"Bristol-Myers Squibb's Earnings Get a Boost From Celgene Acquisition","The pharmaceutical giant's guidance also looks good.",newsfeedback@fool.com (Brian Orelli),https://www.fool.com/investing/2020/02/06/bristol-myers-squibbs-earnings-get-a-boost-from-ce.aspx,Fool.com,,2020-02-06T17:08:00Z,0.68
748870,BMY,Bristol-Myers Squibb Company 2019 Q4 - Results - Earnings Call Presentation,,SA Transcripts,https://seekingalpha.com/article/4322009-bristol-myers-squibb-company-2019-q4-results-earnings-call-presentation,Seekingalpha.com,,2020-02-06T16:49:20Z,0
749076,LLY,"Thinking about trading options or stock in Apple, Eli Lilly, Microchip Technology, Tesla, or UnitedHealth Group?","NEW YORK, Feb. 6, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, LLY, MCHP, TSLA, and UNH. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade idea…",,https://prnmedia.prnewswire.com:443/news-releases/thinking-about-trading-options-or-stock-in-apple-eli-lilly-microchip-technology-tesla-or-unitedhealth-group-301000320.html,Prnewswire.com,,2020-02-06T14:31:00Z,0.27
748761,ABBV,"Top Analyst Upgrades and Downgrades: AbbVie, Biogen, Boeing, Etsy, Gilead, GoPro, Micron, Newmont, Peloton, Pfizer, Valero, Zynga and More","Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Biogen, Boeing, Etsy, Gilead Sciences, GoPro, Micron Technology, Newmont, Peloton Interactive, Pfizer, Valero Energy and Zynga.",Jon C. Ogg,https://247wallst.com/investing/2020/02/06/top-analyst-upgrades-and-downgrades-abbvie-biogen-boeing-etsy-gilead-gopro-micron-newmont-peloton-pfizer-valero-zynga-and-more/,247wallst.com,,2020-02-06T13:45:23Z,0.57
748871,BMY,Bristol-Myers +3% premarket on Q4 beat,"<ul><li>Bristol-Myers Squibb (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) Q4 results: Revenues: $7,945M (+33.0%); R&D Expense: $7,662M (+34.1%).</li><li>Net loss: ($1,056M); loss/share: ($0.55); non-GAAP Net Inc…",Mamta Mayani,https://seekingalpha.com/news/3539183-bristol-myersplus-3-premarket-on-q4-beat,Seekingalpha.com,,2020-02-06T13:13:55Z,-0.32
748872,BMY,"Bristol-Myers Squibb reports 33% jump in Q4 revenue, Opdivo sales fall 2%","Shares of Bristol-Myers Squibb were up 2% in premarket trading on Thursday after the company beat earnings estimates for the fourth quarter of 2019. The company had a net loss of $1.1 billion, or 44 cents per share, in the fourth quarter of 2019, after earnin…",Jaimy Lee,https://www.marketwatch.com/story/bristol-myers-squibb-reports-33-jump-in-q4-revenue-opdivo-sales-fall-2-2020-02-06,Marketwatch.com,,2020-02-06T12:49:46Z,-0.03
748762,ABBV,Mizuho likes AbbVie in premarket analyst action,"<ul><li>AbbVie (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) initiated with Buy rating and $96 (11% upside) price target at Mizuho Securities. Shares up a fraction premarket.</li><li>Alkermes plc (NASDAQ:<a href='https://s…",Douglas W. House,https://seekingalpha.com/news/3539113-mizuho-likes-abbvie-in-premarket-analyst-action,Seekingalpha.com,,2020-02-06T12:19:24Z,0.74
748873,BMY,Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019,NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019,,https://www.businesswire.com/news/home/20200206005479/en/Bristol-Myers-Squibb-Reports-Fourth-Quarter-Full-Year,Businesswire.com,,2020-02-06T12:10:12Z,0
748874,BMY,"Bristol-Myers Squibb EPS beats by $0.28, beats on revenue","<ul><li>Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>): Q4 Non-GAAP EPS of $1.22 <font color=""green"">beats by $0.28</font>; GAAP EPS of -$0.55 <font color=""red"">misses by $1.39</font>.</l…",Mamta Mayani,https://seekingalpha.com/news/3539094-bristol-myers-squibb-eps-beats-0_28-beats-on-revenue,Seekingalpha.com,,2020-02-06T12:08:25Z,0
748875,BMY,Bristol-Myers earnings rise due to Celgene deal,"Bristol-Myers Squibb Co said on Thursday its operating profit rose by around a third from a year ago because fourth-quarter results included some revenue from Celgene, which the U.S. drugmaker bought in a $74 billion deal that closed in late November. Bristol…",,https://finance.yahoo.com/news/bristol-myers-earnings-rise-due-115900546.html,Yahoo.com,,2020-02-06T11:59:00Z,0.44
747578,ABBV,AbbVie Reports Successful Trial Results for Arthritis Drug,A future blockbuster scores another success as AbbVie works to replace Humira losses.,newsfeedback@fool.com (Jim Crumly),https://www.fool.com/investing/2020/02/05/abbvie-reports-successful-trial-results-for-arthri.aspx,Fool.com,,2020-02-05T21:12:48Z,0.87
746829,MRK,"Merck to streamline business, separate into two companies","Merck & Co. Inc. unveiled plans Wednesday to spin off products from its women’s health and biosimilars businesses, along with certain legacy brands, into a new independent and publicly traded company. Going forward, Merck (NYSE: MRK) will focus on its oncolog…",John George,https://www.bizjournals.com/philadelphia/news/2020/02/05/merck-to-streamline-business-separate-into-two.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_philadelphia+%28Philadelphia+Business+Journal%29,Bizjournals.com,,2020-02-05T14:26:55Z,0.27
746506,ABBV,"AbbVie's Rinvoq successful in second late-stage psoriatic arthritis study","<ul><li>AbbVie (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) <a href=""https://seekingalpha.com/pr/17769867-rinvoq-upadacitinib-meets-primary-and-key-secondary-endpoints-in-phase-3-study-in-psoriatic"" target=""_blank"">announ…",Douglas W. House,https://seekingalpha.com/news/3538534-abbvies-rinvoq-successful-in-second-late-stage-psoriatic-arthritis-study,Seekingalpha.com,,2020-02-05T14:12:03Z,0.59
746527,ALLY,Ally Transforms How People Save,"SANDY, Utah, Feb. 5, 2020 /PRNewswire/ -- Ally Bank (Ally), the customer-obsessed banking arm of Ally Financial (NYSE: ALLY), which has grown to be the largest fully digital bank in the U.S., today introduced a collection of smart savings tools to its Online …",,https://www.prnewswire.com/news-releases/ally-transforms-how-people-save-300998972.html,Prnewswire.com,,2020-02-05T14:00:00Z,0.4
746507,ABBV,RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis,"NORTH CHICAGO, Ill., Feb. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-PsA 1 clinical trial. In this study, both doses of RINVOQTM (upadacitin…",,https://prnmedia.prnewswire.com:443/news-releases/rinvoq-upadacitinib-meets-primary-and-key-secondary-endpoints-in-phase-3-study-in-psoriatic-arthritis-300999462.html,Prnewswire.com,,2020-02-05T13:45:00Z,0.56
746155,MRK,Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results,"KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2019.",,https://www.businesswire.com/news/home/20200205005307/en/Merck-Announces-Fourth-Quarter-Full-Year-2019-Financial-Results,Businesswire.com,,2020-02-05T11:52:16Z,0.42
745935,BMY,What Are Bristol-Myers Squibb’s Top 3 Drugs?,"Bristol-Myers Squibb’s top 3 selling drugs (excluding that of Celgene) are Eliquis, Opdivo, and Orencia. These three drugs combined, likely accounted for three-fourths of the company’s total sales in 2019. However, with the Celgene acquisition, revenues are e…","Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/",https://www.forbes.com/sites/greatspeculations/2020/02/05/what-are-bristol-myers-squibbs-top-3-drugs/,Forbes.com,,2020-02-05T11:00:00Z,0.38
744053,BMY,Bristol-Myers Squibb and BioMotiv Launch Fibrosis Specialist Anteros Pharmaceuticals,The big pharma has the right to acquire the start-up later a predetermined price.,newsfeedback@fool.com (Brian Orelli),https://www.fool.com/investing/2020/02/04/bristol-myers-squibb-and-biomotiv-launch-fibrosis.aspx,Fool.com,,2020-02-04T17:56:00Z,0
744054,BMY,"Bristol-Myers forms fibrotic disease biotech, bags buyout option","Bristol-Myers Squibb has created a fibrotic and inflammatory disease biotech through its partnership with BioMotiv. The biotech, Anteros Pharmaceuticals, starts life with materials from Bristol-Myers to support development of small molecules and the potential…",Nick Paul,https://www.fiercebiotech.com/biotech/bristol-myers-forms-fibrotic-disease-biotech-bags-buyout-option,Fiercebiotech.com,,2020-02-04T12:36:18Z,0.57
743468,BMY,BioMotiv and Bristol-Myers Squibb Announce the Launch of Anteros Pharmaceuticals,"CLEVELAND & NEW YORK--(BUSINESS WIRE)-- #collaboration--BioMotiv and Bristol-Myers Squibb launch of Anteros Pharmaceuticals, focused on developing drugs for fibrotic and other inflammatory diseases",,https://www.businesswire.com/news/home/20200204005078/en/BioMotiv-Bristol-Myers-Squibb-Announce-Launch-Anteros-Pharmaceuticals,Businesswire.com,,2020-02-04T12:12:25Z,0.38
743469,BMY,"Bristol-Myers, BioMotiv Pact Leads to a New Fibrosis-Focused Startup","<p>Bristol-Myers Squibb is still digesting the commercialized and clinical-stage assets that came with its $74 billion acquisition of Celgene, but the pharmaceutical giant has also been making moves to feed its pipeline with compounds at earlier points of dev…",Frank Vinluan,https://xconomy.com/new-york/2020/02/04/bristol-myers-biomotiv-pact-leads-to-a-new-fibrosis-focused-startup/,Xconomy.com,,2020-02-04T12:00:55Z,0.09
742134,LLY,"Are You An Income Investor? Don't Miss Out On Eli Lilly and Company (NYSE:LLY)",Could Eli Lilly and Company (NYSE:LLY) be an attractive dividend share to own for the long haul? Investors are often...,Simply Wall St,https://finance.yahoo.com/news/income-investor-dont-miss-eli-181315741.html,Yahoo.com,,2020-02-03T18:13:15Z,0.71
742782,ZTS,Eli Lilly’s First Ever CISO Turned CIO Has Joined $5.8B Zoetis As Chief Information And Digital Officer,"On January 28, Wafaa Mamilli joined $5.8 billion Zoetis, the world's largest producer of medicine and vaccinations for pets and livestock, as its new Executive Vice President and Chief Information and Digital Officer.","Peter High, Contributor, Peter High, Contributor https://www.forbes.com/sites/peterhigh/",https://www.forbes.com/sites/peterhigh/2020/02/03/eli-lillys-first-ever-ciso-turned-cio-has-joined-58b-zoetis-as-chief-information-and-digital-officer/,Forbes.com,,2020-02-03T14:46:30Z,0
742135,LLY,Eli Lilly’s First Ever CISO Turned CIO Has Joined $5.8B Zoetis As Chief Information And Digital Officer,"On January 28, Wafaa Mamilli joined $5.8 billion Zoetis, the world's largest producer of medicine and vaccinations for pets and livestock, as its new Executive Vice President and Chief Information and Digital Officer.","Peter High, Contributor, Peter High, Contributor https://www.forbes.com/sites/peterhigh/",https://www.forbes.com/sites/peterhigh/2020/02/03/eli-lillys-first-ever-ciso-turned-cio-has-joined-58b-zoetis-as-chief-information-and-digital-officer/,Forbes.com,,2020-02-03T14:46:30Z,0
741808,ABBV,"Thinking about trading options or stock in AbbVie, IBM, Nike, Roku, or Tesla?","NEW YORK, Feb. 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABBV, IBM, NKE, ROKU, and TSLA. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade idea…",,https://prnmedia.prnewswire.com:443/news-releases/thinking-about-trading-options-or-stock-in-abbvie-ibm-nike-roku-or-tesla-300997639.html,Prnewswire.com,,2020-02-03T14:31:00Z,0.27
741397,ALLY,Ally Financial: Betting On Convergence,"Ally Financial reported in-line earnings, with EPS marginally beating Street consensus estimates amid strong origination volumes; the 2020 outlook was similarly above expectations.Positive tailwinds, e.g., an ongoing shift in origination volumes toward the hi…",Opal Investment Research,https://seekingalpha.com/article/4320874-ally-financial-betting-on-convergence,Seekingalpha.com,,2020-02-03T06:38:44Z,0.15
741185,ABBV,The Passive-Aggressive Investor For 1/27-1/31,"The model portfolios held up well this week, which shows the benefit of using equities and bonds to minimize volatility.I still like the three stocks I've recommended.It's time to sell Target and AbbVie (for now).",Hale Stewart,https://seekingalpha.com/article/4320865-passive-aggressive-investor-for-1-27minus-1-31,Seekingalpha.com,,2020-02-03T03:46:52Z,0.77
741233,JNJ,Johnson & Johnson: Why You Should Own This Cash Flow Beast,"JNJ is a low-risk company which was able to keep growing its free cash flows during the last recession and raised its dividend pay-out consistently.While 2019 results were in-line with historical growth, its 2020 guidance of 5.5% sales growth was very strong.…",Robbe Delaet,https://seekingalpha.com/article/4320854-johnson-johnson-why-you-should-own-this-cash-flow-beast,Seekingalpha.com,,2020-02-03T01:30:55Z,0.75
740131,LLY,"Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study","Lilly's (LLY) JAK inhibitor Olumiant meets primary endpoint of phase III BREEZE-AD5 study, evaluating the drug as a monotherapy in atopic dermatitis patients.",Zacks Equity Research,https://finance.yahoo.com/news/lillys-olumiant-succeeds-another-stage-215309395.html,Yahoo.com,,2020-01-31T21:53:09Z,0.44
740031,BMY,CORRECTED-UPDATE 1-Bristol-Myers Squibb pulls Opdivo+Yervoy lung application in Europe,"Drugmaker Bristol-Myers Squibb Co said on Friday it was pulling the application to have its immunotherapies Opdivo and Yervoy approved in Europe as an initial treatment for advanced lung cancer, after regulators there balked at changes to the design of its cl…",Reuters Editorial,https://www.reuters.com/article/us-bristol-myers-opdivo-idUSKBN1ZU300,Reuters,,2020-01-31T21:29:42Z,-0.15
740032,BMY,CORRECTED-Bristol-Myers pulls Opdivo+Yervoy lung application in Europe,"Drugmaker Bristol-Myers Squibb Co said on Friday it was pulling the application to have its immunotherapies Opdivo and Yervoy approved in Europe as an initial treatment for advanced lung cancer, after regulators there balked at changes to the design of its cl…",Reuters Editorial,https://www.reuters.com/article/bristol-myers-opdivo-idUSL1N2A01KF,Reuters,,2020-01-31T21:27:53Z,-0.15
740033,BMY,Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer,"PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Withdraws European Application of Opdivo Plus Yervoy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer",,https://www.businesswire.com/news/home/20200131005545/en/Bristol-Myers-Squibb-Withdraws-European-Application-Opdivo-nivolumab,Businesswire.com,,2020-01-31T21:26:42Z,-0.34
739349,LLY,Eli Lilly prices migraine therapy at $640 for pack of eight pills,"Lilly expanded its migraine offerings in October by winning FDA approval for the therapy, Reyvow, but analysts had said that side-effects such as dizziness and sleepiness could limit its uptake. Reyvow, intended to be taken after the onset of migraine, could …",Reuters,https://finance.yahoo.com/news/eli-lilly-prices-migraine-therapy-155104435.html,Yahoo.com,,2020-01-31T15:51:04Z,0.5
739350,LLY,"Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription","INDIANAPOLIS, Jan. 31, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that REYVOW™ (lasmiditan) C-V 50 mg and 100 mg tablets, an oral medication for the acute treatment of migraine with or without aura in adults, is now available for p…",,https://www.prnewswire.com/news-releases/lillys-reyvow-lasmiditan-c-v-the-first-and-only-medicine-in-a-new-class-of-acute-treatment-for-migraine-ditan-now-available-for-prescription-300996903.html,Prnewswire.com,,2020-01-31T15:43:00Z,0
739018,ABBV,European advisory backs new labeling for two AbbVie meds; shares up 1% PM,"<ul><li>The European Medicines Agency's advisory group CHMP has adopted positive opinions recommending expanded uses of AbbVie's (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) HCV med Maviret (glecaprevir/pibrentasvir) and …",Douglas W. House,https://seekingalpha.com/news/3536869-european-advisory-backs-new-labeling-for-two-abbvie-meds-shares-up-1-pm,Seekingalpha.com,,2020-01-31T14:05:07Z,0.68
739019,ABBV,"AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis","AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a change to the marketing authorization for …",PR Newswire,https://news.yahoo.com/abbvie-receives-positive-chmp-opinion-121500034.html,Yahoo.com,,2020-01-31T12:15:00Z,0.66
738497,ABBV,AbbVie Receives Positive CHMP Opinion for VENCLYXTO® as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia,"AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for VENCLYXTO® (venetoclax) in combina…",PR Newswire,https://news.yahoo.com/abbvie-receives-positive-chmp-opinion-115500733.html,Yahoo.com,,2020-01-31T11:55:00Z,0.85
738662,LLY,"CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes","Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Lilly's new mealtime insulin for the treatment of adults with diabetes as part…",,https://news.yahoo.com/chmp-recommends-approval-lillys-fast-111500896.html,Yahoo.com,,2020-01-31T11:15:00Z,0.89
738510,ALLY,Top 5 Reasons To Own Ally Financial,Ally Financial is trading at about 30% below its value.The company will generate EPS growth of 10-15% and perhaps higher.It will keep growing its online deposit franchise.The company will continue returning significant capital to shareholders as buybacks and …,Alexander Steinberg,https://seekingalpha.com/article/4320455-top-5-reasons-to-own-ally-financial,Seekingalpha.com,,2020-01-31T06:56:40Z,0.71
737958,LLY,Eli Lilly & Co (LLY) Q4 2019 Earnings Call Transcript - Motley Fool,Eli Lilly & Co (LLY) Q4 2019 Earnings Call Transcript Motley Fool,Motley Fool Transcribers,https://www.fool.com/earnings/call-transcripts/2020/01/30/eli-lilly-co-lly-q4-2019-earnings-call-transcript.aspx,Fool.com,,2020-01-31T03:00:43Z,-0.44
737959,LLY,Eli Lilly smashed Wall Street projections thanks to its diabetes drugs,"Lilly bested Wall Street estimates, sending the big pharma's stock up 2% Thursday.",Sy Mukherjee,https://fortune.com/2020/01/30/eli-lilly-stock-earnings/,Fortune,,2020-01-30T23:11:14Z,0.44
737960,LLY,Eli Lilly and Company (LLY) CEO Dave Ricks on Q4 2019 Results - Earnings Call Transcript,,SA Transcripts,https://seekingalpha.com/article/4320345-eli-lilly-and-company-lly-ceo-dave-ricks-on-q4-2019-results-earnings-call-transcript,Seekingalpha.com,,2020-01-30T21:43:04Z,0
736799,LLY,How Eli Lilly Wowed With Its Q4 Earnings Results,The big drugmaker posted solid revenue and earnings growth thanks to fast-rising sales for several key drugs.,newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2020/01/30/how-eli-lilly-wowed-with-its-q4-earnings-results.aspx,Fool.com,,2020-01-30T18:00:00Z,0.87
736800,LLY,Is Eli Lilly Stock Overvalued?,"Eli Lilly's strong Q4 numbers aren't reason enough to buy this pricey pharma stock.",newsfeedback@fool.com (George Budwell),https://www.fool.com/investing/2020/01/30/is-eli-lilly-stock-overvalued.aspx,Fool.com,,2020-01-30T15:41:00Z,0.51
736802,LLY,Eli Lilly and Company 2019 Q4 - Results - Earnings Call Presentation,,SA Transcripts,https://seekingalpha.com/article/4320143-eli-lilly-and-company-2019-q4-results-earnings-call-presentation,Seekingalpha.com,,2020-01-30T15:25:02Z,0
736803,LLY,Eli Lilly beats profit estimates on strong demand for diabetes drug Trulicity,"Eli Lilly and Co reported a higher-than-expected quarterly profit on Thursday, helped by strong demand for its newer treatments such as diabetes drug Trulicity and psoriasis therapy Taltz, sending its shares up more than 2%.",Saumya Joseph,https://in.reuters.com/article/lilly-results-idINKBN1ZT1ZD,Reuters,,2020-01-30T15:08:15Z,0.91
736804,LLY,Eli Lilly cuts three cancer drugs amid Q4 clear-out,"It’s that time of year when Big Pharmas are reporting revenues and zeroing in on the pipeline updates they want you to know about, but as so often is the case, is being very quiet about any negative news.",Ben Adams,https://www.fiercebiotech.com/biotech/eli-lilly-cuts-three-cancer-drugs-amid-q4-clear-out,Fiercebiotech.com,,2020-01-30T14:49:38Z,-0.85
736805,LLY,"Thinking about buying stock in Applied Materials, General Electric, Eli Lilly, Qorvo, or Tesla?","NEW YORK, Jan. 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMAT, GE, LLY, QRVO, and TSLA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selec…",,https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-applied-materials-general-electric-eli-lilly-qorvo-or-tesla-300996161.html,Prnewswire.com,,2020-01-30T14:31:00Z,-0.03
736806,LLY,Will Eli Lilly Outperform in 2020?,Recent progress in its drug pipeline and a focus on dealmaking offer strong value for shareholders.,newsfeedback@fool.com (Amar Khatri),https://www.fool.com/investing/2020/01/30/will-eli-lilly-outperform-in-2020.aspx,Fool.com,,2020-01-30T12:30:00Z,0.82
736807,LLY,Eli Lilly profit beats estimates on strong Trulicity sales,"Eli Lilly and Co reported a higher-than-expected quarterly profit on Thursday, helped by strong demand for its diabetes drug Trulicity and psoriasis treatment Taltz.",Reuters,https://www.cnbc.com/2020/01/30/eli-lilly-lly-earnings-q4-2019.html,CNBC,,2020-01-30T12:20:26Z,0.9
735926,BMY,FORMA Reports Achievement of Early-stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol-Myers Squibb,"WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA announces the achievement of clinical development milestones for assets licensed to Boehringer Ingelheim and Bristol-Myers Squibb",,https://www.businesswire.com/news/home/20200130005064/en/FORMA-Reports-Achievement-Early-stage-Clinical-Development-Milestones,Businesswire.com,,2020-01-30T12:12:01Z,0.34
736040,LLY,Lilly baricitinib successful in fourth late-stager dermatitis study,"<ul><li>Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) and licensor Incyte (NASDAQ:<a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a>) <a href=""https://seekingalpha.com/pr/1…",Douglas W. House,https://seekingalpha.com/news/3536233-lilly-baricitinib-successful-in-fourth-late-stage-dermatitis-study,Seekingalpha.com,,2020-01-30T12:04:39Z,0.59
736042,LLY,"Eli Lilly's stock gains after earnings, revenue rise above expectations","Shares of Eli Lilly & Co. rose 1.3% in premarket trading Thursday, after the drug maker reported fourth-quarter earnings and revenue that rose above expectations. Net income grew to $1.50 billion, or $1.64 a share, from $1.13 billion, or $1.10 a share, in the…",Tomi Kilgore,https://www.marketwatch.com/story/eli-lillys-stock-gains-after-earnings-revenue-rise-above-expectations-2020-01-30,Marketwatch.com,,2020-01-30T11:38:23Z,0.7
736043,LLY,Eli Lilly quarterly profit jumps 33% on strong Trulicity demand,"Eli Lilly and Co reported a 33% rise in fourth-quarter profit on Thursday, boosted by higher sales of its top-selling diabetes drug, Trulicity.",Reuters Editorial,https://www.reuters.com/article/us-lilly-results-idUSKBN1ZT1C8,Reuters,,2020-01-30T11:36:23Z,0.89
736044,LLY,"Eli Lilly EPS beats by $0.21, beats on revenue","<ul><li>Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>): Q4 Non-GAAP EPS of $1.73 <font color=""green"">beats by $0.21</font>; GAAP EPS of $1.64 <font color=""green"">beats by $0.10</font>.</li><li>Revenue of $…",Mamta Mayani,https://seekingalpha.com/news/3536180-eli-lilly-eps-beats-0_21-beats-on-revenue,Seekingalpha.com,,2020-01-30T11:26:52Z,0
736046,LLY,"Lilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition","INDIANAPOLIS, Jan. 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2019. $ in millions, except per share data Fourth Quarter % Full Year % 2019 2018 Change 2019 2018 Change R…",,https://prnmedia.prnewswire.com:443/news-releases/lilly-reports-strong-fourth-quarter-and-full-year-2019-financial-results-updates-2020-guidance-for-pending-dermira-acquisition-300996069.html,Prnewswire.com,,2020-01-30T11:25:00Z,0.67
736047,LLY,Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate to Severe Atopic Dermatitis,"INDIANAPOLIS, Jan. 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD5, an investigational Phase 3, randomized, placebo-controlled study evaluating the sa…",,https://www.prnewswire.com/news-releases/lilly-and-incyte-announce-positive-top-line-results-from-the-north-american-breeze-ad5-phase-3-study-of-oral-selective-jak-inhibitor-baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-300995759.html,Prnewswire.com,,2020-01-30T11:15:00Z,0.18
734870,ABBV,"Botox maker's boss seeks wrinkle-free transition as AbbVie merger looms","As Brent Saunders likes to tell the tale, the Allergan chief has been CEO of three pharmaceutical companies in barely six years - and never had to change his position. His career moves provide a dizzying primer on the rise and fall of tax inversions.",Shawn Pogatchnik,https://www.independent.ie/business/irish/botox-makers-boss-seeks-wrinkle-free-transition-as-abbvie-merger-looms-38908159.html,Independent.ie,,2020-01-30T02:30:00Z,0.42
734869,ABBV,Allergan launches €145m Botox site as merger nears,Allergan says its future as one of the biggest employers in the west of Ireland is secure despite the firm’s imminent takeover by rival pharmaceutical group AbbVie.,Shawn Pogatchnik in Westport,https://www.independent.ie/business/irish/allergan-launches-145m-botox-site-as-merger-nears-38905999.html,Independent.ie,,2020-01-30T02:30:00Z,0.34
734311,PRGO,Will Perrigo (PRGO) Beat Estimates Again in Its Next Earnings Report?,Perrigo (PRGO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,Zacks Equity Research,https://finance.yahoo.com/news/perrigo-prgo-beat-estimates-again-171005969.html,Yahoo.com,,2020-01-29T17:10:05Z,0.66
734011,JNJ,Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat,"Johnson & Johnson (NYSE: JNJ) today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak. As part of this work, th…",PR Newswire,https://news.yahoo.com/johnson-johnson-launches-multi-pronged-134800609.html,Yahoo.com,,2020-01-29T13:48:00Z,0.32
733223,LLY,Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application,"INDIANAPOLIS, Jan. 29, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for selpercatinib (LOXO-292), for the treatment of pa…",,https://www.prnewswire.com/news-releases/lilly-receives-fda-priority-review-for-the-selpercatinib-new-drug-application-300995006.html,Prnewswire.com,,2020-01-29T11:45:00Z,0.25
732325,ALLY,Ally Financial: Perpetually Cheap,"Ally Financial beat Q4 analyst estimates.The auto financial company trades at only 6.8x '21 EPS estimates.The company offers a net payout yield of ~11%.",Stone Fox Capital,https://seekingalpha.com/article/4319641-ally-financial-perpetually-cheap,Seekingalpha.com,,2020-01-28T23:20:19Z,0
731501,LLY,"FDA Approves Eli Lilly's and Boehringer Ingelheim Pharmaceuticals' Triple-Combination Diabetes Drug Trijardy XR","The combination treatment offers patients more convenience, but could also help the duo fight off competition.",newsfeedback@fool.com (Brian Orelli),https://www.fool.com/investing/2020/01/28/fda-approves-eli-lilly-and-boehringer-ingelheim-ph.aspx,Fool.com,,2020-01-28T14:43:00Z,0.25
731182,ABBV,"Abbott's Pending Loss Ushers In Ongoing Prosperity","Abbott's CEO White has orchestrated two of the grandest coups in pharma history: the Humira juggernaut and the AbbVie creation.The company's acquisition and successful integration of St. Jude has created an amalgam of top-ranked devices to treat cardiovascula…",Out of Ignorance,https://seekingalpha.com/article/4319431-abbotts-pending-loss-ushers-in-ongoing-prosperity,Seekingalpha.com,,2020-01-28T12:26:13Z,0.86
730816,LLY,"Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities","INDIANAPOLIS, Jan. 28, 2020 /PRNewswire/ -- Starting this month, Eli Lilly and Company (NYSE: LLY) will donate at least 200,000 KwikPens® to three relief organizations – Americares, Direct Relief and Dispensary of Hope – to stock insulin at nearly 200 U.S. fr…",,https://prnmedia.prnewswire.com:443/news-releases/lilly-plans-donation-of-200-000-insulin-kwikpens-over-next-three-years-to-support-lower-income-communities-300994038.html,Prnewswire.com,,2020-01-28T11:45:00Z,0.9
730141,BMY,Bristol-Myers Squibb: Strong Quality And Attractive Valuation,Bristol-Myers Squibb is a high quality player in pharmaceuticals.The company has an outstanding track record of consistent revenue growth and superior profitability.The Celgene acquisition makes sense from a financial and strategic perspective.The stock is ve…,"Andres Cardenal, CFA",https://seekingalpha.com/article/4319375-bristol-myers-squibb-strong-quality-and-attractive-valuation,Seekingalpha.com,,2020-01-28T01:40:06Z,0.95
730057,ABBV,Alector: A Promising Neuro-Immunology Pick For 2020,Alector is deploying neuro-immunology approach to target neurodegenerative diseases.Collaboration with AbbVie lends credibility to the company’s research platform.Investors should consider these risks.,Healthcare on the Move,https://seekingalpha.com/article/4319372-alector-promising-neuro-immunology-pick-for-2020,Seekingalpha.com,,2020-01-28T01:00:11Z,0.15
730267,LLY,"FDA OKs Trijardy for patients with type 2 diabetes, Eli Lilly says","<ul><li>Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) says the Food and Drug  Administration <a href=""https://seekingalpha.com/pr/17760458-us-fda-approves-only-triple-combination-tablet-jardiance-for-adul…",Carl Surran,https://seekingalpha.com/news/3534972-fda-oks-trijardy-for-patients-type-2-diabetes-eli-lilly-says,Seekingalpha.com,,2020-01-27T23:57:54Z,0
730268,LLY,"Eli Lilly and Incyte's Olumiant Helps Eczema Patients in a Late-Stage Clinical Trial","The results could help expand use of the drug that's currently approved to treat rheumatoid arthritis.",newsfeedback@fool.com (Brian Orelli),https://www.fool.com/investing/2020/01/27/eli-lilly-and-incytes-olumiant-helps-eczema-patien.aspx,Fool.com,,2020-01-27T23:08:33Z,0.9
730269,LLY,"Diabetes Drug Market Insights, 2020-2026, Featuring Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim, and More","DUBLIN, Jan. 27, 2020 /PRNewswire/ -- The ""Diabetes Drug Market Global & Forecast By Disease, Oral Therapy, Injection, Insulin, Regions, Company"" report has been added to ResearchAndMarkets.com's offering. According to the report, the Diabetes Drug Market is …",,https://www.prnewswire.com/news-releases/diabetes-drug-market-insights-2020-2026-featuring-novo-nordisk-merck--co-eli-lilly-astrazeneca-johnson--johnson-boehringer-ingelheim-and-more-300993708.html,Prnewswire.com,,2020-01-27T20:30:00Z,0
729114,ABBV,"AbbVie's Acquisition of Allergan Gets Help From Nestle and AstraZeneca",A pair of deals will remove some regulatory impediments to the merger.,newsfeedback@fool.com (Cory Renauer),https://www.fool.com/investing/2020/01/27/abbvies-acquisition-of-allergan-gets-help-from-nes.aspx,Fool.com,,2020-01-27T16:35:00Z,0.4
729115,ABBV,AbbVie: Potential 20% To 30% Share Price Gains,"Benefits of the Allergan acquisition for AbbVie EPS are not yet reflected in the AbbVie share price.
        As investors come to better understand the impact on AbbVie of the Allergan acquisition, expect the recent contraction of the P/E multiple to be rever…",Robert Honeywill,https://seekingalpha.com/article/4319239-abbvie-potential-20-to-30-share-price-gains,Seekingalpha.com,,2020-01-27T15:48:44Z,0.74
729116,ABBV,Allergan Offloads Two Drugs to Secure Approval of Merger With AbbVie,"<p>Allergan is selling off an experimental drug and a commercialized product in order to allay antitrust concerns from regulators reviewing the company’s $63 billion acquisition by AbbVie. The rights to brazikumab, which is currently in testing for Crohn’s di…",Frank Vinluan,https://xconomy.com/national/2020/01/27/allergan-offloads-two-drugs-to-secure-approval-of-merger-with-abbvie/,Xconomy.com,,2020-01-27T14:56:09Z,0.67
729390,JNJ,The Small Stock That’s Eating Procter And Gamble’s Core Business,One small stock is stealing heaps of business from formerly safe giants like Procter and Gamble (PG) and Johnson and Johnson (JNJ).,"Stephen McBride, Contributor, Stephen McBride, Contributor https://www.forbes.com/sites/stephenmcbride1/",https://www.forbes.com/sites/stephenmcbride1/2020/01/27/the-small-stock-thats-eating-procter-and-gambles-core-business/,Forbes.com,,2020-01-27T14:47:40Z,0.18
729117,ABBV,"Allergan to divest two drugs, to move forward with AbbVie deal","Shares of AbbVie Inc. were up 2% in trading on Monday morning after the drugmaker said Allergan, which it is in the process of acquiring, plans to divest two therapies. Allergan's stock is up 1%. It is selling brazikumab, an experimental Crohn's disease and u…",Jaimy Lee,https://www.marketwatch.com/story/allergan-to-divest-two-drugs-to-move-forward-with-abbvie-deal-2020-01-27,Marketwatch.com,,2020-01-27T14:41:49Z,0
730050,ZTS,Is Zoetis Stock a Buy?,"Solid growth prospects make this animal health company an investor favorite, but the price right now may be too high.",newsfeedback@fool.com (Jim Crumly),https://www.fool.com/investing/2020/01/27/is-zoetis-stock-a-buy.aspx,Fool.com,,2020-01-27T13:17:00Z,0.53
729394,LLY,"Lilly and Incyte's Olumiant shows mixed results in late-stage dermatitis study","<ul><li>Incyte (NASDAQ:<a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a>) and licensee Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) <a href=""https://seekingalpha.com/pr/1…",Douglas W. House,https://seekingalpha.com/news/3534611-lilly-and-incytes-olumiant-shows-mixed-results-in-late-stage-dermatitis-study,Seekingalpha.com,,2020-01-27T12:48:56Z,0
728814,LLY,Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine,"Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD4, an investigational Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy of baricitinib in combinat…",PR Newswire,https://news.yahoo.com/lilly-incyte-announce-top-line-114500196.html,Yahoo.com,,2020-01-27T11:45:00Z,-0.03
728692,ABBV,AbbVie and Allergan to divest Brazikumab and Zenpep,"<ul><li>AbbVie (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) and Allergan (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>) <a href=""https://seekingalpha.com/pr/17759269-abbvie-and-allergan-…",Mamta Mayani,https://seekingalpha.com/news/3534562-abbvie-and-allergan-to-divest-brazikumab-and-zenpep,Seekingalpha.com,,2020-01-27T11:30:29Z,0
728694,ABBV,"AbbVie-Allergan US$63 billion deal aided by Nestle, AstraZeneca buys","U.S. drugmaker AbbVie's  US$63 billion tie-up with Allergan  is getting help from Nestle  and AstraZeneca  buying up products the Irish-domiciled company is shedding to placate regulators.",CNA,https://www.channelnewsasia.com/news/business/abbvie-allergan-us-63-billion-deal-aided-by-nestle--astrazeneca-buys-12358170,Channelnewsasia.com,,2020-01-27T09:36:25Z,0.4
728695,ABBV,"AbbVie-Allergan $63 billion deal aided by Nestle, AstraZeneca buys","U.S. drugmaker AbbVie's $63 billion tie-up with Allergan is getting help from Nestle and AstraZeneca buying up products the Irish-domiciled company is shedding to placate regulators.",John Miller,https://ca.reuters.com/article/businessNews/idCAKBN1ZQ0RC,Reuters,,2020-01-27T09:26:32Z,0.4
728696,ABBV,"AbbVie-Allergan $63 bln deal aided by Nestle, AstraZeneca buys","U.S. drugmaker AbbVie's $63 billion tie-up with Allergan is getting help from Nestle and AstraZeneca buying up products the Irish-domiciled company is shedding to placate regulators.",John Miller,https://www.reuters.com/article/us-allergan-m-a-abbvie-idUSKBN1ZQ0RC,Reuters,,2020-01-27T09:20:24Z,0.4
728698,ABBV,AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep,"NORTH CHICAGO, Ill. and DUBLIN, Jan. 27, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan (NYSE: AGN), a leading global pharmaceutical company, today announced that Allergan has entered into definitive …",,https://www.prnewswire.com/news-releases/abbvie-and-allergan-announce-agreements-to-divest-brazikumab-and-zenpep-300993294.html,Prnewswire.com,,2020-01-27T06:15:00Z,-0.18
728301,ABBV,Should You Buy Allergan Before the AbbVie Acquisition Closes?,"The clock's ticking on this big pharmaceutical buyout.",newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2020/01/26/should-you-buy-allergan-before-the-abbvie-acquisit.aspx,Fool.com,,2020-01-26T14:30:00Z,0
728186,ABBV,China names HIV drugs as part of treatment plan for Wuhan virus,"China is using AbbVie Inc.'s HIV drugs as an ad-hoc treatment for pneumonia caused by the novel coronavirus while the global search for a cure continues. T","No Author, No Author",https://www.japantimes.co.jp/news/2020/01/26/asia-pacific/science-health-asia-pacific/china-hiv-drugs-treatment-wuhan-virus/,Japantimes.co.jp,,2020-01-26T08:06:33Z,0.32
727836,ALLY,Ally Financial: Another Bargain Bin Stock That Just Keeps Growing EPS,"Ally is selling at a 55% discount to the market P/E, yet is growing earnings faster.Auto loan credit risk remains moderate.Ally's online bank keeps adding value.Ally's capital management is outstanding.Management's 10-15% EPS growth estimate for 2020 requires…",Gary J. Gordon,https://seekingalpha.com/article/4319058-ally-financial-another-bargain-bin-stock-just-keeps-growing-eps,Seekingalpha.com,,2020-01-25T14:18:02Z,0.74
727864,BMY,"Are You An Income Investor? Don't Miss Out On Bristol-Myers Squibb Company (NYSE:BMY)","Dividend paying stocks like Bristol-Myers Squibb Company (NYSE:BMY) tend to be popular with investors, and for good...",Simply Wall St,https://finance.yahoo.com/news/income-investor-dont-miss-bristol-120220599.html,Yahoo.com,,2020-01-25T12:02:20Z,0.69
727837,ALLY,Is It Smart To Buy Ally Financial Inc. (NYSE:ALLY) Before It Goes Ex-Dividend?,"Readers hoping to buy Ally Financial Inc. (NYSE:ALLY) for its dividend will need to make their move shortly, as the...",Simply Wall St,https://finance.yahoo.com/news/smart-buy-ally-financial-inc-115146603.html,Yahoo.com,,2020-01-25T11:51:46Z,0.67
727368,LLY,Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know,"Eli Lilly (LLY) closed at $139.07 in the latest trading session, marking a -1.52% move from the prior day.",Zacks Equity Research,https://finance.yahoo.com/news/eli-lilly-lly-dips-more-225010907.html,Yahoo.com,,2020-01-24T22:50:10Z,0
727271,BMY,"Global Stroke Treatment Market Report 2019-2027 Featuring Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Roche, Johnson & Johnson Services, Sanofi, Amgen, Biogen, and AstraZeneca","DUBLIN, Jan. 24, 2020 /PRNewswire/ -- The ""Stroke Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027"" report has been added to ResearchAndMarkets.com's offering. This report on the global stroke treatment marke…",,https://www.prnewswire.com/news-releases/global-stroke-treatment-market-report-2019-2027-featuring-bristol-myers-squibb-boehringer-ingelheim-daiichi-sankyo-roche-johnson--johnson-services-sanofi-amgen-biogen-and-astrazeneca-300992836.html,Prnewswire.com,,2020-01-24T21:45:00Z,0.59
726438,BMY,Here is Why Growth Investors Should Buy Bristol-Myers (BMY) Now,Bristol-Myers (BMY) could produce exceptional returns because of its solid growth attributes.,Zacks Equity Research,https://finance.yahoo.com/news/why-growth-investors-buy-bristol-174505961.html,Yahoo.com,,2020-01-24T17:45:05Z,0.7
726657,MRK,Koneksa Health Announces Study Publication Validating mHealth Technologies in Early-Stage Clinical Trial Safety Monitoring,"NEW YORK, Jan. 24, 2020 /PRNewswire/ -- Koneksa Health, the leader in developing and implementing patient-focused digital biomarkers for drug development, along with Merck & Co, Inc. (NYSE: MRK) announced the publication of a peer-reviewed Phase I clinical tr…",,https://www.prnewswire.com/news-releases/koneksa-health-announces-study-publication-validating-mhealth-technologies-in-early-stage-clinical-trial-safety-monitoring-300992910.html,Prnewswire.com,,2020-01-24T17:37:00Z,0.64
726439,BMY,"Zacks.com featured highlights include: SNX, ICHR, TECD, NSIT and BMY","Zacks.com featured highlights include: SNX, ICHR, TECD, NSIT and BMY",Zacks Equity Research,https://finance.yahoo.com/news/zacks-com-featured-highlights-snx-152703571.html,Yahoo.com,,2020-01-24T15:27:03Z,0
726637,JNJ,"Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU","J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.",Kinjel Shah,https://finance.yahoo.com/news/pharma-stock-roundup-j-js-141702322.html,Yahoo.com,,2020-01-24T14:17:02Z,0.74
726031,LLY,Anat Hakim to join Lilly as General Counsel,"Eli Lilly and Company (NYSE: LLY) announced today that Anat Hakim will join the company on February 3, 2020 as senior vice-president and general counsel. Hakim succeeds Michael J. Harrington who will retire on January 31, 2020.",PR Newswire,https://news.yahoo.com/anat-hakim-join-lilly-general-113000918.html,Yahoo.com,,2020-01-24T11:30:00Z,0.77
725911,ALLY,Ally reports strong deposit growth as it expands lending product suite,"Ally Financial this week reported it’s continuing its winning streak in deposit growth. In a third-quarter earnings report, the bank reported total deposits of $119.2 billion, up 18% year over year. Meanwhile, the bank’s customer retention rate stands at 96%,…",Suman Bhattacharyya,https://bankinnovation.net/allposts/biz-lines/payments/ally-reports-strong-deposit-growth-as-it-expands-lending-product-suite/,Bankinnovation.net,,2020-01-24T05:05:20Z,0.91
725440,LLY,Poxel Picks Sigilon’s Moller for Chief Scientific Officer Post,"<p>David Moller has joined Poxel as its chief scientific officer, the same position he held most recently at Sigilon Therapeutics. Moller’s experience also includes research and development roles at Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK). Lyon, France-ba…",Frank Vinluan,https://xconomy.com/boston/2020/01/23/poxel-picks-sigilons-moller-for-chief-scientific-officer-post/,Xconomy.com,,2020-01-23T20:50:01Z,0
725171,ZTS,"Here's Why I Think Zoetis (NYSE:ZTS) Is An Interesting Stock","Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...",,https://finance.yahoo.com/news/heres-why-think-zoetis-nyse-173607491.html,Yahoo.com,,2020-01-23T17:36:07Z,0.3
724027,ABBV,2 Dividend-Paying Biotech Stocks Worth Owning in 2020,Dividend investors may want to strongly consider buying AbbVie and Gilead Sciences right now.,newsfeedback@fool.com (George Budwell),https://www.fool.com/investing/2020/01/23/2-dividend-paying-biotech-stocks-worth-owning-in-2.aspx,Fool.com,,2020-01-23T16:29:00Z,0.51
724169,BMY,"Bristol-Myers Squibb: The Merger Is Complete, Time To Shine","Bristol-Myers Squibb has finally completed the acquisition of Celgene, now is the time to shine.The company performed incredibly well in 2019 - better than it originally anticipated - especially with asset spin-offs. That is expected to continue into the 2020…",The Value Portfolio,https://seekingalpha.com/article/4318551-bristol-myers-squibb-merger-is-complete-time-to-shine,Seekingalpha.com,,2020-01-23T13:49:01Z,0.79
723692,LLY,What Company Will Eli Lilly Buy Next?,"Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.",newsfeedback@fool.com (David Haen),https://www.fool.com/investing/2020/01/23/what-company-will-eli-lilly-buy-next.aspx,Fool.com,,2020-01-23T12:00:00Z,0
722900,ALLY,Ally Financial (ALLY) Q4 2019 Earnings Call Transcript,"ALLY earnings call for the period ending December 31, 2019.",newsfeedback@fool.com (Motley Fool Transcribing),https://www.fool.com/earnings/call-transcripts/2020/01/22/ally-financial-ally-q4-2019-earnings-call-transcri.aspx,Fool.com,,2020-01-23T02:01:00Z,0
723123,JNJ,Johnson & Johnson (JNJ) Q4 2019 Earnings Call Transcript,"JNJ earnings call for the period ending December 31, 2019.",newsfeedback@fool.com (Motley Fool Transcribers),https://www.fool.com/earnings/call-transcripts/2020/01/22/johnson-johnson-jnj-q4-2019-earnings-call-transcri.aspx,Fool.com,,2020-01-22T21:30:38Z,0
722901,ALLY,Ally Financial Inc. (ALLY) CEO Jeffrey Brown on Q4 2019 Results - Earnings Call Transcript,,SA Transcripts,https://seekingalpha.com/article/4318413-ally-financial-inc-ally-ceo-jeffrey-brown-on-q4-2019-results-earnings-call-transcript,Seekingalpha.com,,2020-01-22T21:03:14Z,0
721777,ALLY,Ally Financial Inc. 2019 Q4 - Results - Earnings Call Presentation,,SA Transcripts,https://seekingalpha.com/article/4318283-ally-financial-inc-2019-q4-results-earnings-call-presentation,Seekingalpha.com,,2020-01-22T13:54:02Z,0
721778,ALLY,Ally Financial Reports Fourth Quarter and Full Year 2019 Financial Results,Ally Financial Inc. (NYSE: ALLY) today reported its fourth quarter and full year 2019 financial results. View the full press release in PDF.,PR Newswire,https://news.yahoo.com/ally-financial-reports-fourth-quarter-123000279.html,Yahoo.com,,2020-01-22T12:30:00Z,0
722137,JNJ,"Johnson & Johnson Earnings Mixed; JNJ Stock Falls - Investor's Business Daily","Johnson & Johnson Earnings Mixed; JNJ Stock Falls Investor's Business Daily Johnson & Johnson beats Wall Street expectations on profit, misses on revenue CNBC Johnson & Johnson’s Profit, Sales Rise The Wall Street Journal Here's How Much Investing $100 In Joh…","Investor's Business Daily",https://www.investors.com/news/technology/jnj-stock-johnson-and-johnson-earnings-q4-2019/,Investors.com,,2020-01-22T12:02:00Z,0.6
721385,JNJ,Johnson & Johnson Reports 2019 Fourth-Quarter And Full Year Results:,"NEW BRUNSWICK, N.J., Jan. 22, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2019. ""We delivered strong underlying sales and earnings growth in 2019, driven by the strength of our Pharmaceutical bus…",,https://www.prnewswire.com/news-releases/johnson--johnson-reports-2019-fourth-quarter-and-full-year-results-300991143.html,Prnewswire.com,,2020-01-22T11:30:00Z,0.84
721388,LLY,"Eli Lilly's Acquisition Strategy, And Other News: The Good, Bad And Ugly Of Biopharma",Eli Lilly provided an update on panned acquisition for 2020.HSDT collaborates with University Health Network in Canada.DRRX gets a split vote from the FDA advisory committee.,Avisol Capital Partners,https://seekingalpha.com/article/4318229-eli-lillys-acquisition-strategy-and-news-good-bad-and-ugly-of-biopharma,Seekingalpha.com,,2020-01-22T09:25:17Z,-0.6
720445,ALLY,"Notable earnings before Wednesday's open","<ul><li><a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a>, <a href='https://seekingalpha.com/symbol/ALLY' title='Ally Financial Inc.'>ALLY</a>, <a href='https://seekingalpha.com/symbol/APH' title='Amphenol Corporation'>APH</a>,…",Akanksha Bakshi,https://seekingalpha.com/news/3533073-notable-earnings-wednesdays-open,Seekingalpha.com,,2020-01-21T22:30:44Z,0
719651,LLY,Governor Cooper Announces over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant,"RALEIGH, N.C., Jan. 21, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), a global healthcare and biopharmaceutical company, will invest over $470 million and create more than 460 new jobs in Durham, Governor Roy Cooper announced today. The project will…",,https://www.prnewswire.com/news-releases/governor-cooper-announces-over-460-jobs-in-durham-as-eli-lilly-and-company-selects-north-carolina-for-major-pharmaceutical-plant-300990502.html,Prnewswire.com,,2020-01-21T17:47:00Z,0.27
719652,LLY,Pharma giant Eli Lilly and Company taps Durham for 450+ jobs,Eli Lilly and Company plans to bring more than 462 jobs to a new Durham County facility. The drug giant picked Durham County for a $474 million investment over competing sites in both Indiana and Pennsylvania. The announcement was made Tuesday. Eli Lilly (NYS…,Lauren Ohnesorge,https://www.bizjournals.com/triangle/news/2020/01/21/pharma-giant-eli-lilly-and-company-taps-durham-for.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_national+%28Bizjournals+National+Feed%29,Bizjournals.com,,2020-01-21T16:23:30Z,0
719464,BMY,How Does Bristol-Myers Squibb’s Revenue And Other Key Metrics Compare With That of Merck?,"Bristol-Myers Squibb and Merck primarily serve the pharmaceuticals products markets. The companies discover, develop, and sell pharmaceutical products globally. Their drugs are used for the treatment of various types of diseases, including cancer, heart-relat…","Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/",https://www.forbes.com/sites/greatspeculations/2020/01/21/how-does-bristol-myers-squibbs-revenue-and-other-key-metrics-compare-with-that-of-merck/,Forbes.com,,2020-01-21T15:30:00Z,-0.66
719335,ABBV,AbbVie: Undervalued And Poised For A 2020 Breakout,"With many stocks at all-time highs, the bar for 2020 is extremely high and it gets more and more difficult to find stocks at attractive valuations.One of these very few stocks left which offer such a profile is healthcare large-cap AbbVie, a stock which had a…",Stefan Redlich,https://seekingalpha.com/article/4317971-abbvie-undervalued-and-poised-for-2020-breakout,Seekingalpha.com,,2020-01-21T13:45:06Z,0.21
718947,BMY,"I'm Buying 2 Of These 3 Fast-Growing Blue Chips For My Retirement Portfolio","Each week, I buy quality dividend stocks based on the principle of ""quality first, valuation second, and prudent risk management always.""This week, I'm buying $750 worth of two stocks.The candidates are: Polaris Industries, Broadcom and Bristol-Myers Squibb.E…",Dividend Sensei,https://seekingalpha.com/article/4317979-buying-2-of-3-fast-growing-blue-chips-for-retirement-portfolio,Seekingalpha.com,,2020-01-21T08:45:47Z,-0.05
718045,ABBV,"AbbVie Stock's 7.3% Total Yield Leaves It Very Undervalued","The Allergan deal, closing shortly, will boost earnings and dividends and push AbbVie's stock higher.AbbVie has had consistent and regular dividend growth, making the stock very attractive to dividend investors.I estimate the stock is worth $135.62, or 54% hi…",Mark Hake CFA,https://seekingalpha.com/article/4317901-abbvie-stocks-7_3-total-yield-leaves-undervalued,Seekingalpha.com,,2020-01-20T17:02:33Z,0.86
718114,BMY,Should Value Investors Buy Bristol-Myers Squibb (BMY) Stock?,"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong pi…",Zacks Equity Research,https://finance.yahoo.com/news/value-investors-buy-bristol-myers-165004294.html,Yahoo.com,,2020-01-20T16:50:04Z,0.93
718224,MRK,Is Merck & Co. (MRK) a Profitable Pick for Value Investors?,Merck & Co. (MRK) stock may be a good choice for value-oriented investors right now from multiple angles.,Zacks Equity Research,https://finance.yahoo.com/news/merck-co-mrk-profitable-pick-143502227.html,Yahoo.com,,2020-01-20T14:35:02Z,0.8
717352,LLY,I don’t let my work affect me emotionally: Luca Visini,"Some #MondayMotivation from 47-year-old MD of Eli Lilly for India, Nepal, Sri Lanka and Bangladesh",Rashmi Menon,https://www.livemint.com/mint-lounge/business-of-life/i-don-t-let-my-work-affect-me-emotionally-luca-visini-11579446822950.html,Livemint.com,,2020-01-19T17:48:44Z,0
717269,ABBV,"American Airlines, Netflix, Starbucks and More Major Earnings This Week","24/7 Wall St. has put together a preview of AbbVie, American Airlines, Netflix, Starbucks and some of the other most prominent earnings reports due in this truncated trading week.",247chrislange,https://247wallst.com/investing/2020/01/19/abbvie-american-airlines-netflix-starbucks-and-more-major-earnings-this-week/,247wallst.com,,2020-01-19T12:05:41Z,0.38
717270,ABBV,Better Buy: Abbott Laboratories vs. AbbVie,Which stock wins in a matchup between these two healthcare siblings?,newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2020/01/19/better-buy-abbott-laboratories-vs-abbvie.aspx,Fool.com,,2020-01-19T12:03:00Z,0.77
716883,LLY,What Does the Future Hold for Nextcure?,"Nextcure's solid footing should sustain it despite Eli Lilly walking away from an R&D pact.",newsfeedback@fool.com (David Haen),https://www.fool.com/investing/2020/01/18/what-does-the-future-hold-for-nextcure.aspx,Fool.com,,2020-01-18T15:00:00Z,0.15
716882,JNJ,"If You Had Bought Johnson & Johnson (NYSE:JNJ) Shares Five Years Ago You'd Have Made 46%","If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share...",Simply Wall St,https://finance.yahoo.com/news/had-bought-johnson-johnson-nyse-143510510.html,Yahoo.com,,2020-01-18T14:35:10Z,0.91
716884,MRK,Significant Study on Veterinary Wellbeing Reveals Importance of Continued Focus on Personal and Professional Health and Wellbeing Among Veterinarians,"ORLANDO, Fla., Jan. 18, 2020 /PRNewswire/ -- Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the results of a comprehensive study of wellbeing and mental health among U.S. veterinarians, which are critic…",,https://prnmedia.prnewswire.com:443/news-releases/significant-study-on-veterinary-wellbeing-reveals-importance-of-continued-focus-on-personal-and-professional-health-and-wellbeing-among-veterinarians-300989201.html,Prnewswire.com,,2020-01-18T14:00:00Z,0.65
715606,LLY,"Eli Lilly's Shopping Spree Won't Stop With Dermira, CFO Shares Plans For More Deals In 2020","The Midwest's largest drugmaker isn't finished making mid-sized deals.",newsfeedback@fool.com (Cory Renauer),https://www.fool.com/investing/2020/01/17/eli-lillys-shopping-spree-wont-stop-with-dermira-c.aspx,Fool.com,,2020-01-17T15:53:00Z,0.47
715592,JNJ,Is Johnson & Johnson (JNJ) A Good Pick for Value Investors?,"Is Johnson & Johnson (JNJ) a great pick from the value investor's perspective right now? Read on to know more.",Zacks Equity Research,https://finance.yahoo.com/news/johnson-johnson-jnj-good-pick-144502783.html,Yahoo.com,,2020-01-17T14:45:02Z,0.9
715410,BMY,Is Bristol-Myers Squibb (BMY) a Good Stock to Pick Now?,"Is Bristol-Myers Squibb (BMY) a great pick from the value investor's perspective right now? Read on to know more.",Zacks Equity Research,https://finance.yahoo.com/news/bristol-myers-squibb-bmy-good-143502012.html,Yahoo.com,,2020-01-17T14:35:02Z,0.87
715607,LLY,"Eli Lilly targets quarterly deals of $1 billion to $5 billion in 2020, CFO says","Eli Lilly aims to announce roughly one $1 billion to $5 billion deal every quarter in 2020, its chief financial officer told Reuters, as the U.S. drugmaker looks to build up its pipeline of future products.",Reuters,https://www.cnbc.com/2020/01/17/eli-lilly-targets-quarterly-deals-of-1-billion-to-5-billion-in-2020-cfo-says.html,CNBC,,2020-01-17T11:30:50Z,0
714998,LLY,Eli Lilly targets buying spree in 2020,"Looking to build up its pipeline of future products, Eli Lilly (NYSE:LLY) aims to announce a $1B-$5B deal for each quarter of 2020.The acquisitions will focus largely on earlier stage opportunities ac",SA Editor Yoel Minkoff,https://seekingalpha.com/news/3532615-eli-lilly-targets-buying-spree-in-2020,Seekingalpha.com,,2020-01-17T08:51:57Z,0.38
714375,LLY,Eli Lilly targets quarterly deals of US$1 billion-US$5 billion in 2020: CFO,"Eli Lilly and Co  aims to announce roughly one US$1 billion to US$5 billion deal every quarter in 2020, its chief financial officer told Reuters, as the U.S. drugmaker looks to build up its pipeline of future products.",CNA,https://www.channelnewsasia.com/news/business/eli-lilly-targets-quarterly-deals-of-us-1-billion-us-5-billion-in-2020--cfo-12270318,Channelnewsasia.com,,2020-01-16T23:30:55Z,0
714376,LLY,Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - CFO,"Eli Lilly and Co aims to announce roughly one $1 billion (765 million pounds) to $5 billion (3.8 billion pounds) deal every quarter in 2020, its chief financial officer told Reuters, as the U.S. drugmaker looks to build up its pipeline of future products. It …","By Carl O'Donnell",https://finance.yahoo.com/news/eli-lilly-targets-quarterly-deals-232354218.html,Yahoo.com,,2020-01-16T23:23:54Z,0
714377,LLY,Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020: CFO,"Eli Lilly and Co aims to announce roughly one $1 billion to $5 billion deal every quarter in 2020, its chief financial officer told Reuters, as the U.S. drugmaker looks to build up its pipeline of future products. It will focus largely on earlier stage opport…","By Carl O'Donnell",https://finance.yahoo.com/news/eli-lilly-targets-quarterly-deals-232341310.html,Yahoo.com,,2020-01-16T23:23:41Z,0
714378,LLY,Eli Lilly targets quarterly deals of $1 bln-$5 bln in 2020 -CFO,"Eli Lilly and Co aims to announce roughly one $1 billion to $5 billion deal every quarter in 2020, its chief financial officer told Reuters, as the U.S. drugmaker looks to build up its pipeline of future products.","Carl O'Donnell",https://www.reuters.com/article/us-usa-healthcare-jpmorgan-eli-lilly-idUSKBN1ZF2YJ,Reuters,,2020-01-16T23:20:47Z,0
714379,LLY,Eli Lilly (LLY) Gains But Lags Market: What You Should Know,"Eli Lilly (LLY) closed the most recent trading day at $141.43, moving +0.23% from the previous trading session.",Zacks Equity Research,https://finance.yahoo.com/news/eli-lilly-lly-gains-lags-225010353.html,Yahoo.com,,2020-01-16T22:50:10Z,-0.03
714380,LLY,Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement,"INDIANAPOLIS, Jan. 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2019 financial results on Thursday, January 30, 2020. Lilly will also conduct a conference call on that day with the investment commun…",,https://www.prnewswire.com/news-releases/lilly-confirms-date-and-conference-call-for-fourth-quarter-2019-financial-results-announcement-300988567.html,Prnewswire.com,,2020-01-16T20:45:00Z,0
713111,ABBV,"Like AbbVie, Buy Allergan, It's A No-Brainer","The AbbVie bid for Allergan follows close on the heels of and has some similarities to the Bristol-Myers acquisition of Celgene.Similar to Bristol-Myers/Celgene, there's much discussion of arbitrage opportunities and which strategy (buying AbbVie or Allergan)…",Robert Honeywill,https://seekingalpha.com/article/4317282-like-abbvie-buy-allergan-no-brainer,Seekingalpha.com,,2020-01-16T16:02:53Z,0.62
713113,ABBV,Why AbbVie Stock Dipped in 2019,"AbbVie's shares had an off year in 2019. Here's why.",newsfeedback@fool.com (George Budwell),https://www.fool.com/investing/2020/01/16/why-abbvie-stock-dipped-in-2019.aspx,Fool.com,,2020-01-16T15:00:00Z,0.3
713400,LLY,"Collins lies about Sackler contribution, won't return Eli Lilly money (Mike Tipping/Beacon)","Mike Tipping / Beacon : Collins lies about Sackler contribution, won't return Eli Lilly money — In a conversation with a constituent last week, U.S. Senator Susan Collins at first flatly denied she had accepted money from both the Sackler family, owners of Pu…",,https://www.memeorandum.com/200116/p26,Memeorandum.com,,2020-01-16T14:30:02Z,-0.75
713420,MRK,Merck Completes Acquisition of ArQule,"KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Completes Acquisition of ArQule",,https://www.businesswire.com/news/home/20200116005463/en/Merck-Completes-Acquisition-ArQule,Businesswire.com,,2020-01-16T13:52:44Z,0
713401,LLY,Collins Falsely Denies Taking Money from Sacklers,"Sen. Susan Collins (R-ME) was caught on video flatly denying that she had accepted campaign contributions from both the Sackler family, owners of Purdue Pharmaceuticals, and drug company giant Eli Lilly. Collins has, in fact, received contributions from both …",Taegan Goddard,https://politicalwire.com/2020/01/16/collins-falsely-denies-taking-money-from-sacklers/,Politicalwire.com,,2020-01-16T13:39:29Z,-0.48
713114,ABBV,5 Key Things Investors Should Look Forward to With AbbVie in 2020,"The big drugmaker's top executives laid out a vision for AbbVie's future at the J.P. Morgan Healthcare Conference this week.",newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2020/01/16/5-key-things-investors-should-look-forward-to-with.aspx,Fool.com,,2020-01-16T12:31:00Z,0.42
712688,ZTS,Zoetis (ZTS) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow,,SA Transcripts,https://seekingalpha.com/article/4317110-zoetis-zts-presents-38th-annual-j-p-morgan-healthcare-conference-slideshow,Seekingalpha.com,,2020-01-15T20:24:13Z,0
710569,BMY,U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer,"PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo Plus Yervoy in First-Line Non-Small Cell Lung Cancer",,https://www.businesswire.com/news/home/20200115005245/en/U.S.-Food-Drug-Administration-Accepts-Priority-Review,Businesswire.com,,2020-01-15T12:08:30Z,-0.2
710082,LLY,"Eli Lilly and Company's (LLY) CEO Dave Ricks Presents at 38th Annual JPMorgan Healthcare Conference (Transcript)",,SA Transcripts,https://seekingalpha.com/article/4316909-eli-lilly-and-companys-lly-ceo-dave-ricks-presents-38th-annual-jpmorgan-healthcare-conference,Seekingalpha.com,,2020-01-15T01:46:32Z,0
709828,ABBV,"AbbVie And Allergan Merger, And Other News: The Good, Bad And Ugly Of Biopharma",AbbVie gets conditional approval for Allergan merger in Europe.Akari reports positive nomacopan data.Cryoport slumps on Q4 results.,Avisol Capital Partners,https://seekingalpha.com/article/4316881-abbvie-and-allergan-merger-and-news-good-bad-and-ugly-of-biopharma,Seekingalpha.com,,2020-01-14T22:07:58Z,0.42
710223,PRGO,Why Perrigo Shares Are Jumping Today,"Investors responded positively to the drugmaker's sneak peek at its Q4 and full-year results.",newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2020/01/14/why-perrigo-shares-are-jumping-today.aspx,Fool.com,,2020-01-14T20:33:00Z,0.68
709034,LLY,"Eli Lilly Interested in Bolt-On Acquisitions, CEO Says",,,https://www.bloomberg.com/news/videos/2020-01-14/eli-lilly-interested-in-bolt-on-acquisitions-ceo-says-video,Bloomberg,,2020-01-14T17:54:32Z,0.4
709035,LLY,Eli Lilly Releasing Cheaper Insulin Generic to Compete With Lispro Products,"Eli Lilly's introducing lower-priced generic versions of its most popular insulin products.",newsfeedback@fool.com (Cory Renauer),https://www.fool.com/investing/2020/01/14/eli-lilly-releasing-cheaper-insulin-generic-to-com.aspx,Fool.com,,2020-01-14T16:46:00Z,0.48
708816,BMY,Bristol-Myers Squibb (BMY) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow,,,https://seekingalpha.com/article/4316743-bristol-myers-squibb-bmy-presents-38th-annual-j-p-morgan-healthcare-conference-slideshow?source=feed_tag_us,Seekingalpha.com,,2020-01-14T16:42:19Z,0
709267,PRGO,"Perrigo stock up 9% as Leerink says sales guidance was 'particularly strong'","Shares of Perrigo Co. Plc rallied about 9% on Tuesday, after Leerink said sales guidance offered earlier in the day was strong. The company said it expects sales to total about $1.3 billion for the fourth quarter and $4.8 billion for the full year, both numbe…",Ciara Linnane,https://www.marketwatch.com/story/perrigo-stock-up-9-as-leerink-says-sales-guidance-was-particularly-strong-2020-01-14,Marketwatch.com,,2020-01-14T16:25:03Z,0.51
708713,ALLY,Ally Financial declares $0.19 dividend,"Ally Financial (NYSE:ALLY) declares $0.19/share quarterly dividend, 11.8% increase from prior dividend of $0.17.Forward yield 2.54%Payable Feb. 14; for shareholders of record Jan. 31; ex-div Jan. 30.S",SA Dividend Announcements,https://seekingalpha.com/news/3531658-ally-financial-declares-0_19-dividend,Seekingalpha.com,,2020-01-14T14:03:02Z,0.32
709268,PRGO,Perrigo shares jump 2.8% premarket after offering above-consensus sales guidance,"Perrigo Co. Plc said Tuesday it expects 2019 sales to come to $4.8 billion, up 2% from the year-earlier period and ahead of the $3.98 billion FactSet consensus. In a statement released ahead of an investor conference, the Dublin-based company said it had an ""…",Ciara Linnane,https://www.marketwatch.com/story/perrigo-shares-jump-28-premarket-after-offering-above-consensus-sales-guidance-2020-01-14,Marketwatch.com,,2020-01-14T13:47:34Z,0.3
709269,PRGO,Perrigo To Provide Self-Care Transformation Update At J.P. Morgan Healthcare Conference; Announces Robust Preliminary Unaudited Fourth Quarter 2019 Net Sales,"Perrigo Company plc (NYSE: PRGO) (TASE: PRGO) Chief Executive Officer and President Murray S. Kessler will highlight the progress of the Company's transformation into a consumer self-care company and discuss certain financial metrics for recently completed pe…",PR Newswire,https://news.yahoo.com/perrigo-self-care-transformation-j-133000286.html,Yahoo.com,,2020-01-14T13:30:00Z,0.83
709036,LLY,Eli Lilly to launch half-priced versions of two more insulin treatments,"Eli Lilly and Co said on Tuesday it planned to sell two versions of insulin at half their current list prices, eight months after it started selling a half-priced version of its popular Humalog injection.",Reuters Editorial,https://www.reuters.com/article/us-lilly-insulin-idUSKBN1ZD1JN,Reuters,,2020-01-14T12:29:03Z,0.42
708695,ABBV,"AbbVie's Maviret now listed on the Newfoundland and Labrador Formulary",AbbVie (NYSE:ABBV) announces that MAVIRET (glecaprevir/pibrentasvir tablets) is now listed on the Newfoundland and Labrador Formulary.MAVIRET is a once-daily ribavirin-free treatment for adults and a,Mamta Mayani,https://seekingalpha.com/news/3531598-abbvies-maviret-now-listed-on-newfoundland-and-labrador-formulary,Seekingalpha.com,,2020-01-14T12:19:27Z,0
708304,LLY,Lilly expands low-priced insulin offerings,"Eli Lilly (NYSE:LLY) intends to add two more cost-saving options to its lineup of solutions for its insulin users, specifically, lower-priced versions of Humalog Mix75/25 KwikPen (insulin lispro prota",SA Editor Douglas W. House,https://seekingalpha.com/news/3531587-lilly-expands-low-priced-insulin-offerings,Seekingalpha.com,,2020-01-14T11:59:35Z,0.27
708305,LLY,Lilly expands insulin affordability options with lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen®,"INDIANAPOLIS, Jan. 14, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to add two more cost-saving options to its suite of solutions for people who use Lilly insulin by introducing lower-priced versions of Humalog® Mix75/25™ KwikP…",,https://www.prnewswire.com/news-releases/lilly-expands-insulin-affordability-options-with-lower-priced-versions-of-humalog-mix7525-kwikpen-and-humalog-junior-kwikpen-300986041.html,Prnewswire.com,,2020-01-14T11:45:00Z,0.27
707679,MRK,"Merck & Co., Inc. (MRK) CEO Ken Frazier Presents Annual J.P. Morgan Healthcare Conference (Transcript)",,SA Transcripts,https://seekingalpha.com/article/4316624-merck-co-inc-mrk-ceo-ken-frazier-presents-annual-j-p-morgan-healthcare-conference-transcript,Seekingalpha.com,,2020-01-14T03:59:05Z,0
708150,ZTS,"Global Veterinary Pharmaceuticals Market Analysis and Outlook, 2015-2030 - Zoetis Led the Market in 2018, Commanding 16.6% of the Market, Followed by Boehringer Ingelheim (14.9%) and Merck & Co (14%)","DUBLIN, Jan. 13, 2020 /PRNewswire/ -- The ""Veterinary Pharmaceuticals Global Market Opportunities And Strategies To 2030"" report has been added to ResearchAndMarkets.com's offering. The report values the veterinary pharmaceuticals market at $33,762.4 million …",,https://prnmedia.prnewswire.com:443/news-releases/global-veterinary-pharmaceuticals-market-analysis-and-outlook-2015-2030---zoetis-led-the-market-in-2018--commanding-16-6-of-the-market-followed-by-boehringer-ingelheim-14-9-and-merck--co-14-300985840.html,Prnewswire.com,,2020-01-13T21:45:00Z,0.65
706289,ABBV,Why AbbVie Could Be a Great Buy in 2020,"The stock has already rallied 20% over the past three months, and with a new drug in the mix, it could continue to climb even higher.",newsfeedback@fool.com (David Jagielski),https://www.fool.com/investing/2020/01/13/why-abbvie-could-be-a-great-buy-in-2020.aspx,Fool.com,,2020-01-13T17:04:10Z,0.62
706636,LLY,Eli Lilly ditches NextCure pact,Eli Lilly has killed off its deal with immuno-oncology biotech NextCure after spending $25 million upfront on the pact just over a year ago.,Ben Adams,https://www.fiercebiotech.com/biotech/eli-lilly-ditches-nextcure-pact,Fiercebiotech.com,,2020-01-13T15:15:32Z,-0.67
706315,ALLY,"Sathish Muthukrishnan joins Ally Financial as Chief Information, Data and Digital Officer","DETROIT, Jan. 13, 2020 /PRNewswire/ -- Ally Financial announced that Sathish Muthukrishnan has joined the company as chief information, data and digital officer. Muthukrishnan will lead Ally's technology, data and digital transformation teams, with a focus on…",,https://www.prnewswire.com/news-releases/sathish-muthukrishnan-joins-ally-financial-as-chief-information-data-and-digital-officer-300985583.html,Prnewswire.com,,2020-01-13T15:00:00Z,0
705956,LLY,Tyvyt® (Sintilimab Injection) Combined with ALIMTA® (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC,"Today, Eli Lilly and Company (NYSE: LLY) jointly announced with Innovent Biologics, Inc. the results of a Phase 3 study in China; the ORIENT-11 trial of Tyvyt® (sintilimab injection) in combination with ALIMTA® (pemetrexed) and platinum in first-line advanced…",PR Newswire,https://news.yahoo.com/tyvyt-sintilimab-injection-combined-alimta-113000491.html,Yahoo.com,,2020-01-13T11:30:00Z,0
705957,LLY,Eli Lilly: More M&A To Add To The Pipeline Momentum,"Eli Lilly has seen a great run in 2019 driven by pipeline conversion into actual approved products, and thus growth.The company has at times engaged in dealmaking and now announces another $1 billion deal for Dermira.I like the progress of the business, yet r…",The Value Investor,https://seekingalpha.com/article/4316405-eli-lilly-m-to-add-to-pipeline-momentum,Seekingalpha.com,,2020-01-13T05:03:25Z,0.93
704916,ABBV,The AbbVie (NYSE:ABBV) Share Price Is Up 44% And Shareholders Are Holding On,You can receive the average market return by buying a low-cost index fund. But you can make superior returns by...,,https://finance.yahoo.com/news/abbvie-nyse-abbv-share-price-121800790.html,Yahoo.com,,2020-01-11T12:18:00Z,0.69
704538,LLY,Eli Lilly (LLY) Gains As Market Dips: What You Should Know,"In the latest trading session, Eli Lilly (LLY) closed at $138, marking a +1.53% move from the previous day.",Zacks Equity Research,https://finance.yahoo.com/news/eli-lilly-lly-gains-market-225010155.html,Yahoo.com,,2020-01-10T22:50:10Z,0.34
704535,JNJ,Janssen to expand R&D footprint in San Francisco,"Johnson &amp; Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies announces that Janssen Research and Development, LLC plans to expand its presence in the San Francisco Bay area with a new R&amp;",SA Editor Douglas W. House,https://seekingalpha.com/news/3531088-janssen-to-expand-r-and-d-footprint-in-san-francisco,Seekingalpha.com,,2020-01-10T21:32:44Z,0.56
704540,LLY,"SHAREHOLDER ALERT: WeissLaw LLP Investigates Dermira, Inc.","WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Dermira, Inc. (""DERM"" or the ""Company"") (NASDAQ: DERM) in connection with the proposed acquisition of the Company by Eli Lilly and Compa…",PR Newswire,https://news.yahoo.com/shareholder-alert-weisslaw-llp-investigates-202300524.html,Yahoo.com,,2020-01-10T20:23:00Z,-0.12
704031,PRGO,Are Investors Undervaluing Perrigo Company plc (NYSE:PRGO) By 50%?,"Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Perrigo Company plc...",Simply Wall St,https://finance.yahoo.com/news/investors-undervaluing-perrigo-company-plc-172823320.html,Yahoo.com,,2020-01-10T17:28:23Z,0.42
703833,LLY,"ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Dermira, Inc.","NEW YORK, Jan. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Dermira, Inc. (NASDAQ: DERM) and its board of directors concerning the proposed acquisition of the company by Eli Lilly and Company (NYSE: LLY). St…",,https://prnmedia.prnewswire.com:443/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-dermira-inc-300985030.html,Prnewswire.com,,2020-01-10T17:13:00Z,0.19
703834,LLY,Eli Lilly Gets Skin in the Eczema Game With $1.1B Deal for Dermira,"<p>Eli Lilly has agreed to acquire dermatology drug developer Dermira and its late-stage atopic dermatitis drug for $1.1 billion. Lilly will pay $18.75 per share, a 2.2 percent premium over Dermira’s closing stock price on Thursday. But the deal price represe…",Frank Vinluan,https://xconomy.com/indiana/2020/01/10/eli-lilly-gets-skin-in-the-eczema-game-with-1-1b-deal-for-dermira/,Xconomy.com,,2020-01-10T16:13:43Z,0.44
703835,LLY,Eli Lilly to Boost Its Dermatology Pipeline with $1.1 Billion Dermira Acquisition,It looks like Eli Lilly will compete with Sanofi and Regeneron in the lucrative eczema arena.,newsfeedback@fool.com (Cory Renauer),https://www.fool.com/investing/2020/01/10/eli-lilly-to-boost-its-dermatology-pipeline-with-1.aspx,Fool.com,,2020-01-10T16:08:00Z,0.64
703836,LLY,Lilly agrees to pay $1.1B to buy Peninsula medical dermatology business,Eli Lilly & Co. on Friday said it plans to buy agreed to medical dermatology company Dermira Inc. in a deal valued at $1.1 billion. The Menlo Park business that Lilly is acquiring focuses on the treatment of common skin conditions. One product in its pipeline…,Cromwell Schubarth,https://www.bizjournals.com/sanfrancisco/news/2020/01/10/lilly-agrees-to-pay-1-1b-to-buy-peninsulamedical.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_sanfrancisco+%28San+Francisco+Business+Times%29,Bizjournals.com,,2020-01-10T16:07:49Z,0.66
703837,LLY,Lilly agrees to pay $1.1B to buy Menlo Park medical dermatology business,Eli Lilly & Co. on Friday said it plans to buy medical dermatology company Dermira Inc. in a deal valued at $1.1 billion. The Menlo Park business that Lilly is acquiring focuses on the treatment of common skin conditions. One product in its pipeline is an ecz…,Cromwell Schubarth,https://www.bizjournals.com/sanjose/news/2020/01/10/lilly-agrees-to-pay-1-1b-to-buy-menlo-park-medical.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_sanjose+%28Silicon+Valley+%2F+San+Jose+Business+Journal%29,Bizjournals.com,,2020-01-10T15:57:50Z,0.51
703838,LLY,"Eli Lilly, Apple, Yum! Brands, Nintendo: Companies to watch","Eli Lilly, Apple, Yum! Brands, Nintendo are the companies to watch on Friday, January 10, 2020.",,https://finance.yahoo.com/news/eli-lilly-apple-yum-brands-nintendo-companies-to-watch-154307247.html,Yahoo.com,,2020-01-10T15:43:07Z,0
703839,LLY,How This Dermira Acquisition Will Round Out Eli Lilly,Dermira shares made a handy gain to close out the week after it was announced that Eli Lilly would be acquiring the firm.,247chrislange,https://247wallst.com/healthcare-business/2020/01/10/how-this-dermira-acquisition-will-round-out-eli-lilly/,247wallst.com,,2020-01-10T15:05:26Z,0.68
703840,LLY,Deals of the day-Mergers and acquisitions,"(Adds Eli Lilly, Sorrento Therapeutics, Takeaway.com)",Reuters Editorial,https://uk.reuters.com/article/deals-day-idUKL4N29F2QT,Reuters,,2020-01-10T14:56:15Z,0
703529,ABBV,EU conditionally approves Allergan takeover by Abbvie,"The European Commission has approved US drugmaker AbbVie's planned $63 billion acquisition of Dublin headquartered Botox-maker Allergan, subject to conditions.",RTÉ News,https://www.rte.ie/news/business/2020/0110/1105588-eu-conditionally-approves-allergan-takeover-by-abbvie/,RTE,,2020-01-10T14:47:37Z,0.67
703530,ABBV,"AbbVie/Allergan tie-up conditionally OK'd in Europe","The European Commission has signed off on AbbVie's (ABBV -0.3%) planned merger with Allergan (AGN +0.3%) with the proviso that Allergan sell IL-23 inhibitor brazikumab to a third party.AbbVie planned",SA Editor Douglas W. House,https://seekingalpha.com/news/3530980-abbvie-allergan-tie-up-conditionally-okd-in-europe,Seekingalpha.com,,2020-01-10T14:40:39Z,-0.08
703659,BMY,"The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS","The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS",Zacks Equity Research,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-novartis-143802854.html,Yahoo.com,,2020-01-10T14:38:02Z,0
703532,ABBV,EU clears AbbVie takeover of Allergan subject to conditions,"The European Commission said on Friday it had approved U.S. drugmaker AbbVie's planned $63 billion acquisition of Botox-maker Allergan, subject to conditions.",Reuters Editorial,https://www.reuters.com/article/allergan-ma-abbvie-eu-idUSB5N27Y03C,Reuters,,2020-01-10T14:02:48Z,0.48
703841,LLY,"(DERM) Alert: Johnson Fistel Investigates Proposed Sale of Dermira, Inc.; Is $19.30 a Fair Price?","Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Dermira, Inc. (NASDAQ: DERM) (""Dermira"") breached their fiduciary duties in connection with the proposed sale of the Company to Eli Lilly and Compa…",PR Newswire,https://finance.yahoo.com/news/derm-alert-johnson-fistel-investigates-133500532.html,Yahoo.com,,2020-01-10T13:35:00Z,0.61
703661,BMY,Nektar up 3% premarket on new Bristol-Myers collaboration,Nektar Therapeutics (NASDAQ:NKTR) is up 3% premarket on light volume in reaction to its revised collaboration agreement with Bristol-Myers Squibb (NYSE:BMY) aimed at advancing the combination of bempe,SA Editor Douglas W. House,https://seekingalpha.com/news/3530937-nektar-up-3-premarket-on-new-bristol-myers-collaboration,Seekingalpha.com,,2020-01-10T13:18:30Z,0.49
703534,ABBV,Chinook Therapeutics Obtains Worldwide Rights from AbbVie to Atrasentan with Plans to Develop for the Treatment of Kidney Diseases,"VANCOUVER, British Columbia--(BUSINESS WIRE)--Chinook Therapeutics, Inc., a biotechnology company focused on developing precision medicines for kidney diseases, today announced it has entered into a license agreement with AbbVie, a research-based global bioph…",,https://www.businesswire.com/news/home/20200110005075/en/Chinook-Therapeutics-Obtains-Worldwide-Rights-AbbVie-Atrasentan,Businesswire.com,,2020-01-10T13:06:01Z,0.7
703842,LLY,Lilly bags late-phase Dupixent rival in $1.1B Dermira buyout,"Eli Lilly has struck a $1.1 billion deal to acquire Dermira, landing it a late-phase rival to Regeneron and Sanofi’s blockbuster atopic dermatitis drug Dupixent. The takeover, which values Dermira at just a whisker above its closing price yesterday, comes mon…",Nick Paul,https://www.fiercebiotech.com/biotech/lilly-bags-late-phase-dupixent-rival-1-1b-dermira-buyout,Fiercebiotech.com,,2020-01-10T12:30:12Z,0.68
703185,BMY,Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab),SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)---- $BMY--Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab),,https://www.businesswire.com/news/home/20200110005103/en/Nektar-Therapeutics-Bristol-Myers-Squibb-Amend-Strategic-Collaboration,Businesswire.com,,2020-01-10T12:13:08Z,0.75
703253,LLY,UPDATE 1-Eli Lilly to buy skin disease specialist Dermira for $1.1 billion,"Eli Lilly and Co said on Friday it would buy Dermira Inc for about $1.1 billion in cash, gaining access to the drugmaker's skin disease drugs.",Reuters Editorial,https://www.reuters.com/article/us-dermira-m-a-lilly-idUSKBN1Z917Z,Reuters,,2020-01-10T11:58:15Z,0.42
703254,LLY,Eli Lilly to acquire Dermira for $1.1B,"Eli Lilly (NYSE:LLY) has agreed to acquire Dermira (NASDAQ:DERM) for $18.75 in cash for a total of $1.1B. The transaction should close by quarter-end.The company markets one product, Qbrexza (glycopyr",SA Editor Douglas W. House,https://seekingalpha.com/news/3530903-eli-lilly-to-acquire-dermira-for-1_1b,Seekingalpha.com,,2020-01-10T11:44:54Z,0.27
703256,LLY,Eli Lilly to buy Dermira in a deal valued at $1.1 billion,"Eli Lilly & Co. announced Friday a deal to buy medical dermatology company Dermira Inc. in a deal valued at $1.1 billion. Under terms of the deal, Lilly will pay $18.75 in cash for each Dermira share outstanding, a 2.2% premium to Thursday's closing price of …",Tomi Kilgore,https://www.marketwatch.com/story/eli-lilly-to-buy-dermira-in-a-deal-valued-at-11-billion-2020-01-10,Marketwatch.com,,2020-01-10T11:42:17Z,0.89
703257,LLY,Eli Lilly to buy skin disease specialist Dermira for $1.1 billion,"Eli Lilly and Co said on Friday it would buy Dermira Inc for about $1.1 billion in cash to get access to the drugmaker's skin disease drugs.",Reuters Editorial,https://www.reuters.com/article/dermira-ma-lilly-idUSL4N29F2IF,Reuters,,2020-01-10T11:37:18Z,0
703258,LLY,Lilly Announces Agreement to Acquire Dermira,"INDIANAPOLIS and MENLO PARK, Calif., Jan. 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Dermira, Inc. (NASDAQ: DERM) today announced a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion, in a…",,https://www.prnewswire.com/news-releases/lilly-announces-agreement-to-acquire-dermira-300984850.html,Prnewswire.com,,2020-01-10T11:30:00Z,0.82
702644,BMY,"B-MS, Sanofi Claim Hawaii is Violating Their Free Speech in Plavix Suit","Bristol-Myers Squibb (B-MS) and Sanofi filed a complaint this week in the US District Court for Hawaii to fight a lawsuit brought on by the state, which sought hundreds of millions in civil penalties for the companies’ failure to make certain statements about…",,https://www.raps.org/news-and-articles/news-articles/2020/1/b-ms-sanofi-claim-hawaii-is-violating-their-free?feed=Regulatory-Focus,Raps.org,,2020-01-09T21:49:11Z,-0.8
702645,BMY,Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference (Transcript),,SA Transcripts,https://seekingalpha.com/article/4316059-bristol-myers-squibb-company-bmy-presents-goldman-sachs-12th-annual-healthcare-ceos,Seekingalpha.com,,2020-01-09T21:31:19Z,0
701788,LLY,Lilly launches new robotic drug discovery laboratory,"Eli Lilly (LLY +1.7%), in collaboration with lab automation developer Strateos, announces a new San Diego-based robotic laboratory, called the Lilly Life Sciences Studio Lab, designed to accelerate th",SA Editor Douglas W. House,https://seekingalpha.com/news/3530737-lilly-launches-new-robotic-drug-discovery-laboratory,Seekingalpha.com,,2020-01-09T16:18:12Z,0
701409,ABBV,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results",The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 8.) Allergan plc (NYSE: AGN ):  AbbVie Inc ...,,https://finance.yahoo.com/news/daily-biotech-pulse-mercks-keytruda-133954562.html,Yahoo.com,,2020-01-09T13:39:54Z,0.69
701789,LLY,"Eli Lilly and Company in Collaboration with Strateos, Inc. Launch Remote-Controlled Robotic Cloud Lab","Eli Lilly and Company (NYSE: LLY) and Strateos, Inc. today unveiled a new robotic laboratory in San Diego, California designed to accelerate the drug discovery process. The Lilly Life Sciences Studio lab was conceptualized and designed by Lilly as part of a $…",PR Newswire,https://news.yahoo.com/eli-lilly-company-collaboration-strateos-130000852.html,Yahoo.com,,2020-01-09T13:00:00Z,0
700477,BMY,Celgene backs out of $55M settlement over alleged efforts to thwart generics,Bristol-Myers Squibb (BMY +0.5%) unit Celgene has apparently backed out of a $55M settlement that it agreed to in July 2019 over its activities to delay generic encroachment on Revlimid (lenalidomide),SA Editor Douglas W. House,https://seekingalpha.com/news/3530515-celgene-backs-out-of-55m-settlement-over-alleged-efforts-to-thwart-generics,Seekingalpha.com,,2020-01-08T20:37:47Z,-0.08
700411,ABBV,"AbbVie to separate Botox in new aesthetics unit; Brent Saunders won't have role",Shares of AbbVie Inc. and Allergan plc were both up about 1% in trading on Wednesday after AbbVie announced new plans for the combined company once the pending $63 billion acquisition of Allergan closes. Allergan CEO Brent Saunders will be on the board of dir…,Jaimy Lee,https://www.marketwatch.com/story/abbvie-to-separate-botox-in-new-aesthetics-unit-brent-saunders-wont-have-role-2020-01-08,Marketwatch.com,,2020-01-08T20:20:40Z,0
699662,LLY,Polaris Partners Announces Hiring of Darren Carroll as Partner in Boston,"BOSTON--(BUSINESS WIRE)--Polaris Partners, an investment firm with a long history of partnering with repeat entrepreneurs and world-class innovators, is pleased to announce Darren Carroll has joined the firm after completing a 22-year tenure with Eli Lilly an…",,https://www.businesswire.com/news/home/20200108005230/en/Polaris-Partners-Announces-Hiring-Darren-Carroll-Partner,Businesswire.com,,2020-01-08T14:12:40Z,0.44
699322,ABBV,AbbVie sets executive team to lead company after Allergan merger,"AbbVie (NYSE:ABBV) announces a new global business, Allergan Aesthetics, which includes BOTOX Cosmetic, Juvederm and Coolsculpting body contouring, that will be led by Allergan's current SVP, U.S. Med",SA Editor Douglas W. House,https://seekingalpha.com/news/3530374-abbvie-sets-executive-team-to-lead-company-after-allergan-merger,Seekingalpha.com,,2020-01-08T13:27:51Z,0
699324,ABBV,"AbbVie Announces Leadership Team and Creation of New Business, Allergan Aesthetics, Upon Completion of Acquisition","AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the creation of a new global business, Allergan Aesthetics, an AbbVie company, and the proposed leadership team for the combined company, effective upon the expected first…",PR Newswire,https://news.yahoo.com/abbvie-announces-leadership-team-creation-130000368.html,Yahoo.com,,2020-01-08T13:00:00Z,0.74
699325,ABBV,Better Buy: AbbVie vs. Biogen,"Both of these pharma giants have encountered obstacles recently, but which of them is the better buy now?",newsfeedback@fool.com (Prosper Junior Bakiny),https://www.fool.com/investing/2020/01/08/better-buy-abbvie-vs-biogen.aspx,Fool.com,,2020-01-08T12:00:00Z,0.61
698453,LLY,Eli Lilly Veteran Enrique Conterno Named FibroGen CEO,"<p>Enrique Conterno, a 27-year veteran of Eli Lilly, has been appointed CEO of FibroGen (NASDAQ: FGEN). He is also joining the San Francisco company’s board of directors. Conterno retired from Lilly last year, where he was most recently president of Lilly USA…",Frank Vinluan,https://xconomy.com/san-francisco/2020/01/07/eli-lilly-veteran-enrique-conterno-named-fibrogen-ceo/,Xconomy.com,,2020-01-07T21:40:45Z,0
698251,ABBV,"AbbVie's Rheumatoid Arthritis Drug Receives Approval from Health Canada","It's another win for the company's highly priced blockbuster candidate.",newsfeedback@fool.com (Mark Prvulovic),https://www.fool.com/investing/2020/01/07/abbvies-rheumatoid-arthritis-drug-receives-approva.aspx,Fool.com,,2020-01-07T20:53:28Z,0.9
698454,LLY,"Facing criticism over insulin prices, drugmakers offer more affordable options","Eli Lilly and Novo Nordisk are separately offering help to people who are struggling to pay for their insulin, in a move that underscores how differently drugmakers are approaching the highly politicized topic of insulin prices.",Jaimy Lee,https://www.marketwatch.com/story/facing-criticism-over-insulin-prices-drugmakers-offer-more-affordable-options-2020-01-07,Marketwatch.com,,2020-01-07T20:18:27Z,-0.53
697491,JNJ,What’s Driving Johnson & Johnson’s Stock Price Growth?,"Johnson & Johnson’s (NYSE: JNJ) stock price grew 33% from around $105 levels by the end of 2016 to around $140 in 2019, primarily driven by revenue growth, expansion of the P/E multiple, and margins. Johnson & Johnson’s stock price growth was in line with gro…","Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/",https://www.forbes.com/sites/greatspeculations/2020/01/07/whats-driving-johnson--johnsons-stock-price-growth/,Forbes.com,,2020-01-07T16:00:00Z,0.64
697166,ABBV,AbbVie loses bid to reverse adverse ruling on Humira patents,"Without issuing an opinion, the U.S. Court of Appeals for the Federal Circuit affirmed a Patent Trial and Appeal Board &#40;PTAB&#41; decision invaliding three patents (Nos. 8,889,135, 9,017,680 and 9",SA Editor Douglas W. House,https://seekingalpha.com/news/3530126-abbvie-loses-bid-to-reverse-adverse-ruling-on-humira-patents,Seekingalpha.com,,2020-01-07T15:11:01Z,-0.59
697294,BMY,Celgene-Seeded PharmAkea Sells Last Fibrotic Drug Candidate to Galecto,"<p>When a group of scientists from Amira Pharmaceuticals wanted to start a new biotech after the company’s 2011 acquisition by Bristol-Myers Squibb, Celgene provided seed funding. Eventually Celgene kicked in $35 million more for a research collaboration, an …",Sarah de Crescenzo,https://xconomy.com/san-diego/2020/01/07/celgene-seeded-pharmakea-sells-last-fibrotic-drug-candidate-to-galecto/,Xconomy.com,,2020-01-07T12:34:29Z,0
696771,BMY,Evotec and Bristol-Myers expand iPSC collaboration,"Evotec SE (OTCPK:EVOTF) has received a $6M payment from Bristol-Myers Squibb (NYSE:BMY) following the decision to expand the collaboration to include additional cell lines.Evotec and Celgene, which i",Mamta Mayani,https://seekingalpha.com/news/3530014-evotec-and-bristol-myers-expand-ipsc-collaboration,Seekingalpha.com,,2020-01-07T11:47:04Z,0.56
696750,ALLY,"Here's Why I Think Ally Financial (NYSE:ALLY) Is An Interesting Stock","It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...",Simply Wall St,https://finance.yahoo.com/news/heres-why-think-ally-financial-102915946.html,Yahoo.com,,2020-01-07T10:29:15Z,0.75
696772,BMY,"Bristol-Myers Squibb Completes Divestment of Manufacturing Facility in Anagni, Italy","NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol-Myers Squibb Completes Divestment of Manufacturing Facility in Anagni, Italy",,https://www.businesswire.com/news/home/20200107005282/en/Bristol-Myers-Squibb-Completes-Divestment-Manufacturing-Facility-Anagni,Businesswire.com,,2020-01-07T08:12:05Z,0
696390,LLY,"Four months after CEO's death, biotech company names Lilly vet as leader","Enrique Conterno, a 27-year veteran of Eli Lilly and Co., was named Monday as the new CEO of FibroGen Inc., stepping into a role vacated with the death of founder, chairman and CEO Thomas Neff on Aug. 25. The 64-year-old Neff died unexpectedly after the 500-e…",Ron Leuty,https://www.bizjournals.com/sanfrancisco/news/2020/01/06/fibrogen-ceo-thomas-neff-enrique-conterno-fgen-lly.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_sanfrancisco+%28San+Francisco+Business+Times%29,Bizjournals.com,,2020-01-06T23:03:24Z,-0.91
696387,JNJ,Final 2019 Update For The Millennial Portfolio,JNJ led the portfolio higher in December with a solid 6.1% increase for the month.ABBV was the big winner for the portfolio gaining 33% in the short 4+ months of owning the stock. ABBV was the first position I bought into for this portfolio.Initiated a positi…,Mark Roussin,https://seekingalpha.com/article/4315498-final-2019-update-for-millennial-portfolio,Seekingalpha.com,,2020-01-06T22:14:32Z,0.86
696174,ABBV,Final 2019 Update For The Millennial Portfolio,JNJ led the portfolio higher in December with a solid 6.1% increase for the month.ABBV was the big winner for the portfolio gaining 33% in the short 4+ months of owning the stock. ABBV was the first position I bought into for this portfolio.Initiated a positi…,Mark Roussin,https://seekingalpha.com/article/4315498-final-2019-update-for-millennial-portfolio,Seekingalpha.com,,2020-01-06T22:14:32Z,0.86
696268,BMY,Bristol-Myers Squibb to Present at the 38th Annual J.P. Morgan Healthcare Conference,NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol-Myers Squibb to Present at the 38th Annual J.P. Morgan Healthcare Conference,,https://www.businesswire.com/news/home/20200106005136/en/Bristol-Myers-Squibb-Present-38th-Annual-J.P.-Morgan,Businesswire.com,,2020-01-06T21:27:56Z,0
696176,ABBV,One Analyst Thinks AbbVie Is Grossly Undervalued,"The stock was static in 2019, but a Wall Street veteran thinks investors are overlooking the company's outstanding pipeline and strong upward momentum Continue reading...",GuruFocus.com,https://finance.yahoo.com/news/one-analyst-thinks-abbvie-grossly-211320322.html,Yahoo.com,,2020-01-06T21:13:20Z,0.89
695501,LLY,FibroGen Appoints Enrique Conterno as Its New CEO,"The former Eli Lilly executive will be tasked with launching the biotech's anemia drug roxadustat.",newsfeedback@fool.com (Brian Orelli),https://www.fool.com/investing/2020/01/06/fibrogen-appoints-enrique-conterno-as-its-new-ceo.aspx,Fool.com,,2020-01-06T17:54:27Z,0
695754,PRGO,Perrigo buys toothbrush accessory brand,"Perrigo (PRGO -0.9%) unit Ranir has acquired Steripod, a toothbrush accessory brand that includes toothbrush protectors, kids products and tongue cleaners, from Bonfit America for an undisclosed sum.",SA Editor Douglas W. House,https://seekingalpha.com/news/3529843-perrigo-buys-toothbrush-accessory-brand,Seekingalpha.com,,2020-01-06T16:25:00Z,0
695502,LLY,"Worldwide Diabetes Insulin Delivery Pen Market Analysis, 2013-2019 & 2020-2026, Featuring Novo Nordisk, Eli Lilly, Sanofi, Owen Mumford, Ypsomed, Biocon, and Berlin-Chemie","DUBLIN, Jan. 6, 2020 /PRNewswire/ -- The ""Global Diabetes Insulin Delivery Pen Market Analysis, Trends, and Forecasts to 2026"" report has been added to ResearchAndMarkets.com's offering. The Global Diabetes Insulin Delivery Pen Market size is expected to exce…",,https://www.prnewswire.com/news-releases/worldwide-diabetes-insulin-delivery-pen-market-analysis-2013-2019--2020-2026-featuring-novo-nordisk-eli-lilly-sanofi-owen-mumford-ypsomed-biocon-and-berlin-chemie-300981541.html,Prnewswire.com,,2020-01-06T16:15:00Z,0
695538,MRK,"What Does Merck & Co., Inc.'s (NYSE:MRK) P/E Ratio Tell You?",This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it...,,https://finance.yahoo.com/news/does-merck-co-inc-nyse-145808299.html,Yahoo.com,,2020-01-06T14:58:08Z,0.49
695503,LLY,"If You Had Bought Eli Lilly (NYSE:LLY) Stock Five Years Ago, You Could Pocket A 88% Gain Today",Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...,,https://finance.yahoo.com/news/had-bought-eli-lilly-nyse-142859047.html,Yahoo.com,,2020-01-06T14:28:59Z,0.86
695755,PRGO,Perrigo Advances Consumer Self-Care Growth Strategy with Ranir Subsidiary Acquisition of Steripod® Toothbrush Accessory Brand,"Perrigo Company plc (NYSE; TASE: PRGO) announced today that its Ranir subsidiary has acquired the assets of Steripod®, a leading toothbrush accessory brand and innovator in the toothbrush protector market, from Bonfit America Inc. The deal includes the Sterip…",PR Newswire,https://news.yahoo.com/perrigo-advances-consumer-self-care-140000973.html?_guc_consent_skip=1578319888,Yahoo.com,,2020-01-06T14:00:00Z,0.51
695494,JNJ,Mabpharm files NDA for Remicade biosimilar in China,"Sorrento Therapeutics' (NASDAQ:SRNE) partner Mabpharm has recently filed a marketing application in China for a biosimilar to Johnson &amp; Johnson's (NYSE:JNJ) Remicade (infliximab).The Company plan",Mamta Mayani,https://seekingalpha.com/news/3529712-mabpharm-files-application-for-remicade-biosimilar-in-china,Seekingalpha.com,,2020-01-06T12:42:59Z,0
695539,MRK,Merck teams up with Taiho Pharma and Astex Pharma in cancer,"Merck (NYSE:MRK) inks an exclusive global research collaboration and license agreement with Taiho Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co. (OTCPK:OTSKF) unit Astex Pharmaceuticals aimed",SA Editor Douglas W. House,https://seekingalpha.com/news/3529706-merck-teams-up-taiho-pharma-and-astex-pharma-in-cancer,Seekingalpha.com,,2020-01-06T12:24:14Z,0.57
694758,BMY,"Here's Why Bristol-Myers Squibb Jumped 12.7% in December",Investors breathed a sign of relief as multiple pipeline assets from Celgene closed the year with positive updates.,newsfeedback@fool.com (Maxx Chatsko),https://www.fool.com/investing/2020/01/05/heres-why-bristol-myers-squibb-jumped-127-in-decem.aspx,Fool.com,,2020-01-06T04:26:40Z,0.81
694272,PRGO,"Perrigo wants 'uncertainty' to end over €1.64bn tax bill","Perrigo, a US pharmaceutical company headquartered in Ireland, has said it is focusing on taking some of the ""uncertainty off the table"" regarding tax cases here and across the Atlantic, including its €1.64bn one with Revenue.",Unknown,https://www.independent.ie/business/world/perrigo-wants-uncertainty-to-end-over-164bn-tax-bill-38834561.html,Independent.ie,,2020-01-05T07:00:00Z,-0.34
520493,ZTS,ATO data reveals one third of large companies pay no tax - ABC ...,"Dec 11, 2019 ... BAIN INTERNATIONAL INC, 153,104,059, 20,655,534, 6,196,660 ... ZOETIS 
AUSTRALIA PTY LIMITED, 297,105,254, 11,320,943, 2,866,196.",-,https://www.abc.net.au/news/2019-12-12/ato-corporate-tax-transparency-data-companies-no-tax-paid/11789048,abc.net.au,1578096000,2020-01-04T00:00:00Z,-0.64
520492,ZTS,"Minimizing IPO Investing Risks in 2020: The ETFs to Own | 24/7 Wall ...","Jan 3, 2020 ... ... National Information Services (2.90%). Tesla (2.83%). Zoetis (2.69%) ... 
Firsthand Technology Value Fund Inc. (NASDAQ: SVVC) offers a ...",Chris Lange,https://247wallst.com/investing/2020/01/03/minimizing-ipo-investing-risks-in-2020-the-etfs-to-own/,247wallst.com,1578096000,2020-01-04T00:00:00Z,0.08
692909,BMY,Are You Looking for a Top Momentum Pick? Why Bristol-Myers Squibb (BMY) is a Great Choice,"Does Bristol-Myers Squibb (BMY) have what it takes to be a top stock pick for momentum investors? Let's find out.",Zacks Equity Research,https://finance.yahoo.com/news/looking-top-momentum-pick-why-170005002.html,Yahoo.com,,2020-01-03T17:00:05Z,0.79
692827,ABBV,Is AbbVie (ABBV) Stock Outpacing Its Medical Peers This Year?,Is (ABBV) Outperforming Other Medical Stocks This Year?,Zacks Equity Research,https://finance.yahoo.com/news/abbvie-abbv-stock-outpacing-medical-163004537.html,Yahoo.com,,2020-01-03T16:30:04Z,0
693044,JNJ,4 Reasons Why You Should Invest in J&J (JNJ) Stock in 2020,"Here are four reasons which investors may consider while investing in J&J's (JNJ) stock.",Zacks Equity Research,https://finance.yahoo.com/news/4-reasons-why-invest-j-141602795.html,Yahoo.com,,2020-01-03T14:16:02Z,0
692829,ABBV,AbbVie to Present at the 38th Annual J.P. Morgan Healthcare Conference,"AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020. Richard A. Gonzalez, chairman and chief executive officer, will present at 9:30 a.m. …",PR Newswire,https://news.yahoo.com/abbvie-present-38th-annual-j-130000203.html,Yahoo.com,,2020-01-03T13:00:00Z,0
692221,LLY,Lilly to Participate in J.P. Morgan Healthcare Conference,"INDIANAPOLIS, Jan. 2, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020. David A. Ricks, Lilly's chairman and chief executive officer, will participate in …",,https://prnmedia.prnewswire.com:443/news-releases/lilly-to-participate-in-jp-morgan-healthcare-conference-300980677.html,Prnewswire.com,,2020-01-02T21:30:00Z,0
691641,MRK,How Much Revenue Does Merck Generate From The United States?,"Merck (NYSE: MRK) generates its revenue primarily from sales of pharmaceutical products. The company generated $18 billion in sales in the United States, accounting for over 40% of its total revenue in 2018. This figure has been on a decline and it dropped fr…","Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/",https://www.forbes.com/sites/greatspeculations/2020/01/02/how-much-revenue-does-merck-generate-from-the-united-states/,Forbes.com,,2020-01-02T17:00:00Z,0.68
692087,ZTS,Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2019 Financial Results,"PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis to report Q4 and full year 2019 financial results on Thursday, Feb. 13.",,https://www.businesswire.com/news/home/20200102005085/en/Zoetis-Host-Webcast-Conference-Call-Fourth-Quarter,Businesswire.com,,2020-01-02T13:42:43Z,0
691461,BMY,"Worldwide Insulin Markets, 2015-2018 & 2019-2025 - Key Players are Sanofi, Takeda, Novo Nordisk, Bristol-Myers Squibb, Novartis, Eli Lilly, Oramed, Dongbao Enterprise Group, and Biocon","DUBLIN, Jan. 2, 2020 /PRNewswire/ -- The ""Insulin Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018-2025"" report has been added to ResearchAndMarkets.com's offering. The global demand for insulin market was valued at approximately…",,https://www.prnewswire.com/news-releases/worldwide-insulin-markets-2015-2018--2019-2025---key-players-are-sanofi-takeda-novo-nordisk-bristol-myers-squibb-novartis-eli-lilly-oramed-dongbao-enterprise-group-and-biocon-300980402.html,Prnewswire.com,,2020-01-02T13:00:00Z,0.53
691626,LLY,"Worldwide Insulin Markets, 2015-2018 & 2019-2025 - Key Players are Sanofi, Takeda, Novo Nordisk, Bristol-Myers Squibb, Novartis, Eli Lilly, Oramed, Dongbao Enterprise Group, and Biocon","DUBLIN, Jan. 2, 2020 /PRNewswire/ -- The ""Insulin Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018-2025"" report has been added to ResearchAndMarkets.com's offering. The global demand for insulin market was valued at approximately…",,https://www.prnewswire.com/news-releases/worldwide-insulin-markets-2015-2018--2019-2025---key-players-are-sanofi-takeda-novo-nordisk-bristol-myers-squibb-novartis-eli-lilly-oramed-dongbao-enterprise-group-and-biocon-300980402.html,Prnewswire.com,,2020-01-02T13:00:00Z,0.53
691462,BMY,Bristol-Myers Squibb to Take Part at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference,NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol-Myers Squibb to Take Part at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference,,https://www.businesswire.com/news/home/20200102005111/en/Bristol-Myers-Squibb-Part-Goldman-Sachs-12th-Annual,Businesswire.com,,2020-01-02T12:11:02Z,0
691162,JNJ,Johnson & Johnson Announces Quarterly Dividend for First Quarter 2020,"NEW BRUNSWICK, N.J., Jan. 2, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2020 of $0.95 per share on the company's common stock. The dividend is payable on…",,https://www.prnewswire.com/news-releases/johnson--johnson-announces-quarterly-dividend-for-first-quarter-2020-300980357.html,Prnewswire.com,,2020-01-02T11:45:00Z,0.3
691129,BMY,Drugmakers hike U.S. prices as 2020 begins,"The drug price hike of 2020 has commenced, with costs rising for more than 250 medicines, according to data analyzed by 3 Axis Advisors.Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD),",SA Editor Yoel Minkoff,https://seekingalpha.com/news/3529032-drugmakers-hike-u-s-prices-2020-begins,Seekingalpha.com,,2020-01-02T08:57:30Z,0
690780,ABBV,Why the Earnings Surprise Streak Could Continue for AbbVie (ABBV),AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,Zacks Equity Research,https://finance.yahoo.com/news/why-earnings-surprise-streak-could-171005811.html,Yahoo.com,,2020-01-01T17:10:05Z,0.76
690782,ABBV,Are Investors Undervaluing AbbVie (ABBV) Right Now?,"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong pi…",Zacks Equity Research,https://finance.yahoo.com/news/investors-undervaluing-abbvie-abbv-now-165004285.html,Yahoo.com,,2020-01-01T16:50:04Z,0.91
690804,BMY,More drugmakers hike US prices as new year begins,"NEW YORK: Drug manufacturers including Bristol-Myers Squibb Co, Gilead Sciences Inc, and Biogen Inc hiked US list prices on more than 50 drugs on Wednesday (Jan 1), bringing total New Year's Day drug price increases to more than 250, according to data analyse…",CNA,https://www.channelnewsasia.com/news/business/more-drugmakers-hike-us-prices-as-new-year-begins-12225812,Channelnewsasia.com,,2020-01-01T16:25:39Z,0
690783,ABBV,"Is AbbVie's Stock a Buy?",The stock is trading near its 52-week high even though its returns are flat this year.,newsfeedback@fool.com (David Jagielski),https://www.fool.com/investing/2020/01/01/is-abbvies-stock-a-buy.aspx,Fool.com,,2020-01-01T13:00:00Z,0
690438,ABBV,Company news: Alkem Laboratories,"Alkem Laboratories has entered into an agreement with AbbVie Inc, US, for acquisition of certain assets related to API Dronabinol for $10 million, plus working capital, on closing of the deal. The ass",The Hindu BusinessLine,https://www.thehindubusinessline.com/markets/stock-markets/alkem-laboratories/article30445447.ece,Thehindubusinessline.com,,2020-01-01T03:54:00Z,0.36
690098,LLY,"Top Analyst Upgrades and Downgrades: Activision, Amazon, Apple, Boeing, Eli Lilly, J&J, Lennar, Nio, Nvidia, Tesla and More","Stocks have risen into year-end and exceeded almost all targets from a year ago, but the last trading day of the year is looking directionless after year-end profit-taking was seen on Monday. This is the time on the calendar of that seasonal “Santa Claus Rall…",Jon C. Ogg,https://247wallst.com/investing/2019/12/31/top-analyst-upgrades-and-downgrades-activision-amazon-apple-boeing-eli-lilly-jj-lennar-nio-nvidia-tesla-and-more/,247wallst.com,,2019-12-31T13:55:46Z,0.19
689396,JNJ,Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc.,"The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) announced today the completion of the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees, from…",PR Newswire,https://news.yahoo.com/janssen-announces-completion-acquisition-investigational-210500823.html,Yahoo.com,,2019-12-30T21:05:00Z,0.27
688841,LLY,U.S. District Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit,"INDIANAPOLIS, Dec. 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana ruled in favor of Lilly that the Alimta® (pemetrexed for injection) vitamin regimen patent would be…",,https://www.prnewswire.com/news-releases/us-district-court-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-patent-lawsuit-300979927.html,Prnewswire.com,,2019-12-30T18:09:00Z,0.83
688731,BMY,"What Does Bristol-Myers Squibb Company's (NYSE:BMY) P/E Ratio Tell You?","The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll show how you can use...",,https://finance.yahoo.com/news/does-bristol-myers-squibb-companys-170219625.html,Yahoo.com,,2019-12-30T17:02:19Z,0
688842,LLY,Lilly launches late-stage study of LOXO-292 in medullary thyroid cancer,"Eli Lilly (NYSE:LLY) initiates a Phase 3 clinical trial, LIBRETTO-531, evaluating selpercatinib (LOXO-292) in previously untreated patients with RET-mutation-positive medullary thyroid cancer, a Break",SA Editor Douglas W. House,https://seekingalpha.com/news/3528700-lilly-launches-late-stage-study-of-loxominus-292-in-medullary-thyroid-cancer,Seekingalpha.com,,2019-12-30T12:55:22Z,-0.66
688421,LLY,Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer,"INDIANAPOLIS, Dec. 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the opening of the LIBRETTO-531 clinical trial [NCT04211337] for selpercatinib, also known as LOXO-292, for treatment-naïve RET-mutant medullary thyroid cancer (MTC)…",,https://www.prnewswire.com/news-releases/lilly-opens-phase-3-clinical-trial-in-ret-mutant-medullary-thyroid-cancer-300979626.html,Prnewswire.com,,2019-12-30T11:45:00Z,-0.66
688015,ABBV,How Did AbbVie Inc (ABBV) Perform In Comparison to Hedge Fund Favorites in 2019?,"Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 57%. Our research shows that most of the stocks that smart…",Abigail Fisher,https://finance.yahoo.com/news/did-abbvie-inc-abbv-perform-170535731.html,Yahoo.com,,2019-12-29T17:05:35Z,0.84
687947,LLY,"In rural New York state's Trump country, a season of need on family farms","Under fire over high prices, Eli Lilly promised cheaper insulin in 2019. The result has some senators steamed.",By Annie Gowen / The Washington Post,https://www.bhmgnews.com/news/trending/article_a7037082-281c-11ea-8330-20677ceff39c.html,Bhmgnews.com,,2019-12-29T12:00:00Z,0.03
687365,BMY,How Did Bristol Myers Squibb Company (BMY) Compare Against Hedge Fund Darlings in 2019?,"Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 57%. Our research shows that most of the stocks that smart…",,https://finance.yahoo.com/news/did-bristol-myers-squibb-company-212037109.html,Yahoo.com,,2019-12-27T21:20:37Z,0.85
686989,LLY,"Under fire over high prices, Eli Lilly promised cheaper insulin in 2019. The result has some senators steamed.","Sens. Warren and Blumenthal surveyed 400 pharmacies and found a scarcity of the drug giant's ""authorized generic.""",By Christopher Rowland / The Washington Post,https://www.bhmgnews.com/news/trending/article_3c5a9910-28a6-11ea-9cc6-20677cef02cc.html,Bhmgnews.com,,2019-12-27T15:00:00Z,0.03
687309,ZTS,"The Zacks Analyst Blog Highlights: Texas Instruments, Charter, Lowe's, Caterpillar and Zoetis","The Zacks Analyst Blog Highlights: Texas Instruments, Charter, Lowe's, Caterpillar and Zoetis",,https://news.yahoo.com/zacks-analyst-blog-highlights-texas-132701317.html,Yahoo.com,,2019-12-27T13:27:01Z,0
686982,JNJ,"Johnson & Johnson's Tremfya gets China approval","China's National Medical Products Administration approves imports of Johnson &amp; Johnson's (NYSE:JNJ) Tremfya.Tremfya will be used to treat moderate to severe plaque psoriasis in adults who aren't c",SA Editor Brandy Betz,https://seekingalpha.com/news/3528535-johnson-johnsons-tremfya-gets-china-approval,Seekingalpha.com,,2019-12-27T12:36:19Z,0.42
685559,ABBV,AbbVie gets a price target boost from Cowen,"Cowen analyst Steve Scala boosts price target on AbbVie (ABBV +0.8%) to $98 from $90, citing the importance of the Allergan's (AGN +0.4%) Ubrelvy migraine drug approval.The drug's oral option in a mar",Liz Kiesche,https://seekingalpha.com/news/3528468-abbvie-gets-price-target-boost-from-cowen,Seekingalpha.com,,2019-12-26T15:08:24Z,0.76
685138,ALLY,Hedge Fund Darlings vs. Ally Financial Inc (ALLY) In 2019,"We are still in an overall bull market and many stocks that smart money investors were piling into surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained more than 57% each. Hedge funds' top 3 stock picks retur…",Debasis Saha,https://finance.yahoo.com/news/hedge-fund-darlings-vs-ally-015330879.html,Yahoo.com,,2019-12-26T01:53:30Z,0.88
685393,ZTS,2019 Review: Top Hedge Fund Stocks vs. Zoetis Inc (ZTS),"Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make…",Abigail Fisher,https://finance.yahoo.com/news/2019-review-top-hedge-fund-231512591.html,Yahoo.com,,2019-12-25T23:15:12Z,0.38
685236,LLY,How Did Eli Lilly and Company (LLY) Compare Against Hedge Fund Darlings in 2019?,"It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and r…",Debasis Saha,https://finance.yahoo.com/news/did-eli-lilly-company-lly-230754708.html,Yahoo.com,,2019-12-25T23:07:54Z,0.79
684942,BMY,2 Pharmaceutical Companies Offering Above-Average Dividend Growth,"Companies offering dividend growth well above their historical averages should be appealing to income investors.This higher rate of growth is often due to improving business fundamentals.Bristol-Myers Squibb has a very low payout ratio, and the addition of Ce…",The Dividend Bro,https://seekingalpha.com/article/4314072-2-pharmaceutical-companies-offering-above-average-dividend-growth,Seekingalpha.com,,2019-12-25T07:12:52Z,0.77
684822,MRK,Merck (MRK) Dips More Than Broader Markets: What You Should Know,"Merck (MRK) closed the most recent trading day at $91.44, moving -0.33% from the previous trading session.",Zacks Equity Research,https://finance.yahoo.com/news/merck-mrk-dips-more-broader-224510355.html,Yahoo.com,,2019-12-24T22:45:10Z,0
684815,JNJ,Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know,"In the latest trading session, Johnson & Johnson (JNJ) closed at $145.93, marking a -0.35% move from the previous day.",Zacks Equity Research,https://finance.yahoo.com/news/johnson-johnson-jnj-dips-more-224510962.html,Yahoo.com,,2019-12-24T22:45:10Z,0
684395,JNJ,How Did Johnson & Johnson (JNJ) Compare Against Top Hedge Fund Stocks in 2019?,"It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity po…",,https://finance.yahoo.com/news/did-johnson-johnson-jnj-compare-164044864.html,Yahoo.com,,2019-12-24T16:40:44Z,0.87
684411,MRK,"Hedge Fund Consensus Stocks vs. Merck & Co., Inc. (MRK) In 2019","While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their …",Debasis Saha,https://finance.yahoo.com/news/hedge-fund-consensus-stocks-vs-163652175.html,Yahoo.com,,2019-12-24T16:36:52Z,0.2
684275,BMY,10 Biotech M&A Targets Under The Scanner For 2020,"Biopharma M&A activity scaled record highs in 2019, with a few mega mergers announced involving names such as Bristol-Myers Squibb Co (NYSE: BMY ), Roche Holdings AG Basel ADR (OTC: RHHBY ) and AbbVie ...",,https://finance.yahoo.com/news/10-biotech-m-targets-under-123033664.html,Yahoo.com,,2019-12-24T12:30:33Z,0
684192,ABBV,10 Biotech M&A Targets Under The Scanner For 2020,"Biopharma M&A activity scaled record highs in 2019, with a few mega mergers announced involving names such as Bristol-Myers Squibb Co (NYSE: BMY ), Roche Holdings AG Basel ADR (OTC: RHHBY ) and AbbVie ...",,https://finance.yahoo.com/news/10-biotech-m-targets-under-123033664.html,Yahoo.com,,2019-12-24T12:30:33Z,0
683552,BMY,"FDA approves first generic of Bristol-Myers, Pfizer's blood thinner Eliquis","REUTERS: The U.S. Food and Drug Administration said on Monday it has approved the first generic version of Bristol-Myers Squibb Co and Pfizer Inc's blood thinner Eliquis.",CNA,https://www.channelnewsasia.com/news/world/fda-approves-first-generic-of-bristol-myers--pfizer-s-blood-thinner-eliquis-12207810,Channelnewsasia.com,,2019-12-23T21:35:26Z,0.67
683082,PRGO,"OurCrowd, Perrigo and BOL Win the Israeli Government Tender for Operation of a Medical Cannabis Incubator in Yeruham","YERUHAM, Israel--(BUSINESS WIRE)--OurCrowd, the leading global investment platform and the most active venture capital investor in Israel, Perrigo, the world’s largest non-prescription drug company, and BOL Pharma, the leading medical cannabis company in Isra…",,https://www.businesswire.com/news/home/20191223005336/en/%C2%A0OurCrowd-Perrigo-BOL-Win-Israeli-Government-Tender,Businesswire.com,,2019-12-23T15:24:49Z,0.78
682710,BMY,"Bristol-Myers' Revlimid Combo Gets EU Nod for New Indication","The EC approves Bristol-Myers' (BMY) Revlimid in combination with Rituxan for the treatment of previously-treated FL (Grade 1-3a).",Zacks Equity Research,https://finance.yahoo.com/news/bristol-myers-revlimid-combo-gets-142002891.html,Yahoo.com,,2019-12-23T14:20:02Z,0.4
682559,ALLY,"Ally Financial's Ratings Upgraded by Moody's, Outlook Stable","Strong funding profile and improving profitability drive Ally Financial's (ALLY) ratings upgrade by Moody's.",Zacks Equity Research,https://finance.yahoo.com/news/ally-financials-ratings-upgraded-moodys-134801791.html,Yahoo.com,,2019-12-23T13:48:01Z,0.6
682896,JNJ,Johnson & Johnson’s COGS On the Rise?,"Johnson & Johnson’s (NYSE: JNJ) cost of goods sold has been on a rise. It accounted for 41% of its total expenses in 2018, compared to 39% in 2016. In fact, Johnson & Johnson’s COGS, when looked at as a percentage of its revenue, grew from 30% in 2016 to 33% …","Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/",https://www.forbes.com/sites/greatspeculations/2019/12/23/johnson--johnsons-cogs-on-the-rise/,Forbes.com,,2019-12-23T13:30:00Z,0
681394,BMY,"How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition","But the big biotech isn't a happy camper about its contribution.",newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2019/12/21/how-gilead-sciences-is-helping-fund-bristol-myers.aspx,Fool.com,,2019-12-21T12:30:00Z,-0.2
680833,BMY,Bristol-Myers Squibb: 2020 Total Return Play With A 2.8% Dividend Yield,,,https://seekingalpha.com/article/4313613-bristol-myers-squibb-2020-total-return-play-2_8-dividend-yield?source=feed_all_articles,Seekingalpha.com,,2019-12-20T21:31:12Z,0.34
679530,BMY,Bristol-Myers Squibb Receives European Commission Approval for Revlimid® (lenalidomide) in Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma,"PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS receives European Commission approval for Revlimid® (lenalidomide) in combination with rituximab for the treatment of adult patients....",,https://www.businesswire.com/news/home/20191220005238/en/Bristol-Myers-Squibb-Receives-European-Commission-Approval-Revlimid%C2%AE,Businesswire.com,,2019-12-20T12:05:17Z,0.74
679602,JNJ,Johnson & Johnson Announces Agreement to Acquire Remaining Stake in Verb Surgical Inc.,"Dedicated to shaping the next frontier of surgery, Johnson & Johnsoni (NYSE: JNJ) today announced an agreement to acquire the remaining stake in Verb Surgical Inc. following a successful strategic collaboration with Verily, an Alphabet company. Verb Surgical'…",PR Newswire,https://news.yahoo.com/johnson-johnson-announces-agreement-acquire-114500090.html,Yahoo.com,,2019-12-20T11:45:00Z,0.88
679035,LLY,"Outlook on Europe's Diabetes Market to 2025 Featuring Abbott, B. Braun, Eli Lilly, Medtronic, Novo Nordisk, and More","The ""Diabetes Market Analysis, Size, Trends | Europe | 2019-2025"" report has been added to ResearchAndMarkets.com's offering.",PR Newswire,https://news.yahoo.com/outlook-europes-diabetes-market-2025-214500680.html,Yahoo.com,,2019-12-19T21:45:00Z,0
678027,JNJ,Have Insiders Been Buying Johnson & Johnson (NYSE:JNJ) Shares?,We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...,Simply Wall St,https://finance.yahoo.com/news/insiders-buying-johnson-johnson-nyse-170748355.html,Yahoo.com,,2019-12-19T17:07:48Z,0.51
678031,JNJ,Johnson & Johnson to Participate in 38th Annual JP Morgan Health Care Conference,"NEW BRUNSWICK, N.J., Dec. 19, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 38th Annual JP Morgan Health Care Conference on Monday, January 13, at the Westin St. Francis in San Francisco. Ashley McEvoy, Executive Vice President, W…",,https://www.prnewswire.com/news-releases/johnson--johnson-to-participate-in-38th-annual-jp-morgan-health-care-conference-300977772.html,Prnewswire.com,,2019-12-19T16:40:00Z,0.89
677667,ABBV,2 Must-Own Dividend Growth Stocks in 2020,"AbbVie and Gilead Sciences are two outstanding dividend growth plays for 2020. Here's why.",newsfeedback@fool.com (George Budwell),https://www.fool.com/investing/2019/12/19/2-must-own-dividend-growth-stocks-in-2020.aspx,Fool.com,,2019-12-19T15:00:00Z,0.88
678043,LLY,"Thinking about trading options or stock in Apple, Axsome Therapeutics, Deere & Co, Johnson & Johnson, or Eli Lilly?","NEW YORK, Dec. 19, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, AXSM, DE, JNJ, and LLY. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas…",,https://www.prnewswire.com/news-releases/thinking-about-trading-options-or-stock-in-apple-axsome-therapeutics-deere--co-johnson--johnson-or-eli-lilly-300977636.html,Prnewswire.com,,2019-12-19T14:31:00Z,0.27
677252,BMY,"Bristol-Myers Squibb to Announce Results for Fourth Quarter 2019 on February 6, 2020","NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol-Myers Squibb to Announce Results for Fourth Quarter 2019 on February 6, 2020",,https://www.businesswire.com/news/home/20191219005069/en/Bristol-Myers-Squibb-Announce-Results-Fourth-Quarter-2019,Businesswire.com,,2019-12-19T12:11:56Z,0
677341,LLY,Lilly Launches Campaign to Increase Awareness of Insulin Cost-Saving Options,"INDIANAPOLIS, Dec. 19, 2019 /PRNewswire/ -- In an open letter published today in several top U.S. newspapers, Eli Lilly and Company (NYSE: LLY) Chairman and CEO Dave Ricks encouraged anyone who needs help affording their monthly prescription of Lilly insulin …",,https://www.prnewswire.com/news-releases/lilly-launches-campaign-to-increase-awareness-of-insulin-cost-saving-options-300977149.html,Prnewswire.com,,2019-12-19T11:45:00Z,0.81
677337,JNJ,"J&J's Spravato OK'd in Europe for treatment-resistant depression","As expected, the European Commission approves Johnson &amp; Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies' Spravato (esketamine) nasal spray for the treatment of adults with treatment-resis",SA Editor Douglas W. House,https://seekingalpha.com/news/3527331-j-and-js-spravato-okd-in-europe-for-treatment-resistant-depression,Seekingalpha.com,,2019-12-19T11:35:02Z,0.4
677342,LLY,Eli Lilly Stock Jumps Higher After Analyst Upgrade,"Eli Lilly shares moved sharply higher during Wednesday's session after Morgan Stanley upgraded the stock to Overweight.",Justin Kuepper,https://www.investopedia.com/eli-lilly-stock-jumps-higher-after-analyst-upgrade-4779265,Investopedia.com,,2019-12-19T09:55:15Z,-0.08
676637,BMY,Bristol-Myers Squibb files U.S. application for CAR T for treatment-resistant LBCL,Bristol-Myers Squibb (NYSE:BMY) has submitted its marketing application to the FDA seeking approval of CAR T therapy lisocabtagene maraleucel (liso-cel) (formerly JCAR017) for the treatment of adult p,SA Editor Douglas W. House,https://seekingalpha.com/news/3527256-bristol-myers-squibb-files-u-s-application-for-car-t-for-treatment-resistant-lbcl,Seekingalpha.com,,2019-12-18T21:30:37Z,0.48
676638,BMY,Bristol-Myers Squibb Announces Submission of Biologics License Application for CAR T-Cell Therapy Lisocabtagene Maraleucel (liso-cel) to FDA,"PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BLA--Bristol-Myers Squibb Announces Submission of Biologics License Application for CAR T-Cell Therapy Lisocabtagene Maraleucel (liso-cel) to FDA",,https://www.businesswire.com/news/home/20191218005737/en/Bristol-Myers-Squibb-Announces-Submission-Biologics-License-Application,Businesswire.com,,2019-12-18T21:23:40Z,0
675795,LLY,Determining The Potential Leader Of The Migraine Market,Comparative overview of current treatment options prior to important late-stage trial data releases.Current migraine market.Recently approved medicines.Expectations from late-stage drug candidates.Eli Lilly bears the best potential in the migraine market.,Mehdi Mehdiyev,https://seekingalpha.com/article/4313146-determining-potential-leader-of-migraine-market,Seekingalpha.com,,2019-12-18T17:04:09Z,0.83
675796,LLY,"Everything Jim Cramer said about the stock market on 'Mad Money,' including housing recovery, Eli Lilly CEO, bargain stocks","CNBC's Jim Cramer breaks down the positive signs in the latest housing data. The ""Mad Money"" host sits down with the CEO of Eli Lilly and reveals a batch of stocks that are worth buying as the market continues to hit record levels.",Tyler Clifford,https://www.cnbc.com/2019/12/18/jim-cramers-mad-money-recap-stock-picks-dec-17-2019.html,CNBC,,2019-12-18T16:57:24Z,-0.03
675831,MRK,"FDA Panel Laps Up Merck's Keytruda & Lynparza for New Maladies","The FDA's ODAC votes in favor of Merck's (MRK) Keytruda for non-muscle invasive bladder cancer. The panel also backs Lynparza as a first-line maintenance monotherapy for pancreatic cancer.",Zacks Equity Research,https://finance.yahoo.com/news/fda-panel-laps-mercks-keytruda-160004338.html,Yahoo.com,,2019-12-18T16:00:04Z,-0.81
675428,ABBV,AbbVie Receives European Commission Approval of RINVOQ™ (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis,"NORTH CHICAGO, Ill., Dec. 18, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Commission (EC) has approved RINVOQ™ (upadacitinib) for the treatment of adult patients with moderate …",,https://www.prnewswire.com/news-releases/abbvie-receives-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-with-moderate-to-severe-active-rheumatoid-arthritis-300976990.html,Prnewswire.com,,2019-12-18T15:50:00Z,0.72
675454,ALLY,Ally Financial Schedules Release of Fourth Quarter and Full Year Financial Results,"Ally Financial Inc. (NYSE: ALLY) has scheduled the release of its fourth quarter and full year financial results for Wednesday, January 22, 2020. The press release will be issued at 7:30 a.m. ET via PR Newswire and on the Ally Press Room website (http://media…",PR Newswire,https://news.yahoo.com/ally-financial-schedules-release-fourth-150000420.html,Yahoo.com,,2019-12-18T15:00:00Z,0
675798,LLY,"Stock indexes open slightly higher, led by communications",NEW YORK (AP) — Communicastions and health care stocks are leading major US indexes slightly higher in early trading on Wall Street. Facebook rose 1.6% and Eli Lilly added 3.1%. FedEx plunged after reporting a 40% earnings drop in its most recent quarter. The…,The Associated Press,https://www.seattletimes.com/business/stock-indexes-open-slightly-higher-led-by-communications/,Seattletimes.com,,2019-12-18T14:43:06Z,0.27
675799,LLY,"Here are Wednesday's biggest analyst calls: FedEx, Eli Lilly, AMC & more",Here are the biggest calls on Wall Street on Wednesday,Michael Bloom,https://www.cnbc.com/2019/12/18/wednesdays-biggest-analyst-calls-fedex-eli-lilly-amc-more.html,CNBC,,2019-12-18T14:08:00Z,0
675800,LLY,"Top Analyst Upgrades and Downgrades: Datadog, Delta Air, Eli Lilly, FedEx, Halliburton, Kinder Morgan, Skechers, Teladoc, Waste Management and More","Wednesday's included Activision Blizzard, Datadog, Delta Air Lines, Eli Lilly, FedEx, Halliburton, Kinder Morgan, Skechers, Teladoc and Waste Management.",Jon C. Ogg,https://247wallst.com/investing/2019/12/18/top-analyst-upgrades-and-downgrades-datadog-delta-air-eli-lilly-fedex-halliburton-kinder-morgan-skechers-teladoc-waste-management-and-more/,247wallst.com,,2019-12-18T13:51:41Z,0.38
676555,ZTS,Zoetis to Participate in the 38th Annual J.P. Morgan Healthcare Conference,"PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis Inc. will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2020, in San Francisco, Calif.",,https://www.businesswire.com/news/home/20191218005052/en/Zoetis-Participate-38th-Annual-J.P.-Morgan-Healthcare,Businesswire.com,,2019-12-18T13:38:01Z,0
675801,LLY,"Morgan Stanley upgrades Eli Lilly, seeing growth for diabetes drugs and a strong pipeline","Eli Lilly could be one of the best growth options in the pharmaceutical industry through the next decade, according to Morgan Stanley.",Jesse Pound,https://www.cnbc.com/2019/12/18/morgan-stanley-upgrades-eli-lilly-seeing-growth-for-diabetes-drugs.html,CNBC,,2019-12-18T13:32:00Z,0.91
675802,LLY,Lilly launches real-world Emgality study,"Eli Lilly (NYSE:LLY) commences a long-term study, TRIUMPH, evaluating the real-world effectiveness of Emgality (galcanezumab-gnlm) compared to other preventative treatments for migraine among people r",SA Editor Douglas W. House,https://seekingalpha.com/news/3527019-lilly-launches-real-world-emgality-study,Seekingalpha.com,,2019-12-18T12:31:40Z,0.59
675111,LLY,"Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm)","Eli Lilly and Company (NYSE: LLY) announced today the launch of TRIUMPH, a long-term, real-world evidence study of Emgality® (galcanezumab-gnlm). The objective of the TRIUMPH study (Preventive Treatment of Migraine: Outcomes for Patients in Real-World Healthc…",PR Newswire,https://news.yahoo.com/lilly-announces-launch-triumph-first-114500224.html,Yahoo.com,,2019-12-18T11:45:00Z,0.91
674577,LLY,"Elizabeth Warren claims Eli Lilly failed on cheaper insulin. CEO says 'nonsense'","Warren's report shows ""what's broken in the rest of the pharmaceutical system,"" Eli Lilly CEO David Ricks tells Cramer.",Berkeley Lovelace Jr.,https://www.cnbc.com/2019/12/17/warren-claims-eli-lilly-failed-on-cheaper-insulin-ceo-says-nonsense.html,CNBC,,2019-12-17T23:34:32Z,-0.75
674578,LLY,"HIMSS, Forrester Research partner to explore digital adoption; Eli Lilly integrating Dexcom's CGMs and more digital health deals","Also: Sutter Health and Aetna's joint venture partners with house call startup Heal; SideKickHealth announces strategic partnership with Bayer.",dave.muoio@himssmedia.com (Dave Muoio),https://www.mobihealthnews.com/news/himss-forrester-research-partner-explore-digital-adoption-eli-lilly-integrating-dexcoms-cgms,Mobihealthnews.com,,2019-12-17T20:32:29Z,0
673445,BMY,"Here's Why Bristol-Myers Squibb (BMY) is a Great Momentum Stock to Buy","Does Bristol-Myers Squibb (BMY) have what it takes to be a top stock pick for momentum investors? Let's find out.",Zacks Equity Research,https://finance.yahoo.com/news/heres-why-bristol-myers-squibb-170005455.html,Yahoo.com,,2019-12-17T17:00:05Z,0.71
673644,LLY,RPT-UPDATE 1-Eli Lilly sees higher-than-expected 2020 profit,"Eli Lilly and Co on Tuesday forecast a higher-than-expected profit for 2020, citing growing demand for its medicines including diabetes drug Trulicity and psoriatic arthritis treatment Taltz.",Reuters Editorial,https://www.reuters.com/article/lilly-outlook-idUSL4N28R3IG,Reuters,,2019-12-17T15:32:14Z,0.48
673645,LLY,"Eli Lilly sees higher-than-expected 2020, citing growing demand for its medicines","Eli Lilly on Tuesday forecast a higher-than-expected profit for 2020, citing growing demand for its medicines. Lilly has been banking on drugs such as Trulicity and Taltz as it faces competition from cheap generic versions of its older medicines.",Reuters,https://www.cnbc.com/2019/12/17/eli-lilly-sees-higher-than-expected-2020.html,CNBC,,2019-12-17T13:56:15Z,0.51
672988,LLY,UPDATE 1-Eli Lilly sees higher-than-expected 2020 profit,"Eli Lilly and Co on Tuesday forecast a higher-than-expected profit for 2020, citing growing demand for its medicines including diabetes drug Trulicity and psoriatic arthritis treatment Taltz.",Reuters Editorial,https://www.reuters.com/article/us-lilly-outlook-idUSKBN1YL1AA,Reuters,,2019-12-17T12:09:49Z,0.48
672989,LLY,Lilly sees 16% non-GAAP EPS growth next year,Eli Lilly (NYSE:LLY) updates its 2019 guidance this morning and provides its 2020 outlook. Key points:2019: Revenue: $22.0B 0 22.5B (unch); EPS: $8.57 - 8.67 from $8.59 - 8.69; non-GAAP EPS: $5.75 - 5,SA Editor Douglas W. House,https://seekingalpha.com/news/3526686-lilly-sees-16-non-gaap-eps-growth-next-year,Seekingalpha.com,,2019-12-17T11:49:18Z,0.38
672990,LLY,"Eli Lilly's stock set to rally after upbeat profit, revenue guidance","Shares of Eli Lilly & Co. were indicated up nearly 1% in premarket trading Tuesday, after the drug maker provided an upbeat financial outlook for next year. The company said it expects 2020 net earnings per share of $6.38 to $6.48. Excluding non-recurring ite…",Tomi Kilgore,https://www.marketwatch.com/story/eli-lillys-stock-set-to-rally-after-upbeat-profit-revenue-guidance-2019-12-17,Marketwatch.com,,2019-12-17T11:47:32Z,0.62
672991,LLY,Eli Lilly expects higher-than-expected 2020 profit,"Eli Lilly and Co on Tuesday forecast a higher-than-expected profit for 2020, citing growing demand for its medicines including diabetes drug Trulicity and psoriatic arthritis treatment Taltz.",Reuters Editorial,https://www.reuters.com/article/lilly-outlook-idUSL4N28R2XB,Reuters,,2019-12-17T11:45:34Z,0.48
672992,LLY,"Lilly Announces 2020 Financial Guidance, Updates 2019 Guidance","Eli Lilly and Company (NYSE: LLY) today announced its 2020 financial guidance, highlighted by volume-based revenue growth and improving productivity, which are expected to result in operating margin expansion and strong earnings performance. The company also …",PR Newswire,https://news.yahoo.com/lilly-announces-2020-financial-guidance-113000407.html,Yahoo.com,,2019-12-17T11:30:00Z,0.83
672505,LLY,Lilly board hikes dividend by 15%,"Eli Lilly & Co. said late Monday that its board approved a 15% hike to the company's quarterly dividend. Lilly said it will pay a dividend of 74 cents a share, up from 64.5 cents a share, on March 10, 2020 to shareholders of record as of Feb. 14. Lilly shares…",Wallace Witkowski,https://www.marketwatch.com/story/lilly-board-hikes-dividend-by-15-2019-12-16,Marketwatch.com,,2019-12-16T21:57:52Z,0.7
672506,LLY,Eli Lilly announces 15% dividend increase,"Eli Lilly (NYSE:LLY) declares $0.74/share quarterly dividend, 14.7% increase from prior dividend of $0.645.Forward yield 2.41%Payable March 10; for shareholders of record Feb. 14; ex-div Feb. 13.See L",SA Editor Jignesh Mehta,https://seekingalpha.com/news/3526603-eli-lilly-announces-15-dividend-increase,Seekingalpha.com,,2019-12-16T21:28:48Z,0.32
672507,LLY,Lilly Announces 15 Percent Dividend Increase,The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 15 percent increase in its quarterly dividend. The dividend for the first quarter of 2020 will be $0.74 per share on outstanding common stock. This raises the annual indicated rate …,PR Newswire,https://news.yahoo.com/lilly-announces-15-percent-dividend-212500987.html,Yahoo.com,,2019-12-16T21:25:00Z,0.82
671372,BMY,"After jumping the BMS-Celgene ship, Paul Biondi boards Flagship Pioneering","Days after leaving Bristol-Myers Squibb (and amid its big merger deal with Celgene), its former dealmaker Paul Biondi has landed at major biotech VC Flagship Pioneering.",Ben Adams,https://www.fiercebiotech.com/biotech/after-jumping-bms-celgene-ship-paul-biondi-boards-flagship-pioneering,Fiercebiotech.com,,2019-12-16T14:59:53Z,0.2
671190,ABBV,"BeiGene cancer drug fails in study against AbbVie: J&J's Imbruvica","BeiGene Ltd said on Monday a late-stage trial failed to show that its cancer treatment Brukinsa was superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc. The results come merely a month after BeiGene scored a win with Brukinsa's approval …",Manojna Maddipatla,https://uk.reuters.com/article/us-beigene-study-idUKKBN1YK165,Reuters,,2019-12-16T14:56:50Z,-0.67
671191,ABBV,Is AbbVie’s Dividend Capable Of Long-Term Growth?,This pharmaceutical giant is a victim of its own success. Will an $86 billion acquisition stave off its impending patent cliff?,newsfeedback@fool.com (Jon Younkman),https://www.fool.com/investing/2019/12/16/is-abbvies-dividend-capable-of-long-term-growth.aspx,Fool.com,,2019-12-16T14:32:14Z,0.68
671192,ABBV,BeiGene drug fails comparative study against AbbVie: J&J rival Imbruvica,"BeiGene Ltd said on Monday a late-stage trial showed that its cancer treatment did not meet the main goal of proving superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc.",CNA,https://www.channelnewsasia.com/news/world/beigene-drug-fails-comparative-study-against-abbvie--j-j-rival-imbruvica-12188400,Channelnewsasia.com,,2019-12-16T13:00:33Z,-0.57
671194,ABBV,BeiGene drug fails main goal in late-stage study against AbbVie-J&J rival Imbruvica,"BeiGene Ltd said on Monday a late-stage trial testing its recently approved cancer treatment Brukinsa did not meet the main goal of proving superior to Imbruvica, a rival medicine from Johnson & Johnson and AbbVie Inc.",Reuters Editorial,https://www.reuters.com/article/beigene-study-idUSL4N28Q2Y4,Reuters,,2019-12-16T12:10:58Z,-0.23
670811,LLY,Lilly to use DexCom CGMs in automated insulin dosing system,"Eli Lilly (NYSE:LLY) inks a non-exclusive agreement with DexCom (NASDAQ:DXCM) for the integration of the latter's continuous glucose monitoring &#40;CGM&#41; devices in both pen- and pump-based platfo",SA Editor Douglas W. House,https://seekingalpha.com/news/3526343-lilly-to-use-dexcom-cgms-in-automated-insulin-dosing-system,Seekingalpha.com,,2019-12-16T12:02:52Z,0.49
670812,LLY,Lilly to Integrate Dexcom CGM into Personalized Diabetes Management System,"INDIANAPOLIS, Dec. 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has announced a global commercialization agreement to integrate DexCom, Inc. (NASDAQ: DXCM) products into Lilly's personalized diabetes management system, currently in development t…",,https://www.prnewswire.com/news-releases/lilly-to-integrate-dexcom-cgm-into-personalized-diabetes-management-system-300975004.html,Prnewswire.com,,2019-12-16T11:45:00Z,0.49
670722,BMY,Bristol-Myers Squibb win $752M patent infringement award against Gilead,A Los Angeles jury has awarded $752M to Bristol-Myers Squibb (NYSE:BMY) in a dispute with Gilead Sciences (NASDAQ:GILD) over a CAR T patent exclusively licensed to BMY unit Juno Therapeutics.The compa,SA Editor Douglas W. House,https://seekingalpha.com/news/3526332-bristol-myers-squibb-win-752m-patent-infringement-award-against-gilead,Seekingalpha.com,,2019-12-16T11:31:28Z,0.64
670723,BMY,Bristol-Myers Squibb wins $752M patent infringement award against Gilead,A Los Angeles jury has awarded $752M to Bristol-Myers Squibb (NYSE:BMY) in a dispute with Gilead Sciences (NASDAQ:GILD) over a CAR T patent exclusively licensed to BMY unit Juno Therapeutics.The compa,SA Editor Douglas W. House,https://seekingalpha.com/news/3526332-bristol-myers-squibb-wins-752m-patent-infringement-award-against-gilead,Seekingalpha.com,,2019-12-16T11:31:28Z,0.62
670724,BMY,"bluebird bio's Advancement With Zynteglo Gene Therapy Is Properly Set Up For Commercial Success","bluebird bio and its partner Bristol-Myers Squibb announced a positive, long-term follow-up of 5 years for beta-thalassemia patients who have been transfusion-free for an extended period of time.The rolling BLA submission for ZYNTEGLO to the FDA for transfusi…",Terry Chrisomalis,https://seekingalpha.com/article/4312630-bluebird-bios-advancement-zynteglo-gene-therapy-is-properly-set-up-for-commercial-success,Seekingalpha.com,,2019-12-16T06:22:54Z,0.56
669724,LLY,Better Buy: Eli Lilly vs. Merck,Which of these two pharmaceutical giants is poised to produce healthier returns?,newsfeedback@fool.com (Prosper Junior Bakiny),https://www.fool.com/investing/2019/12/14/better-buy-eli-lilly-vs-merck.aspx,Fool.com,,2019-12-14T13:30:00Z,0.6
669123,BMY,Bristol-Myers wins US$752 million in US patent case against Gilead,Bristol-Myers Squibb Co  on Friday said it won a US$752 million jury verdict against Gilead Sciences Inc  in a U.S. patent dispute relating to technology for treating cancer.,CNA,https://www.channelnewsasia.com/news/business/bristol-myers-wins-us-752-million-in-us-patent-case-against-gilead-12183814,Channelnewsasia.com,,2019-12-13T22:35:24Z,0.23
668314,BMY,Why Bristol-Myers Squibb Could Be the Best Large-Cap Pharmaceutical Stock for 2020,Independent research firm Argus sees better than 25% potential upside for Bristol-Myers Squibb in the coming year.,Jon C. Ogg,https://247wallst.com/healthcare-business/2019/12/13/why-bristol-myers-squibb-could-be-the-best-large-cap-pharmaceutical-stock-for-2020/,247wallst.com,,2019-12-13T14:55:13Z,0.8
668492,JNJ,"European advisory group backs new use of J&J's Erleada","The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Johnson &amp; Johnson (NYSE:JNJ) unit Janssen Biotech's Erleada (apalutamide) for adult men",SA Editor Douglas W. House,https://seekingalpha.com/news/3526139-european-advisory-group-backs-new-use-of-j-and-js-erleada,Seekingalpha.com,,2019-12-13T13:04:15Z,0.76
668486,LLY,Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure,"RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 13, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to functional endpoints with Jardiance® (empag…",,https://www.prnewswire.com/news-releases/boehringer-ingelheim-and-lilly-provide-update-on-jardiance-phase-iii-exercise-ability-studies-in-chronic-heart-failure-300974452.html,Prnewswire.com,,2019-12-13T13:00:00Z,0.32
667822,BMY,Bristol-Myers Squibb Announces Leadership Changes,NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol-Myers Squibb Announces Leadership Changes,,https://www.businesswire.com/news/home/20191213005070/en/Bristol-Myers-Squibb-Announces-Leadership,Businesswire.com,,2019-12-13T12:05:13Z,0
667892,LLY,CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,"INDIANAPOLIS, Dec. 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending a new indication and associat…",,https://prnmedia.prnewswire.com:443/news-releases/chmp-issues-positive-opinion-to-expand-cyramza-ramucirumab-label-to-include-results-from-relay-study-in-patients-with-metastatic-egfr-mutated-non-small-cell-lung-cancer-300974577.html,Prnewswire.com,,2019-12-13T11:47:00Z,0.86
667778,ABBV,"Allergan: Don't Ring The Bell Yet","The AbbVie acquisition of Allergan is expected to close in the next couple of months.The deal value offers a nearly 5% upside to Allergan shareholders.The new AbbVie trades at a '20 P/E multiple of below 9x.",Stone Fox Capital,https://seekingalpha.com/article/4312287-allergan-dont-ring-bell-yet,Seekingalpha.com,,2019-12-13T06:08:51Z,0.34
667504,PRGO,Is Perrigo Company (PRGO) Another High Profile Starboard Failed Bet?,"Is Perrigo Company (NASDAQ:PRGO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more inc…",Debasis Saha,https://finance.yahoo.com/news/perrigo-company-prgo-another-high-230849291.html,Yahoo.com,,2019-12-12T23:08:49Z,0.35
665555,ABBV,"Should We Worry About AbbVie Inc.'s (NYSE:ABBV) P/E Ratio?","The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll apply a basic P/E...",Simply Wall St,https://finance.yahoo.com/news/worry-abbvie-inc-nyse-abbv-100039868.html,Yahoo.com,,2019-12-12T10:00:39Z,-0.44
665549,ZTS,Zoetis Declares First Quarter 2020 Dividend; Board Approves 22% Payment Increase,"PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Fortune500--Zoetis declares Q1'20 dividend; Board approves 22% payment increase.",,https://www.businesswire.com/news/home/20191211005920/en/Zoetis-Declares-Quarter-2020-Dividend-Board-Approves,Businesswire.com,,2019-12-11T21:42:17Z,0.77
665550,ZTS,Zoetis declares $0.20 dividend,"Zoetis (NYSE:ZTS) declares $0.20/share quarterly dividend, 22% increase from prior dividend of $0.164.Forward yield 0.65%Payable March 3; for shareholders of record Jan. 17; ex-div Jan. 16.See ZTS Div",Akanksha Bakshi,https://seekingalpha.com/news/3525677-zoetis-declares-0_20-dividend,Seekingalpha.com,,2019-12-11T21:27:53Z,0.32
664413,PRGO,"Here's What Perrigo Company plc's (NYSE:PRGO) P/E Is Telling Us","The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll...",Simply Wall St,https://finance.yahoo.com/news/heres-perrigo-company-plcs-nyse-160819572.html,Yahoo.com,,2019-12-11T16:08:19Z,0
664414,PRGO,"Last year's worst stocks were some of 2019's best. Here are 2 pros' favorites","Coty, General Electric, Perrigo, Lennar, Applied Materials, Tyson Foods and other stocks that posted big losses in 2018 reversed course this year, and investing pros say some could continue winning in 2020.",Lizzy Gurdus,https://www.cnbc.com/2019/12/11/2018-worst-performing-stocks-become-top-stocks-in-2019.html,CNBC,,2019-12-11T16:00:44Z,0.2
663432,LLY,Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer,"INDIANAPOLIS, Dec. 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the opening of the LIBRETTO-431 clinical trial [NCT04194944] for selpercatinib, also known as LOXO-292, for treatment-naïve RET fusion-positive non-small cell lung c…",,https://www.prnewswire.com/news-releases/lilly-opens-first-ever-randomized-phase-3-clinical-trial-in-treatment-naive-ret-fusion-positive-non-small-cell-lung-cancer-300972812.html,Prnewswire.com,,2019-12-11T11:45:00Z,0
663349,BMY,"Bristol-Myers' Dividend Increase Changes Everything","BMY just announced a 9.8% dividend increase.This is the stock's largest increase in years.Because of this, I'm raising my fair value estimate to $66.",Nicholas Ward,https://seekingalpha.com/article/4311775-bristol-myers-dividend-increase-changes-everything,Seekingalpha.com,,2019-12-11T05:12:37Z,0.81
662775,ABBV,Amgen rejigs Bay Area presence with deal for new R&D facility,"Amgen has signed a lease on a 240,000-square-foot facility in South San Francisco, positioning it to join AbbVie in a new campus. The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.",Nick Paul,https://www.fiercebiotech.com/biotech/amgen-rejigs-bay-area-presence-deal-for-new-r-d-facility,Fiercebiotech.com,,2019-12-10T13:24:48Z,0.3
662841,BMY,"Bristol-Myers' CC-486 extends survival in late-stage AML study","Bristol-Myers Squibb (NYSE:BMY) announces positive results from a Phase 3 clinical trial, QUAZAR AML-001, evaluating CC-486 as maintenance therapy in newly diagnosed patients with acute myeloid leukem",SA Editor Douglas W. House,https://seekingalpha.com/news/3525079-bristol-myers-ccminus-486-extends-survival-in-late-stage-aml-study,Seekingalpha.com,,2019-12-10T12:59:28Z,0.88
662777,ABBV,"Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer","<p>The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other kinds of disease. Scripps’s early-stage drug discovery division, Calibr, last year …",Sarah de Crescenzo,https://xconomy.com/san-diego/2019/12/10/scripps-research-abbvie-expand-drug-discovery-deal-beyond-cancer/,Xconomy.com,,2019-12-10T12:25:52Z,0.59
662369,BMY,"Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb's Opdivo® (Nivolumab)","CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate In Combination with Bristol-Myers Squibb's Opdivo",,https://www.businesswire.com/news/home/20191209005828/en/Vedanta-Biosciences-Announces-Initiation-First-in-Patient-Study-Immuno-Oncology,Businesswire.com,,2019-12-10T07:08:23Z,0
660909,MRK,Merck drops $2.7B on 26-year-old Burlington biotech,"Drug giant Merck & Co. announced Monday that it will spend billions to buy a 26-year old biotech company that's struggled to bring a cancer drug to market. Merck (NYSE: MRK) will spend approximately $2.7 billion to acquire Burlington-based ArQule Inc. (Nasdaq…",Allison DeAngelis,https://www.bizjournals.com/boston/news/2019/12/09/merck-drops-2-7b-on-26-year-old-burlington-biotech.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_national+%28Bizjournals+National+Feed%29,Bizjournals.com,,2019-12-09T14:59:32Z,-0.78
660525,ABBV,Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule,"<p>Merck is acquiring cancer drug developer ArQule for $2.7 billion, a cash deal that brings it a promising early-stage compound that could challenge a blockbuster leukemia drug from AbbVie. According to terms of the agreement announced Monday, a Merck (NYSE:…",Frank Vinluan,https://xconomy.com/new-york/2019/12/09/merck-makes-a-big-blood-cancer-bet-with-2-7b-deal-for-arqule/,Xconomy.com,,2019-12-09T14:59:21Z,0.08
660876,JNJ,Can Johnson & Johnson’s Imbruvica Sales Beat Roche’s Rituxan In Chronic Lymphocytic Leukemia Market By 2021?,"Johnson & Johnson’s (NYSE: JNJ) Imbruvica is poised to beat Roche’s top selling drug in the chronic lymphocytic leukemia drugs market over the next few years. This can be attributed to expected competition for Rituxan from biosimilars, given its market exclus…","Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/",https://www.forbes.com/sites/greatspeculations/2019/12/09/can-johnson--johnsons-imbruvica-sales-beat-roches-rituxan-in-chronic-lymphocytic-leukemia-market-by-2021/,Forbes.com,,2019-12-09T14:30:00Z,0.42
660910,MRK,"Three Things You Should Check Before Buying Merck & Co., Inc. (NYSE:MRK) For Its Dividend","Is Merck & Co., Inc. (NYSE:MRK) a good dividend stock? How can we tell? Dividend paying companies with growing...",Simply Wall St,https://finance.yahoo.com/news/three-things-check-buying-merck-122708648.html,Yahoo.com,,2019-12-09T12:27:08Z,0.5
659776,BMY,"Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting","PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Studies Evaluating Liso-Cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology",,https://www.businesswire.com/news/home/20191208005049/en/Bristol-Myers-Squibb-Announces%C2%A0Studies-Evaluating-liso-cel-Multiple-Additional,Businesswire.com,,2019-12-08T21:36:57Z,0.75
659878,LLY,Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting,"INDIANAPOLIS, Dec. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced interim clinical data from the LOXO-305 global Phase 1/2 BRUIN dose escalation trial. LOXO-305 is an investigational, highly selective, non-covalent Bruton's tyrosine…",,https://www.newswire.ca:443/news-releases/lilly-presents-interim-clinical-data-from-loxo-305-dose-escalation-trial-in-b-cell-leukemias-and-lymphomas-at-the-american-society-hematology-annual-meeting-300970995.html,Newswire.ca,,2019-12-08T21:30:00Z,0
659595,JNJ,"Johnson & Johnson Announces Commitment to Support Republic of Rwanda's Preparedness Against Ebola Outbreak","NEW BRUNSWICK, N.J., Dec. 8, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Janssen Pharmaceutical Companies will provide up to 200,000 Ebola vaccine regimens to the Republic of Rwanda. This commitment will support a new immunizat…",,https://www.newswire.ca:443/news-releases/johnson--johnson-announces-commitment-to-support-republic-of-rwandas-preparedness-against-ebola-outbreak-300971018.html,Newswire.ca,,2019-12-08T13:00:00Z,0.86
659530,ABBV,New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL),"AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented long-term data from a post-hoc analysis, further supporting the sustained clinical benefit of fixed duration treatment with VENCLEXTA®/VENCLYXTO® (venetoclax) in combinati…",PR Newswire,https://news.yahoo.com/long-term-data-continues-demonstrate-123000151.html,Yahoo.com,,2019-12-08T12:30:00Z,0.82
659554,BMY,Better Buy: Pfizer vs. Bristol-Myers Squibb,Which stock wins in a matchup between these two big drugmakers?,newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2019/12/08/better-buy-pfizer-vs-bristol-myers-squibb.aspx,Fool.com,,2019-12-08T12:00:00Z,0.77
659245,BMY,"Bristol-Myers CAR T successful in pivotal NHL study, but with four deaths","Bristol-Myers Squibb (NYSE:BMY) announces positive results from a pivotal open-label Phase 1 clinical trial, TRANSCEND-NHL-001, evaluating CAR T therapy lisocabtagene maraleucel (liso-cel) (JCAR017) i",SA Editor Douglas W. House,https://seekingalpha.com/news/3524626-bristol-myers-car-t-successful-in-pivotal-nhl-study-four-deaths,Seekingalpha.com,,2019-12-07T23:02:02Z,0.81
659304,JNJ,J&J CAR-T shows significant treatment benefit in refractory MM patients,"Preliminary data from a Phase 1b/2 clinical trial, CARTITUDE-1, evaluating Johnson &amp; Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies' BCMA-targeted CAR T candidate JNJ-68284528 (JNJ-4528)",SA Editor Douglas W. House,https://seekingalpha.com/news/3524625-j-and-j-car-t-shows-significant-treatment-benefit-in-refractory-mm-patients,Seekingalpha.com,,2019-12-07T22:17:32Z,0.59
659306,JNJ,XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B,"XBiotech (NASDAQ:XBIT) inks an agreement with Johnson &amp; Johnson (NYSE:JNJ) unit Janssen Biotech for global rights to anti-inflammatory candidate bermekimab.Under the terms of the deal, XBIT will r",SA Editor Douglas W. House,https://seekingalpha.com/news/3524623-xbiotech-out-licenses-anti-inflammatory-antibody-to-janssen-for-up-to-1_35b,Seekingalpha.com,,2019-12-07T20:46:54Z,0.49
659224,ZTS,Zoetis (ZTS) Up 0.6% Since Last Earnings Report: Can It Continue?,"Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",Zacks Equity Research,https://finance.yahoo.com/news/zoetis-zts-0-6-since-163104883.html,Yahoo.com,,2019-12-07T16:31:04Z,0
658982,ABBV,More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen,"AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results of a 7.5-year pooled analysis showing earlier treatment with IMBRUVICA® (ibrutinib) monotherapy compared to later lines of therapy (LOT) extended progression-free …",PR Newswire,https://news.yahoo.com/more-seven-analysis-early-treatment-140000862.html,Yahoo.com,,2019-12-07T14:00:00Z,0.48
659011,BMY,Bristol Myers Squibb: A Cash-Generating Machine at a Cheap Price,This big pharma stock provides value in an increasingly expensive market.,newsfeedback@fool.com (Greg Jones),https://www.fool.com/investing/2019/12/07/bristol-myers-squibb-a-cash-generating-machine-at.aspx,Fool.com,,2019-12-07T13:00:00Z,0.34
658983,ABBV,Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL),"AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results from an extended follow-up analysis of the Phase 3 E1912 clinical study – designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored…",,https://news.yahoo.com/extended-phase-3-data-underscore-123300771.html,Yahoo.com,,2019-12-07T12:33:00Z,-0.38
658985,ABBV,IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL),"AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial,1 evaluating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA®/VENCLYXTO® (venetoclax) in previously unt…",PR Newswire,https://news.yahoo.com/imbruvica-ibrutinib-plus-venclexta-venclyxto-123000438.html,Yahoo.com,,2019-12-07T12:30:00Z,0
658473,BMY,"UPDATE 1-Bristol-Myers, bluebird therapy for multiple myeloma succeeds in mid-stage trial","Bristol-Myers Squibb Co and bluebird bio Inc said on Friday their experimental therapy for a type of multiple myeloma met the main goal in a mid-stage study. The study evaluated the efficacy and safety of the therapy, Ide-cel, in patients who had received thr…",,https://finance.yahoo.com/news/1-bristol-myers-bluebird-therapy-223511685.html,Yahoo.com,,2019-12-06T22:35:11Z,0.72
658475,BMY,"Bristol-Myers, bluebird therapy for multiple myeloma succeeds in mid-stage trial","REUTERS: Bristol-Myers Squibb Co and bluebird bio Inc said on Friday their experimental therapy for a type of multiple myeloma met the main goal in a mid-stage study. The study evaluated the efficacy and safety of the therapy, Ide-cel, in patients who had rec…",CNA,https://www.channelnewsasia.com/news/world/bristol-myers--bluebird-therapy-for-multiple-myeloma-succeeds-in-mid-stage-trial-12162408,Channelnewsasia.com,,2019-12-06T22:11:01Z,0.72
658477,BMY,"Bristol-Myers and bluebird bio's CAR T successful in mid-stage MM study","Bluebird bio (NASDAQ:BLUE) and licensee Bristol-Myers Squibb (NYSE:BMY) announce positive topline results from a Phase 2 clinical trial, KarMMa, evaluating CAR T therapy idecabtagene vicleucel (ide-ce",SA Editor Douglas W. House,https://seekingalpha.com/news/3524568-bristol-myers-and-bluebird-bios-car-t-successful-in-mid-stage-mm-study,Seekingalpha.com,,2019-12-06T21:47:00Z,0.81
658478,BMY,"Bluebird, Celgene Cancer Therapy Gets Boost From New Study","(Bloomberg) -- An experimental therapy from Bluebird Bio Inc. and Bristol-Myers Squibb Co. benefited more than 80% of patients nearing death from an advanced form of blood cancer in a pivotal study, clearing a hurdle in its path to U.S. approval.A single high…",,https://finance.yahoo.com/news/bluebird-celgene-cancer-therapy-gets-213040677.html,Yahoo.com,,2019-12-06T21:30:40Z,-0.88
658479,BMY,Bristol-Myers Squibb Prescribed For The Newborn Portfolio,"Newborn Portfolio update; increase in cash position, as well as a new position added in the portfolio.After a lot of homework and research, Bristol-Myers Squibb was added to the Newborn Portfolio.BMY: good dividend, currently underpriced, with a strong pipeli…",Courtney LaCalamito,https://seekingalpha.com/article/4311141-bristol-myers-squibb-prescribed-for-newborn-portfolio,Seekingalpha.com,,2019-12-06T20:35:33Z,0.86
657495,BMY,"No Ad Com review for Bristol-Myers' luspatercept for MDS","Bristol-Myers Squibb (BMY +2.2%) and collaboration partner Acceleron Pharma (XLRN -1.3%) announce that, following a meeting with the FDA two days ago, there will be no advisory committee review of Cel",SA Editor Douglas W. House,https://seekingalpha.com/news/3524513-no-ad-com-review-for-bristol-myers-luspatercept-for-mds,Seekingalpha.com,,2019-12-06T17:15:41Z,-0.53
657496,BMY,Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt),"PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #BMS--Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)",,https://www.businesswire.com/news/home/20191206005374/en/Bristol-Myers-Squibb-Acceleron-Pharma-Provide-Update-FDA,Businesswire.com,,2019-12-06T17:12:21Z,0
657388,ABBV,Best Large-Cap Stocks To Buy Now,"The best ranked large-cap sector is industrial goods.The top industry is trucking.The highest-rated large-cap stocks are Centene, AbbVie, and Biogen, despite healthcare ranking neutral overall.",Limelight Alpha Management Partners,https://seekingalpha.com/article/4310979-best-large-cap-stocks-to-buy-now,Seekingalpha.com,,2019-12-06T13:01:00Z,0.88
656384,ALLY,Ally Financial (ALLY) Outpaces Stock Market Gains: What You Should Know,"Ally Financial (ALLY) closed the most recent trading day at $31.19, moving +0.39% from the previous trading session.",Zacks Equity Research,https://finance.yahoo.com/news/ally-financial-ally-outpaces-stock-225010079.html,Yahoo.com,,2019-12-05T22:50:10Z,0.34
656451,BMY,Bristol-Myers Squibb raises dividend,"Bristol-Myers Squibb Co. late Thursday announced a 9.8% dividend increase, beginning in the first quarter of 2020. The dividend increase will bring the drug maker's quarterly dividend to 45 cents. The next quarterly dividend is payable Feb. 3 to stockholders …",Claudia Assis,https://www.marketwatch.com/story/bristol-myers-squibb-raises-dividend-2019-12-05,Marketwatch.com,,2019-12-05T21:52:59Z,0.56
656452,BMY,Bristol-Myers Squibb Announces Dividend Increase,NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol-Myers Squibb Announces Dividend Increase,,https://www.businesswire.com/news/home/20191205005803/en/Bristol-Myers-Squibb-Announces-Dividend-Increase,Businesswire.com,,2019-12-05T21:42:08Z,0.32
656566,JNJ,"Johnson & Johnson Names Hubert Joly, Executive Chairman of Best Buy and Mark A. Weinberger, Former EY Global Chairman and CEO to its Board of Directors","NEW BRUNSWICK, N.J., Dec. 5, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that Hubert Joly, Executive Chairman of Best Buy Co., Inc, and Mark A. Weinberger, Former EY Global Chairman and CEO, have been appointed to its Board of Directors…",,https://www.prnewswire.com/news-releases/johnson--johnson-names-hubert-joly-executive-chairman-of-best-buy-and-mark-a-weinberger-former-ey-global-chairman-and-ceo-to-its-board-of-directors-300970329.html,Prnewswire.com,,2019-12-05T21:15:00Z,0.86
656683,PRGO,Perrigo (PRGO) Presents At Morgan Stanley Global Consumer and Retail Conference - Slideshow,,SA Transcripts,https://seekingalpha.com/article/4310884-perrigo-prgo-presents-morgan-stanley-global-consumer-and-retail-conference-slideshow,Seekingalpha.com,,2019-12-05T20:43:46Z,0
655546,LLY,Lilly to combine Loxo with oncology research group,"Aimed at scaling up its discovery and development efforts in cancer, Eli Lilly (NYSE:LLY) will combine Loxo Oncology, acquired in February, with the Lilly Research Laboratories oncology unit which wil",SA Editor Douglas W. House,https://seekingalpha.com/news/3523979-lilly-to-combine-loxo-oncology-research-group,Seekingalpha.com,,2019-12-05T13:35:52Z,-0.66
654816,LLY,Eli Lilly to put Loxo executives in charge of new cancer research unit,"U.S. drugmaker Eli Lilly and Co said on Thursday it will create a new cancer research division that will be run by top executives from Loxo Oncology, a cancer-focused biotech company it acquired earlier this year.",CNA,https://www.channelnewsasia.com/news/world/eli-lilly-to-put-loxo-executives-in-charge-of-new-cancer-research-unit-12156352,Channelnewsasia.com,,2019-12-05T11:40:28Z,-0.78
655548,LLY,REFILE-Eli Lilly to put Loxo executives in charge of new cancer research unit,"U.S. drugmaker Eli Lilly and Co said on Thursday it will create a new cancer research division that will be run by top executives from Loxo Oncology, a cancer-focused biotech company it acquired earlier this year. The move highlights Lilly's efforts to double…",,https://finance.yahoo.com/news/embargoed-eli-lilly-put-loxo-113000756.html,Yahoo.com,,2019-12-05T11:30:00Z,-0.78
654817,LLY,Lilly Announces New Leadership and Strategy in Oncology Research and Development,"Eli Lilly and Company (NYSE: LLY) today announced new leadership and strategic direction in oncology R&D;, combining the Lilly Research Laboratories (LRL) oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019. The new organization…",PR Newswire,https://news.yahoo.com/lilly-announces-leadership-strategy-oncology-113000452.html,Yahoo.com,,2019-12-05T11:30:00Z,0
654818,LLY,"Here's Why I Think Eli Lilly (NYSE:LLY) Is An Interesting Stock","Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...",Simply Wall St,https://finance.yahoo.com/news/heres-why-think-eli-lilly-100411123.html,Yahoo.com,,2019-12-05T10:04:11Z,0.4
654743,BMY,Numerous Readouts And Pipeline Updates Coming For Bristol-Myers Squibb; Timing Key To CVR Payout,"Opdivo is expected to see 2020 sales declines, but key upcoming readouts could drive growth in 2021.Within the pipeline, Ozanimod, Liso-cel, and Ide-cel all are expected to receive approval and have shown promising data.This bodes well for the CVR, but note t…",The Non-Consensus,https://seekingalpha.com/article/4310677-numerous-readouts-and-pipeline-updates-coming-for-bristol-myers-squibb-timing-key-to-cvr,Seekingalpha.com,,2019-12-05T06:20:08Z,0.93
520490,ZTS,"HON | 24/7 Wall St. | Page 2","Honeywell International Inc. (NYSE: HON) is scheduled to report its ... eBay, 
Groupon, Honeywell, Mastercard, Newmont Goldcorp, Roku, Zoetis and More.",Jon C. Ogg,https://247wallst.com/companies/HON/page/2/,247wallst.com,1575504000,2019-12-05T00:00:00Z,0
520491,ZTS,"Six Flags, Inc. (NYSE:SIX)","Top Analyst Upgrades and Downgrades: Apple, Carnival, Generac, Lyft, Six 
Flags, Square, Tecnoglass, Yum Brands, Western Digital, Zoetis and More.",Jon C. Ogg,https://247wallst.com/companies/six/,247wallst.com,1575504000,2019-12-05T00:00:00Z,0
653973,ABBV,Nektar Therapeutics Names John Northcott Chief Commercial Officer,<p>John Northcott has joined Nektar Therapeutics (NASDAQ: NKTR) in the newly created role of senior vice president and chief commercial officer. Northcott was most recently the chief commercial officer of AbbVie (NYSE: ABBV) subsidiary Pharmacyclics. His expe…,Frank Vinluan,https://xconomy.com/san-francisco/2019/12/04/nektar-therapeutics-names-john-northcott-chief-commercial-officer/,Xconomy.com,,2019-12-04T21:54:37Z,0.25
652839,ALLY,"LISC, Ally Financial launch program to spur economic opportunity for micro-entrepreneurs, homeowners","Ally Financial, Inc. (NYSE: ALLY) and the Local Initiatives Support Corporation (LISC) are teaming up on a new $3 million program to fuel entrepreneurship and homeownership, focusing particularly on people who might not otherwise have access to the capital an…",PR Newswire,https://news.yahoo.com/lisc-ally-financial-launch-program-152400411.html,Yahoo.com,,2019-12-04T15:24:00Z,0.67
652396,BMY,"Bristol-Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for ORENCIA® (abatacept) to Help Prevent Acute Graft-Versus-Host Disease, a Potentially Life-Threatening Complication After Stem Cell Transplant","PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BristolMyers--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ORENCIA® (abatacept) for the prevention of mode…",,https://www.businesswire.com/news/home/20191204005265/en/Bristol-Myers-Squibb-Announces-U.S.-FDA-Breakthrough-Therapy,Businesswire.com,,2019-12-04T12:06:41Z,0.59
652961,BMY,Calculating The Intrinsic Value Of Bristol-Myers Squibb Company (NYSE:BMY),"Does the December share price for Bristol-Myers Squibb Company (NYSE:BMY) reflect what it's really worth? Today, we...",,https://finance.yahoo.com/news/calculating-intrinsic-value-bristol-myers-120222980.html,Yahoo.com,,2019-12-04T12:02:22Z,0.7
652397,BMY,Roche wins FDA approval for immunotherapy cocktail against lung cancer,"Roche's Tecentriq immunotherapy mixed with chemotherapy won U.S. approval as an initial treatment for a form of lung cancer as the Swiss drugmaker seeks to establish its alternative to drugs from Merck and Bristol-Myers Squibb.",CNA,https://www.channelnewsasia.com/news/world/roche-wins-fda-approval-for-immunotherapy-cocktail-against-lung-cancer-12151676,Channelnewsasia.com,,2019-12-04T06:20:33Z,0.85
651818,JNJ,"Company Investigation Confirms No Asbestos in Johnson's Baby Powder","NEW BRUNSWICK, N.J., Dec. 3, 2019 /PRNewswire/ -- Johnson & Johnson Consumer Inc. (NYSE: JNJ) (the Company) today reaffirmed that its Johnson's Baby Powder is safe and free of asbestos after a comprehensive investigation into the United States Food and Drug A…",,https://www.prnewswire.com/news-releases/company-investigation-confirms-no-asbestos-in-johnsons-baby-powder-300968701.html,Prnewswire.com,,2019-12-03T22:39:00Z,0.83
650266,ABBV,"Despite the Naysayers, AbbVie Keeps Marching On","Although sales of Humira are declining in Europe, AbbVie isn’t dead in the water.",newsfeedback@fool.com (Prosper Junior Bakiny),https://www.fool.com/investing/2019/12/03/despite-the-naysayers-abbvie-keeps-marching-on.aspx,Fool.com,,2019-12-03T16:15:51Z,-0.65
650689,JNJ,Can Johnson & Johnson’s Stelara Become Number 2 Drug In Crohn’s Disease Market?,Johnson & Johnson’s(NYSE:JNJ) Stelara could become the #2 drug in the Crohn’s Disease market over the next few years. Crohn’s Disease causes inflammation of the digestive tract. J&J’s top selling drugs in this therapeutic area are Remicade and Stelara. AbbVie…,"Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/",https://www.forbes.com/sites/greatspeculations/2019/12/03/can-johnson--johnsons-stelara-become-number-2-drug-in-crohns-disease-market/,Forbes.com,,2019-12-03T15:00:00Z,0.27
650306,ALLY,Majority of Americans Would Consider Buying Used Vehicles,"DETROIT, Dec. 3, 2019 /PRNewswire/ -- Nearly 70 percent of Americans (69%) would be likely to consider a used vehicle for their next auto purchase, according to a survey from Ally Financial conducted online by The Harris Poll among more than 2000 American adu…",,https://www.prnewswire.com/news-releases/majority-of-americans-would-consider-buying-used-vehicles-300967731.html,Prnewswire.com,,2019-12-03T14:30:00Z,0
650415,BMY,Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes,"PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #BMS--Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® for Use in Patients With Myelodysplastic Syndromes",,https://www.businesswire.com/news/home/20191203005566/en/Bristol-Myers-Squibb-Acceleron-Pharma-Announce-FDA-Advisory,Businesswire.com,,2019-12-03T12:42:24Z,0
650267,ABBV,"3 Words AbbVie Investors Really Didn't Want to Hear","The latest ICER report doesn't paint AbbVie's new rheumatoid arthritis drug Rinvoq in as favorable a light as hoped.",newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2019/12/03/3-words-abbvie-investors-really-didnt-want-to-hear.aspx,Fool.com,,2019-12-03T12:00:00Z,0.64
649654,ABBV,Mission and AbbVie’s Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Milestone,"CAMBRIDGE, England--(BUSINESS WIRE)--Mission Therapeutics and AbbVie have identified several DUBs as potential drug targets in their Alzheimer’s and Parkinson’s R&D collaboration.",,https://www.businesswire.com/news/home/20191203005451/en/Mission-AbbVie%E2%80%99s-Collaboration-Alzheimer%E2%80%99s-Parkinson%E2%80%99s-Diseases-Reaches,Businesswire.com,,2019-12-03T10:10:21Z,0.05
649195,LLY,Lilly to Participate in Evercore ISI 2nd Annual HealthCONx Conference,"Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Research Laboratories, will partici…",PR Newswire,https://news.yahoo.com/lilly-participate-evercore-isi-2nd-213300369.html,Yahoo.com,,2019-12-02T21:33:00Z,0
649337,PRGO,"Perrigo Announces Closing of Prevacid®24HR (OTC) Acquisition, Advancing Consumer Self-Care Growth Strategy","DUBLIN, Dec. 2, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has completed the acquisition of the branded over-the-counter (OTC) rights to Prevacid®24HR. Jeff Needham, Executive Vice President and President Consumer Self…",,https://www.prnewswire.com/news-releases/perrigo-announces-closing-of-prevacid24hr-otc-acquisition-advancing-consumer-self-care-growth-strategy-300967692.html,Prnewswire.com,,2019-12-02T21:30:00Z,0.38
648153,LLY,Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco,"INDIANAPOLIS, Dec. 2, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today unveiled its first shared innovation lab, located in South San Francisco, designed to speed the discovery of innovative medicines through collaboration with local biotech compa…",,https://www.prnewswire.com/news-releases/eli-lilly-and-company-unveils-shared-innovation-laboratory-in-south-san-francisco-300967130.html,Prnewswire.com,,2019-12-02T14:00:00Z,0.9
648154,LLY,Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory Bowel Disease (IBD),"INDIANAPOLIS, Dec. 2, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) first digital health open innovation challenge, ""Transforming IBD Care: Better Disease Monitoring, Management, and Care for People with Inflammatory Bowel Disease,"" has concluded, …",,https://www.prnewswire.com/news-releases/lilly-names-healthvoyager-as-winner-of-digital-health-innovation-challenge-for-inflammatory-bowel-disease-ibd-300967281.html,Prnewswire.com,,2019-12-02T12:22:00Z,0.96
647256,MRK,"FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)","KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics L…",,https://www.businesswire.com/news/home/20191202005300/en/FDA-Grants-Priority-Review-Merck%E2%80%99s-Supplemental-Biologics,Businesswire.com,,2019-12-02T11:52:44Z,0.54
646769,LLY,Innovent Presents Co-developed Cancer-Fighting Tyvyt(R) (Sintilimab Injection) at CIIE 2019 with Eli Lilly,"SUZHOU, China, Nov. 28, 2019 /PRNewswire/ -- Innovent Biologics (01801.HK), a multinational biopharmaceutical company, and Eli Lilly and Company presented their co-developed Tyvyt® (generic name: sintilimab injection), a fully human anti-programmed cell death…",,https://www.prnewswire.com/news-releases/innovent-presents-co-developed-cancer-fighting-tyvytr-sintilimab-injection-at-ciie-2019-with-eli-lilly-300967135.html,Prnewswire.com,,2019-12-02T01:37:00Z,0
646310,ABBV,AbbVie (ABBV) Up 10.3% Since Last Earnings Report: Can It Continue?,"AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",Zacks Equity Research,https://finance.yahoo.com/news/abbvie-abbv-10-3-since-143002317.html,Yahoo.com,,2019-12-01T14:30:02Z,0
645980,BMY,Is Bristol Myers Squibb Company (BMY) A Good Stock To Buy?,"We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge fund…",Abigail Fisher,https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-000132875.html,Yahoo.com,,2019-12-01T00:01:32Z,0.89
645932,ABBV,Did Hedge Funds Drop The Ball On AbbVie Inc (ABBV) ?,"We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge fund…",,https://finance.yahoo.com/news/did-hedge-funds-drop-ball-221416289.html,Yahoo.com,,2019-11-30T22:14:16Z,0.75
645563,ABBV,"Assessing If AbbVie's Dividend Is Safe","Humira's patent cliff is an issue, but it's manageable.Imbruvica's competitive threat is increasing, but clinical trials are expanding its market opportunity.The company remains highly profitable.Its cash dividend payout ratio suggests financial flexibility r…",Limelight Alpha Management Partners,https://seekingalpha.com/article/4309824-assessing-abbvies-dividend-safe,Seekingalpha.com,,2019-11-30T11:08:44Z,-0.12
644198,JNJ,"2020 US presidential election is Trump's to lose, says BET founder Bob Johnson","Johnson, who described himself as a longtime Democrat, has made headlines multiple times for praising Trump for the ""positive things"" he's done to grow the U.S. economy.",Yen Nee Lee,https://www.cnbc.com/2019/11/29/2020-election-is-trumps-to-lose-says-bet-founder-bob-johnson.html,CNBC,,2019-11-29T08:34:00Z,0.66
643736,LLY,Here is What Hedge Funds Think About Eli Lilly and Company (LLY),"We are still in an overall bull market and many stocks that smart money investors were piling into surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 52% and 49% respectively. Hedge funds' top…",Asma UL Husna,https://finance.yahoo.com/news/hedge-funds-think-eli-lilly-011104935.html,Yahoo.com,,2019-11-29T01:11:04Z,0.82
644023,ZTS,Do Hedge Funds Really Love Zoetis Inc (ZTS)?,"Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make…",Nina Todic,https://finance.yahoo.com/news/hedge-funds-really-love-zoetis-000117250.html,Yahoo.com,,2019-11-29T00:01:17Z,0.6
643224,LLY,"Global Diabetes Care (Insulin, OAD & GLP-1) Market 2019-2023 - Key Players are Novo Nordisk, Sanofi, and Eli Lilly","DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The ""Global Diabetes Care Market (Insulin, OAD & GLP-1): Industry Analysis & Outlook (2019-2023)"" report has been added to ResearchAndMarkets.com's offering. Diabetic population is growing considerably all over the world.…",,https://prnmedia.prnewswire.com:443/news-releases/global-diabetes-care-insulin-oad--glp-1-market-2019-2023---key-players-are-novo-nordisk-sanofi-and-eli-lilly-300966197.html,Prnewswire.com,,2019-11-28T18:00:00Z,0.8
643108,BMY,"What Percent Does Bristol-Myers Squibb Spend On R&D, 30%, 40%, Or 50%?","Bristol-Myers Squibb’s (NYSE: BMY) R&D expenses were 36% of its total revenues in 2018. Total expenses were largely driven by cost of goods sold and research and development (R&D), which together accounted for three-fourths of the company’s total expenditure …","Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/",https://www.forbes.com/sites/greatspeculations/2019/11/28/what-percent-does-bristol-myers-squibb-spend-on-rd-30-40-or-50/,Forbes.com,,2019-11-28T15:30:00Z,0
643110,BMY,Here is the 24th Most Popular Stock Among 752 Hedge Funds,"Is Booking Holdings Inc. (NASDAQ:BKNG) a good place to invest some of your money right now? We are going to take a look at hedge fund activity surrounding BKNG as well as its peers like Bristol Myers Squibb Company (NYSE:BMY), CVS Health Corporation (NYSE:CVS…",Asma UL Husna,https://finance.yahoo.com/news/24th-most-popular-stock-among-144517326.html,Yahoo.com,,2019-11-28T14:45:17Z,0.86
643226,LLY,"Analysis on the World Alzheimer's Therapeutics Market 2019-2025 - Eisai Co, Novartis, Pfizer, Eli Lilly & Company, and Johnson & Johnson are Dominating","DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The ""Alzheimer's Therapeutics Market By Molecule Type (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E Pharmacies), By Region - Glo…",,https://www.prnewswire.com/news-releases/analysis-on-the-world-alzheimers-therapeutics-market-2019-2025---eisai-co-novartis-pfizer-eli-lilly--company-and-johnson--johnson-are-dominating-300966121.html,Prnewswire.com,,2019-11-28T14:45:00Z,-0.57
643219,JNJ,Hedge Funds Are Standing By Johnson & Johnson (JNJ),"Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 750 active hedge funds and notable in…",Reymerlyn Martin,https://finance.yahoo.com/news/hedge-funds-standing-johnson-johnson-143753670.html,Yahoo.com,,2019-11-28T14:37:53Z,0.6
642450,ABBV,AbbVie Still Yields Over 5%,"Despite a $25 rally from the 2019 lows, AbbVie still yields over 5%.The combination with Allergan provides a strong pipeline to offset the LOE from Humira that has already started.The dividend yield is projected to top 6% by 2021.The stock trades at a'20 P/E …",Stone Fox Capital,https://seekingalpha.com/article/4309633-abbvie-still-yields-5-percent,Seekingalpha.com,,2019-11-28T11:53:45Z,0.51
641080,ABBV,"Why AbbVie Is a Dividend Growth Stock That's Too Cheap to Ignore",The Allergan deal will cement AbbVie’s position as a diversified pharmaceutical company with sustainable growth. It’s time for the shares to play catchup.,newsfeedback@fool.com (Greg Jones),https://www.fool.com/investing/2019/11/27/why-abbvie-is-a-dividend-growth-stock-thats-too-ch.aspx,Fool.com,,2019-11-27T12:00:00Z,0.83
639720,ABBV,Why AbbVie Might Fall After The Mega-Merger With Allergan,,,https://seekingalpha.com/article/4309295-abbvie-might-fall-mega-merger-allergan?source=feed_all_articles,Seekingalpha.com,,2019-11-26T20:45:09Z,0
638617,ALLY,Are Hedge Funds Right About Ally Financial Inc (ALLY) ?,"How do we determine whether Ally Financial Inc (NYSE:ALLY) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They …",Abigail Fisher,https://finance.yahoo.com/news/hedge-funds-ally-financial-inc-141407852.html,Yahoo.com,,2019-11-26T14:14:07Z,0.83
638124,BMY,Bristol-Myers Squibb to Hold Investor Webcast to Discuss ASH Highlights,NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol-Myers Squibb to Hold Investor Webcast to Discuss ASH Highlights,,https://www.businesswire.com/news/home/20191126005162/en/Bristol-Myers-Squibb-Hold-Investor-Webcast-Discuss-ASH,Businesswire.com,,2019-11-26T12:05:27Z,0
638063,ZTS,Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio,Zoetis (ZTS) acquires ZNLabs and expands its reference laboratory capabilities in the United States.,Zacks Equity Research,https://finance.yahoo.com/news/zoetis-zts-acquires-znlabs-bolster-220810477.html,Yahoo.com,,2019-11-25T22:08:10Z,0.49
636663,MRK,"Hedge Funds Are Optimistic About Merck & Co., Inc. (MRK)","We can judge whether Merck & Co., Inc. (NYSE:MRK) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabili…",,https://finance.yahoo.com/news/hedge-funds-optimistic-merck-co-140143262.html,Yahoo.com,,2019-11-25T14:01:43Z,0.88
636325,ABBV,AbbVie Is The First Addition To The Motorhome Retirement 72T Portfolio,Healthcare via the Affordable Care Act (ACA) has been a part of our early retirement plan.The ACA has been challenged in the federal courts and the supreme court will likely determine its fate.We changed the plan and now use a 72T withdrawal to address the un…,GrayBeard Retirement,https://seekingalpha.com/article/4308909-abbvie-first-addition-motorhome-retirement-72t-portfolio,Seekingalpha.com,,2019-11-25T14:00:00Z,0.76
635850,MRK,New Survey of Young Adults Uncovers Low Levels of Accurate Knowledge About HIV Transmission Coupled with High-Risk Sexual Behaviors,"Merck (NYSE: MRK) known as MSD outside the United States and Canada, in partnership with Prevention Access Campaign today launched Owning HIV: Young Adults and the Fight Ahead, a new campaign featuring results from a first-of-its-kind survey to better underst…",PR Newswire,https://news.yahoo.com/survey-young-adults-uncovers-low-114500639.html,Yahoo.com,,2019-11-25T11:45:00Z,0.36
635089,ABBV,Better Buy: AbbVie vs. GlaxoSmithKline,"AbbVie and GlaxoSmithKline are both poised for a big 2020. Still, one stock is clearly the better buy right now.",newsfeedback@fool.com (George Budwell),https://www.fool.com/investing/2019/11/24/better-buy-abbvie-vs-glaxosmithkline.aspx,Fool.com,,2019-11-24T13:25:00Z,0.86
634975,BMY,"Why I'm Holding On to My Bristol-Myers Squibb Shares Now That the Celgene Acquisition Has Closed","There are two reasons this Fool isn't selling his newfound shares from the Celgene buyout.",newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2019/11/24/why-im-holding-onto-my-bristol-myers-squibb-shares.aspx,Fool.com,,2019-11-24T12:00:00Z,0.01
634619,LLY,Better Buy: Johnson & Johnson vs. Eli Lilly,Which stock wins in a head-to-head matchup between these two healthcare giants?,newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2019/11/23/better-buy-johnson-johnson-vs-eli-lilly.aspx,Fool.com,,2019-11-23T13:00:00Z,0.77
632879,BMY,"Pharma Stock Roundup: FDA Nod to NVS' & AZN's Drugs, BMY-CELG Merger Closes","The FDA approves Novartis' (NVS) sickle cell disease candidate Adakveo and AstraZeneca's (AZN) Calquence for chronic lymphocytic leukemia. Bristol-Myers (BMY) completes $74 billion-buyout of Celgene.",Kinjel Shah,https://finance.yahoo.com/news/pharma-stock-roundup-fda-nod-155703573.html,Yahoo.com,,2019-11-22T15:57:03Z,0.4
632764,ABBV,AstraZeneca shares rise on early U.S. approval for leukemia drug,"AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukemia drug, in a challenge to rival AbbVie .",Reuters Editorial,https://www.reuters.com/article/us-astrazeneca-approval-idUSKBN1XW1OI,Reuters,,2019-11-22T15:16:59Z,0.93
632765,ABBV,AstraZeneca shares rise on early US approval for leukemia drug,"AstraZeneca shares rose 2.7per cent on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukemia drug, in a challenge to rival AbbVie.",CNA,https://www.channelnewsasia.com/news/world/astrazeneca-shares-rise-on-early-us-approval-for-leukemia-drug-12118558,Channelnewsasia.com,,2019-11-22T15:10:48Z,0.93
633068,LLY,Lilly (LLY) Up 6.4% Since Last Earnings Report: Can It Continue?,"Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",Zacks Equity Research,https://finance.yahoo.com/news/lilly-lly-6-4-since-143102584.html,Yahoo.com,,2019-11-22T14:31:02Z,0
633097,MRK,Merck (MRK) is an Incredible Growth Stock: 3 Reasons Why,"Merck (MRK) possesses solid growth attributes, which could help it handily outperform the market.",Zacks Equity Research,https://finance.yahoo.com/news/merck-mrk-incredible-growth-stock-134501127.html,Yahoo.com,,2019-11-22T13:45:01Z,0.82
633835,ZTS,Zoetis buys network of veterinary reference labs,"Zoetis (NYSE:ZTS) acquires ZNLabs, a full-service veterinary clinical reference laboratory company with a network of labs across the U.S.Zoetis entered reference lab services with its acquisition of P",Liz Kiesche,https://seekingalpha.com/news/3521504-zoetis-buys-network-veterinary-reference-labs,Seekingalpha.com,,2019-11-22T13:09:07Z,0
633836,ZTS,"Zoetis Acquires ZNLabs, a Nationwide Veterinary Reference Laboratory, to Further Strengthen its Comprehensive Diagnostics Portfolio","PARSIPPANY, N.J. & TAMPA, Fla.--(BUSINESS WIRE)---- $ZTS #acquisition--Zoetis expands its reference laboratory capabilities in the U.S. with the acquisition of ZNLabs.",,https://www.businesswire.com/news/home/20191122005045/en/Zoetis-Acquires-ZNLabs-Nationwide-Veterinary-Reference-Laboratory,Businesswire.com,,2019-11-22T13:05:24Z,0.57
632880,BMY,"Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More","<p>Bristol-Myers Squibb this week completed its acquisition of Celgene, a $74 billion deal that creates a pharmaceutical juggernaut. And all it took was the largest asset sale ever required by federal antitrust regulators. As the Federal Trade Commission revi…",Frank Vinluan,https://xconomy.com/national/2019/11/22/bio-roundup-so-long-celgene-rnais-arrival-pharma-in-2020-more/,Xconomy.com,,2019-11-22T12:50:36Z,0.56
632209,ABBV,"Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales","The small drugmaker depends on royalties from HCV drug Mavyret. And those sales aren't as strong as they used to be.",newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2019/11/22/enanta-pharmaceuticals-q4-results-pulled-down-by-a.aspx,Fool.com,,2019-11-22T11:00:00Z,-0.4
631797,LLY,"Why Eli Lilly Can't Match Novo Nordisk","Like Novo Nordisk, Eli Lilly is one of the major players in the diabetes market.While the diabetes/endocrinology segment outperformed in the recent past, the overall performance of Eli Lilly was mixed.Compared to Novo Nordisk, the Danish diabetes company seem…",Daniel Schönberger,https://seekingalpha.com/article/4308457-eli-lilly-match-novo-nordisk,Seekingalpha.com,,2019-11-22T03:19:50Z,0
631606,BMY,"Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal","Bristol-Myers' (BMY) late-stage study evaluating the Opdivo-Yervoy combo fails to meet a co-primary endpoint of recurrence-free survival in melanoma patients. The company wraps up Celgene acquisition.",Zacks Equity Research,https://finance.yahoo.com/news/bristol-myers-melanoma-study-misses-225810954.html,Yahoo.com,,2019-11-21T22:58:10Z,-0.57
631891,PRGO,"Taro's tavaborole gets tentative FDA OK","The FDA has granted tentative approval to Taro Pharmaceutical Industries' (NYSE:TARO) tavaborole, the generic active ingredient in Kerydin (by Novartis (NYSE:NVS) and Pfizer (NYSE:PFE)). Perrigo (NYS",Jason Aycock,https://seekingalpha.com/news/3521393-taros-tavaborole-gets-tentative-fda-ok,Seekingalpha.com,,2019-11-21T22:03:24Z,0.78
631521,ABBV,AbbVie Shareholders Have a Lot to Look Forward To With Allergan,The big drugmaker shared a little more color on the potentially transformative acquisition in its third-quarter call.,newsfeedback@fool.com (Michael Afshar),https://www.fool.com/investing/2019/11/21/abbvie-shareholders-have-a-lot-to-look-forward-to.aspx,Fool.com,,2019-11-21T20:24:00Z,0.34
630365,ABBV,"AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting","NORTH CHICAGO, Ill., Nov. 21, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that more than 40 abstracts, including 18 oral presentations, will be presented during the upcoming American Society of …",,https://www.prnewswire.com/news-releases/abbvie-to-present-latest-clinical-research-in-the-treatment-of-leukemias-lymphomas-and-other-blood-cancers-at-2019-ash-annual-meeting-300962704.html,Prnewswire.com,,2019-11-21T13:30:00Z,0
630366,ABBV,Neurocrine Making The Most Of A Strong Ingrezza Launch,"Ingrezza continues to beat raised expectations, with sales up 10% over the second quarter and a large potential untapped market still out there.
        Orlissa sales continue to disappoint, but AbbVie now seems to be ready to try something new and different …","Stephen Simpson, CFA",https://seekingalpha.com/article/4308228-neurocrine-making-strong-ingrezza-launch,Seekingalpha.com,,2019-11-21T13:09:26Z,0.57
630367,ABBV,"The Top Large-Cap Sectors, Industries, And Stocks To Buy Now","The best-ranked large-cap sector is industrial goods.The top-rated industry is trucking.The strongest-scoring stocks include AbbVie, Eaton Vance, and Carlisle Companies.",Limelight Alpha Management Partners,https://seekingalpha.com/article/4308176-top-large-cap-sectors-industries-stocks-buy-now,Seekingalpha.com,,2019-11-21T13:00:00Z,0.2
629953,BMY,Bristol-Myers Squibb Company Announces Final Results of Exchange Offers for Celgene Corporation Notes,NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol-Myers Squibb Company Announces Final Results of Exchange Offers for Celgene Corporation Notes,,https://www.businesswire.com/news/home/20191121005279/en/Bristol-Myers-Squibb-Company-Announces-Final-Results-Exchange,Businesswire.com,,2019-11-21T12:06:35Z,0
629367,BMY,Bristol-Myers Squibb completes $74 billion acquisition of Celgene,"Bristol-Myers Squibb Co. on Wednesday said it completed its $74 billion acquisition of Celgene Corp., nearly a year after announcing the controversial deal. The completion comes after the Federal Trade Commission cleared the merger in a statement on Friday. T…",Jon Swartz,https://www.marketwatch.com/story/bristol-myers-squibb-completes-74-billion-acquisition-of-celgene-2019-11-20,Marketwatch.com,,2019-11-20T21:36:06Z,-0.1
629369,BMY,Celgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristol-Myers Squibb,"SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) announced today that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company (NYSE: BMY), Bristol-Myers Squibb and Celgene plan to transfer the listing of Celgene’s co…",,https://www.businesswire.com/news/home/20191120005937/en/Celgene-Announces-Plans-Transfer-Listing-Celgene%E2%80%99s-Contingent,Businesswire.com,,2019-11-20T21:24:16Z,0.34
629368,BMY,"Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company",NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger a…,,https://www.businesswire.com/news/home/20191120005929/en/Bristol-Myers-Squibb-Completes-Acquisition-Celgene-Creating-Leading,Businesswire.com,,2019-11-20T21:24:16Z,0.65
628333,BMY,"Zacks.com featured highlights include: Bristol-Myers Squibb, Urban Outfitters, Hewlett Packard, Cardinal Health and British American Tobacco","Zacks.com featured highlights include: Bristol-Myers Squibb, Urban Outfitters, Hewlett Packard, Cardinal Health and British American Tobacco",Zacks Equity Research,https://finance.yahoo.com/news/zacks-com-featured-highlights-bristol-144702708.html,Yahoo.com,,2019-11-20T14:47:02Z,0
628178,ABBV,"California Life Sciences Association (CLSA) Adds Leaders from AbbVie, Merck and Lasana Partners to Board of Directors","SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)-- #Abbvie--California Life Sciences Association (CLSA) Adds Leaders from AbbVie, Merck and Lasana Partners to Board of Directors",,https://www.businesswire.com/news/home/20191120005232/en/California-Life-Sciences-Association-CLSA-Adds-Leaders,Businesswire.com,,2019-11-20T14:42:32Z,0
628335,BMY,"Thinking about buying stock in Aurora Cannabis, Advanced Micro Devices, Bristol-Myers Squibb, Nike, or Visa?","NEW YORK, Nov. 20, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AMD, BMY, NKE, and V. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting…",,https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-aurora-cannabis-advanced-micro-devices-bristol-myers-squibb-nike-or-visa-300962029.html,Prnewswire.com,,2019-11-20T14:31:00Z,0.23
628179,ABBV,"Neurocrine Bounces Back With Authority, But Little Upside Appears Evident As New Year Approaches","When Neurocrine dipped into the $70s in late 2018, it seemed like an obvious buy.Now that Neurocrine is nearing all-time highs again on the heels of Ingrezza, additional upside heading into the new year is difficult to find.Orilissa, with AbbVie as partner, c…",Clover Biotech Research,https://seekingalpha.com/article/4307989-neurocrine-bounces-back-authority-little-upside-appears-evident-new-year-approaches,Seekingalpha.com,,2019-11-20T13:55:11Z,0.08
628544,JNJ,"JNJ Stock Is a Buy Because the Pharma Business Will Grow More - Barron's","JNJ Stock Is a Buy Because the Pharma Business Will Grow More Barron's",Josh Nathan-Kazis,https://www.barrons.com/articles/jnj-stock-pharma-business-51574256960,Barrons.com,,2019-11-20T13:42:00Z,0
628336,BMY,UPDATE 1-Bristol-Myers misses main goal of late-stage skin cancer trial,"Bristol-Myers Squibb Co said on Wednesday a late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients, sending its shares down nearly 1%. The company said the trial wi…",,https://finance.yahoo.com/news/1-bristol-myers-misses-main-123632906.html,Yahoo.com,,2019-11-20T12:36:32Z,-0.93
628337,BMY,Bristol-Myers misses main goal of late-stage skin cancer trial,Bristol-Myers Squibb Co said on Wednesday its late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients.,CNA,https://www.channelnewsasia.com/news/world/bristol-myers-misses-main-goal-of-late-stage-skin-cancer-trial-12111546,Channelnewsasia.com,,2019-11-20T12:25:52Z,-0.95
627814,LLY,Eli Lilly to create 100 jobs in Indianapolis as it adds capacity to its technology center campus,Eli Lilly & Co. said Wednesday that it will create 100 new jobs in Indianapolis as it invests $400 million in its manufacturing facilities at its Lilly Technology Center campus. The drug maker said its plans are a result of increased demand for its medicines …,Tomi Kilgore,https://www.marketwatch.com/story/eli-lilly-to-create-100-jobs-in-indianapolis-as-it-adds-capacity-to-its-technology-center-campus-2019-11-20,Marketwatch.com,,2019-11-20T12:09:08Z,0.59
627815,LLY,Lilly to invest $400M in Indianapolis manufacturing facilities,"Aimed at boosting manufacturing capacity for future drugs from its pipeline, Eli Lilly (NYSE:LLY) will invest $400M in its Lilly Technology Center campus in Indianapolis. The action will create ~100 n",SA Editor Douglas W. House,https://seekingalpha.com/news/3520758-lilly-invest-400m-indianapolis-manufacturing-facilities,Seekingalpha.com,,2019-11-20T12:09:02Z,0.54
627738,BMY,Bristol-Myers stock slides premarket after melanoma trial fails to meet main goal,"Bristol-Myers Squibb Co. shares slid 0.9% in premarket trade Wednesday, after the drug company said a trial of opdivo plus yervoy in treating patients who have had surgery to treat melanoma failed to meet its main goal. ""A statistically significant benefit wa…",Ciara Linnane,https://www.marketwatch.com/story/bristol-myers-stock-slides-premarket-after-melanoma-trial-fails-to-meet-main-goal-2019-11-20,Marketwatch.com,,2019-11-20T12:08:36Z,0.38
627739,BMY,Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1,"PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol-Myers Squibb Announces Topline Results for Opdivo Plus Yervoy Versus Opdivo Alone in Resected High-Risk Melanoma Patients",,https://www.businesswire.com/news/home/20191120005427/en/Bristol-Myers-Squibb-Announces-Update-CheckMate--915-Opdivo,Businesswire.com,,2019-11-20T12:07:17Z,-0.46
627816,LLY,Lilly announces $400 million capital investment in manufacturing facilities in Indianapolis,"INDIANAPOLIS, Nov. 20, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest $400 million in its manufacturing facilities at its Lilly Technology Center campus in Indianapolis. The plans are driven by increasing demand for Lil…",,https://www.prnewswire.com/news-releases/lilly-announces-400-million-capital-investment-in-manufacturing-facilities-in-indianapolis-300961247.html,Prnewswire.com,,2019-11-20T11:30:00Z,-0.13
627932,PRGO,Perrigo appoints Wavemaker for European and Australian markets,Publicis Media previously handled business.,Gurjit Degun,https://www.campaignlive.co.uk/article/perrigo-appoints-wavemaker-european-australian-markets/1666332,Campaignlive.co.uk,,2019-11-20T11:07:37Z,0
627156,BMY,Celgene: Bargain Bin At Bristol-Myers Squibb Deal Closing,"Bristol-Myers expects to close the Celgene acquisition on November 20.The merger is immediately 40% accretive to BMY earnings placing 2020 estimates far above $6 per share.The stock only trades at 7.5x '21 EPS estimates suggesting investors immediately flip t…",Stone Fox Capital,https://seekingalpha.com/article/4307885-celgene-bargain-bin-bristol-myers-squibb-deal-closing,Seekingalpha.com,,2019-11-19T22:17:09Z,0.2
627252,LLY,Lilly Confirms Date and Conference Call for 2020 Financial Guidance Announcement,"INDIANAPOLIS, Nov. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2020 on Tuesday, December 17, 2019. Lilly will also conduct a conference call on that day with the investment community and media to further…",,https://prnmedia.prnewswire.com:443/news-releases/lilly-confirms-date-and-conference-call-for-2020-financial-guidance-announcement-300961328.html,Prnewswire.com,,2019-11-19T21:15:00Z,0
625787,ABBV,"Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira",The approval of Humira biosimilar is the fourth U.S. approval of a biosimilar product for Pfizer (PFE) in 2019.,Zacks Equity Research,https://finance.yahoo.com/news/pfizer-gets-fda-approval-biosimilar-152303398.html,Yahoo.com,,2019-11-19T15:23:03Z,0.85
625788,ABBV,Dividend Aristocrats And Credit Spreads,"Following the recent $30B mega bond deal for AbbVie, this article looks at bond spreads among fellow Dividend Aristocrats.
        Each of the Dividend Aristocrats is rated investment grade, and their average bond spread is meaningfully tighter than the IG co…",Ploutos,https://seekingalpha.com/article/4307696-dividend-aristocrats-credit-spreads,Seekingalpha.com,,2019-11-19T14:53:14Z,0.38
625789,ABBV,"Top Analyst Upgrades and Downgrades: AbbVie, AMD, AT&T, Broadcom, Energy Transfer, Ford, Fortinet, Intel, Intelsat, Shake Shack, T-Mobile and More","Tuesday's top analyst upgrades, downgrades and initiations included AbbVie, AMD, AT&T, Broadcom, Energy Transfer, Ford, Fortinet, Intel, Intelsat, Shake Shack and T-Mobile.",Jon C. Ogg,https://247wallst.com/investing/2019/11/19/top-analyst-upgrades-and-downgrades-abbvie-amd-att-broadcom-energy-transfer-ford-fortinet-intel-intelsat-shake-shack-t-mobile-and-more/,247wallst.com,,2019-11-19T13:59:36Z,0.53
625940,BMY,3 Reasons Growth Investors Will Love Bristol-Myers (BMY),Bristol-Myers (BMY) could produce exceptional returns because of its solid growth attributes.,Zacks Equity Research,https://finance.yahoo.com/news/3-reasons-growth-investors-love-134501603.html,Yahoo.com,,2019-11-19T13:45:01Z,0.88
625440,MRK,"FDA accepts Bioepis' application for Avastin biosimilar","The FDA accepts for review a marketing application from Samsung Bioepis Co., Ltd. for SB8, a biosimilar to Roche's (OTCQX:RHHBY) Avastin (bevacizumab).If approved, Merck (NYSE:MRK) will commercialize.",SA Editor Douglas W. House,https://seekingalpha.com/news/3520355-fda-accepts-bioepis-application-avastin-biosimilar,Seekingalpha.com,,2019-11-19T11:51:05Z,0.75
625318,BMY,Nektar: Poised For A Rebound,"Nektar and its partner (Bristol-Myers Squibb) are advancing NKTR-214 in the Phase 2 PIVOT trial in combinations with other immune checkpoint inhibitors for various cancers.The other potential blockbuster, NKTR-358, is being progressed into a Phase 1b trial fo…",BioSci Capital Partners,https://seekingalpha.com/article/4307652-nektar-poised-rebound,Seekingalpha.com,,2019-11-19T10:53:59Z,0.73
624284,BMY,ServiceNow stock up 4% on news it is joining the S&P 500,"ServiceNow Inc. will replace Celgene Corp. in the S&P 500 index before the open on Thursday, S&P Global said late Monday. Bristol-Myers Squibb Co. is acquiring Celgene in a deal expected to close soon. Lab equipment maker Thermo Fisher Scientific Inc. will jo…",Claudia Assis,https://www.marketwatch.com/story/servicenow-stock-up-4-on-news-it-is-joining-the-sp-500-2019-11-18,Marketwatch.com,,2019-11-18T22:58:39Z,0
623292,JNJ,"Should You Be Pleased About The CEO Pay At Johnson & Johnson's (NYSE:JNJ)","In 2012 Alex Gorsky was appointed CEO of Johnson & Johnson (NYSE:JNJ). This report will, first, examine the CEO...",Simply Wall St,https://finance.yahoo.com/news/pleased-ceo-pay-johnson-johnsons-161752715.html,Yahoo.com,,2019-11-18T16:17:52Z,0.36
623293,JNJ,J&J launches innovative study for expanded use of Invokana,"Johnson &amp; Johnson (JNJ) unit Janssen Pharmaceutical Companies, together with PRA Health Sciences (PRAH), initiates a first-of-its-kind clinical trial evaluating Invokana (canagliflozin) in adults",SA Editor Douglas W. House,https://seekingalpha.com/news/3520157-j-and-j-launches-innovative-study-expanded-use-invokana,Seekingalpha.com,,2019-11-18T16:05:18Z,0.44
622598,ABBV,"Pfizer scores FDA nod for biosim to AbbVie's Humira, but it'll have to wait til 2023 to launch","Pfizer has scored FDA approval for its biosimilar to AbbVie's megablockbuster Humira, but it can't launch the product for several years under a patent settlement the companies inked last year. Meanwhile, the company is planning some oncology biosimilar rollou…",Eric Sagonowsky,https://www.fiercepharma.com/pharma/pfizer-scores-fda-nod-for-biosim-to-abbvie-s-humira-but-it-ll-have-to-wait-til-2023-to,Fiercepharma.com,,2019-11-18T16:01:08Z,0.63
622599,ABBV,"What's $30B Among Friends?",AbbVie issued $30B of debt as part of the financing for its $63B acquisition of Allergan.The bond market readily received the supply with limited new issue concessions and the new bonds now trading through pre-deal spread levels.The success of this transactio…,Ploutos,https://seekingalpha.com/article/4307408-30b-among-friends,Seekingalpha.com,,2019-11-18T14:10:37Z,0.08
622884,BMY,Edited Transcript of BMY earnings conference call or presentation 31-Oct-19 12:30pm GMT,Q3 2019 Bristol-Myers Squibb Co Earnings Call,,https://finance.yahoo.com/news/edited-transcript-bmy-earnings-conference-135032117.html,Yahoo.com,,2019-11-18T13:50:32Z,0
622600,ABBV,AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes,"NORTH CHICAGO, Ill., Nov. 18, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) (""AbbVie"") announced today the extension of the expiration date of the offers to exchange (each, an ""Exchange Offer"" and, collectively, the ""Exchange Offers"") any and all outstanding n…",,https://www.prnewswire.com/news-releases/abbvie-announces-extension-of-expiration-date-for-exchange-offers-for-allergan-notes-300959740.html,Prnewswire.com,,2019-11-18T13:00:00Z,0.61
622602,ABBV,"AbbVie, Cigna and Other Health Care Stocks With Recent Golden Crosses","Here are five health-care-related stocks that recently saw their 50-day moving average cross above the 200-day average, a golden cross.",Trey Thoelcke,https://247wallst.com/healthcare-business/2019/11/18/abbvie-cigna-and-other-health-care-stocks-with-recent-golden-crosses/,247wallst.com,,2019-11-18T12:45:47Z,0.49
620857,ABBV,"AbbVie's Humira on Pace to Become Biggest Seller by 2024","Immunology drug scheduled to supplant the widely used heart medication Lipitor, tallying cumulative sales of $240 billion Continue reading...",,https://finance.yahoo.com/news/abbvies-humira-pace-become-biggest-204035530.html,Yahoo.com,,2019-11-17T20:40:35Z,0
618180,BMY,"Irregular heartbeat, stroke more likely in tall people - The Asian Age","Irregular heartbeat, stroke more likely in tall people The Asian Age Taller people may develop atrial fibrillation: Study ANI News Atrial fibrillation: Height could predict risk Medical News Today Bristol-Myers Squibb and Pfizer Announce Randomized, Controlle…",ANI,https://asianage.com/life/health/161119/irregular-heartbeat-stroke-more-likely-in-tall-people.html,Asianage.com,,2019-11-16T05:44:34Z,-0.27
617118,BMY,Bristol-Myers Squibb Company Announces It Expects No Further Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes,NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol-Myers Squibb Company Announces It Expects No Further Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes,,https://www.businesswire.com/news/home/20191115005524/en/Bristol-Myers-Squibb-Company-Announces-Expects-Extension-Expiration,Businesswire.com,,2019-11-15T23:53:29Z,-0.53
617119,BMY,"Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug","Bristol-Myers Squibb Co  and Celgene Corp  have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday.",CNA,https://www.channelnewsasia.com/news/business/bristol-myers-squibb-wins-antitrust-approval-to-buy-celgene--but-must-divest-psoriasis-drug-12099314,Channelnewsasia.com,,2019-11-15T23:05:22Z,0.93
617120,BMY,"FTC makes Celgene's Otezla divestiture official condition for Bristol-Myers acquisition","Celgene Corp. is required to divest its most popular psoriasis treatment in order to be acquired by Bristol-Myers Squibb Co., the Federal Trade Commission announced Friday. For Bristol-Myers to close on its $74 billion acquisition, Celgene will have to sell i…",Wallace Witkowski,https://www.marketwatch.com/story/ftc-makes-celgenes-otezla-divestiture-official-condition-for-bristol-myers-acquisition-2019-11-15,Marketwatch.com,,2019-11-15T22:43:39Z,0.48
617121,BMY,"UPDATE 1-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug","Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. Bristol-Myers Squibb said in a statement Friday…",,https://finance.yahoo.com/news/1-bristol-myers-squibb-wins-221842591.html,Yahoo.com,,2019-11-15T22:18:42Z,0.93
617122,BMY,Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition,NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Federal Trade Commission (FTC) has accepted the proposed consent order in connection with the pending merger of Bristol-Myers Squibb and Celgene Corporation (NASD…,,https://www.businesswire.com/news/home/20191115005499/en/Bristol-Myers-Squibb-Receives-Clearance-U.S.-Federal-Trade,Businesswire.com,,2019-11-15T22:09:18Z,0.46
617123,BMY,FTC on board with Bristol-Myers/Celgene tie-up on Otezla sale,"The U.S. Federal Trade Commission &#40;FTC&#41; says Celgene's (CELG) divestment of psoriasis med Otezla (apremilast) will settle its charges that its planned merger with Bristol-Myers Squibb (NYSE:BM",SA Editor Douglas W. House,https://seekingalpha.com/news/3519945-ftc-board-bristol-myers-celgene-tie-otezla-sale,Seekingalpha.com,,2019-11-15T22:03:39Z,-0.27
617124,BMY,Bristol-Myers Squibb wins antitrust approval to buy Celgene on condition it sell psoriasis drug,"Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. (Reporting by Diane Bartz; Editing by Sandra Ma…",Reuters Editorial,https://www.reuters.com/article/us-celgene-m-a-bristol-myers-idUSKBN1XP2CH,Reuters,,2019-11-15T21:56:14Z,0.93
617125,BMY,Bristol-Myers Wins U.S. Antitrust Approval for Celgene Takeover,"Bristol-Myers Squibb Co. won U.S. antitrust approval for its acquisition of Celgene Corp., the last regulatory approval needed for the blockbuster pharmaceutical deal.",David McLaughlin,https://www.bloomberg.com/news/articles/2019-11-15/bristol-myers-wins-u-s-antitrust-approval-for-celgene-takeover,Bloomberg,,2019-11-15T21:52:24Z,0.97
615363,BMY,"Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals","PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals). The…",,https://www.businesswire.com/news/home/20191115005062/en/Bristol-Myers-Squibb-Pfizer-Announce-Randomized-Controlled-Trial,Businesswire.com,,2019-11-15T14:06:27Z,0
615366,BMY,What’s Bristol-Myers Squibb’s Fair Stock Price Estimate Based On Expected 2019 Earnings?,"Bristol-Myers Squibb’s (NYSE: BMY) fair price estimate based on expected 2019 earnings is $59, according to Trefis estimates. This is in line with the current market price of around $58. Bristol-Myers Squibb is a biopharmaceutical company that discovers, deve…","Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/",https://www.forbes.com/sites/greatspeculations/2019/11/15/whats-bristol-myers-squibbs-fair-stock-price-estimate-based-on-expected-2019-earnings/,Forbes.com,,2019-11-15T12:30:00Z,0.56
614269,MRK,"Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates","Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.",Kinjel Shah,https://finance.yahoo.com/news/pharma-stock-roundup-mrk-gsk-121212806.html,Yahoo.com,,2019-11-15T12:12:12Z,0.48
615052,ZTS,Recognising todays leading young vets,"By Georgina Mills 



BVA’s Young Vet of the Year Emily Craven

Emily Craven is the recipient of the BVA’s inaugural Young Vet of the Year Award. 

Sponsored by Zoetis, the award recognises an exceptional young vet who leads and inspires, and goes above and b…",,https://veterinaryrecord.bmj.com/content/185/19/591,Bmj.com,,2019-11-15T09:00:38Z,0.87
612321,ABBV,Proposals To Determine Feasibility of Incorporating Drug Pricing Risks,"Shareholders Renew Their Campaign To Curb Escalating Prices At U.S. Drug Makers. 2020 Shareholder Proposals at AbbVie, Amgen, Biogen Eli Lilly and Pfizer Ask... The post Proposals To Determine Feasibility of Incorporating Drug Pricing Risks appeared first on …",Jacob Wolinsky,https://www.valuewalk.com/2019/11/abbvie-amgen-biogen-eli-lilly-pfizer/,Valuewalk.com,,2019-11-14T23:33:32Z,-0.27
612802,LLY,Proposals To Determine Feasibility of Incorporating Drug Pricing Risks,"Shareholders Renew Their Campaign To Curb Escalating Prices At U.S. Drug Makers. 2020 Shareholder Proposals at AbbVie, Amgen, Biogen Eli Lilly and Pfizer Ask... The post Proposals To Determine Feasibility of Incorporating Drug Pricing Risks appeared first on …",Jacob Wolinsky,https://www.valuewalk.com/2019/11/abbvie-amgen-biogen-eli-lilly-pfizer/,Valuewalk.com,,2019-11-14T23:33:32Z,-0.27
608793,ABBV,"Stockstowatchtoday Blog: AbbVie Sold $30 Billion in Bonds, and Two More Numbers to Know",Why Google wants to offer checking accounts. The asteroid Psyche is said to be the most valuable object in the solar system—except it isn’t. And AbbVie is piling on debt so it can go shopping.,,https://www.barrons.com/articles/google-wants-to-offer-checking-accounts-in-2020-51573725665,Barrons.com,,2019-11-14T10:01:00Z,0.22
607713,LLY,"FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug",Independent experts on an FDA advisory panel on Wednesday voted against the use of an already approved diabetes drug from Eli Lilly and Co and Boehringer Ingelheim as an add-on to insulin therapy in patients with type 1 diabetes.,CNA,https://www.channelnewsasia.com/news/world/fda-panel-votes-against-lilly-boehringer-ingelheim-s-diabetes-drug-12092282,Channelnewsasia.com,,2019-11-13T21:12:26Z,0.42
605164,ABBV,The Wall Street Journal: AbbVie sells $30 billion in bonds to help fund Allergan acquisition,The AbbVie deal was the fourth-largest investment-grade bond sale on record,Sam Goldfarb,https://www.wsj.com/articles/abbvie-prepares-large-bond-sale-to-fund-allergan-purchase-11573581779,The Wall Street Journal,,2019-11-13T17:40:30Z,0.4
605166,ABBV,AbbVie Inc Takes on Debt to Buy Allergan,The $30 billion corporate loan is intended to finance the acquisition of Allergan Continue reading...,,https://finance.yahoo.com/news/abbvie-inc-takes-debt-buy-170345370.html,Yahoo.com,,2019-11-13T17:03:45Z,-0.36
605853,LLY,Avidity Bio Adds $100M to Advance R&D of Muscle Disorder Drugs,"<p>Earlier this year, Avidity Biosciences and Eli Lilly began a partnership to develop new drugs based on the biotech’s technology for delivering genetic material to cells. On Wednesday, Lilly was among a group of investors that joined a $100 million financin…",Frank Vinluan,https://xconomy.com/san-diego/2019/11/13/avidity-bio-adds-100m-to-advance-rd-of-muscle-disorder-drugs/,Xconomy.com,,2019-11-13T15:23:21Z,-0.4
606288,PRGO,Perrigo to Present at the Morgan Stanley Global Consumer & Retail Conference,"DUBLIN, Nov. 13, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will present at the Morgan Stanley Global Consumer & Retail Conference at 10:00 AM EST on Wednesday, …",,https://www.prnewswire.com/news-releases/perrigo-to-present-at-the-morgan-stanley-global-consumer--retail-conference-300957527.html,Prnewswire.com,,2019-11-13T14:29:00Z,0
605174,ABBV,Why Does AbbVie Pay a Much Higher Dividend Than Its Peers?,"This major drug manufacturer pays the highest dividend yield among major drug manufacturers. What is causing this, and is it a viable income play?",newsfeedback@fool.com (Ryan Patrick),https://www.fool.com/investing/2019/11/13/why-does-abbvie-pay-a-much-higher-dividend-than-it.aspx,Fool.com,,2019-11-13T13:00:00Z,0.33
604052,ABBV,AbbVie prices $30B senior unsecured notes,AbbVie (NYSE:ABBV) has priced its private offering of senior unsecured notes in a combined aggregate principal amount of $30B.The Notes will be issued in ten tranches: (i) $750M senior floating rate,Mamta Mayani,https://seekingalpha.com/news/3518520-abbvie-prices-30b-senior-unsecured-notes,Seekingalpha.com,,2019-11-13T11:18:24Z,-0.64
604053,ABBV,AbbVie sells $30B in bonds for Allergan takeover,"Encouraged by low funding costs amid narrowing credit risk premiums, U.S. drugmaker AbbVie (NYSE:ABBV) has sold the largest block of bonds of the year to finance its $83B takeover of rival Allergan (N",SA Editor Yoel Minkoff,https://seekingalpha.com/news/3518483-abbvie-sells-30b-bonds-allergan-takeover,Seekingalpha.com,,2019-11-13T09:24:34Z,-0.54
602559,ABBV,AbbVie Prices $30 Billion of Senior Unsecured Notes,"NORTH CHICAGO, Ill., Nov. 12, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) (""AbbVie"") announced today that it has priced its previously announced private offering (the ""Offering"") of senior unsecured notes in a combined aggregate principal amount of $30 billi…",,https://www.prnewswire.com/news-releases/abbvie-prices-30-billion-of-senior-unsecured-notes-300957026.html,Prnewswire.com,,2019-11-13T02:45:00Z,-0.64
602561,ABBV,AbbVie eyes largest bond sale of 2019,"Drug maker AbbVie is issuing bonds to help finance its $63bn (€57bn) acquisition of botox maker Allergan, in what will likely be the largest bond sale this year.",Elizabeth Rembert,https://www.independent.ie/business/irish/abbvie-eyes-largest-bond-sale-of-2019-38687635.html,Independent.ie,,2019-11-13T02:30:00Z,0.4
602563,ABBV,AbbVie: 5.5% Yield And Recent 10% Dividend Increase,AbbVie reliance on Humira has some investors worried as the product losses its patent protection in 2023. But the company has several other promising products t,Sure Dividend,https://seekingalpha.com/article/4305992-abbvie-5_5-percent-yield-recent-10-percent-dividend-increase,Seekingalpha.com,,2019-11-13T02:16:10Z,-0.3
602979,JNJ,Johnson & Johnson’s Legal Challenges Mount,"Johnson & Johnson, JNJ +1.97% facing lawsuits from more than 100,000 plaintiffs over its product safety and marketing tactics, has taken the aggressive strategy of battling many of the cases in court. And it is losing. A lot. Juries and judges have ordered th…","Loftus, Peter",https://law.stanford.edu/press/johnson-johnsons-legal-challenges-mount/,Stanford.edu,,2019-11-13T00:49:33Z,-0.32
602566,ABBV,"AbbVie: Amazing Dividend, Attractive Valuation, Uncertain Future",,,https://seekingalpha.com/article/4305904-abbvie-amazing-dividend-attractive-valuation-uncertain-future?source=feed_tag_us,Seekingalpha.com,,2019-11-12T20:38:12Z,0.67
600396,ABBV,New Positive Data for RINVOQ™ (upadacitinib) on Signs and Symptoms in Patients with Ankylosing Spondylitis Presented at 2019 ACR/ARP Annual Meeting,"NORTH CHICAGO, Ill., Nov. 12, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2/3 SELECT-AXIS 1 trial in which twice as many adult patients with active ankylosing spondy…",,https://www.prnewswire.com/news-releases/new-positive-data-for-rinvoq-upadacitinib-on-signs-and-symptoms-in-patients-with-ankylosing-spondylitis-presented-at-2019-acrarp-annual-meeting-300956524.html,Prnewswire.com,,2019-11-12T16:15:00Z,0.87
600398,ABBV,AbbVie Begins Mega Bond Sale to Finance Allergan Acquisition,"(Bloomberg) -- AbbVie Inc. is selling what could be $28 billion of bonds to help finance its acquisition of Allergan Plc, which would be the largest bond sale this year.The drug maker is capitalizing on some of the cheapest borrowing costs of the year, with r…",,https://finance.yahoo.com/news/abbvie-kicks-off-mega-bond-131359841.html,Yahoo.com,,2019-11-12T15:50:56Z,0.4
600700,BMY,"Thinking about buying stock in Apple, Bristol-Myers Squibb, Cronos Group, Coca-Cola, or Walgreens Boots Alliance?","NEW YORK, Nov. 12, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, BMY, CRON, KO, and WBA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by select…",,https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-apple-bristol-myers-squibb-cronos-group-coca-cola-or-walgreens-boots-alliance-300956374.html,Prnewswire.com,,2019-11-12T14:31:00Z,-0.03
600473,ALLY,Ally Financial Loses Momentum as Auto Sales Sputter,"Ally has reported solid earnings and revenue growth this year, but negative consumer sentiment and deteriorating credit conditions could dampen vehicle sales, a key source of loan growth.",newsfeedback@fool.com (Rob Williams),https://www.fool.com/investing/2019/11/12/ally-financial-loses-momentum-as-auto-sales-sputte.aspx,Fool.com,,2019-11-12T14:03:00Z,0.3
601073,LLY,Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized,"RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth phase III study in the Jardiance® (empagliflozin) heart failure program. The stud…",,https://www.prnewswire.com/news-releases/boehringer-ingelheim-and-lilly-initiate-first-ever-study-to-assess-jardiance-in-people-hospitalized-for-acute-heart-failure-who-have-been-stabilized-300956005.html,Prnewswire.com,,2019-11-12T13:30:00Z,-0.77
601074,LLY,ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis,"Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis INDIANAPOLIS, Nov. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today the 52-w... Bio…",Eli Lilly,https://salesandmarketingnetwork.com/news_release_bs.html?ID=2045523,Salesandmarketingnetwork.com,,2019-11-12T13:11:52Z,0.4
601118,MRK,"Merck's Ebola Vaccine Gets Conditional Approval in Europe","European Commission grants approval to Merck's (MRK) Ervebo (V920) for active immunization of individuals 18 years and above to protect against Ebola Virus Disease caused by Zaire Ebola virus.",Zacks Equity Research,https://finance.yahoo.com/news/mercks-ebola-vaccine-gets-conditional-130501906.html,Yahoo.com,,2019-11-12T13:05:01Z,0.91
601075,LLY,"ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz(R) (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis","Based on these positive results, Lilly has submitted for U.S. regulatory approval for adults with active non-radiographic axial spondyloarthritis INDIANAPOLIS, Nov. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY)... Bio…",Eli Lilly,https://salesandmarketingnetwork.com/news_release_bs.html?ID=2045521,Salesandmarketingnetwork.com,,2019-11-12T12:57:45Z,0.92
599532,LLY,ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis,"INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the 52-week results from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study of Taltz® (ixekizumab) versus Humira® (adalimumab) in biologic-naïve patients with active pso…",,https://www.prnewswire.com/news-releases/acr-2019-lilly-presents-52-week-head-to-head-spirit-h2h-data-from-taltz-ixekizumab-versus-humira-adalimumab-trial-in-psoriatic-arthritis-300954994.html,Prnewswire.com,,2019-11-12T12:00:00Z,0.4
599383,BMY,"Why Celgene's Latest FDA Approval Makes Bristol-Myers Squibb's Dividend Look Even Better","Good news for Celgene is good news for Bristol-Myers Squibb -- and investors who like the big drugmaker's juicy dividend.",newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2019/11/12/why-celgenes-latest-fda-approval-makes-bristol-mye.aspx,Fool.com,,2019-11-12T12:00:00Z,0.82
599534,LLY,"ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis","INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) presented detailed results today demonstrating Taltz® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a 52-week placebo-controlled Phase 3 study evaluatin…",,https://www.prnewswire.com/news-releases/acr-2019-lilly-presents-positive-new-data-from-coast-x-a-phase-3-study-of-taltz-ixekizumab-in-patients-with-non-radiographic-axial-spondyloarthritis-300954995.html,Prnewswire.com,,2019-11-12T11:45:00Z,0.56
597981,ZTS,"Zoetis: Near-Term Headwinds, But Long-Term 10% Annual Growth","Zoetis shares have fallen 7.9% this month, including 2.6% since Q3 results last week, returning only 5% since our Buy rating in June. The 19Q3 results were actu",Blue Sky Capital,https://seekingalpha.com/article/4305435-zoetis-near-term-headwinds-long-term-10-percent-annual-growth,Seekingalpha.com,,2019-11-11T17:09:09Z,-0.08
596192,ABBV,"With Allergan megamerger looming, AbbVie plots massive $28B bond offering: Bloomberg","AbbVie could issue $28 billion in bonds as soon as Tuesday to help fund its massive Allergan buyout, Bloomberg reports—the fourth-largest in history. But CEO Richard Gonzalez says he's not worried about handling the load. Combined, the two companies churned o…",Eric Sagonowsky,https://www.fiercepharma.com/pharma/working-to-close-allergan-deal-abbvie-plans-28b-bond-offering-bloomberg,Fiercepharma.com,,2019-11-11T15:29:53Z,0.47
596472,BMY,Why Bristol-Myers Squibb Stock Gained 13% in October,"Is Bristol's stock still an attractive buy after last month's uptick?",newsfeedback@fool.com (George Budwell),https://www.fool.com/investing/2019/11/11/why-bristol-myers-squibb-stock-gained-13-in-octobe.aspx,Fool.com,,2019-11-11T14:23:00Z,0.67
595274,BMY,U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma,"PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--US FDA Accepts for Priority Review BMS’s Application for Opdivo Plus Yervoy Combination for Patients with Previously Treated Advanced HCC",,https://www.businesswire.com/news/home/20191111005122/en/U.S.-Food-Drug-Administration-Accepts-Priority-Review,Businesswire.com,,2019-11-11T12:11:44Z,0.77
593783,ABBV,This Terrific High-Yield Dividend Stock Just Got Even Better,"Add one more year to AbbVie's impressive streak of dividend hikes.",newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2019/11/10/this-terrific-high-yield-dividend-stock-just-got-e.aspx,Fool.com,,2019-11-10T12:00:00Z,0.75
590535,ABBV,AbbVie Looking to Raise $28 Billion in High-Grade Bond Market,,,https://www.bloomberg.com/news/videos/2019-11-08/abbvie-looking-to-raise-28-billion-in-high-grade-bond-market-video,Bloomberg,,2019-11-08T20:22:52Z,0
588954,BMY,"UPDATE 1-U.S. FDA approves Celgene's rare blood disorder drug","The U.S. Food and Drug Administration said on Friday it had approved a treatment for a rare blood disorder from Celgene Corp, which is in the process of being bought by Bristol-Myers Squibb Co. Reblozyl, which has been jointly developed by Celgene and Acceler…",,https://finance.yahoo.com/news/1-u-fda-approves-celgenes-175514386.html,Yahoo.com,,2019-11-08T17:55:14Z,0.03
588699,ABBV,AbbVie: Our Top Dividend Stock To Buy Now,"AbbVie is our top-scoring dividend stock. Optimism is growing that it can navigate Humira's headwinds. AbbVie checks many boxes on our Power 7 screening methodo",Limelight Alpha Management Partners,https://seekingalpha.com/article/4304464-abbvie-top-dividend-stock-buy-now,Seekingalpha.com,,2019-11-08T17:32:57Z,0.72
588700,ABBV,J&J files U.S. application for Imbruvica combo for first-line CLL/SLL,"AbbVie (NYSE:ABBV) has submitted a supplemental marketing application to the FDA seeking approval of Imbruvica (ibrutinib), combined with Roche's Rituxan (rituximab), for the first-line treatment of p",SA Editor Douglas W. House,https://seekingalpha.com/news/3517184-abbvie-files-u-s-application-imbruvica-combo-first-line-cll-sll,Seekingalpha.com,,2019-11-08T13:40:21Z,0.48
587806,LLY,Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting,"INDIANAPOLIS, Nov. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from Taltz® (ixekizumab) and Olumiant® (baricitinib) at the American College of Rheumatology (ACR)/Association of Rheumatology Professio…",,https://www.prnewswire.com/news-releases/lilly-reinforces-its-commitment-to-rheumatology-through-data-showcased-at-the-acrarp-annual-meeting-300954531.html,Prnewswire.com,,2019-11-08T11:45:00Z,0.38
587629,BMY,Have Bristol-Myers Squibb Company (NYSE:BMY) Insiders Been Selling Their Stock?,"We wouldn't blame Bristol-Myers Squibb Company (NYSE:BMY) shareholders if they were a little worried about the fact...",Simply Wall St,https://finance.yahoo.com/news/bristol-myers-squibb-company-nyse-101328616.html,Yahoo.com,,2019-11-08T10:13:28Z,0.03
586124,LLY,"US, EU health care giants jump at opportunities in China during import expo","At this week's China International Import Expo in Shanghai, health care giants such as AstraZeneca, Boston Scientific, Eli Lilly and Thermo Fisher Scientific unveiled massive floor displays to promote their products in the Chinese market.",Evelyn Cheng,https://www.cnbc.com/2019/11/08/us-eu-health-care-giants-jump-at-chinas-international-import-expo.html,CNBC,,2019-11-08T02:49:00Z,0.89
585604,ABBV,AbbVie Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Allergan Notes,"NORTH CHICAGO, Ill., Nov. 7, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) (""AbbVie"") announced today that the requisite number of consents have been received to adopt certain proposed amendments (the ""Amendments"") with respect to all outstanding notes of cert…",,https://www.newswire.ca:443/news-releases/abbvie-announces-results-of-early-participation-in-exchange-offers-and-consent-solicitations-for-allergan-notes-300954511.html,Newswire.ca,,2019-11-08T01:41:00Z,0.92
587488,ZTS,Zoetis Inc. (ZTS) CEO Juan Ramon Alaix on Q3 2019 Results - Earnings Call Transcript,"Zoetis Inc. (NYSE:ZTS) Q3 2019 Earnings Conference Call November 7, 2019, 08:30 AM ET Company Participants Steve Frank - VP of IR Juan Ramon Alaix - CEO Glenn D",SA Transcripts,https://seekingalpha.com/article/4303988-zoetis-inc-zts-ceo-juan-ramon-alaix-q3-2019-results-earnings-call-transcript,Seekingalpha.com,,2019-11-07T22:18:08Z,0
586160,MRK,"Kahn Brothers' 3rd-Quarter Update","Hedge fund buys shares of Pepsi and Keycorp, sells abundance of Merck Continue reading...",GuruFocus.com,https://finance.yahoo.com/news/kahn-brothers-3rd-quarter-203728484.html,Yahoo.com,,2019-11-07T20:37:28Z,0.3
587491,ZTS,Zoetis Inc (ZTS) Q3 2019 Earnings Call Transcript,"ZTS earnings call for the period ending September 30, 2019.",newsfeedback@fool.com (Motley Fool Transcribers),https://www.fool.com/earnings/call-transcripts/2019/11/07/zoetis-inc-zts-q3-2019-earnings-call-transcript.aspx,Fool.com,,2019-11-07T20:30:47Z,0
584472,PRGO,"Witi, Perrigo Partner To Help Smokers Overcome Nicotine Addiction","Witi, a producer of medical-grade vaporization devices, announced Thursday it has partnered with Perrigo (NYSE: PRGO) to create a new smoking cessation product. The two companies plan to work on an electronic nicotine delivery system that would later be submi…",,https://finance.yahoo.com/news/witi-perrigo-partner-help-smokers-180901334.html,Yahoo.com,,2019-11-07T18:09:01Z,0.59
583913,LLY,"Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities","INDIANAPOLIS, Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for up to $2,000,006,000 aggregate principal amount of its outstanding debt securities. Holders of not…",,https://prnmedia.prnewswire.com:443/news-releases/lilly-announces-the-pricing-terms-of-its-cash-tender-offer-for-up-to-2-000-006-000-aggregate-principal-amount-of-its-outstanding-debt-securities-300954097.html,Prnewswire.com,,2019-11-07T17:50:00Z,0.74
585557,ZTS,"Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales","Zoetis (ZTS) beats earnings estimates, while sales are in line in the third quarter of 2019.",Zacks Equity Research,https://finance.yahoo.com/news/zoetis-zts-beats-earnings-q3-160804409.html,Yahoo.com,,2019-11-07T16:08:04Z,0
583529,BMY,"Zacks.com featured highlights include: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard Enterprise and Bristol-Myers Squibb","Zacks.com featured highlights include: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard Enterprise and Bristol-Myers Squibb",Zacks Equity Research,https://finance.yahoo.com/news/zacks-com-featured-highlights-group-154903122.html,Yahoo.com,,2019-11-07T15:49:03Z,0
583223,ABBV,"Zacks.com featured highlights include: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard Enterprise and Bristol-Myers Squibb","Zacks.com featured highlights include: Group 1 Automotive, AbbVie, Brinker International, Hewlett Packard Enterprise and Bristol-Myers Squibb",Zacks Equity Research,https://finance.yahoo.com/news/zacks-com-featured-highlights-group-154903122.html,Yahoo.com,,2019-11-07T15:49:03Z,0
585558,ZTS,"Zoetis Stock Climbs Because the Pet Business Is Still Booming - Barron's","Zoetis Stock Climbs Because the Pet Business Is Still Booming Barron's",Lawrence C. Strauss,https://www.barrons.com/articles/zoetis-stock-climbs-because-the-pet-business-is-still-booming-51573141766,Barrons.com,,2019-11-07T15:49:00Z,0
584474,PRGO,Exclusive: Another Multi-Billion-Dollar Pharma Company Bets On Cannabis Technology For Smoking Cessation,"This time around, it’s NYSE-traded Perrigo, a manufacturer of over-the-counter health and wellness products valued at more than $7 billion.","Javier Hasse, Contributor, Javier Hasse, Contributor https://www.forbes.com/sites/javierhasse/",https://www.forbes.com/sites/javierhasse/2019/11/07/perrigo-witi/,Forbes.com,,2019-11-07T14:41:39Z,0.74
583914,LLY,"Migraine hopefuls from Lilly, Allergan and Biohaven don't beat older drugs: ICER","Forthcoming migraine meds from Eli Lilly, Allergan and Biohaven took some hits in ICER's new data review. While they're clearly better than placebo, the new drugs don't beat existing triptan treatments, ICER figures, except in patients who haven't seen relief…",Eric Sagonowsky,https://www.fiercepharma.com/pharma/forthcoming-migraine-meds-from-lilly-allergan-and-biohaven-don-t-offer-benefits-over-older,Fiercepharma.com,,2019-11-07T14:41:28Z,0.68
583915,LLY,"Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities","INDIANAPOLIS, Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the early tender results for its previously announced cash tender offer of its outstanding debt securities. Lilly also announced that it had increased the previously …",,https://www.prnewswire.com/news-releases/lilly-announces-the-early-tender-results-and-upsizing-of-its-pending-cash-tender-offer-to-up-to-2-000-006-000-aggregate-principal-amount-of-its-outstanding-debt-securities-300953901.html,Prnewswire.com,,2019-11-07T14:00:00Z,0.81
585559,ZTS,Zoetis shares jump 2.9% premarket after earnings top estimates,"Zoetis Inc. shares rose 2.9% in premarket trade Wednesday, after the animal health company beat estimates for the third quarter. Parsippany, N.J.-based Zoetis said it had net income of $433 million. or 90 cents a share, n the quarter, up from $347 million, or…",Ciara Linnane,https://www.marketwatch.com/story/zoetis-shares-jump-29-premarket-after-earnings-top-estimates-2019-11-07,Marketwatch.com,,2019-11-07T12:17:29Z,0.75
582025,BMY,"Bristol-Myers Squibb Underscores Precision-Focused Immunology Leadership with New Data on ORENCIA® (abatacept) in Early RA, ACPA-Positive Patients Presented at 2019 ACR/ARP Annual Meeting1","PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol-Myers Squibb Underscores Precision-Focused Immunology Leadership with New Data on ORENCIA®",,https://www.businesswire.com/news/home/20191107005257/en/Bristol-Myers-Squibb-Underscores-Precision-Focused-Immunology-Leadership-New,Businesswire.com,,2019-11-07T12:12:25Z,0
583213,ZTS,Zoetis Announces Third Quarter 2019 Results,"PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis reports third quarter 2019 financial results.",,https://www.businesswire.com/news/home/20191107005497/en/Zoetis-Announces-Quarter-2019-Results,Businesswire.com,,2019-11-07T12:12:25Z,0
581904,ABBV,"China's Bio-Thera gets approval for Humira biosimilar","REUTERS: China's Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world's second-largest drug market. Humira is t…",CNA,https://www.channelnewsasia.com/news/world/china-s-bio-thera-gets-approval-for-humira-biosimilar-12072708,Channelnewsasia.com,,2019-11-07T08:55:36Z,0.94
582609,PRGO,Perrigo (PRGO) Q3 2019 Earnings Call Transcript,"PRGO earnings call for the period ending September 30, 2019.",newsfeedback@fool.com (Motley Fool Transcribing),https://www.fool.com/earnings/call-transcripts/2019/11/06/perrigo-prgo-q3-2019-earnings-call-transcript.aspx,Fool.com,,2019-11-07T04:31:17Z,0
580545,JNJ,"Gaffes, yes, but strategy may win the election for Boris Johnson",Johnson has form. His Brexit referendum turn was a masterclass in misdirection. And he apparently hasn’t shaken the habit.,Nick Miller,https://www.smh.com.au/world/europe/gaffes-yes-but-strategy-may-win-the-election-for-boris-johnson-20191107-p53881.html,Smh.com.au,,2019-11-07T01:10:03Z,0.77
581052,PRGO,Edited Transcript of PRGO earnings conference call or presentation 6-Nov-19 1:00pm GMT,Q3 2019 Perrigo Company PLC Earnings Call,,https://finance.yahoo.com/news/edited-transcript-prgo-earnings-conference-232803107.html,Yahoo.com,,2019-11-06T23:28:03Z,0
581877,ZTS,Zoetis Q3 2019 Earnings Preview,"Zoetis (NYSE:ZTS) is scheduled to announce Q3 earnings results on Thursday, November 7th, before market open.The consensus EPS Estimate is $0.88 (+6.0% Y/Y) and the consensus Revenue Estimate is $1.58",SA Editor Gaurav Batavia,https://seekingalpha.com/news/3515470-zoetis-q3-2019-earnings-preview,Seekingalpha.com,,2019-11-06T22:30:59Z,0
580011,ABBV,AbbVie launches debt offering to fund Allergan merger,AbbVie (ABBV -0.1%) has initiated a private offering of senior unsecured notes aimed at funding its acquisition of Allergan (AGN -0.2%). Additional details unavailable at present.,SA Editor Douglas W. House,https://seekingalpha.com/news/3515630-abbvie-launches-debt-offering-fund-allergan-merger,Seekingalpha.com,,2019-11-06T20:19:30Z,-0.62
579977,ZTS,"Is Zoetis Inc.'s (NYSE:ZTS) CEO Pay Justified?",Juan Alaix has been the CEO of Zoetis Inc. (NYSE:ZTS) since 2012. This analysis aims first to contrast CEO...,,https://finance.yahoo.com/news/zoetis-inc-nyse-zts-ceo-181549198.html,Yahoo.com,,2019-11-06T18:15:49Z,-0.1
578947,PRGO,Perrigo Company plc (PRGO) CEO Murray Kessler on Q3 2019 Results - Earnings Call Transcript,"Perrigo Company plc (NYSE:PRGO) Q3 2019 Results Earnings Conference Call November 6, 2019, 08:00 AM ET Company Participants Bradley Joseph - Vice President, Inv",SA Transcripts,https://seekingalpha.com/article/4303246-perrigo-company-plc-prgo-ceo-murray-kessler-q3-2019-results-earnings-call-transcript,Seekingalpha.com,,2019-11-06T18:11:31Z,0
578433,LLY,Eli Lilly and Company to Present Multiple Abstracts for LOXO-305 at ASH 2019,"INDIANAPOLIS, Nov. 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that multiple abstracts from its LOXO-305 program have been accepted for presentation at the 61st American Society of Hematology Annual Meeting and Exposition to be h…",,https://www.prnewswire.com/news-releases/eli-lilly-and-company-to-present-multiple-abstracts-for-loxo-305-at-ash-2019-300952423.html,Prnewswire.com,,2019-11-06T14:00:00Z,0.27
576598,LLY,"Global Cancer Therapeutics Market to 2023 with Focus on Recurrent and Metastatic Divisions - Profiles of AbbVie, Biogen, GSK, Eli Lilly and Co., Merck & Co. and Pfizer","DUBLIN, Nov. 6, 2019 /PRNewswire/ -- The ""Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions"" report has been added to ResearchAndMarkets.com's offering. Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Di…",,https://www.prnewswire.com/news-releases/global-cancer-therapeutics-market-to-2023-with-focus-on-recurrent-and-metastatic-divisions---profiles-of--abbvie-biogen-gsk-eli-lilly-and-co-merck--co-and-pfizer-300952718.html,Prnewswire.com,,2019-11-06T11:45:00Z,-0.93
576218,ABBV,"Global Cancer Therapeutics Market to 2023 with Focus on Recurrent and Metastatic Divisions - Profiles of AbbVie, Biogen, GSK, Eli Lilly and Co., Merck & Co. and Pfizer","DUBLIN, Nov. 6, 2019 /PRNewswire/ -- The ""Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions"" report has been added to ResearchAndMarkets.com's offering. Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Di…",,https://www.prnewswire.com/news-releases/global-cancer-therapeutics-market-to-2023-with-focus-on-recurrent-and-metastatic-divisions---profiles-of--abbvie-biogen-gsk-eli-lilly-and-co-merck--co-and-pfizer-300952718.html,Prnewswire.com,,2019-11-06T11:45:00Z,-0.93
576933,PRGO,"Perrigo EPS beats by $0.10, misses on revenue",Perrigo (NYSE:PRGO): Q3 Non-GAAP EPS of $1.04 beats by $0.10; GAAP EPS of $0.67 beats by $0.09.Revenue of $1.19B (+5.3% Y/Y) misses by $10M.Shares +0.4% PM.Press Release,SA Editor Gaurav Batavia,https://seekingalpha.com/news/3515115-perrigo-eps-beats-0_10-misses-revenue,Seekingalpha.com,,2019-11-06T11:06:49Z,-0.42
576934,PRGO,Perrigo Company plc Reports Third Quarter 2019 Financial Results,"DUBLIN, Nov. 6, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of ""Quality, Affordable Self-Care ProductsTM"", today announced financial results for the third quarter ended September 28, 2019. President and CEO Murray S.…",,https://www.prnewswire.com/news-releases/perrigo-company-plc-reports-third-quarter-2019-financial-results-300952732.html,Prnewswire.com,,2019-11-06T11:00:00Z,0
576220,ABBV,"Should You Worry About AbbVie Inc.'s (NYSE:ABBV) CEO Pay Cheque?","Rick Gonzalez has been the CEO of AbbVie Inc. (NYSE:ABBV) since 2012. First, this article will compare CEO...",Simply Wall St,https://finance.yahoo.com/news/worry-abbvie-inc-nyse-abbv-101151446.html,Yahoo.com,,2019-11-06T10:11:51Z,-0.51
572053,ABBV,"AbbVie may count on Allergan's Botox for post-merger growth. But what else?","With a $63 billion merger nearing approval, AbbVie is looking to Allergan for a boost in the new company's drug portfolio. In the case of Botox, AbbVie might have a long-term winner, but not every drug in Allergan's stable is shining quite so brightly.",Kyle Blankenship,https://www.fiercepharma.com/pharma/abbvie-looking-to-botox-growth-as-a-major-business-driver-post-allergan-merger,Fiercepharma.com,,2019-11-05T16:04:21Z,0.93
573387,PRGO,"Did You Manage To Avoid Perrigo's (NYSE:PRGO) Painful 65% Share Price Drop?",Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly...,Simply Wall St,https://finance.yahoo.com/news/did-manage-avoid-perrigos-nyse-153617690.html,Yahoo.com,,2019-11-05T15:36:17Z,-0.44
572054,ABBV,"Thinking about buying stock in AbbVie, Agile Therapeutics, Intel, Peloton Interactive, or Under Armour?","NEW YORK, Nov. 5, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABBV, AGRX, INTC, PTON, and UAA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by sele…",,https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-abbvie-agile-therapeutics-intel-peloton-interactive-or-under-armour-300951801.html,Prnewswire.com,,2019-11-05T14:31:00Z,-0.03
520489,ZTS,spirit airlines inc (nasdaq:save),"United Airlines Holdings Inc. (NASDAQ: UAL) said Friday that the airline was ... 
Groupon, Honeywell, Mastercard, Newmont Goldcorp, Roku, Zoetis and More.",Paul Ausick,https://247wallst.com/companies/save/,247wallst.com,1572912000,2019-11-05T00:00:00Z,0.18
569465,LLY,Lilly to Participate in Credit Suisse 28th Annual Healthcare Conference,"INDIANAPOLIS, Nov. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Credit Suisse 28th Annual Healthcare Conference on Wednesday, November 13, 2019. Anne White, president of Lilly Oncology, Kimberly Blackwell, M.D., vice presid…",,https://www.prnewswire.com/news-releases/lilly-to-participate-in-credit-suisse-28th-annual-healthcare-conference-300951049.html,Prnewswire.com,,2019-11-04T21:15:00Z,0.64
566889,BMY,"Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?","While the results are promising, are they enough to threaten Merck's cancer superdrug Keytruda?",newsfeedback@fool.com (Mark Prvulovic),https://www.fool.com/investing/2019/11/04/should-merck-investors-worry-about-bristol-myers-l.aspx,Fool.com,,2019-11-04T15:18:40Z,-0.92
566495,ABBV,AbbVie to Showcase Depth of Immunology Portfolio and Pipeline at the 2019 ACR/ARP Annual Meeting,"NORTH CHICAGO, Ill., Nov. 4, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present data from multiple studies of RINVOQ™ (upadacitinib), HUMIRA® (adalimumab) and SKYRIZI™ (risankizumab) at…",,https://www.prnewswire.com/news-releases/abbvie-to-showcase-depth-of-immunology-portfolio-and-pipeline-at-the-2019-acrarp-annual-meeting-300950462.html,Prnewswire.com,,2019-11-04T13:31:00Z,0
564612,ABBV,Edited Transcript of ABBV earnings conference call or presentation 1-Nov-19 1:00pm GMT,Q3 2019 Abbvie Inc Earnings Call,,https://finance.yahoo.com/news/edited-transcript-abbv-earnings-conference-223208609.html,Yahoo.com,,2019-11-04T02:47:08Z,0
564763,LLY,Top Insider Buys Highlight for the Week of Nov. 1,"The largest insider buys this week were in American Airlines, Eli Lilly, Keurig Dr Pepper and Ford Continue reading...",,https://finance.yahoo.com/news/top-insider-buys-highlight-week-223254014.html,Yahoo.com,,2019-11-03T22:32:54Z,0.49
564839,MRK,Merck & Co Inc Stock as Institutional Investors Enter - The York Reporter,"Sentiment for Merck & Co Inc (NYSE:MRK)Merck & Co Inc (NYSE:MRK) institutional sentiment increased to 1.09 in Q2 2019. Its up 0.27, from 0.82 in 2019Q1. The ratio is positive, as 715 investmen",12,https://yorkreporter.com/2019/11/03/market-news/merck-co-inc-stock-as-institutional-investors-enter/,Yorkreporter.com,,2019-11-03T21:33:00Z,0.69
561432,ABBV,"3 Most Important Takeaways From AbbVie's Q3 Results",The big pharma company delivered a surprisingly solid performance in the third quarter.,newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2019/11/02/3-most-important-takeaways-from-abbvies-q3-results.aspx,Fool.com,,2019-11-02T11:00:00Z,0.6
560374,ABBV,The Top Large-Cap Stocks To Buy Now,"The best ranked large-cap sector is industrial goods. The top-scoring industry is trucking. The highest scoring stocks include AbbVie, Teradyne, and C.H. Robins",Limelight Alpha Management Partners,https://seekingalpha.com/article/4301661-top-large-cap-stocks-buy-now,Seekingalpha.com,,2019-11-01T21:30:37Z,0.72
558271,ABBV,AbbVie Inc (ABBV) Q3 2019 Earnings Call Transcript,"ABBV earnings call for the period ending September 30, 2019.",newsfeedback@fool.com (Motley Fool Transcribers),https://www.fool.com/earnings/call-transcripts/2019/11/01/abbvie-inc-abbv-q3-2019-earnings-call-transcript.aspx,Fool.com,,2019-11-01T17:30:44Z,0
558272,ABBV,AbbVie earnings even better than normal [Followup],AbbVie earnings even better than normal,,https://www.fark.com/comments/10607029/AbbVie-earnings-even-better-than-normal,Fark.com,,2019-11-01T17:10:00Z,0.7
558273,ABBV,"Is AbbVie's Imbruvica concerned about AZ's rising Calquence? We've got this covered, execs say","AbbVie has a lot on its plate with an Allergan megamerger in the works and a new rollout for blockbuster hopeful Rinvoq. One thing it hasn't had to worry about much is its blood cancer franchise—and, despite a rising challenger in AstraZeneca's Calquence, Abb…",Kyle Blankenship,https://www.fiercepharma.com/pharma/abbvie-s-imbruvica-concerned-about-az-s-rising-calquence-we-ve-got-covered-execs-say,Fiercepharma.com,,2019-11-01T15:06:09Z,0.59
558275,ABBV,"Novartis' Cosentyx can't top AbbVie's Humira in head-to-head psoriatic arthritis contest",Eli Lilly’s Taltz and Novartis’ Cosentyx have been battling it out lately in the next-gen psoriatic arthritis field. But Lilly’s drug has a big win under its belt that Novartis can’t tout. Cosentyx failed to outdo AbbVie behemoth Humira in a head-to-head tria…,Carly Helfand,https://www.fiercepharma.com/pharma/novartis-cosentyx-can-t-top-abbvie-s-humira-head-to-head-psoriatic-arthritis-contest,Fiercepharma.com,,2019-11-01T14:12:03Z,-0.4
559029,LLY,"Novartis' Cosentyx can't top AbbVie's Humira in head-to-head psoriatic arthritis contest",Eli Lilly’s Taltz and Novartis’ Cosentyx have been battling it out lately in the next-gen psoriatic arthritis field. But Lilly’s drug has a big win under its belt that Novartis can’t tout. Cosentyx failed to outdo AbbVie behemoth Humira in a head-to-head tria…,Carly Helfand,https://www.fiercepharma.com/pharma/novartis-cosentyx-can-t-top-abbvie-s-humira-head-to-head-psoriatic-arthritis-contest,Fiercepharma.com,,2019-11-01T14:12:03Z,-0.4
558276,ABBV,AbbVie says multiple parties vying for assets related to Allergan deal approval,"The company said it had notified the U.S. antitrust watchdog of its intention to divest its experimental inflammatory bowel disease therapy, brazikumab, and its treatment for a type of pancreatic disease, Zenpep. The agency asked the companies for additional …",,https://finance.yahoo.com/news/abbvie-says-multiple-parties-vying-141007770.html,Yahoo.com,,2019-11-01T14:10:07Z,0.53
558277,ABBV,AbbVie boosts 2019 profit outlook as Humira helps beat revenue estimates,"AbbVie Inc  posted quarterly sales above estimates on Friday and raised the lower end of its 2019 profit forecast, helped by strong demand for cancer medicine Imbruvica and a lower-than-expected drop in bestseller Humira's revenue.",CNA,https://www.channelnewsasia.com/news/business/abbvie-boosts-2019-profit-outlook-as-humira-helps-beat-revenue-estimates-12055696,Channelnewsasia.com,,2019-11-01T12:55:44Z,0.59
558278,ABBV,UPDATE 1-AbbVie boosts 2019 profit outlook as Humira helps beat revenue estimates,"AbbVie Inc posted quarterly sales above estimates on Friday and raised the lower end of its 2019 profit forecast, getting a boost from strong demand for cancer medicine Imbruvica and a lower-than-expected drop in bestseller Humira's revenue. In June, AbbVie a…",,https://finance.yahoo.com/news/1-abbvie-boosts-2019-profit-124639233.html,Yahoo.com,,2019-11-01T12:46:39Z,0.76
560350,ZTS,"Zacks.com featured highlights include: Heico, Microsoft, Zoetis and Cadence","Zacks.com featured highlights include: Heico, Microsoft, Zoetis and Cadence",Zacks Equity Research,https://finance.yahoo.com/news/zacks-com-featured-highlights-heico-121912186.html,Yahoo.com,,2019-11-01T12:19:12Z,0
558279,ABBV,AbbVie: 3Q Earnings Snapshot,"NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported third-quarter earnings of $1.88 billion.",,https://www.stltoday.com/business/national-and-international/abbvie-q-earnings-snapshot/article_7bba0a0a-7d4b-534e-a461-19d02694eb33.html,Stltoday.com,,2019-11-01T11:57:04Z,-0.42
556835,ABBV,AbbVie lifts 2019 profit forecast as Humira helps beat revenue estimates,"In June, AbbVie announced a $63 billion deal for Botox-maker Allergan Plc, in a bid to diversify its drug pipeline amid growing threats to Humira's longevity. Humira sales totaled about $20 billion last year and the drug has accounted for the bulk of AbbVie's…",Reuters,https://finance.yahoo.com/news/abbvie-lifts-2019-profit-forecast-115205364.html,Yahoo.com,,2019-11-01T11:52:05Z,0.53
556836,ABBV,AbbVie Reports Third-Quarter 2019 Financial Results,"NORTH CHICAGO, Ill., Nov. 1, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2019. ""Strong performance from our Immunology and Hematologic Oncology portfolios led our growth this quarter. We are al…",,https://www.prnewswire.com/news-releases/abbvie-reports-third-quarter-2019-financial-results-300949811.html,Prnewswire.com,,2019-11-01T11:47:00Z,0.71
557035,BMY,Bristol-Myers extends exchange offer for Celgene debt,"Bristol-Myers Squibb (NYSE:BMY) has extended the end date of its exchange offer, up to $19.85B, for Celgene (NASDAQ:CELG) debt to November 6 to complete the transaction. $19.85B of Celgene notes were",SA Editor Douglas W. House,https://seekingalpha.com/news/3512944-bristol-myers-extends-exchange-offer-celgene-debt,Seekingalpha.com,,2019-11-01T11:19:25Z,-0.25
558281,ABBV,"AbbVie beats earnings expectations and raises outlook, boosts dividend by 10%","AbbVie Inc. reported Friday a third-quarter adjusted profit and revenue that rose above expectations, helped by strength in its immunology and oncology business segments, and raised its earnings outlook. The stock slipped 0.4% in premarket trading. The compan…",Tomi Kilgore,https://www.marketwatch.com/story/abbvie-beats-earnings-expectations-and-raises-outlook-boosts-dividend-by-10-2019-11-01,Marketwatch.com,,2019-11-01T11:06:22Z,0.81
558260,ZTS,Finalists announced for Young Vet of the Year,BVA and Zoetis have announced the three finalists for the Young Vet of the Year award 2019. Amy Barstow is a Royal Veterinary College graduate and now works in equine practice. She has volunteered abroad and has a PhD in equine biomechanics. Andreia Dias grad…,,https://veterinaryrecord.bmj.com/content/185/17/522.2,Bmj.com,,2019-11-01T09:35:34Z,0.54
558261,ZTS,Finalists announced for BVA Young Vet of the Year Award,"BVA and Zoetis are delighted to announce the three finalists who are in the running to be named BVA Young Vet of the Year 2019. Adam Rawcliffe , BVA Corporate Partnerships Manager, introduces them.",,https://veterinaryrecord.bmj.com/content/185/17/547.2,Bmj.com,,2019-11-01T09:35:34Z,0.51
556824,ZTS,Zoetis (ZTS) Gains As Market Dips: What You Should Know,"In the latest trading session, Zoetis (ZTS) closed at $127.92, marking a +0.25% move from the previous day.",Zacks Equity Research,https://finance.yahoo.com/news/zoetis-zts-gains-market-dips-215009420.html,Yahoo.com,,2019-10-31T21:50:09Z,0.34
556825,ZTS,"Zoetis Completes Acquisition of Phoenix Lab, a Leading Veterinary Reference Laboratory, to Enhance its Comprehensive Offering in Veterinary Diagnostics","PARSIPPANY, N.J. & MUKILTEO, Wash.--(BUSINESS WIRE)---- $ZTS #acquisition--Zoetis has completed the acquisition of Phoenix Lab, a leading veterinary reference laboratory.",,https://www.businesswire.com/news/home/20191031005825/en/Zoetis-Completes-Acquisition-Phoenix-Lab-Leading-Veterinary,Businesswire.com,,2019-10-31T20:37:54Z,0.25
553310,BMY,Bristol-Myers Squibb Beats Expectations in Q3 as Its Celgene Acquisition Nears the Finish Line,"Opdivo didn't turn in an impressive performance, but BMS' other drugs generated more than enough growth to top Wall Street's estimates.",newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2019/10/31/bristol-myers-squibb-beats-expectations-in-q3-as-i.aspx,Fool.com,,2019-10-31T17:00:00Z,0.8
553311,BMY,Bristol-Myers Squibb Co (BMY) Q3 2019 Earnings Call Transcript,"BMY earnings call for the period ending September 30, 2019.",newsfeedback@fool.com (Motley Fool Transcribers),https://www.fool.com/earnings/call-transcripts/2019/10/31/bristol-myers-squibb-co-bmy-q3-2019-earnings-call.aspx,Fool.com,,2019-10-31T16:30:50Z,0
552965,ABBV,AbbVie eyes 2nd Rinvoq nod as it hits its marks in psoriatic arthritis,"AbbVie blockbuster-to-be Rinvoq only just hit the scene in rheumatoid arthritis, but it’s already on its way to a second indication. Thrusday, the Illinois drugmaker said its newcomer had hit its primary endpoint in a phase 3 psoriatic arthritis (PsA) trial, …",Carly Helfand,https://www.fiercepharma.com/pharma/abbvie-eyes-2nd-rinvoq-nod-as-it-hits-its-marks-psoriatic-arthritis,Fiercepharma.com,,2019-10-31T15:28:45Z,0
552967,ABBV,EuroBiotech: More Articles of Note - FierceBiotech,"In our EuroBiotech roundup this week, BioMed X advances AbbVie Alzheimer’s program, ObsEva OKed to start trial and Futura erectile dysfunction data.",,https://www.fiercebiotech.com/biotech/eurobiotech-more-articles-note-166,Fiercebiotech.com,,2019-10-31T13:45:00Z,-0.42
553312,BMY,Is Bristol-Myers Squibb (BMY) a Great Value Stock Right Now?,"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong pi…",Zacks Equity Research,https://finance.yahoo.com/news/bristol-myers-squibb-bmy-great-131001900.html,Yahoo.com,,2019-10-31T13:10:01Z,0.96
552970,ABBV,RINVOQ™ (upadacitinib) Meets Primary and All Ranked Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis,"NORTH CHICAGO, Ill., Oct. 31, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line data from the SELECT-PsA 2 Phase 3 study. In this study, both doses of RINVOQ™ (upadacitinib; 15 mg an…",,https://www.prnewswire.com/news-releases/rinvoq-upadacitinib-meets-primary-and-all-ranked-secondary-endpoints-in-phase-3-study-in-psoriatic-arthritis-300948804.html,Prnewswire.com,,2019-10-31T12:45:00Z,0.56
553314,BMY,Bristol-Myers Squibb (BMY) Q3 Earnings and Revenues Top Estimates,"Bristol-Myers (BMY) delivered earnings and revenue surprises of 10.38% and 3.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?",Zacks Equity Research,https://finance.yahoo.com/news/bristol-myers-squibb-bmy-q3-122512616.html,Yahoo.com,,2019-10-31T12:25:12Z,0.32
551575,BMY,"Stocks making the biggest moves premarket: Altria, Bristol-Myers Squibb, Generac, Apple and more",These are the stocks posting the largest moves before the bell.,Peter Schacknow,https://www.cnbc.com/2019/10/31/stocks-making-the-biggest-moves-premarket-altria-bristol-myers-squibb-generac-apple-and-more.html,CNBC,,2019-10-31T11:47:00Z,0
551576,BMY,"Bristol-Myers posts better-than-expected results, Opdivo growth slows","U.S. drugmaker Bristol-Myers Squibb Co reported higher-than-expected third-quarter profit on Thursday, helped by strong sales of blood thinner Eliquis, even as growth of its blockbuster cancer treatment Opdivo slowed.",Michael Erman,https://www.reuters.com/article/us-bristol-myers-results-idUSKBN1XA1G2,Reuters,,2019-10-31T11:14:00Z,0.87
551577,BMY,Bristol-Myers Squibb Reports Third Quarter Financial Results,NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol-Myers Squibb Reports Third Quarter Financial Results,,https://www.businesswire.com/news/home/20191031005196/en/Bristol-Myers-Squibb-Reports-Quarter-Financial-Results,Businesswire.com,,2019-10-31T11:10:41Z,0
551578,BMY,Bristol-Myers tops earnings estimates but lowers guidance,"Bristol-Myers Squibb Co. shares rose 0.9% after the company beat earnings estimates but lowered its full-year per-share earnings guidance. The New York-based drug company said it had net income of $1.353 billion, or 83 cents a share, in the quarter, down from…",Ciara Linnane,https://www.marketwatch.com/story/bristol-myers-tops-earnings-estimates-but-lowers-guidance-2019-10-31,Marketwatch.com,,2019-10-31T10:09:53Z,0.64
549434,ABBV,AbbVie (ABBV) Set to Report Q3 Results: Can Things Turnaround?,"AbbVie (ABBV) is set to report its third quarter results before the opening bell on Friday, November 1.",Christopher Vargas,https://finance.yahoo.com/news/abbvie-abbv-set-report-q3-203208611.html,Yahoo.com,,2019-10-30T20:32:08Z,0
549733,BMY,Bristol-Myers Squibb to Take Part at the Wolfe Research Healthcare Conference,NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol-Myers Squibb to Take Part at the Wolfe Research Healthcare Conference,,https://www.businesswire.com/news/home/20191030006014/en/Bristol-Myers-Squibb-Part-Wolfe-Research-Healthcare-Conference,Businesswire.com,,2019-10-30T20:23:38Z,0
548087,LLY,"Eli Lilly's Approval For Migraine Drug Provides A Unique Treatment Option",Eli Lilly received FDA approval for Reyvow to treat patients with acute migraine. Reyvow is the first and only medicine of its class - serotonin (5-HT) 1F recep,Terry Chrisomalis,https://seekingalpha.com/article/4300401-eli-lillys-approval-migraine-drug-provides-unique-treatment-option,Seekingalpha.com,,2019-10-30T16:52:16Z,0.84
548063,JNJ,"UK's stance of Kashmir being bilateral issue between India, Pak remains unchanged: Boris Johnson","Johnson's statement came in the backdrop of the two-day trip of 23 members of European Parliament to Jammu and Kashmir to assess the situation. The visiting EU parliamentarians on Wednesday termed the dilution of Article 370 an internal issue of India and sai…",Times Of India,https://timesofindia.indiatimes.com/world/uk/uks-stance-of-kashmir-being-bilateral-issue-between-india-pak-remains-unchanged-boris-johnson/articleshow/71824714.cms,The Times of India,,2019-10-30T16:01:57Z,0
545942,BMY,"Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Carmine Therapeutics, STIMIT","PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY--Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Carmine Therapeutics, STIMIT",,https://www.businesswire.com/news/home/20191030005268/en/Bristol-Myers-Squibb-Awards-%E2%80%9CGolden-Tickets%E2%80%9D-LabCentral-Carmine,Businesswire.com,,2019-10-30T11:12:17Z,0.72
544846,MRK,Edited Transcript of MRK earnings conference call or presentation 29-Oct-19 12:00pm GMT,Q3 2019 Merck & Co Inc Earnings Call,Thomson Reuters StreetEvents,https://finance.yahoo.com/news/edited-transcript-mrk-earnings-conference-230034276.html,Yahoo.com,,2019-10-29T23:00:34Z,0
544803,JNJ,J&J Gets $10 Billion Gift as Lab Results Show No Asbestos in Baby Powder,Source: Zolnierek / Getty ImagesJohnson & Johnson (NYSE: JNJ) has found itself involved in more controversy than the company would prefer to see. The consumer and health products company has been dogged in the public view by stories of asbestos in its talcum …,Jon C. Ogg,https://247wallst.com/consumer-products/2019/10/29/jj-gets-10-billion-gift-as-lab-results-show-no-asbestos-in-baby-powder/,247wallst.com,,2019-10-29T21:12:48Z,0.18
544275,ABBV,"McDonald's, AbbVie nab 2019 Chicago Innovation Awards","The 18th annual Chicago Innovation Awards took place Monday night, and 25 local companies and organizations were recognized for their innovative contributions. After reviewing more than 450 nominations, 100 finalists were announced in September and a panel of…",Katherine Davis,https://www.bizjournals.com/chicago/news/2019/10/29/mcdonalds-abbvie-nab-2019-chicago-innovation.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+industry_7+%28Industry+Technology%29,Bizjournals.com,,2019-10-29T21:01:09Z,0.88
544805,LLY,Insider Weekends: Tile Shop Insiders Continue Buying After Company Decides To Delist,"Insider buying increased last week. Notable Insider Buys: Tile Shop Holdings, Inc., OPKO Health, Inc., Assured Guaranty Ltd., JPMorgan Chase & Co., Eli Lilly an",Asif Suria,https://seekingalpha.com/article/4300094-insider-weekends-tile-shop-insiders-continue-buying-company-decides-delist,Seekingalpha.com,,2019-10-29T20:57:24Z,0.56
542878,MRK,Merck & Co Inc (MRK) Q3 2019 Earnings Call Transcript,"MRK earnings call for the period ending September 30, 2019.",newsfeedback@fool.com (Motley Fool Transcribers),https://www.fool.com/earnings/call-transcripts/2019/10/29/merck-co-inc-mrk-q3-2019-earnings-call-transcript.aspx,Fool.com,,2019-10-29T17:30:37Z,0
542879,MRK,"Merck & Co., Inc. (MRK) CEO Ken Frazier on Q3 2019 Results - Earnings Call Transcript","Merck &amp; Co., Inc. (NYSE:MRK) Q3 2019 Earnings Conference Call October 29, 2019 8:00 AM ET Company Participants Peter Dannenbaum - Vice President of Investor",SA Transcripts,https://seekingalpha.com/article/4299956-merck-and-co-inc-mrk-ceo-ken-frazier-q3-2019-results-earnings-call-transcript,Seekingalpha.com,,2019-10-29T17:16:25Z,0
542401,BMY,Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q3 Earnings?,"Investors will focus on the performance of Opdivo and Eliquis along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter result...",Zacks Equity Research,https://finance.yahoo.com/news/opdivo-eliquis-drive-bristol-myers-160104218.html,Yahoo.com,,2019-10-29T16:01:04Z,0
542882,MRK,"Merck (MRK) Beats on Q3 Earnings & Sales, Raises '19 View","Merck (MRK) beats estimates for earnings as well as sales in third-quarter 2019. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand. Shares up.",Zacks Equity Research,https://finance.yahoo.com/news/merck-mrk-beats-q3-earnings-143002459.html,Yahoo.com,,2019-10-29T14:30:02Z,0.79
542839,JNJ,Could Johnson & Johnson’s Revenue Growth Stall?,"Johnson & Johnson (NYSE: JNJ) generates its revenues from sales of pharmaceutical products, medical devices, and consumer products. The company’s revenues have grown 14% between 2016 and 2018, led by Actelion and Abbott Medical Optics acquisitions, and growth…","Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/",https://www.forbes.com/sites/greatspeculations/2019/10/29/could-johnson--johnsons-revenue-growth-stall/,Forbes.com,,2019-10-29T13:30:00Z,0.38
542036,ABBV,AbbVie Launches Let Me Be Clear to Empower People with Psoriasis to Speak Up and Seek Freedom from Their Disease,"NORTH CHICAGO, Ill., Oct. 29, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the launch of Let Me Be Clear, an empowerment platform for people living with psoriasis. The initiative, which launches …",,https://www.prnewswire.com/news-releases/abbvie-launches-let-me-be-clear-to-empower-people-with-psoriasis-to-speak-up-and-seek-freedom-from-their-disease-300947191.html,Prnewswire.com,,2019-10-29T13:03:00Z,0.86
542038,ABBV,Disc Medicine Expands Pipeline Focused on Hepcidin Pathway,"Enters into exclusive agreement with AbbVie for series of Hemojuvelin Antagonist Monoclonal Antibodies CAMBRIDGE, Mass., Oct. 29, 2019 -- (Healthcare Sales & Marketing Network) -- Disc Medicine, a hematology company that is applying new insights in hep... Bio…",Disc Medicine,https://salesandmarketingnetwork.com/news_release_bs.html?ID=2045483,Salesandmarketingnetwork.com,,2019-10-29T12:59:24Z,0.59
542039,ABBV,"Disc Medicine nabs cash, big backers and biopharma drug deal","Not a bad day’s work for Atlas-seeded startup Disc Medicine: It’s managed a healthy $50 million series A, led by Novo Nordisk’s VC arm, gained a new executive chair from Nimbus and nabbed a deal with AbbVie.",Ben Adams,https://www.fiercebiotech.com/biotech/disc-medicine-nabs-cash-big-backers-and-biopharma-drug-deal,Fiercebiotech.com,,2019-10-29T12:55:45Z,0.2
541041,JNJ,"Lanny's November Dividend Stock Watch List","Trading at $128.35, JNJ is trading far from their 52-week high of $148.99. That's a solid 14% from their high! JNJ currently yields 2.96%, which yields higher t",Dividend Diplomats,https://seekingalpha.com/article/4299793-lannys-november-dividend-stock-watch-list,Seekingalpha.com,,2019-10-29T10:12:35Z,0.22
541045,JNJ,Grand jury subpoenas in J&J opioid probe,Johnson &amp; Johnson (NYSE:JNJ) received grand jury subpoenas in August from the U.S. attorney’s office for the Eastern District of New York related to its opioid medication policies.That includes an,SA Editor Yoel Minkoff,https://seekingalpha.com/news/3510498-grand-jury-subpoenas-j-and-j-opioid-probe,Seekingalpha.com,,2019-10-29T07:55:39Z,0.72
537806,LLY,Weekly CEO Buys Highlight,"Insiders invest in OPKO Health, Eli Lilly, Wesbanco, New Mountain Finance and Hersha Hospitality Continue reading...",GuruFocus.com,https://finance.yahoo.com/news/weekly-ceo-buys-highlight-160618792.html,Yahoo.com,,2019-10-28T16:06:18Z,0
536119,LLY,"HVS Market Pulse: Downtown Indianapolis | By Justin Kaminski","The Circle City is currently experiencing a period of growth led by the hospitality sector, sporting events, and citywide conventions, coupled with added jobs and expansions throughout the CBD from companies such as Salesforce, Rolls-Royce, and Eli Lilly. Dow…",Justin  Kaminski,https://www.hospitalitynet.org/opinion/4095628.html,Hospitalitynet.org,,2019-10-28T12:11:01Z,0.38
534803,LLY,Insider Buying: The Eli Lilly and Company (NYSE:LLY) Chairman Just Bought US$500k Worth Of Shares,Those following along with Eli Lilly and Company (NYSE:LLY) will no doubt be intrigued by the recent purchase of...,Simply Wall St,https://finance.yahoo.com/news/insider-buying-eli-lilly-company-141647036.html,Yahoo.com,,2019-10-27T14:16:47Z,-0.42
532492,ABBV,"Bert's Dividend Stock Purchases - October 2019","I purchased six shares of AbbVie, Inc. I actually purchased shares of Canadian Imperial twice this month. I made two separate purchases and added 25 shares of D",Dividend Diplomats,https://seekingalpha.com/article/4299354-berts-dividend-stock-purchases-october-2019,Seekingalpha.com,,2019-10-26T11:04:52Z,0.68
532611,JNJ,"Retailers are pulling Johnson's baby powder from store shelves - CNN","Retailers are pulling Johnson's baby powder from store shelvesCNN Investors Should Short JNJ Stock and Buy Boeing StockInvestorplace.com CVS, Walmart pull select Johnson & Johnson baby powders over asbestosFox News Big US retailers pull some baby powder off s…",feedfeeder,https://slashdot.org/firehose.pl?op=view&amp;id=118114420,Slashdot.org,,2019-10-26T05:12:48Z,0
531286,ALLY,Ally Turned Personal Finance Into A Game Of Augmented Reality Monopoly,The board game that people don’t seem to get bored of is the star of a new campaign from Ally Financially.,"Marty Swant, Forbes Staff, Marty Swant, Forbes Staff https://www.forbes.com/sites/martyswant/",https://www.forbes.com/sites/martyswant/2019/10/25/ally-turned-personal-finance-into-a-game-of-augmented-reality-monopoly/,Forbes.com,,2019-10-25T21:02:12Z,-0.27
529972,JNJ,"Johnson & Johnson update: More retailers pull baby powder, opioid settlement possible","CVS Health and Target have joined the list of retailers who've said they will no longer sell 22-ounce bottles of Johnson & Johnson's baby powder, as a precautionary measure. Separately, Johnson & Johnson (NYSE: JNJ) confirmed in an SEC filing Wednesday night …",Greg Edwards,https://www.bizjournals.com/stlouis/news/2019/10/25/johnson-johnson-update-more-retailers-pull-baby.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_stlouis+%28St.+Louis+Business+Journal%29,Bizjournals.com,,2019-10-25T16:55:34Z,-0.3
529224,ABBV,"What's in the Cards for AbbVie (ABBV) This Earnings Season?","AbbVie's (ABBV) Q3 sales may have been weighed down by biosimilar competition for Humira in international markets. However, strong growth of oncology drugs might have offset impact of Humira's international sales erosion.",,https://news.yahoo.com/whats-cards-abbvie-abbv-earnings-151003918.html,Yahoo.com,,2019-10-25T15:10:03Z,0.71
530388,PRGO,"Boots and Morrisons' own version of Zantac are recalled",Perrigo Company supplies ranitidine - the generic form of the branded heartburn drug - to both of the British retail giants. It announced the recall in an alert sent out by UK health chiefs today.,By Stephen Matthews Health Editor For Mailonline,https://www.dailymail.co.uk/health/article-7614079/Boots-Morrisons-version-Zantac-recalled.html,Dailymail.co.uk,,2019-10-25T14:56:16Z,0.3
530390,PRGO,Ranitidine – MHRA drug alerts issued as Perrigo recalls prescription only and over-the-counter products,"The MHRA has issued alerts to healthcare professionals and retailers, as Perrigo Company plc is recalling all unexpired stock of certain batches of Ranitidine medicines used to treat conditions such as heartburn and stomach ulcers.",Medicines and Healthcare products Regulatory Agency,https://www.gov.uk/government/news/ranitidine-mhra-drug-alerts-issued-as-perrigo-recalls-prescription-only-and-over-the-counter-products,Www.gov.uk,,2019-10-25T12:27:06Z,0.59
529225,ABBV,AbbVie Announces Commencement of Exchange Offers and Consent Solicitations for Allergan Notes,"NORTH CHICAGO, Ill., Oct. 25, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) (""AbbVie"") announced today the commencement, in connection with its previously announced acquisition of Allergan plc (NYSE:AGN), of offers to exchange any and all outstanding notes of …",,https://www.prnewswire.com/news-releases/abbvie-announces-commencement-of-exchange-offers-and-consent-solicitations-for-allergan-notes-300945529.html,Prnewswire.com,,2019-10-25T12:11:00Z,0.71
528116,JNJ,Three top retailers pull 22-ounce J&J Baby Powder off shelves,"Walmart (NYSE:WMT), CVS (NYSE:CVS) and Rite Aid (NYSE:RAD) are removing all 22-ounce bottles of Johnson &amp; Johnson's (NYSE:JNJ) Baby Powder from their stores, following last week's recall of one lo",SA Editor Carl Surran,https://seekingalpha.com/news/3509527-three-top-retailers-pull-22-ounce-j-and-j-baby-powder-shelves,Seekingalpha.com,,2019-10-25T07:49:11Z,0.2
523417,ABBV,AbbVie and AstraZeneca settle respective patent suits over rival cancer drugs,AstraZeneca (AZN +5.7%) and AbbVie (ABBV -1.5%) have agreed to settle their tit-for-tat patent infringement complaints related to their respective kinase inhibitors Calquence (acalabrutinib) and Imbru,SA Editor Douglas W. House,https://seekingalpha.com/news/3509214-abbvie-astrazeneca-settle-respective-patent-suits-rival-cancer-drugs,Seekingalpha.com,,2019-10-24T17:01:51Z,-0.67
524248,LLY,Lilly Announces Cash Tender Offer for Up to $2.0 Billion Aggregate Principal Amount of Its Outstanding Debt Securities,"INDIANAPOLIS, Oct. 24, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $2.0 billion aggregate principal amount (the ""tender cap"") of specified series of its outstanding debt. Pursuant …",,https://www.prnewswire.com/news-releases/lilly-announces-cash-tender-offer-for-up-to-2-0-billion-aggregate-principal-amount-of-its-outstanding-debt-securities-300944931.html,Prnewswire.com,,2019-10-24T14:17:00Z,0.61
523788,BMY,"Bristol-Myers: Dividend Stock, Low Valuation, Boost From Celgene",Bristol-Myers Squibb is trading at an attractive valuation. The Celgene acquisition might not be fully reflected in the stock price. Management is building a so,David Zanoni,https://seekingalpha.com/article/4298554-bristol-myers-dividend-stock-low-valuation-boost-celgene,Seekingalpha.com,,2019-10-24T13:47:17Z,0.54
524250,LLY,Is Eli Lilly Stock a Buy?,"Investors weren't impressed with the drugmaker's Q3 report. Should bargain hunters take advantage of this recent weakness in its shares?",newsfeedback@fool.com (George Budwell),https://www.fool.com/investing/2019/10/24/is-eli-lilly-stock-a-buy.aspx,Fool.com,,2019-10-24T12:44:00Z,-0.18
523420,ABBV,AbbVie to Present at the Wolfe Research Inaugural Healthcare Conference,"NORTH CHICAGO, Ill., Oct. 24, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Wolfe Research Inaugural Healthcare Conference on Wednesday, November 6. Richard A. Gonzalez, chairman and chief…",,https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-wolfe-research-inaugural-healthcare-conference-300944391.html,Prnewswire.com,,2019-10-24T12:30:00Z,0
522068,BMY,"With EPS Growth And More, Bristol-Myers Squibb (NYSE:BMY) Is Interesting","It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...",,https://finance.yahoo.com/news/eps-growth-more-bristol-myers-103055023.html,Yahoo.com,1505520,2019-10-24T10:30:55Z,0.74
522311,LLY,Eli Lilly and Company (LLY) Q3 2019 Earnings Call Transcript,"LLY earnings call for the period ending September 30, 2019.",newsfeedback@fool.com (Motley Fool Transcribing),https://www.fool.com/earnings/call-transcripts/2019/10/24/eli-lilly-and-company-lly-q3-2019-earnings-call-tr.aspx,Fool.com,1456272,2019-10-24T05:25:04Z,0
520732,JNJ,"J&J's proposed opioid settlement to cut Q3 profit by $3B","Johnson &amp; Johnson (NYSE:JNJ) confirms its agreement in principle to settle opioid litigation in which it would contribute $4B, according to an SEC filing.JNJ says the proposed settlement would red",SA Editor Carl Surran,https://seekingalpha.com/news/3508849-j-and-js-proposed-opioid-settlement-cut-q3-profit-3b,Seekingalpha.com,1510704,2019-10-23T22:58:29Z,0.49
520737,LLY,Eli Lilly and Company (LLY) CEO Dave Ricks on Q3 2019 Results - Earnings Call Transcript,"Eli Lilly and Company (NYSE:LLY) Q3 2019 Earnings Conference Call October 23, 2019 09:00 ET Company Participants Kevin Hern - VP IR Dave Ricks - Chairman &amp;",SA Transcripts,https://seekingalpha.com/article/4298376-eli-lilly-company-lly-ceo-dave-ricks-q3-2019-results-earnings-call-transcript,Seekingalpha.com,1510704,2019-10-23T22:26:25Z,0
521180,PRGO,"Perrigo Company plc Issues Voluntary Worldwide Recall of Ranitidine Due to Possible Presence of Impurity, N-nitrosodimethylamine (NDMA) Impurity in the Product","As a precautionary measure, Perrigo Company plc announced today that it has initiated a voluntary, worldwide product recall to the retail customer level of ranitidine (all pack sizes). The recall is being taken due to possible presence of a nitrosamine impuri…",FDA,https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/perrigo-company-plc-issues-voluntary-worldwide-recall-ranitidine-due-possible-presence-impurity-n,Fda.gov,1562544,2019-10-23T22:06:44Z,0
518780,LLY,Recon: Eli Lilly Raises Guidance on New Drug Sales; Alkermes to Lay Off 160,"Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.",,https://www.raps.org/news-and-articles/news-articles/2019/10/recon-eli-lilly-raises-guidance-on-new-drug-sales?feed=Regulatory-Focus,Raps.org,1515888,2019-10-23T17:27:12Z,0.48
518781,LLY,Why Eli Lilly Stock Fell Despite Its Solid Q3 Earnings Beat,The big drugmaker seemingly did what it needed to do in Q3. Except for one thing.,newsfeedback@fool.com (Keith Speights),https://www.fool.com/investing/2019/10/23/why-eli-lilly-stock-fell-despite-its-solid-q3-earn.aspx,Fool.com,1515888,2019-10-23T17:00:00Z,-0.11
518782,LLY,"Lilly USA, diabetes chief Enrique Conterno bows out after 27 years","Eli Lilly's top U.S. executive is on the way out. Enrique Conterno, who heads up Lilly's worldwide diabetes business as well as Lilly USA, plans to retire after 27 years at the company. Mike Mason, who led a couple of Lilly's most successful diabetes rollouts…",Eric Sagonowsky,https://www.fiercepharma.com/pharma/lilly-s-longtime-diabetes-chief-enrique-conterno-set-to-retire-internal-successor-named,Fiercepharma.com,1515888,2019-10-23T15:19:30Z,0.79
518274,BMY,Bristol-Myers Up as Pivotal NSCLC Study Meets Primary Endpoint,"Bristol-Myers' (BMY) phase III study evaluating a combination regimen of Opdivo meets primary endpoint of superior overall survival in patients with advanced lung cancer in first-line setting.",Zacks Equity Research,https://finance.yahoo.com/news/bristol-myers-pivotal-nsclc-study-151303711.html,Yahoo.com,1502928,2019-10-23T15:13:03Z,0.03
518783,LLY,Eli Lilly to target cancer drug developers for deals,"Eli Lilly and Co will target cancer drug developers for deals, Chief Executive Officer Dave Ricks said on a post-earnings conference call on Wednesday.",CNA,https://www.channelnewsasia.com/news/world/eli-lilly-to-target-cancer-drug-developers-for-deals-12028630,Channelnewsasia.com,1515888,2019-10-23T14:35:47Z,-0.87
518785,LLY,Eli Lilly Just Couldn’t Get It Together in Q3,Eli Lilly shares retreated after it released mixed third-quarter financial results before the markets opened on Wednesday.,247chrislange,https://247wallst.com/healthcare-business/2019/10/23/eli-lilly-just-couldnt-get-it-together-in-q3/,247wallst.com,1515888,2019-10-23T14:25:10Z,0.3
518786,LLY,Eli Lilly and Company 2019 Q3 - Results - Earnings Call Presentation,The following slide deck was published by Eli Lilly and Company in conjunction with their 2019 Q3 earnings call.,SA Transcripts,https://seekingalpha.com/article/4298172-eli-lilly-company-2019-q3-results-earnings-call-presentation,Seekingalpha.com,1515888,2019-10-23T14:01:55Z,0
518777,JNJ,Does Johnson & Johnson (NYSE:JNJ) Have A Healthy Balance Sheet?,"Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...",,https://finance.yahoo.com/news/does-johnson-johnson-nyse-jnj-132211065.html,Yahoo.com,1513296,2019-10-23T13:22:11Z,0.15
519289,PRGO,Hedge Funds Are Betting On Perrigo Company plc (PRGO),"Is Perrigo Company plc (NYSE:PRGO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more i…",Abigail Fisher,https://finance.yahoo.com/news/hedge-funds-betting-perrigo-company-130100642.html,Yahoo.com,1575504,2019-10-23T13:01:00Z,0.66
516813,LLY,Lilly down 3% as sales lag expectations,"Eli Lilly (NYSE:LLY) slips 3% premarket on light volume on the heels of its Q3 report. Despite an earnings beat and subsequent (modest) guidance raise, investors are still waiting for a ramp in sales",SA Editor Douglas W. House,https://seekingalpha.com/news/3508322-lilly-3-percent-sales-lag-expectations,Seekingalpha.com,1474416,2019-10-23T12:10:12Z,-0.34
516814,LLY,"Stocks making the biggest moves premarket: Boeing, Caterpillar, Blackstone, Eli Lilly, Nike & more",These are the stocks posting the largest moves before the bell.,Peter Schacknow,https://www.cnbc.com/2019/10/23/stocks-making-the-biggest-moves-premarket-boeing-caterpillar-blackstone-eli-lilly-nike-more.html,CNBC,1474416,2019-10-23T12:09:00Z,0
516815,LLY,Eli Lilly (LLY) Surpasses Q3 Earnings Estimates,"Lilly (LLY) delivered earnings and revenue surprises of 3.50% and -1.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?",Zacks Equity Research,https://finance.yahoo.com/news/eli-lilly-lly-surpasses-q3-114511207.html,Yahoo.com,1477008,2019-10-23T11:45:11Z,0.13
516816,LLY,Eli Lilly tops profit estimates in latest quarter as revenue falls short,"Eli Lilly & Co. said Wednesday it had net income of $1.254 billion, or $1.37 a share, in the third quarter, up from $1.149 billion, or $1.12 a share, in the year-earlier period. Adjusted per-share earnings came to $1.48, ahead of the $1.40 FactSet consensus. …",Ciara Linnane,https://www.marketwatch.com/story/eli-lilly-tops-profit-estimates-in-latest-quarter-as-revenue-falls-short-2019-10-23,Marketwatch.com,1477008,2019-10-23T10:58:01Z,0.86
516817,LLY,UPDATE 1-Eli Lilly lifts 2019 profit forecast after third-quarter beat,"Eli Lilly and Co raised its 2019 profit forecast after reporting a better-than-expected quarterly profit on Wednesday, helped by performance of its diabetes drug, Humalog, and lower tax bill. The drugmaker is one of the three main providers of insulin product…",,https://finance.yahoo.com/news/1-eli-lilly-lifts-2019-105432679.html,Yahoo.com,1477008,2019-10-23T10:54:32Z,0.76
516818,LLY,Eli Lilly lifts 2019 profit forecast after third-quarter beat,"Eli Lilly and Co  reported a 9.1per cent increase in third-quarter profit on Wednesday, helped by higher sales of its top-selling diabetes drug, Trulicity, and lower tax expense.",CNA,https://www.channelnewsasia.com/news/business/eli-lilly-lifts-2019-profit-forecast-after-third-quarter-beat-12027918,Channelnewsasia.com,1479600,2019-10-23T10:41:52Z,0.71
516819,LLY,Eli Lilly reports 9per cent rise in third-quarter profit,"Eli Lilly and Co  reported a 9.1per cent increase in third-quarter profit on Wednesday, helped by higher sales of its top-selling diabetes drug, Trulicity, and lower tax expense.",CNA,https://www.channelnewsasia.com/news/business/eli-lilly-reports-9per-cent-rise-in-third-quarter-profit-12027918,Channelnewsasia.com,1479600,2019-10-23T10:41:52Z,0.46
516820,LLY,Eli Lilly reports 9% rise in third-quarter profit,"Eli Lilly reported a 9.1% increase in third-quarter profit on Wednesday, helped by higher sales of its top-selling diabetes drug, Trulicity, and lower tax expense.",Reuters,https://www.cnbc.com/2019/10/23/eli-lilly-reports-9percent-rise-in-third-quarter-profit.html,CNBC,1479600,2019-10-23T10:36:00Z,0.46
516822,LLY,"Lilly Reports Strong Third-Quarter 2019 Financial Results, Raises 2019 EPS Guidance","INDIANAPOLIS, Oct. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2019. $ in millions, except per share data Third Quarter % 2019 2018 Change Revenue $ 5,476.6 $ 5,306.9 3% Net Income – Re…",,https://www.prnewswire.com/news-releases/lilly-reports-strong-third-quarter-2019-financial-results-raises-2019-eps-guidance-300943585.html,Prnewswire.com,1479600,2019-10-23T10:25:00Z,0.67
516823,LLY,"Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to Retire at End of Year; Mike Mason to Succeed Conterno","INDIANAPOLIS, Oct. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will retire at the end of the year after 27 years of service wit…",,https://www.prnewswire.com/news-releases/enrique-conterno-senior-vice-president-and-president-of-lilly-diabetes-and-lilly-usa-to-retire-at-end-of-year-mike-mason-to-succeed-conterno-300943583.html,Prnewswire.com,1482192,2019-10-23T10:00:00Z,0.49
512839,BMY,Merck Sheds $10 Billion as Bristol-Myers Study Dents Euphoria,Positive results from a late-stage study of Bristol-Myers Squibb Co.’s combination therapy for lung cancer dented some of investors’ euphoria about Merck & Co.’s Keytruda heading into a closely watched earnings season.,Bailey Lipschultz,https://www.bloomberg.com/news/articles/2019-10-22/merck-sheds-10-billion-as-bristol-myers-study-dents-euphoria,Bloomberg,1518480,2019-10-22T16:34:25Z,-0.03
512842,BMY,"Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise",REUTERS: Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending life of previously untreated lung cancer patients. Shares of the com…,CNA,https://www.channelnewsasia.com/news/world/bristol-myers--immunotherapies-show-promise-in-lung-cancer-trial--shares-rise-12024460,Channelnewsasia.com,1521072,2019-10-22T13:16:43Z,-0.62
514897,ZTS,Zoetis to Participate in the Credit Suisse 28th Annual Healthcare Conference,"PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. will participate in the Credit Suisse 28th Annual Healthcare Conference on Nov. 12, 2019, in Scottsdale, Ariz.",,https://www.businesswire.com/news/home/20191022005126/en/Zoetis-Participate-Credit-Suisse-28th-Annual-Healthcare,Businesswire.com,1557360,2019-10-22T12:41:29Z,0.64
512519,ABBV,Which High-Yield Dividend Aristocrat Is the Best Buy?,"Among high-yield Dividend Aristocrats, AbbVie is the best stock you can buy right now.",newsfeedback@fool.com (George Budwell),https://www.fool.com/investing/2019/10/22/1-high-yield-dividend-aristocrat-to-buy-now.aspx,Fool.com,1557360,2019-10-22T12:00:00Z,0.86
511036,ALLY,Need To Know: Ally Financial Inc. (NYSE:ALLY) Insiders Have Been Selling Shares,"We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...",Simply Wall St,https://finance.yahoo.com/news/know-ally-financial-inc-nyse-105228091.html,Yahoo.com,1554768,2019-10-22T10:52:28Z,0.42
509797,BMY,Bristol-Myers Squibb (BMY) Gains But Lags Market: What You Should Know,"Bristol-Myers Squibb (BMY) closed the most recent trading day at $53.20, moving +0.32% from the previous trading session.",,https://news.yahoo.com/bristol-myers-squibb-bmy-gains-214509326.html,Yahoo.com,1445904,2019-10-21T21:45:09Z,-0.03
508153,JNJ,How Much Litigation Risk Is Priced Into Johnson & Johnson?,"Johnson & Johnson (NYSE: JNJ) just can't seem to shake its talcum powder problems. On Friday, Johnson & Johnson recalled 33,000 bottles of baby powder after a bottle purchased online by the FDA tested positive to asbestos. Last year, a jury awarded a group of…",,https://finance.yahoo.com/news/much-litigation-risk-priced-johnson-154005253.html,Yahoo.com,1435536,2019-10-21T15:40:05Z,0.3
508160,JNJ,"Why I Added More Johnson & Johnson During Friday's Overreactive Dip","On Friday, (JNJ) closed -6.22% after they voluntarily recalled a single lot of Baby Powder after trace levels of asbestos were found in tests. I explain why thi",Blue Chip DRiP,https://seekingalpha.com/article/4297589-added-johnson-and-johnson-fridays-overreactive-dip,Seekingalpha.com,1438128,2019-10-21T14:01:13Z,0
508183,JNJ,"FDA OKs J&J's Stelara for ulcerative colitis","The FDA approves Johnson &amp; Johnson (NYSE:JNJ) unit Janssen Pharmaceutical's Stelara (ustekinumab) for the treatment of adults with moderately to severely active ulcerative colitis, its fifth indic",SA Editor Douglas W. House,https://seekingalpha.com/news/3507198-fda-oks-j-and-js-stelara-ulcerative-colitis,Seekingalpha.com,1456272,2019-10-21T12:22:14Z,0.34
506466,JNJ,"Don't Overthink It, Buy Johnson & Johnson","I'm raising my fair value estimate for JNJ from $130 to $140. The company's recent Q3 earnings report impressed. JNJ also had good news on the litigation front",Nicholas Ward,https://seekingalpha.com/article/4297527-overthink-buy-johnson-and-johnson,Seekingalpha.com,1477008,2019-10-21T10:10:31Z,0.84
506465,JNJ,"Don't Over Think It, Buy Johnson & Johnson","I'm raising my fair value estimate for JNJ from $130 to $140. The company's recent Q3 earnings report impressed. JNJ also had good news on the litigation front",Nicholas Ward,https://seekingalpha.com/article/4297527-think-buy-johnson-and-johnson,Seekingalpha.com,1477008,2019-10-21T10:10:31Z,0.84
506151,ABBV,Today in the press,"US pharmaceuticals giant AbbVie is working with its lawyers and tax advisers on ways of getting around an unexpected €572 million Irish stamp duty exposure it has been left with in relation to its planned takeover of Dublin-domiciled peer Allergan, according …",RTÉ News,https://www.rte.ie/news/business/2019/1021/1084683-today-in-the-press/,RTE,1513296,2019-10-21T08:57:06Z,0
506153,ABBV,"AbbVie’s €572m exposure, State to buy green and climate change and the office","Business Today: the best news, analysis and comment from The Irish Times business desk",Conn Ó Midheach,https://www.irishtimes.com/business/abbvie-s-572m-exposure-state-to-buy-green-and-climate-change-and-the-office-1.4057129,The Irish Times,1513296,2019-10-21T05:40:00Z,0.64
506154,ABBV,AbbVie seeks to get around €572m Irish stamp duty levy,Lawyers make efforts to get around surprise tax liability after Budget 2020,Joe Brennan,https://www.irishtimes.com/business/health-pharma/abbvie-seeks-to-get-around-572m-irish-stamp-duty-levy-1.4057130,The Irish Times,1515888,2019-10-21T04:30:33Z,0.08
503278,ALLY,Ally Turns American Cities into Live MONOPOLY® Gameboard to Help People Grow Their Fortune,"DETROIT, Oct. 19, 2019 /PRNewswire/ -- Today, Ally Financial Inc. (NYSE: ALLY) brings MONOPOLY®, a Hasbro Inc. (HASDAQ: HAS) brand, to life by launching Ally + MONOPOLY®, the augmented reality (AR) game that turns six American cities into a live MONOPOLY® boa…",,https://prnmedia.prnewswire.com:443/news-releases/ally-turns-american-cities-into-live-monopoly-gameboard-to-help-people-grow-their-fortune-300941558.html,Prnewswire.com,1575504,2019-10-19T13:00:00Z,0.4
502818,JNJ,J&J Recalls Baby Powder on Asbestos Concern - The Wall Street Journal,"J&J Recalls Baby Powder on Asbestos ConcernThe Wall Street Journal Johnson & Johnson Recalls Baby Powder Due To Asbestos ConcernsCBS New York JNJ Stock Dives After Asbestos Discovery Prompts Baby Powder Lot RecallInvestor's Business Daily Johnson & Johnson re…",feedfeeder,https://slashdot.org/firehose.pl?op=view&amp;id=117611494,Slashdot.org,1502928,2019-10-19T06:13:25Z,0
500035,BMY,"Zacks.com featured highlights include: Hasbro, Atkore International, Target, Hibbett Sports and Bristol-Myers Squibb","Zacks.com featured highlights include: Hasbro, Atkore International, Target, Hibbett Sports and Bristol-Myers Squibb",Zacks Equity Research,https://finance.yahoo.com/news/zacks-com-featured-highlights-hasbro-151603364.html,Yahoo.com,1536624,2019-10-18T15:16:03Z,0
499781,ABBV,"AbbVie's blockbuster hopeful Rinvoq, J&J's Spravato eye EU rollouts, thanks to new backing","Painted as the follow-up drug to megablockbuster Humira, AbbVie’s JAK med Rinvoq is already notching blockbuster forecasts, and Johnson & Johnson's nurturing its own hopes for Spravato. Their preliminary green lights to treat European patients—one of a half-d…",Kyle Blankenship,https://www.fiercepharma.com/pharma/abbvie-s-blockbuster-hopeful-rinvoq-scores-preliminary-nod-to-treat-european-ra-patients,Fiercepharma.com,1531440,2019-10-18T13:57:21Z,0.97
500352,JNJ,Johnson & Johnson just recalled a batch of baby powder after a test found asbestos. The company is facing thousands of lawsuits over the product. (JNJ),"Johnson & Johnson is recalling a single lot of its baby powder after the Food and Drug Administration found a tiny amount of asbestos in samples from a single bottle purchased from an online retailer. Talcum powder, or talc, a mineral that makes up baby powde…",Clarrie Feinstein,https://www.businessinsider.com/johnson-and-johnson-jnj-baby-powder-recall-asbestos-in-talc-2019-10,Business Insider,1495152,2019-10-18T13:35:00Z,-0.15
499785,ABBV,AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ(TM)) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis,"CHMP positive opinion, supported by data from the pivotal Phase 3 SELECT rheumatoid arthritis program evaluating more than 4,400 patients, will now be referred to the European Commission for final approval[1-5] In Phase 3 trials, upadacitinib improved s... Bi…",AbbVie,https://salesandmarketingnetwork.com/news_release_bs.html?ID=2045451,Salesandmarketingnetwork.com,1534032,2019-10-18T13:16:50Z,0.91
500399,MRK,Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice,"Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.",Zacks Equity Research,https://finance.yahoo.com/news/looking-high-growth-dividend-stock-131501599.html,Yahoo.com,1513296,2019-10-18T13:15:01Z,0.93
500036,BMY,Bristol-Myers extends date for exchange offer of Celgene notes,Bristol-Myers Squibb (NYSE:BMY) extends the expiration date of the offers to exchange notes issued by Celgene (NASDAQ:CELG) for up to $19.85B aggregate principal amount of new notes to be issued by B,Mamta Mayani,https://seekingalpha.com/news/3506898-bristol-myers-extends-date-exchange-offer-celgene-notes,Seekingalpha.com,1536624,2019-10-18T13:08:22Z,0.25
498892,JNJ,European advisory group backs J&J antidepressant Spravato,"The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Johnson &amp; Johnson's (NYSE:JNJ) Spravato (esketamine) nasal spray for adults with treatme",SA Editor Douglas W. House,https://seekingalpha.com/news/3506852-european-advisory-group-backs-j-and-j-antidepressant-spravato,Seekingalpha.com,1469232,2019-10-18T11:59:58Z,0.76
498893,JNJ,"European advisory group backs expanded label for J&J's Darzalex","Genmab A/S (OTCPK:GNMSF) announces that the European advisory group CHMP has adopted a positive opinion recommending approval of licensee Johnson &amp; Johnson's (NYSE:JNJ) Darzalex (daratumumab), com",SA Editor Douglas W. House,https://seekingalpha.com/news/3506837-european-advisory-group-backs-expanded-label-j-and-js-darzalex,Seekingalpha.com,1469232,2019-10-18T11:32:47Z,0.76
498603,ABBV,AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ™) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis,"NORTH CHICAGO, Ill., Oct. 18, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opin…",,https://www.prnewswire.com/news-releases/abbvie-receives-chmp-positive-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults-with-moderate-to-severe-active-rheumatoid-arthritis-300940994.html,Prnewswire.com,1477008,2019-10-18T11:30:00Z,0.81
498736,BMY,Fitbit strikes healthcare partnership to detect irregular heart rhythm,Fitbit is developing a method to detect irregular heart rhythm in time through a partnership with Bristol-Myers Squibb-Pfizer Alliance.,Reuters,https://venturebeat.com/2019/10/18/fitbit-strikes-healthcare-partnership-to-detect-irregular-heart-rhythm/,Venturebeat.com,1557360,2019-10-18T07:57:03Z,-0.36
497431,ALLY,Ally Financial: Cheap Even To A Weakening Economy,"Ally beat Q3 forecasts, breaking the $1.00 quarterly EPS barrier. Loan quality weakened a bit, but Ally is well-positioned to weather a weaker job market. Ally’",Gary J. Gordon,https://seekingalpha.com/article/4297214-ally-financial-cheap-even-weakening-economy,Seekingalpha.com,1422576,2019-10-18T04:03:27Z,-0.75
497518,BMY,‘We’re Not As Healthy As We Should Be.’ Fitbit CEO James Park Discusses New AFib Detection Partnership With Bristol-Myers Squibb-Pfizer,"“We’re not as healthy as we should be.” That’s what Fitbit CEO and co-founder James Park said at Thursday’s TIME 100 Health Summit, where MSNBC anchor Stephanie Ruhle interviewed him about the company’s future in the health care space, the impact of wearables…",Patrick Lucas Austin,https://time.com/5702746/fitbit-james-park-afib-time-100-summit/,Time,1471824,2019-10-17T21:38:06Z,-0.08
497781,JNJ,"J&J's Tremfya shows long-term benefit in late-stage psoriasis study","Updated data from the open-label portion of a Phase 3 clinical trial, VOYAGE 1, evaluating Johnson &amp; Johnson (NYSE:JNJ) unit Janssen Pharmaceutical's TREMFYA (guselkumab) in patients with moderate",SA Editor Douglas W. House,https://seekingalpha.com/news/3506737-j-and-js-tremfya-shows-long-term-benefit-late-stage-psoriasis-study,Seekingalpha.com,1557360,2019-10-17T20:59:51Z,0.46
495558,BMY,Fitbit to Take on Apple Watch in Healthcare Market With New ECG Functionality,Fitbit is partnering with Bristol-Myers Squibb-Pfizer Alliance to develop a method to detect irregular heart rhythm.,Charlotte Henry,https://www.macobserver.com/news/fitbit-apple-watch-healthcare-market/,Macobserver.com,1492560,2019-10-17T16:10:59Z,0
495910,JNJ,Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2019,"NEW BRUNSWICK, N.J., Oct. 17, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2019 of $0.95 per share on the company's common stock. The dividend is payable …",,https://www.prnewswire.com/news-releases/johnson--johnson-announces-quarterly-dividend-for-fourth-quarter-2019-300940675.html,Prnewswire.com,1575504,2019-10-17T15:45:00Z,0.3
495559,BMY,FIT taking on Apple in health,"Fitbit (FIT +0.5%) is partnering with Bristol-Myers Squibb-Pfizer Alliance to develop a way to detect an irregular heart rhythm over time.FIT's devices will carry the ability to detect atrial fibrilla",SA Editor Brandy Betz,https://seekingalpha.com/news/3506567-fit-taking-apple-health,Seekingalpha.com,1492560,2019-10-17T15:24:45Z,0.67
495560,BMY,Fitbit in healthcare partnership to take on Apple Watch,"Fitbit Inc is developing a method to detect irregular heart rhythm in time through a partnership with Bristol-Myers Squibb-Pfizer Alliance, as the wearable device maker looks to match a feature available on rival Apple Inc's Watch.",Reuters Editorial,https://ca.reuters.com/article/technologyNews/idCAKBN1WW263-OCATC,Reuters,1492560,2019-10-17T15:15:27Z,0
495561,BMY,Fitbit partners with Pharma to compete with Apple,"Fitbit is looking to take on Apple by expanding into the health care space. It's teaming up with the Bristol-Myers Squibb-Pfizer Alliance to help users with a particular heart condition. Yahoo Finance’s Brian Sozzi, Alexis Christoforous and Dan Howley discuss…",Yahoo Finance Video,https://finance.yahoo.com/video/fitbit-partners-pharma-compete-apple-133351946.html,Yahoo.com,1495152,2019-10-17T13:33:51Z,0.71
495562,BMY,Fitbit stock gains after company announces biotech partnership,Fitbit Inc. shares are up 3.7% in premarket trading Thursday after the company announced a partnership with the Bristol-Myers Squibb-Pfizer Alliance focused on the diagnosis of atrial fibrillation using Fitbit devices. As atrial fibrillation is a risk factor …,Emily Bary,https://www.marketwatch.com/story/fitbit-stock-gains-after-company-announces-biotech-partnership-2019-10-17,Marketwatch.com,1500336,2019-10-17T13:28:20Z,0.62
495563,BMY,The Bristol-Myers Squibb-Pfizer Alliance and Fitbit Collaborate to Address Gaps in Atrial Fibrillation Detection with the Aim of Accelerating Diagnosis,"PRINCETON, N.J. & NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--The Bristol-Myers Squibb-Pfizer Alliance and Fitbit today announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of atrial fibrillation (AF…",,https://www.businesswire.com/news/home/20191017005136/en/Bristol-Myers-Squibb-Pfizer-Alliance-Fitbit-Collaborate-Address-Gaps,Businesswire.com,1500336,2019-10-17T13:06:00Z,0.4
495564,BMY,"Fitbit, Bristol-Myers Squibb, Pfizer to collaborate on connection to cardiac care resources","Once Fitbit has cleared its own atrial fibrillation detection feature, it will be working with the pharmas to develop content that will help at-risk users discuss their heart health with a provider.",dave.muoio@himssmedia.com (Dave Muoio),https://www.mobihealthnews.com/news/fitbit-bristol-myers-squibb-pfizer-collaborate-connection-cardiac-care-resources,Mobihealthnews.com,1502928,2019-10-17T13:03:23Z,0.74
497294,ZTS,3 Reasons Why Zoetis (ZTS) Is a Great Growth Stock,Zoetis (ZTS) could produce exceptional returns because of its solid growth attributes.,Zacks Equity Research,https://finance.yahoo.com/news/3-reasons-why-zoetis-zts-124512285.html,Yahoo.com,1523664,2019-10-17T12:45:12Z,0.87
495915,LLY,"Here are the biggest analyst calls of the day: Apple, Netflix, Monster, Eli Lilly & more",Here are the biggest calls on Wall Street on Thursday,Michael Bloom,https://www.cnbc.com/2019/10/17/analyst-calls-of-the-day-apple-netflix-monster-eli-lilly-more.html,CNBC,1578096,2019-10-17T12:44:00Z,0
494301,JNJ,J&J offers $4B opioid litigation settlement - WSJ,"Johnson &amp; Johnson (NYSE:JNJ) reportedly has offered to pay $4B to settle all claims accusing the company of contributing to the opioid epidemic, a deal that likely would please J&amp;J investors s",SA Editor Carl Surran,https://seekingalpha.com/news/3506389-j-and-j-offers-4b-opioid-litigation-settlement-wsj,Seekingalpha.com,1461456,2019-10-17T08:41:48Z,-0.15
492715,ALLY,Ally Financial (ALLY) Q3 2019 Earnings Call Transcript,"ALLY earnings call for the period ending September 30, 2019.",newsfeedback@fool.com (Motley Fool Transcribing),https://www.fool.com/earnings/call-transcripts/2019/10/16/ally-financial-ally-q3-2019-earnings-call-transcri.aspx,Fool.com,1526256,2019-10-16T22:23:59Z,0
491170,LLY,PhRMA Appoints New Leadership to Board of Directors,"WASHINGTON, Oct. 16, 2019 /PRNewswire/ -- Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) appointed new leadership to its board of directors. David Ricks, chairman and CEO of Eli Lilly and Company, was named chairman-elect and Ramona S…",,https://prnmedia.prnewswire.com:443/news-releases/phrma-appoints-new-leadership-to-board-of-directors-300939763.html,Prnewswire.com,1570320,2019-10-16T18:00:00Z,0
490570,ALLY,Ally Financial Inc. (ALLY) CEO Jeff Brown on Q3 2019 Results - Earnings Call Transcript,"Ally Financial Inc. (NYSE:ALLY) Q3 2019 Earnings Conference Call October 16, 2019, 09:00 AM ET Company Participants Daniel Eller - Lead, IR Jeff Brown - CEO Jen",SA Transcripts,https://seekingalpha.com/article/4296837-ally-financial-inc-ally-ceo-jeff-brown-q3-2019-results-earnings-call-transcript,Seekingalpha.com,1464048,2019-10-16T17:15:55Z,0
276962,ALLY,Ally Financial Inc. (ALLY) CEO Jeff Brown on Q3 2019 Results - Earnings Call Transcript,"Ally Financial Inc. (NYSE:ALLY) Q3 2019 Earnings Conference Call October 16, 2019, 09:00 AM ET Company Participants Daniel Eller - Lead, IR Jeff Brown - CEO Jen",SA Transcripts,https://seekingalpha.com/article/4296837-ally-financial-inc-ally-ceo-jeff-brown-q3-2019-results-earnings-call-transcript,seekingalpha.com,1571246155,2019-10-16T17:15:55Z,0
491158,JNJ,St. Louis court tosses $110M talc verdict against Johnson & Johnson,"Johnson & Johnson has had a $110 million verdict reversed and vacated by a Missouri appellate court in a case claiming that the company's talcum powder caused cancer. In 2017, a St. Louis jury ordered Johnson & Johnson to pay more than $110 million to a Virgi…",,https://www.bizjournals.com/stlouis/news/2019/10/16/st-louis-court-tosses-110m-talcverdict-against.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_national+%28Bizjournals+National+Feed%29,Bizjournals.com,1565136,2019-10-16T16:28:41Z,-0.56
491171,LLY,Eli Lilly Drug Acquired in Armo Deal Fails Pancreatic Cancer Test,"<p>An experimental drug that was the centerpiece a $1.6 billion Eli Lilly acquisition last year has now failed a pivotal test in pancreatic cancer. Eli Lilly (NYSE: LLY) said Wednesday that patients treated with its drug candidate pegilodecakin, plus chemothe…",Frank Vinluan,https://xconomy.com/indiana/2019/10/16/eli-lilly-drug-acquired-in-armo-deal-fails-pancreatic-cancer-test/,Xconomy.com,1570320,2019-10-16T16:15:50Z,-0.94
276966,ALLY,Ally Financial -3.5% as analysts pick out Q3 weaknesses,"Ally Financial (NYSE:ALLY) falls 3.5% after its Q3 beat included a couple of weak spots.Credit costs edged higher with auto net charge-offs at 1.38% vs. 1.32%, up Y/Y for the first time since Q4 2017,",SA Editor Liz Kiesche,https://seekingalpha.com/news/3506186-ally-financial-minus-3_5-percent-analysts-pick-q3-weaknesses,seekingalpha.com,1571241115,2019-10-16T15:51:55Z,-0.44
490576,ALLY,Ally Financial -3.5% as analysts pick out Q3 weaknesses,"Ally Financial (NYSE:ALLY) falls 3.5% after its Q3 beat included a couple of weak spots.Credit costs edged higher with auto net charge-offs at 1.38% vs. 1.32%, up Y/Y for the first time since Q4 2017,",SA Editor Liz Kiesche,https://seekingalpha.com/news/3506186-ally-financial-minus-3_5-percent-analysts-pick-q3-weaknesses,Seekingalpha.com,1469232,2019-10-16T15:51:55Z,-0.44
490483,ABBV,Another hit for AbbVie: Unexpected $673M Irish tax bill adds to Allergan merger woes,"Sealing an eight-figure merger is no laughing matter: Just ask AbbVie and Allergan, two drugmakers fighting through regulatory hurdles to consummate their $63 billion deal. And even as a new Irish tax levy threatened to add hundreds of millions to the deal co…",Kyle Blankenship,https://www.fiercepharma.com/pharma/we-still-want-abbvie-despite-unexpected-673m-irish-tax-allergan-investors-still-want,Fiercepharma.com,1438128,2019-10-16T15:26:22Z,-0.53
490582,ALLY,Ally Financial Inc. 2019 Q3 - Results - Earnings Call Presentation,The following slide deck was published by Ally Financial Inc. in conjunction with their 2019 Q3 earnings call.,SA Transcripts,https://seekingalpha.com/article/4296804-ally-financial-inc-2019-q3-results-earnings-call-presentation,Seekingalpha.com,1471824,2019-10-16T14:56:33Z,0
276972,ALLY,Ally Financial Inc. 2019 Q3 - Results - Earnings Call Presentation,The following slide deck was published by Ally Financial Inc. in conjunction with their 2019 Q3 earnings call.,SA Transcripts,https://seekingalpha.com/article/4296804-ally-financial-inc-2019-q3-results-earnings-call-presentation,seekingalpha.com,1571237793,2019-10-16T14:56:33Z,0
490584,ALLY,Ally Financial (ALLY) Tops Q3 Earnings and Revenue Estimates,"Ally Financial (ALLY) delivered earnings and revenue surprises of 3.06% and 2.84%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?",Zacks Equity Research,https://finance.yahoo.com/news/ally-financial-ally-tops-q3-124512757.html,Yahoo.com,1474416,2019-10-16T12:45:12Z,0.59
276973,ALLY,Ally Financial (ALLY) Tops Q3 Earnings and Revenue Estimates,"Ally Financial (ALLY) delivered earnings and revenue surprises of 3.06% and 2.84%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?",Zacks Equity Research,https://finance.yahoo.com/news/ally-financial-ally-tops-q3-124512757.html,yahoo.com,1571229912,2019-10-16T12:45:12Z,0.59
276926,ABBV,Here is Why Growth Investors Should Buy AbbVie (ABBV) Now,"AbbVie (ABBV) possesses solid growth attributes, which could help it handily outperform the market.",Zacks Equity Research,https://finance.yahoo.com/news/why-growth-investors-buy-abbvie-124512538.html,yahoo.com,1571229912,2019-10-16T12:45:12Z,0.82
490485,ABBV,Here is Why Growth Investors Should Buy AbbVie (ABBV) Now,"AbbVie (ABBV) possesses solid growth attributes, which could help it handily outperform the market.",Zacks Equity Research,https://finance.yahoo.com/news/why-growth-investors-buy-abbvie-124512538.html,Yahoo.com,1471824,2019-10-16T12:45:12Z,0.82
490486,ABBV,Should Investors Buy AbbVie Right Now for Its Dividend?,"Amid concerns about its $63 billion Allergan buyout, is now a good time to invest in the pharmaceutical giant?",newsfeedback@fool.com (Mark Prvulovic),https://www.fool.com/investing/2019/10/16/should-investors-buy-abbvie-right-now-for-its-divi.aspx,Fool.com,1471824,2019-10-16T12:00:00Z,0.5
276927,ABBV,Should Investors Buy AbbVie Right Now for Its Dividend?,"Amid concerns about its $63 billion Allergan buyout, is now a good time to invest in the pharmaceutical giant?",newsfeedback@fool.com (Mark Prvulovic),https://www.fool.com/investing/2019/10/16/should-investors-buy-abbvie-right-now-for-its-divi.aspx,fool.com,1571227200,2019-10-16T12:00:00Z,0.5
489143,ALLY,"Ally Financial EPS beats by $0.03, beats on adj. revenue",Ally Financial (NYSE:ALLY): Q3 Non-GAAP EPS of $1.01 beats by $0.03; GAAP EPS of $0.97 beats by $0.01.Adj. Revenue of $1.62B (+6.6% Y/Y) beats by $50M.Press Release,SA Editor Gaurav Batavia,https://seekingalpha.com/news/3506053-ally-financial-eps-beats-0_03-beats-adj-revenue,Seekingalpha.com,1492560,2019-10-16T11:31:52Z,0
276208,ALLY,"Ally Financial EPS beats by $0.03, beats on adj. revenue",Ally Financial (NYSE:ALLY): Q3 Non-GAAP EPS of $1.01 beats by $0.03; GAAP EPS of $0.97 beats by $0.01.Adj. Revenue of $1.62B (+6.6% Y/Y) beats by $50M.Press Release,SA Editor Gaurav Batavia,https://seekingalpha.com/news/3506053-ally-financial-eps-beats-0_03-beats-adj-revenue,seekingalpha.com,1571225512,2019-10-16T11:31:52Z,0
276209,ALLY,Ally Financial Reports Third Quarter 2019 Financial Results,"CHARLOTTE, N.C., Oct. 16, 2019 /PRNewswire/ -- Ally Financial Inc. (NYSE: ALLY) today reported its third quarter 2019 financial results. View the full press release in PDF. The news release, presentation and financial supplement also can be accessed in the fo…",,https://www.prnewswire.com/news-releases/ally-financial-reports-third-quarter-2019-financial-results-300939567.html,prnewswire.com,1571225400,2019-10-16T11:30:00Z,0
489144,ALLY,Ally Financial Reports Third Quarter 2019 Financial Results,"CHARLOTTE, N.C., Oct. 16, 2019 /PRNewswire/ -- Ally Financial Inc. (NYSE: ALLY) today reported its third quarter 2019 financial results. View the full press release in PDF. The news release, presentation and financial supplement also can be accessed in the fo…",,https://www.prnewswire.com/news-releases/ally-financial-reports-third-quarter-2019-financial-results-300939567.html,Prnewswire.com,1492560,2019-10-16T11:30:00Z,0
276418,LLY,"Lilly's Armo buyout drug a bust in pancreatic cancer","Last year, Eli Lilly spent $1.6 billion to get its hands on Armo Biosciences and its lead asset, pegilodecakin. Today, that drug flopped.",Ben Adams,https://www.fiercebiotech.com/biotech/lilly-s-armo-buyout-drug-a-bust-pancreatic-cancer,fiercebiotech.com,1571224540,2019-10-16T11:15:40Z,0.36
489457,LLY,"Lilly's Armo buyout drug a bust in pancreatic cancer","Last year, Eli Lilly spent $1.6 billion to get its hands on Armo Biosciences and its lead asset, pegilodecakin. Today, that drug flopped.",Ben Adams,https://www.fiercebiotech.com/biotech/lilly-s-armo-buyout-drug-a-bust-pancreatic-cancer,Fiercebiotech.com,1549584,2019-10-16T11:15:40Z,0.36
276419,LLY,"Lilly's pegilodecakin flunks late-stage study shares down 2% premarket","Eli Lilly (NYSE:LLY) slips 2% premarket on light volume in reaction to unsuccessful results from a Phase 3 clinical trial, SEQUOIA, evaluating pepilodecakin plus the chemo regimen FOLFOX compared to F",SA Editor Douglas W. House,https://seekingalpha.com/news/3506048-lillys-pegilodecakin-flunks-late-stage-study-shares-2-percent-premarket,seekingalpha.com,1571224510,2019-10-16T11:15:10Z,-0.48
489458,LLY,"Lilly's pegilodecakin flunks late-stage study; shares down 2% premarket","Eli Lilly (NYSE:LLY) slips 2% premarket on light volume in reaction to unsuccessful results from a Phase 3 clinical trial, SEQUOIA, evaluating pepilodecakin plus the chemo regimen FOLFOX compared to F",SA Editor Douglas W. House,https://seekingalpha.com/news/3506048-lillys-pegilodecakin-flunks-late-stage-study-shares-2-percent-premarket,Seekingalpha.com,1554768,2019-10-16T11:15:10Z,-0.48
276420,LLY,Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival,"INDIANAPOLIS, Oct. 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU, oxaliplatin) compared to FOLFOX alone in patients with meta…",,https://www.prnewswire.com/news-releases/lilly-announces-phase-3-study-in-patients-with-metastatic-pancreatic-cancer-did-not-meet-primary-endpoint-of-overall-survival-300939319.html,prnewswire.com,1571222700,2019-10-16T10:45:00Z,-0.75
489459,LLY,Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival,"INDIANAPOLIS, Oct. 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU, oxaliplatin) compared to FOLFOX alone in patients with meta…",,https://www.prnewswire.com/news-releases/lilly-announces-phase-3-study-in-patients-with-metastatic-pancreatic-cancer-did-not-meet-primary-endpoint-of-overall-survival-300939319.html,Prnewswire.com,1557360,2019-10-16T10:45:00Z,-0.75
488178,JNJ,Edited Transcript of JNJ earnings conference call or presentation 15-Oct-19 12:30pm GMT,Q3 2019 Johnson & Johnson Earnings Call,,https://finance.yahoo.com/news/edited-transcript-jnj-earnings-conference-234345229.html,Yahoo.com,1492560,2019-10-16T03:00:27Z,0
275697,JNJ,Edited Transcript of JNJ earnings conference call or presentation 15-Oct-19 12:30pm GMT,Q3 2019 Johnson & Johnson Earnings Call,,https://finance.yahoo.com/news/edited-transcript-jnj-earnings-conference-234345229.html,yahoo.com,1571194827,2019-10-16T03:00:27Z,0
275704,JNJ,Johnson & Johnson sees $110M talc verdict overturned,An appeals court in Missouri has overturned a $110M verdict against Johnson &amp; Johnson (NYSE:JNJ) over whether its talc caused ovarian cancer. That reverses a 2017 decision in favor of a Virginia,Jason Aycock,https://seekingalpha.com/news/3505990-johnson-and-johnson-sees-110m-talc-verdict-overturned,seekingalpha.com,1571177081,2019-10-15T22:04:41Z,-0.13
488187,JNJ,Johnson & Johnson sees $110M talc verdict overturned,An appeals court in Missouri has overturned a $110M verdict against Johnson &amp; Johnson (NYSE:JNJ) over whether its talc caused ovarian cancer. That reverses a 2017 decision in favor of a Virginia,Jason Aycock,https://seekingalpha.com/news/3505990-johnson-and-johnson-sees-110m-talc-verdict-overturned,Seekingalpha.com,1500336,2019-10-15T22:04:41Z,-0.13
487886,ABBV,Allergan (AGN) Shareholders Approve Acquisition by AbbVie,"Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.",Kinjel Shah,https://finance.yahoo.com/news/allergan-agn-shareholders-approve-acquisition-210409307.html,Yahoo.com,1557360,2019-10-15T21:04:09Z,0.34
275533,ABBV,Allergan (AGN) Shareholders Approve Acquisition by AbbVie,"Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.",Kinjel Shah,https://finance.yahoo.com/news/allergan-agn-shareholders-approve-acquisition-210409307.html,yahoo.com,1571173449,2019-10-15T21:04:09Z,0.34
485962,BMY,"AbbVie, Bristol-Myers Squibb Getting the Most From Workers",Pharmaceutical companies that top the list in terms of sales per employee Continue reading...,GuruFocus.com,https://finance.yahoo.com/news/abbvie-bristol-myers-squibb-getting-162136528.html,Yahoo.com,1443312,2019-10-15T16:21:36Z,0.2
485678,ABBV,"AbbVie, Bristol-Myers Squibb Getting the Most From Workers",Pharmaceutical companies that top the list in terms of sales per employee Continue reading...,GuruFocus.com,https://finance.yahoo.com/news/abbvie-bristol-myers-squibb-getting-162136528.html,Yahoo.com,1513296,2019-10-15T16:21:36Z,0.2
274193,ABBV,"AbbVie, Bristol-Myers Squibb Getting the Most From Workers",Pharmaceutical companies that top the list in terms of sales per employee Continue reading...,GuruFocus.com,https://finance.yahoo.com/news/abbvie-bristol-myers-squibb-getting-162136528.html,yahoo.com,1571156496,2019-10-15T16:21:36Z,0.2
274324,BMY,"AbbVie, Bristol-Myers Squibb Getting the Most From Workers",Pharmaceutical companies that top the list in terms of sales per employee Continue reading...,GuruFocus.com,https://finance.yahoo.com/news/abbvie-bristol-myers-squibb-getting-162136528.html,yahoo.com,1571156496,2019-10-15T16:21:36Z,0.2
486375,JNJ,"Higher 3Q profit, improved outlook for Johnson & Johnson","Johnson & Johnson's third-quarter profit jumped 23%, beating Wall Street forecasts, thanks to higher sales of its key medicines for cancer and immune disorders and an acquisition-related charge a year earlier. On Oct. 8, a Philadelphia jury hit J&J with a stu…",LINDA A. JOHNSON,https://news.yahoo.com/johnson-johnson-3q-earnings-snapshot-105410365.html,Yahoo.com,1484784,2019-10-15T14:56:16Z,0.68
274616,JNJ,"Higher 3Q profit, improved outlook for Johnson & Johnson","Johnson & Johnson's third-quarter profit jumped 23%, beating Wall Street forecasts, thanks to higher sales of its key medicines for cancer and immune disorders and an acquisition-related charge a year earlier. On Oct. 8, a Philadelphia jury hit J&J with a stu…",LINDA A. JOHNSON,https://news.yahoo.com/johnson-johnson-3q-earnings-snapshot-105410365.html,yahoo.com,1571151376,2019-10-15T14:56:16Z,0.68
274621,JNJ,Q3 Results Begin: Can We Avoid an Earnings Recession?,"Results from JPM, JNJ help paint the picture whether Q3 will bear out better than expected.",Mark Vickery,https://finance.yahoo.com/news/q3-results-begin-avoid-earnings-141202217.html,yahoo.com,1571148722,2019-10-15T14:12:02Z,0.53
486382,JNJ,Q3 Results Begin: Can We Avoid an Earnings Recession?,"Results from JPM, JNJ help paint the picture whether Q3 will bear out better than expected.",Mark Vickery,https://finance.yahoo.com/news/q3-results-begin-avoid-earnings-141202217.html,Yahoo.com,1492560,2019-10-15T14:12:02Z,0.53
274627,LLY,Eli Lilly to shutter neuroscience R&D center next year,"Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.",Ben Adams,https://www.fiercebiotech.com/biotech/eli-lilly-to-shutter-neuroscience-r-d-center-next-year,fiercebiotech.com,1571145079,2019-10-15T13:11:19Z,-0.3
486390,LLY,Eli Lilly to shutter neuroscience R&D center next year,"Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.",Ben Adams,https://www.fiercebiotech.com/biotech/eli-lilly-to-shutter-neuroscience-r-d-center-next-year,Fiercebiotech.com,1497744,2019-10-15T13:11:19Z,-0.3
484987,PRGO,Perrigo Announces Third Quarter Calendar Year 2019 Earnings Date,"DUBLIN, Oct. 15, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its third quarter calendar year 2019 financial results on Wednesday, November 6, 2019. The Company will host a conference call beginning at 8:00…",,https://www.prnewswire.com/news-releases/perrigo-announces-third-quarter-calendar-year-2019-earnings-date-300938601.html,Prnewswire.com,1528848,2019-10-15T12:05:00Z,0
273842,PRGO,Perrigo Announces Third Quarter Calendar Year 2019 Earnings Date,"DUBLIN, Oct. 15, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its third quarter calendar year 2019 financial results on Wednesday, November 6, 2019. The Company will host a conference call beginning at 8:00…",,https://www.prnewswire.com/news-releases/perrigo-announces-third-quarter-calendar-year-2019-earnings-date-300938601.html,prnewswire.com,1571141100,2019-10-15T12:05:00Z,0
273668,LLY,Lilly to close UK research facility,"In an email statement, Eli Lilly (NYSE:LLY) discloses that it intends to close its research center in Surrey, England, potentially impacting ~270 employees, including ~80 cuts. About 2/3 of the staff",SA Editor Douglas W. House,https://seekingalpha.com/news/3505700-lilly-close-uk-research-facility,seekingalpha.com,1571140077,2019-10-15T11:47:57Z,-0.3
484684,LLY,Lilly to close UK research facility,"In an email statement, Eli Lilly (NYSE:LLY) discloses that it intends to close its research center in Surrey, England, potentially impacting ~270 employees, including ~80 cuts. About 2/3 of the staff",SA Editor Douglas W. House,https://seekingalpha.com/news/3505700-lilly-close-uk-research-facility,Seekingalpha.com,1554768,2019-10-15T11:47:57Z,-0.3
273669,LLY,"Aeglea, long-term Eli Lilly veteran nabs CMO job at Checkmate",Next-gen cancer biotech Checkmate Pharmaceuticals has grabbed a new chief medical officer after a year of C-suite shuffles.,Ben Adams,https://www.fiercebiotech.com/biotech/aeglea-long-term-eli-lilly-veteran-nabs-cmo-job-at-checkmate,fiercebiotech.com,1571138420,2019-10-15T11:20:20Z,-0.66
484685,LLY,"Aeglea, long-term Eli Lilly veteran nabs CMO job at Checkmate",Next-gen cancer biotech Checkmate Pharmaceuticals has grabbed a new chief medical officer after a year of C-suite shuffles.,Ben Adams,https://www.fiercebiotech.com/biotech/aeglea-long-term-eli-lilly-veteran-nabs-cmo-job-at-checkmate,Fiercebiotech.com,1557360,2019-10-15T11:20:20Z,-0.66
273659,JNJ,JNJ up 2% premarket on Q3 beat guidance raised,"Johnson &amp; Johnson (JNJ) Q3 results: Revenues: $20,729M (+1.9%); Consumer: $3,469M (+1.6%); Pharmaceuticals: $10,877M (+5.1%); Medical Devices: $6,383M (-3.1%).Net Income: $4,833M (+22.9%); EPS: $1",Mamta Mayani,https://seekingalpha.com/news/3505685-jnj-2-percent-premarket-q3-beat-guidance-raised,seekingalpha.com,1571138226,2019-10-15T11:17:06Z,0
484672,JNJ,JNJ up 2% premarket on Q3 beat; guidance raised,"Johnson &amp; Johnson (JNJ) Q3 results: Revenues: $20,729M (+1.9%); Consumer: $3,469M (+1.6%); Pharmaceuticals: $10,877M (+5.1%); Medical Devices: $6,383M (-3.1%).Net Income: $4,833M (+22.9%); EPS: $1",Mamta Mayani,https://seekingalpha.com/news/3505685-jnj-2-percent-premarket-q3-beat-guidance-raised,Seekingalpha.com,1544400,2019-10-15T11:17:06Z,0
484675,JNJ,"Johnson & Johnson EPS beats by $0.11, beats on revenue",Johnson &amp; Johnson (NYSE:JNJ): Q3 Non-GAAP EPS of $2.12 beats by $0.11; GAAP EPS of $1.81 beats by $0.23.Revenue of $20.73B (+1.9% Y/Y) beats by $590M.Shares +0.98% PM.Press Release,Mamta Mayani,https://seekingalpha.com/news/3505678-johnson-and-johnson-eps-beats-0_11-beats-revenue,Seekingalpha.com,1549584,2019-10-15T10:45:31Z,0
273662,JNJ,"Johnson & Johnson EPS beats by $0.11, beats on revenue",Johnson &amp; Johnson (NYSE:JNJ): Q3 Non-GAAP EPS of $2.12 beats by $0.11; GAAP EPS of $1.81 beats by $0.23.Revenue of $20.73B (+1.9% Y/Y) beats by $590M.Shares +0.98% PM.Press Release,Mamta Mayani,https://seekingalpha.com/news/3505678-johnson-and-johnson-eps-beats-0_11-beats-revenue,seekingalpha.com,1571136331,2019-10-15T10:45:31Z,0
273663,JNJ,Johnson & Johnson Reports 2019 Third-Quarter Results,"NEW BRUNSWICK, N.J., Oct. 15, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2019. ""Our third-quarter results represent strong performance, driven by competitive underlying growth in Pharmaceuticals and Medical De…",,https://www.prnewswire.com/news-releases/johnson--johnson-reports-2019-third-quarter-results-300938512.html,prnewswire.com,1571136180,2019-10-15T10:43:00Z,0.77
484676,JNJ,Johnson & Johnson Reports 2019 Third-Quarter Results,"NEW BRUNSWICK, N.J., Oct. 15, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2019. ""Our third-quarter results represent strong performance, driven by competitive underlying growth in Pharmaceuticals and Medical De…",,https://www.prnewswire.com/news-releases/johnson--johnson-reports-2019-third-quarter-results-300938512.html,Prnewswire.com,1549584,2019-10-15T10:43:00Z,0.77
483450,JNJ,"Johnson & Johnson's (JNJ) Legal Problems Continue to Worry Investors",Johnson & Johnson (JNJ) is set to report their third quarter results as pending lawsuits loom over the company.,Christopher Vargas,https://finance.yahoo.com/news/johnson-johnsons-jnj-legal-problems-230411015.html,Yahoo.com,1474416,2019-10-14T23:04:11Z,-0.77
273043,JNJ,"Johnson & Johnson's (JNJ) Legal Problems Continue to Worry Investors",Johnson & Johnson (JNJ) is set to report their third quarter results as pending lawsuits loom over the company.,Christopher Vargas,https://finance.yahoo.com/news/johnson-johnsons-jnj-legal-problems-230411015.html,yahoo.com,1571094251,2019-10-14T23:04:11Z,-0.77
272868,BMY,Bristol-Myers Squibb (BMY) Stock Moves -0.1%: What You Should Know,"Bristol-Myers Squibb (BMY) closed at $51.56 in the latest trading session, marking a -0.1% move from the prior day.",Zacks Equity Research,https://finance.yahoo.com/news/bristol-myers-squibb-bmy-stock-214509096.html,yahoo.com,1571089509,2019-10-14T21:45:09Z,0
483182,BMY,Bristol-Myers Squibb (BMY) Stock Moves -0.1%: What You Should Know,"Bristol-Myers Squibb (BMY) closed at $51.56 in the latest trading session, marking a -0.1% move from the prior day.",Zacks Equity Research,https://finance.yahoo.com/news/bristol-myers-squibb-bmy-stock-214509096.html,Yahoo.com,1552176,2019-10-14T21:45:09Z,0
483458,JNJ,Johnson & Johnson Q3 2019 Earnings Preview,"Johnson &amp; Johnson (NYSE:JNJ) is scheduled to announce Q3 earnings results on Tuesday, October 15th, before market open.The consensus EPS Estimate is $2.01 (-2.0% Y/Y) and the consensus Revenue Est",SA Editor Vandana Singh,https://seekingalpha.com/news/3505582-johnson-and-johnson-q3-2019-earnings-preview,Seekingalpha.com,1482192,2019-10-14T21:30:46Z,0
273051,JNJ,Johnson & Johnson Q3 2019 Earnings Preview,"Johnson &amp; Johnson (NYSE:JNJ) is scheduled to announce Q3 earnings results on Tuesday, October 15th, before market open.The consensus EPS Estimate is $2.01 (-2.0% Y/Y) and the consensus Revenue Est",SA Editor Vandana Singh,https://seekingalpha.com/news/3505582-johnson-and-johnson-q3-2019-earnings-preview,seekingalpha.com,1571088646,2019-10-14T21:30:46Z,0
272083,LLY,Lilly Gets FDA Approval for New Oral Tablets for Migraine,Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.,Zacks Equity Research,https://finance.yahoo.com/news/lilly-gets-fda-approval-oral-141402387.html,yahoo.com,1571062442,2019-10-14T14:14:02Z,0.84
481721,LLY,Lilly Gets FDA Approval for New Oral Tablets for Migraine,Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.,Zacks Equity Research,https://finance.yahoo.com/news/lilly-gets-fda-approval-oral-141402387.html,Yahoo.com,1432944,2019-10-14T14:14:02Z,0.84
481159,ABBV,Allergan shareholders give AbbVie takeover green light,Shareholders at Dublin headquartered Botox-maker Allergan have strongly backed its $63bn takeover by US pharmaceutical company AbbVie.,RTÉ News,https://www.rte.ie/news/business/2019/1014/1083314-allergan-shareholders-give-abbvie-takeover-green-light/,RTE,1559952,2019-10-14T14:10:16Z,0.3
271762,ABBV,Allergan shareholders give AbbVie takeover green light,Shareholders at Dublin headquartered Botox-maker Allergan have strongly backed its $63bn takeover by US pharmaceutical company AbbVie.,RTÉ News,https://www.rte.ie/news/business/2019/1014/1083314-allergan-shareholders-give-abbvie-takeover-green-light/,rte.ie,1571062216,2019-10-14T14:10:16Z,0.3
272805,ZTS,Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?,Is (ZTS) Outperforming Other Medical Stocks This Year?,Zacks Equity Research,https://finance.yahoo.com/news/zoetis-zts-stock-outpacing-medical-133001962.html,yahoo.com,1571059801,2019-10-14T13:30:01Z,0
483047,ZTS,Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?,Is (ZTS) Outperforming Other Medical Stocks This Year?,Zacks Equity Research,https://finance.yahoo.com/news/zoetis-zts-stock-outpacing-medical-133001962.html,Yahoo.com,1505520,2019-10-14T13:30:01Z,0
272806,ZTS,"Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?","Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",Zacks Equity Research,https://finance.yahoo.com/news/zoetis-zts-soars-52-week-131501340.html,yahoo.com,1571058901,2019-10-14T13:15:01Z,0.83
483048,ZTS,"Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?","Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",Zacks Equity Research,https://finance.yahoo.com/news/zoetis-zts-soars-52-week-131501340.html,Yahoo.com,1505520,2019-10-14T13:15:01Z,0.83
271764,ABBV,Allergan Shareholders Approve Proposed Acquisition by AbbVie,"DUBLIN, Oct. 14, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE:…",,https://www.prnewswire.com/news-releases/allergan-shareholders-approve-proposed-acquisition-by-abbvie-300937774.html,prnewswire.com,1571058900,2019-10-14T13:15:00Z,-0.71
481161,ABBV,Allergan Shareholders Approve Proposed Acquisition by AbbVie,"DUBLIN, Oct. 14, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE:…",,https://www.prnewswire.com/news-releases/allergan-shareholders-approve-proposed-acquisition-by-abbvie-300937774.html,Prnewswire.com,1562544,2019-10-14T13:15:00Z,-0.71
271792,ALLY,Is a Beat in Store for Ally Financial (ALLY) in Q3 Earnings?,"Owing to a decline in used-vehicle prices, Ally Financial's (ALLY) lease revenues are expected to have been adversely impacted in the third quarter of 2019.",Zacks Equity Research,https://finance.yahoo.com/news/beat-store-ally-financial-ally-125912540.html,yahoo.com,1571057952,2019-10-14T12:59:12Z,-0.2
481212,ALLY,Is a Beat in Store for Ally Financial (ALLY) in Q3 Earnings?,"Owing to a decline in used-vehicle prices, Ally Financial's (ALLY) lease revenues are expected to have been adversely impacted in the third quarter of 2019.",Zacks Equity Research,https://finance.yahoo.com/news/beat-store-ally-financial-ally-125912540.html,Yahoo.com,1425168,2019-10-14T12:59:12Z,-0.2
269925,LLY,Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress,"INDIANAPOLIS, Oct. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demon…",,https://www.prnewswire.com/news-releases/lilly-presents-positive-results-for-taltz-ixekizumab-in-pediatric-patients-with-moderate-to-severe-plaque-psoriasis-at-the-28th-annual-european-academy-of-dermatology-and-venereology-eadv-congress-300937170.html,prnewswire.com,1570877100,2019-10-12T10:45:00Z,0.13
476674,LLY,Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress,"INDIANAPOLIS, Oct. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demon…",,https://www.prnewswire.com/news-releases/lilly-presents-positive-results-for-taltz-ixekizumab-in-pediatric-patients-with-moderate-to-severe-plaque-psoriasis-at-the-28th-annual-european-academy-of-dermatology-and-venereology-eadv-congress-300937170.html,Prnewswire.com,1510704,2019-10-12T10:45:00Z,0.13
475539,LLY,"FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades","<p>Eli Lilly won FDA approval for a migraine drug on Friday, giving the pharmaceutical giant a second medication that addresses the condition that causes millions of people to experience severe headaches and other debilitating symptoms. The FDA approved the d…",Frank Vinluan,https://xconomy.com/indiana/2019/10/11/fda-oks-lillys-lasmiditan-first-new-acute-migraine-drug-in-decades/,Xconomy.com,1432944,2019-10-11T23:49:43Z,0.86
269412,LLY,"FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades","<p>Eli Lilly won FDA approval for a migraine drug on Friday, giving the pharmaceutical giant a second medication that addresses the condition that causes millions of people to experience severe headaches and other debilitating symptoms. The FDA approved the d…",Frank Vinluan,https://xconomy.com/indiana/2019/10/11/fda-oks-lillys-lasmiditan-first-new-acute-migraine-drug-in-decades/,xconomy.com,1570837783,2019-10-11T23:49:43Z,0.86
475349,BMY,BB HEALTHCARE: Invests in medical firms around the world,"BB Healthcare can have a maximum of 35 holdings, and aims to pay a dividend of 3.5 per cent of the value of its assets. One of its best-known top-ten holdings is Bristol-Myers Squibb.",By City & Finance Reporter for the Daily Mail,https://www.thisismoney.co.uk/money/investing/article-7564269/BB-HEALTHCARE-Invests-medical-firms-world.html,Thisismoney.co.uk,1549584,2019-10-11T20:51:07Z,0.4
269260,ZTS,"Is Zoetis Inc.'s (NYSE:ZTS) High P/E Ratio A Problem For Investors?","Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...",Simply Wall St,https://finance.yahoo.com/news/zoetis-inc-nyse-zts-high-174724253.html,yahoo.com,1570816044,2019-10-11T17:47:24Z,-0.4
475212,ZTS,"Is Zoetis Inc.'s (NYSE:ZTS) High P/E Ratio A Problem For Investors?","Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...",Simply Wall St,https://finance.yahoo.com/news/zoetis-inc-nyse-zts-high-174724253.html,Yahoo.com,1541808,2019-10-11T17:47:24Z,-0.4
268314,ABBV,AbbVie faces shock €572m Irish stamp duty for Allergan purchase,Immediate target of Budget 2020 measure was Green Reit takeover,Joe Brennan,https://www.irishtimes.com/business/abbvie-faces-shock-572m-irish-stamp-duty-for-allergan-purchase-1.4047849,irishtimes.com,1570812623,2019-10-11T16:50:23Z,-0.38
473511,ABBV,AbbVie faces shock €572m Irish stamp duty for Allergan purchase,Immediate target of Budget 2020 measure was Green Reit takeover,Joe Brennan,https://www.irishtimes.com/business/abbvie-faces-shock-572m-irish-stamp-duty-for-allergan-purchase-1.4047849,The Irish Times,1554768,2019-10-11T16:50:23Z,-0.38
474058,LLY,Eli Lilly Shows Its Strength With Taltz In Positive Head To Head Study,"Eli Lilly's Taltz achieves superiority over Tremfya in a head to head study based on the primary endpoint at week 12 with PASI 100 skin clearance. Taltz had 41.",Terry Chrisomalis,https://seekingalpha.com/article/4296113-eli-lilly-shows-strength-taltz-positive-head-head-study,Seekingalpha.com,1453680,2019-10-11T16:17:04Z,0.85
268618,LLY,Eli Lilly Shows Its Strength With Taltz In Positive Head To Head Study,"Eli Lilly's Taltz achieves superiority over Tremfya in a head to head study based on the primary endpoint at week 12 with PASI 100 skin clearance. Taltz had 41.",Terry Chrisomalis,https://seekingalpha.com/article/4296113-eli-lilly-shows-strength-taltz-positive-head-head-study,seekingalpha.com,1570810624,2019-10-11T16:17:04Z,0.85
473512,ABBV,ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class,"Drug-cost watchdog Institute for Clinical and Economic Review (ICER) is out with its new draft assessment of JAK inhibitors to treat rheumatoid arthritis, which incorporates different assumptions about how physicians treat the disease and the time horizon tha…",Arlene Weintraub,https://www.fiercepharma.com/pharma/icer-says-abbvie-s-ra-newcomer-rinvoq-may-be-cost-effective-but-still-questions-value-jak,Fiercepharma.com,1562544,2019-10-11T14:50:42Z,0.83
268329,ALLY,Ally Financial Announces Date of 2020 Annual Meeting of Stockholders,"DETROIT, Oct. 11, 2019 /PRNewswire/ -- Ally Financial Inc. (NYSE: ALLY) today announced that it will conduct its 2020 annual meeting of stockholders on Tuesday, April 28, 2020. Additional details will be provided in the company's proxy statement. About Ally F…",,https://www.prnewswire.com/news-releases/ally-financial-announces-date-of-2020-annual-meeting-of-stockholders-300936939.html,prnewswire.com,1570798800,2019-10-11T13:00:00Z,0
473553,ALLY,Ally Financial Announces Date of 2020 Annual Meeting of Stockholders,"DETROIT, Oct. 11, 2019 /PRNewswire/ -- Ally Financial Inc. (NYSE: ALLY) today announced that it will conduct its 2020 annual meeting of stockholders on Tuesday, April 28, 2020. Additional details will be provided in the company's proxy statement. About Ally F…",,https://www.prnewswire.com/news-releases/ally-financial-announces-date-of-2020-annual-meeting-of-stockholders-300936939.html,Prnewswire.com,1458864,2019-10-11T13:00:00Z,0
268307,ZTS,EMS Awards,"Bristol vet school has presented awards for outstanding engagement on EMS placements. Prizes in the form academic book vouchers, provided by Zoetis, were presented at the university’s graduation ceremony in August. Jamie Rahman received the award as the most …",,https://veterinaryrecord.bmj.com/content/185/14/ii.2,bmj.com,1570783535,2019-10-11T08:45:35Z,0.95
473499,ZTS,EMS Awards,"Bristol vet school has presented awards for outstanding engagement on EMS placements. Prizes in the form academic book vouchers, provided by Zoetis, were presented at the university’s graduation ceremony in August. Jamie Rahman received the award as the most …",,https://veterinaryrecord.bmj.com/content/185/14/ii.2,Bmj.com,1425168,2019-10-11T08:45:35Z,0.95
266142,LLY,"Positive Growth of Eli Lilly's Taltz and Stabilization of Novartis' Cosentyx in Psoriasis May be an Indicator for Future Psoriatic Arthritis Market Shift","EXTON, Pa., Oct. 10, 2019 /PRNewswire/ -- Novartis' Cosentyx was first approved by the FDA for the treatment of psoriasis in January 2015, followed by a label extension for both psoriatic arthritis (PsA) and ankylosing spondylitis (AS) a year later – snagging…",,https://www.prnewswire.com/news-releases/positive-growth-of-eli-lillys-taltz-and-stabilization-of-novartis-cosentyx-in-psoriasis-may-be-an-indicator-for-future-psoriatic-arthritis-market-shift-300936743.html,prnewswire.com,1570731000,2019-10-10T18:10:00Z,0.84
469386,LLY,"Positive Growth of Eli Lilly's Taltz and Stabilization of Novartis' Cosentyx in Psoriasis May be an Indicator for Future Psoriatic Arthritis Market Shift","EXTON, Pa., Oct. 10, 2019 /PRNewswire/ -- Novartis' Cosentyx was first approved by the FDA for the treatment of psoriasis in January 2015, followed by a label extension for both psoriatic arthritis (PsA) and ankylosing spondylitis (AS) a year later – snagging…",,https://www.prnewswire.com/news-releases/positive-growth-of-eli-lillys-taltz-and-stabilization-of-novartis-cosentyx-in-psoriasis-may-be-an-indicator-for-future-psoriatic-arthritis-market-shift-300936743.html,Prnewswire.com,1523664,2019-10-10T18:10:00Z,0.84
265768,ABBV,Recon: UCB to Buy Ra for $2.1B Reata to Pay $330M to Reacquire Drug Rights from AbbVie,"Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.",,https://www.raps.org/news-and-articles/news-articles/2019/10/recon-ucb-to-buy-ra-for-21b-reata-to-pay-330m?feed=Regulatory-Focus,raps.org,1570726540,2019-10-10T16:55:40Z,0.4
468742,ABBV,Recon: UCB to Buy Ra for $2.1B; Reata to Pay $330M to Reacquire Drug Rights from AbbVie,"Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.",,https://www.raps.org/news-and-articles/news-articles/2019/10/recon-ucb-to-buy-ra-for-21b-reata-to-pay-330m?feed=Regulatory-Focus,Raps.org,1497744,2019-10-10T16:55:40Z,0.4
266143,LLY,Here’s What Hedge Funds Think About Eli Lilly and Company (LLY),"Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite inv…",,https://finance.yahoo.com/news/hedge-funds-think-eli-lilly-152641439.html,yahoo.com,1570721201,2019-10-10T15:26:41Z,0.36
469387,LLY,Here’s What Hedge Funds Think About Eli Lilly and Company (LLY),"Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite inv…",,https://finance.yahoo.com/news/hedge-funds-think-eli-lilly-152641439.html,Yahoo.com,1523664,2019-10-10T15:26:41Z,0.36
266140,JNJ,J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector,"J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.",Zacks Equity Research,https://finance.yahoo.com/news/j-j-jnj-start-q3-143402721.html,yahoo.com,1570718042,2019-10-10T14:34:02Z,-0.83
469383,JNJ,J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector,"J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.",Zacks Equity Research,https://finance.yahoo.com/news/j-j-jnj-start-q3-143402721.html,Yahoo.com,1521072,2019-10-10T14:34:02Z,-0.83
469075,BMY,"Thinking about buying stock in Bristol-Myers Squibb, Canopy Growth Corp, Intel, Target, or Tilray?","NEW YORK, Oct. 10, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BMY, CGC, INTC, TGT, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selec…",,https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-bristol-myers-squibb-canopy-growth-corp-intel-target-or-tilray-300936488.html,Prnewswire.com,1559952,2019-10-10T13:31:00Z,0.36
265923,BMY,"Thinking about buying stock in Bristol-Myers Squibb, Canopy Growth Corp, Intel, Target, or Tilray?","NEW YORK, Oct. 10, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BMY, CGC, INTC, TGT, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selec…",,https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-bristol-myers-squibb-canopy-growth-corp-intel-target-or-tilray-300936488.html,prnewswire.com,1570714260,2019-10-10T13:31:00Z,0.36
265066,ABBV,Reata reacquires rights to bardoxolone from AbbVie,"Reata Pharmaceuticals (NASDAQ:RETA) has reacquired development and commercialization rights to its Nrf2 activator product platform from licensee AbbVie (NYSE:ABBV). Specifically, it owns exclusive glo",SA Editor Douglas W. House,https://seekingalpha.com/news/3504928-reata-reacquires-rights-bardoxolone-abbvie,seekingalpha.com,1570706546,2019-10-10T11:22:26Z,0.13
467350,ABBV,Reata reacquires rights to bardoxolone from AbbVie,"Reata Pharmaceuticals (NASDAQ:RETA) has reacquired development and commercialization rights to its Nrf2 activator product platform from licensee AbbVie (NYSE:ABBV). Specifically, it owns exclusive glo",SA Editor Douglas W. House,https://seekingalpha.com/news/3504928-reata-reacquires-rights-bardoxolone-abbvie,Seekingalpha.com,1448496,2019-10-10T11:22:26Z,0.13
467677,JNJ,"Boy, 13, who grew 'boobs bigger than girls at his school' sues Johnson & Johnson","Johnson & Johnson is facing thousands of lawsuits over its Risperdal drug, which can lead to men developing 'man boobs'",mirrornews@mirror.co.uk (Matthew Dresch),https://www.mirror.co.uk/news/us-news/boy-13-who-grew-boobs-20549289,Mirror,1578096,2019-10-10T04:44:30Z,-0.15
464786,JNJ,Top Trending: JNJ told to pay $8b to man over breast growth,Drug Giant Johnson & Johnson has been ordered to pay $8 billion in damages to a man who grew breast tissue after taking anti-psychotic drugs as a child. A new book by journalist Ronan Farrow is shedding new light on allegations against former Today Show ancho…,,https://finance.yahoo.com/video/top-trending-jnj-told-pay-175737097.html,Yahoo.com,1539216,2019-10-09T17:57:37Z,-0.44
263704,JNJ,Top Trending: JNJ told to pay $8b to man over breast growth,Drug Giant Johnson & Johnson has been ordered to pay $8 billion in damages to a man who grew breast tissue after taking anti-psychotic drugs as a child. A new book by journalist Ronan Farrow is shedding new light on allegations against former Today Show ancho…,,https://finance.yahoo.com/video/top-trending-jnj-told-pay-175737097.html,yahoo.com,1570643857,2019-10-09T17:57:37Z,-0.44
263434,BMY,Were Hedge Funds Right About Betting On Bristol-Myers Squibb Company (BMY)?,"Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees during the first half of 2019 amid Powell's pivot and optimistic expectations towards a trade d…",Nina Todic,https://finance.yahoo.com/news/were-hedge-funds-betting-bristol-163722505.html,yahoo.com,1570639042,2019-10-09T16:37:22Z,0.6
464360,BMY,Were Hedge Funds Right About Betting On Bristol-Myers Squibb Company (BMY)?,"Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees during the first half of 2019 amid Powell's pivot and optimistic expectations towards a trade d…",Nina Todic,https://finance.yahoo.com/news/were-hedge-funds-betting-bristol-163722505.html,Yahoo.com,1487376,2019-10-09T16:37:22Z,0.6
464796,JNJ,J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case,Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.,Zacks Equity Research,https://finance.yahoo.com/news/j-j-ordered-philadelphia-jury-151503059.html,Yahoo.com,1541808,2019-10-09T15:15:03Z,-0.79
263713,JNJ,J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case,Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.,Zacks Equity Research,https://finance.yahoo.com/news/j-j-ordered-philadelphia-jury-151503059.html,yahoo.com,1570634103,2019-10-09T15:15:03Z,-0.79
464800,JNJ,J&J slides after jury orders it to pay $8 billion in male breast-growth case (JNJ),"A Philadelphia jury ruled Johnson & Johnson must pay $8 billion in damages to a man claiming the company didn't properly warn male consumers its Risperdal drug could prompt breast growth. The company's stock fell as much as 1.5% on Wednesday following the Tue…",Ben Winck,https://markets.businessinsider.com/news/stocks/jnj-stock-price-falls-risperdal-male-breast-growth-jury-decision-2019-10-1028587229,Business Insider,1546992,2019-10-09T13:53:08Z,-0.2
263716,JNJ,J&J slides after jury orders it to pay $8 billion in male breast-growth case (JNJ),"A Philadelphia jury ruled Johnson & Johnson must pay $8 billion in damages to a man claiming the company didn't properly warn male consumers its Risperdal drug could prompt breast growth. The company's stock fell as much as 1.5% on Wednesday following the Tue…",Ben Winck,https://markets.businessinsider.com/news/stocks/jnj-stock-price-falls-risperdal-male-breast-growth-jury-decision-2019-10-1028587229,businessinsider.com,1570629188,2019-10-09T13:53:08Z,-0.2
262808,JNJ,Johnson & Johnson to appeal $8B Risperdal judgement,"Predictably, Johnson &amp; Johnson (NYSE:JNJ) intends to appeal the $8B in punitive damages awarded by a Philadelphia jury to a man who claimed that the company failed to adequately warn about the ris",SA Editor Douglas W. House,https://seekingalpha.com/news/3504671-johnson-and-johnson-appeal-8b-risperdal-judgement,seekingalpha.com,1570622051,2019-10-09T11:54:11Z,-0.8
463104,JNJ,Johnson & Johnson to appeal $8B Risperdal judgement,"Predictably, Johnson &amp; Johnson (NYSE:JNJ) intends to appeal the $8B in punitive damages awarded by a Philadelphia jury to a man who claimed that the company failed to adequately warn about the ris",SA Editor Douglas W. House,https://seekingalpha.com/news/3504671-johnson-and-johnson-appeal-8b-risperdal-judgement,Seekingalpha.com,1466640,2019-10-09T11:54:11Z,-0.8
463110,JNJ,Irish PM Leo Varadkar says ‘very difficult’ to secure Brexit agreement by next week after phone call with Boris Johnson,Johnson has consistently said the United Kingdom would leave the EU on 31 October with or without a deal The post Irish PM Leo Varadkar says ‘very difficult’ to secure Brexit agreement by next week after phone call with Boris Johnson appeared first on Firstpo…,Reuters,https://www.firstpost.com/world/irish-pm-leo-varadkar-says-very-difficult-to-secure-brexit-agreement-by-next-week-after-phone-call-with-boris-johnson-7472531.html,Firstpost.com,1469232,2019-10-09T09:04:56Z,0.92
462789,ABBV,AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress,"NORTH CHICAGO, Ill., Oct. 9, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new results evaluating the safety and efficacy of SKYRIZI™ (risankizumab) at 2.5 years in adult pati…",,https://www.prnewswire.com/news-releases/abbvie-announces-new-data-from-its-dermatology-portfolio-and-pipeline-at-the-28th-european-academy-of-dermatology-and-venereology-eadv-congress-300934529.html,Prnewswire.com,1552176,2019-10-09T06:01:00Z,0.42
262635,ABBV,AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress,"NORTH CHICAGO, Ill., Oct. 9, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new results evaluating the safety and efficacy of SKYRIZI™ (risankizumab) at 2.5 years in adult pati…",,https://www.prnewswire.com/news-releases/abbvie-announces-new-data-from-its-dermatology-portfolio-and-pipeline-at-the-28th-european-academy-of-dermatology-and-venereology-eadv-congress-300934529.html,prnewswire.com,1570600860,2019-10-09T06:01:00Z,0.42
461672,ALLY,JPMorgan makes a call we could be seeing peak consumer,"JPMorgan downgrades Ally Financial. Is there 'car trouble' ahead? With CNBC's Melissa Lee and the Fast Money traders, Pete Najarian, Tim Seymour, Dan Nathan and Guy Adami.",Melissa Lee,https://www.cnbc.com/video/2019/10/08/jpmorgan-makes-a-call-we-could-be-seeing-peak-consumer.html,CNBC,1484784,2019-10-08T22:29:00Z,-0.4
262079,ALLY,JPMorgan makes a call we could be seeing peak consumer,"JPMorgan downgrades Ally Financial. Is there 'car trouble' ahead? With CNBC's Melissa Lee and the Fast Money traders, Pete Najarian, Tim Seymour, Dan Nathan and Guy Adami.",Melissa Lee,https://www.cnbc.com/video/2019/10/08/jpmorgan-makes-a-call-we-could-be-seeing-peak-consumer.html,cnbc.com,1570573740,2019-10-08T22:29:00Z,-0.4
262250,JNJ,"J&J must pay $8B in Risperdal case, jury says",Johnson &amp; Johnson (NYSE:JNJ) -1.9% after-hours following a Philadelphia jury ruling that it must pay $8B billion in punitive damages to a man who previously won $680K over his claims that it faile,SA Editor Carl Surran,https://seekingalpha.com/news/3504615-j-and-j-must-pay-8b-risperdal-case-jury-says,seekingalpha.com,1570572242,2019-10-08T22:04:02Z,-0.51
461966,JNJ,"J&J must pay $8B in Risperdal case, jury says",Johnson &amp; Johnson (NYSE:JNJ) -1.9% after-hours following a Philadelphia jury ruling that it must pay $8B billion in punitive damages to a man who previously won $680K over his claims that it faile,SA Editor Carl Surran,https://seekingalpha.com/news/3504615-j-and-j-must-pay-8b-risperdal-case-jury-says,Seekingalpha.com,1513296,2019-10-08T22:04:02Z,-0.51
262064,ABBV,Were Hedge Funds Right About Snapping Up AbbVie Inc (ABBV)?,"We can judge whether AbbVie Inc (NYSE:ABBV) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities w…",,https://finance.yahoo.com/news/were-hedge-funds-snapping-abbvie-215437888.html,yahoo.com,1570571677,2019-10-08T21:54:37Z,0.83
461644,ABBV,Were Hedge Funds Right About Snapping Up AbbVie Inc (ABBV)?,"We can judge whether AbbVie Inc (NYSE:ABBV) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities w…",,https://finance.yahoo.com/news/were-hedge-funds-snapping-abbvie-215437888.html,Yahoo.com,1461456,2019-10-08T21:54:37Z,0.83
260866,ABBV,AbbVie and Roche price hike leaders past two years,"According to a new report from the nonprofit Institute for Clinical and Economic Review &#40;ICER&#41;, AbbVie (ABBV -0.6%) and Roche (OTCQX:RHHBY -1.6%) were number one and two, respectively, in term",SA Editor Douglas W. House,https://seekingalpha.com/news/3504522-abbvie-roche-price-hike-leaders-past-two-years,seekingalpha.com,1570550597,2019-10-08T16:03:17Z,0.4
459625,ABBV,AbbVie and Roche price hike leaders past two years,"According to a new report from the nonprofit Institute for Clinical and Economic Review &#40;ICER&#41;, AbbVie (ABBV -0.6%) and Roche (OTCQX:RHHBY -1.6%) were number one and two, respectively, in term",SA Editor Douglas W. House,https://seekingalpha.com/news/3504522-abbvie-roche-price-hike-leaders-past-two-years,Seekingalpha.com,1521072,2019-10-08T16:03:17Z,0.4
461622,ZTS,Can Zoetis (ZTS) Keep the Earnings Surprise Streak Alive?,Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,Zacks Equity Research,https://finance.yahoo.com/news/zoetis-zts-keep-earnings-surprise-141002471.html,Yahoo.com,1451088,2019-10-08T14:10:02Z,0.76
262052,ZTS,Can Zoetis (ZTS) Keep the Earnings Surprise Streak Alive?,Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,Zacks Equity Research,https://finance.yahoo.com/news/zoetis-zts-keep-earnings-surprise-141002471.html,yahoo.com,1570543802,2019-10-08T14:10:02Z,0.76
260868,ABBV,"REFILE-Humira, Rituxan top list of U.S. costliest drug price increases -report","AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan top the list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.",Reuters Editorial,https://www.reuters.com/article/usa-healthcare-drugpricing-idUSL2N26S10B,reuters.com,1570541529,2019-10-08T13:32:09Z,-0.13
459627,ABBV,"REFILE-Humira, Rituxan top list of U.S. costliest drug price increases -report","AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan top the list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.",Reuters Editorial,https://www.reuters.com/article/usa-healthcare-drugpricing-idUSL2N26S10B,Reuters,1521072,2019-10-08T13:32:09Z,-0.13
261225,LLY,Can We See Significant Institutional Ownership On The Eli Lilly and Company (NYSE:LLY) Share Register?,The big shareholder groups in Eli Lilly and Company (NYSE:LLY) have power over the company. Large companies usually...,Simply Wall St,https://finance.yahoo.com/news/see-significant-institutional-ownership-eli-131507516.html,yahoo.com,1570540507,2019-10-08T13:15:07Z,0.46
460274,LLY,Can We See Significant Institutional Ownership On The Eli Lilly and Company (NYSE:LLY) Share Register?,The big shareholder groups in Eli Lilly and Company (NYSE:LLY) have power over the company. Large companies usually...,Simply Wall St,https://finance.yahoo.com/news/see-significant-institutional-ownership-eli-131507516.html,Yahoo.com,1482192,2019-10-08T13:15:07Z,0.46
260869,ABBV,AbbVie to Host Third-Quarter 2019 Earnings Conference Call,"NORTH CHICAGO, Ill., Oct. 8, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its third-quarter 2019 financial results on Friday, November 1 before the market opens. AbbVie will host a live webcast of …",,https://www.prnewswire.com/news-releases/abbvie-to-host-third-quarter-2019-earnings-conference-call-300931452.html,prnewswire.com,1570537800,2019-10-08T12:30:00Z,0
459628,ABBV,AbbVie to Host Third-Quarter 2019 Earnings Conference Call,"NORTH CHICAGO, Ill., Oct. 8, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its third-quarter 2019 financial results on Friday, November 1 before the market opens. AbbVie will host a live webcast of …",,https://www.prnewswire.com/news-releases/abbvie-to-host-third-quarter-2019-earnings-conference-call-300931452.html,Prnewswire.com,1521072,2019-10-08T12:30:00Z,0
459629,ABBV,"REFILE-UPDATE 1-Humira, Rituxan top list of U.S. drugs with biggest price increases -report","AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. The price hik…",,https://finance.yahoo.com/news/1-humira-rituxan-top-list-122745086.html,Yahoo.com,1523664,2019-10-08T12:27:45Z,-0.32
260870,ABBV,"REFILE-UPDATE 1-Humira, Rituxan top list of U.S. drugs with biggest price increases -report","AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. The price hik…",,https://finance.yahoo.com/news/1-humira-rituxan-top-list-122745086.html,yahoo.com,1570537665,2019-10-08T12:27:45Z,-0.32
459630,ABBV,"Chasing AbbVie, Gilead files for approval of filgotinib in Japan",Gilead Sciences has filed for approval of JAK1 inhibitor filgotinib in Japan. The submission moves Gilead a step closer to selling the Galapagos-partnered drug to rheumatoid arthritis patients in the country.,Nick Paul,https://www.fiercebiotech.com/biotech/chasing-abbvie-gilead-files-for-approval-filgotinib-japan,Fiercebiotech.com,1523664,2019-10-08T12:11:34Z,0.71
260871,ABBV,"Chasing AbbVie, Gilead files for approval of filgotinib in Japan",Gilead Sciences has filed for approval of JAK1 inhibitor filgotinib in Japan. The submission moves Gilead a step closer to selling the Galapagos-partnered drug to rheumatoid arthritis patients in the country.,Nick Paul,https://www.fiercebiotech.com/biotech/chasing-abbvie-gilead-files-for-approval-filgotinib-japan,fiercebiotech.com,1570536694,2019-10-08T12:11:34Z,0.71
459631,ABBV,"Humira, Rituxan top list of US drugs with biggest price increases - report","AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan top the list of seven treatments whose combined 2017 and 2018 price hikes accounted for a US$5.1 billion increase in U.S. spending, a report released on Tuesday showed.",CNA,https://www.channelnewsasia.com/news/world/humira--rituxan-top-list-of-us-drugs-with-biggest-price-increases---report-11982006,Channelnewsasia.com,1523664,2019-10-08T12:10:56Z,-0.13
260873,ABBV,"Humira, Rituxan top list of US costliest drug price increases - report","AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan top the list of seven treatments whose combined 2017 and 2018 price hikes accounted for a US$5.1 billion increase in U.S. spending, a report released on Tuesday showed.",CNA,https://www.channelnewsasia.com/news/world/humira--rituxan-top-list-of-us-costliest-drug-price-increases---report-11982006,channelnewsasia.com,1570536656,2019-10-08T12:10:56Z,-0.13
459632,ABBV,"Humira, Rituxan top list of US costliest drug price increases - report","AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan top the list of seven treatments whose combined 2017 and 2018 price hikes accounted for a US$5.1 billion increase in U.S. spending, a report released on Tuesday showed.",CNA,https://www.channelnewsasia.com/news/world/humira--rituxan-top-list-of-us-costliest-drug-price-increases---report-11982006,Channelnewsasia.com,1523664,2019-10-08T12:10:56Z,-0.13
260872,ABBV,"Humira, Rituxan top list of US drugs with biggest price increases - report","AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan top the list of seven treatments whose combined 2017 and 2018 price hikes accounted for a US$5.1 billion increase in U.S. spending, a report released on Tuesday showed.",CNA,https://www.channelnewsasia.com/news/world/humira--rituxan-top-list-of-us-drugs-with-biggest-price-increases---report-11982006,channelnewsasia.com,1570536656,2019-10-08T12:10:56Z,-0.13
459668,ALLY,Ally Financial extends Hendrick Motorsports sponsorship,"Ally Financial Inc. has extended its full-season sponsorship of Hendrick Motorsports until 2023, the companies said in a press release last week. The company first sponsored the race team in 2018, establishing Ally (NYSE: ALLY) as Jimmie Johnson’s primary spo…",Sabrina Berndt,https://www.bizjournals.com/charlotte/news/2019/10/08/ally-financial-extends-hendrick-motorsports.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_national+%28Bizjournals+National+Feed%29,Bizjournals.com,1536624,2019-10-08T12:10:00Z,0.13
260890,ALLY,Ally Financial extends Hendrick Motorsports sponsorship,"Ally Financial Inc. has extended its full-season sponsorship of Hendrick Motorsports until 2023, the companies said in a press release last week. The company first sponsored the race team in 2018, establishing Ally (NYSE: ALLY) as Jimmie Johnson’s primary spo…",Sabrina Berndt,https://www.bizjournals.com/charlotte/news/2019/10/08/ally-financial-extends-hendrick-motorsports.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_national+%28Bizjournals+National+Feed%29,bizjournals.com,1570536600,2019-10-08T12:10:00Z,0.13
260874,ABBV,"Humira, Rituxan top list of U.S. costliest drug price increases - report","AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan top the list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.",Reuters Editorial,https://www.reuters.com/article/us-usa-healthcare-drugpricing-idUSKBN1WN1BE,reuters.com,1570536542,2019-10-08T12:09:02Z,-0.13
459633,ABBV,"Humira, Rituxan top list of U.S. costliest drug price increases - report","AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan top the list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.",Reuters Editorial,https://www.reuters.com/article/us-usa-healthcare-drugpricing-idUSKBN1WN1BE,Reuters,1523664,2019-10-08T12:09:02Z,-0.13
459635,ABBV,"Humira, Rituxan top list of U.S. costliest drug price increases -report","AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan top the list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.",Reuters Editorial,https://uk.reuters.com/article/us-usa-healthcare-drugpricing-idUKKBN1WN1BE,Reuters,1523664,2019-10-08T12:00:00Z,-0.13
260875,ABBV,"Humira, Rituxan top list of U.S. costliest drug price increases -report","AbbVie Inc's arthritis drug Humira and Roche Holding AG's cancer drug Rituxan top the list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.",Reuters Editorial,https://uk.reuters.com/article/us-usa-healthcare-drugpricing-idUKKBN1WN1BE,reuters.com,1570536000,2019-10-08T12:00:00Z,-0.13
260363,LLY,Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress,"INDIANAPOLIS, Oct. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will present new data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 28th annual European Academy of Dermatology and Venereology (EAD…",,https://www.prnewswire.com/news-releases/lilly-to-unveil-new-data-for-the-treatments-of-complex-dermatological-conditions-at-the-28th-annual-european-academy-of-dermatology-and-venereology-eadv-congress-300933466.html,prnewswire.com,1570531500,2019-10-08T10:45:00Z,0
458690,LLY,Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress,"INDIANAPOLIS, Oct. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will present new data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 28th annual European Academy of Dermatology and Venereology (EAD…",,https://www.prnewswire.com/news-releases/lilly-to-unveil-new-data-for-the-treatments-of-complex-dermatological-conditions-at-the-28th-annual-european-academy-of-dermatology-and-venereology-eadv-congress-300933466.html,Prnewswire.com,1495152,2019-10-08T10:45:00Z,0
259536,ABBV,AbbVie (ABBV) Stock Moves -0.44%: What You Should Know,"AbbVie (ABBV) closed the most recent trading day at $74.33, moving -0.44% from the previous trading session.",Zacks Equity Research,https://finance.yahoo.com/news/abbvie-abbv-stock-moves-0-214509755.html,yahoo.com,1570484709,2019-10-07T21:45:09Z,0
457074,ABBV,AbbVie (ABBV) Stock Moves -0.44%: What You Should Know,"AbbVie (ABBV) closed the most recent trading day at $74.33, moving -0.44% from the previous trading session.",Zacks Equity Research,https://finance.yahoo.com/news/abbvie-abbv-stock-moves-0-214509755.html,Yahoo.com,1578096,2019-10-07T21:45:09Z,0
259537,ABBV,"'Fast Money Halftime Report' Traders Advise Viewers On AbbVie, Home Depot And More","On CNBC's ""Fast Money Halftime Report,"" Joe Terranova said he owns Lululemon Athletica inc. (NASDAQ: LULU ), but he thinks Nike Inc (NYSE: NKE ) would work, too. Josh Brown said the marijuana ...",,https://finance.yahoo.com/news/fast-money-halftime-report-traders-202737011.html,yahoo.com,1570480057,2019-10-07T20:27:37Z,0
457075,ABBV,"'Fast Money Halftime Report' Traders Advise Viewers On AbbVie, Home Depot And More","On CNBC's ""Fast Money Halftime Report,"" Joe Terranova said he owns Lululemon Athletica inc. (NASDAQ: LULU ), but he thinks Nike Inc (NYSE: NKE ) would work, too. Josh Brown said the marijuana ...",,https://finance.yahoo.com/news/fast-money-halftime-report-traders-202737011.html,Yahoo.com,1578096,2019-10-07T20:27:37Z,0
258769,LLY,52-Week Company Lows,"Eli Lilly, 3M, Simon Property Group, Schlumberger, EOG Resources and Occidental Petroleum present buying opportunities Continue reading...",GuruFocus.com,https://finance.yahoo.com/news/52-week-company-lows-161821503.html,yahoo.com,1570465101,2019-10-07T16:18:21Z,0.38
455758,LLY,52-Week Company Lows,"Eli Lilly, 3M, Simon Property Group, Schlumberger, EOG Resources and Occidental Petroleum present buying opportunities Continue reading...",GuruFocus.com,https://finance.yahoo.com/news/52-week-company-lows-161821503.html,Yahoo.com,1513728,2019-10-07T16:18:21Z,0.38
455759,LLY,"Lilly touts Cyramza lung cancer data, as AZ’s Tagrisso grows even more powerful","Full data supporting Eli Lilly’s Cyramza in previously untreated EGFR lung cancer patients are out. But an approval would mean going up against AstraZeneca's new king, Tagrisso—and it's become an even more formidable force with a growing arsenal of clinical e…",Angus Liu,https://www.fiercepharma.com/marketing/lilly-touts-cyramza-lung-cancer-data-as-az-s-tagrisso-grows-even-more-powerful,Fiercepharma.com,1515628,2019-10-07T14:37:12Z,-0.45
258766,JNJ,J&J files U.S. application for expanded use of Stelara,Johnson &amp; Johnson (NYSE:JNJ) unit Janssen Pharmaceutical has submitted a marketing application to the FDA seeking approval to use Stelara (ustekinumab) to treat pediatric patients ages 6 - 11 year,SA Editor Douglas W. House,https://seekingalpha.com/news/3504163-j-and-j-files-u-s-application-expanded-use-stelara,seekingalpha.com,1570451134,2019-10-07T12:25:34Z,0.7
455753,JNJ,J&J files U.S. application for expanded use of Stelara,Johnson &amp; Johnson (NYSE:JNJ) unit Janssen Pharmaceutical has submitted a marketing application to the FDA seeking approval to use Stelara (ustekinumab) to treat pediatric patients ages 6 - 11 year,SA Editor Douglas W. House,https://seekingalpha.com/news/3504163-j-and-j-files-u-s-application-expanded-use-stelara,Seekingalpha.com,1509494,2019-10-07T12:25:34Z,0.7
257967,JNJ,Johnson & Johnson Releases Inaugural You Belong: Diversity & Inclusion Impact Review,"NEW BRUNSWICK, N.J., Oct. 7, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), the world's largest and most broadly-based healthcare company, today published You Belong: Diversity & Inclusion Impact Review (Impact Review), which demonstrates how a strategic…",,https://www.prnewswire.com/news-releases/johnson--johnson-releases-inaugural-you-belong-diversity--inclusion-impact-review-300932796.html,prnewswire.com,1570449600,2019-10-07T12:00:00Z,0
454129,JNJ,Johnson & Johnson Releases Inaugural You Belong: Diversity & Inclusion Impact Review,"NEW BRUNSWICK, N.J., Oct. 7, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), the world's largest and most broadly-based healthcare company, today published You Belong: Diversity & Inclusion Impact Review (Impact Review), which demonstrates how a strategic…",,https://www.prnewswire.com/news-releases/johnson--johnson-releases-inaugural-you-belong-diversity--inclusion-impact-review-300932796.html,Prnewswire.com,1560729,2019-10-07T12:00:00Z,0
257972,LLY,"Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology","INDIANAPOLIS, Oct. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that results from the global Phase 3 RELAY trial of CYRAMZA® (ramucirumab) in previously untreated patients with metastatic EGFR-mutated non-small cell lung cancer (N…",,https://www.prnewswire.com/news-releases/lillys-cyramza-ramucirumab-phase-3-data-in-first-line-egfr-mutated-non-small-cell-lung-cancer-published-in-the-lancet-oncology-300932733.html,prnewswire.com,1570445100,2019-10-07T10:45:00Z,-0.87
454135,LLY,"Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology","INDIANAPOLIS, Oct. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that results from the global Phase 3 RELAY trial of CYRAMZA® (ramucirumab) in previously untreated patients with metastatic EGFR-mutated non-small cell lung cancer (N…",,https://www.prnewswire.com/news-releases/lillys-cyramza-ramucirumab-phase-3-data-in-first-line-egfr-mutated-non-small-cell-lung-cancer-published-in-the-lancet-oncology-300932733.html,Prnewswire.com,1563321,2019-10-07T10:45:00Z,-0.87
453808,ABBV,Income Investors Should Know That AbbVie Inc. (NYSE:ABBV) Goes Ex-Dividend Soon,"Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see AbbVie Inc...",,https://finance.yahoo.com/news/income-investors-know-abbvie-inc-095500875.html,Yahoo.com,1477440,2019-10-07T09:55:00Z,0.81
257784,ABBV,Income Investors Should Know That AbbVie Inc. (NYSE:ABBV) Goes Ex-Dividend Soon,"Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see AbbVie Inc...",,https://finance.yahoo.com/news/income-investors-know-abbvie-inc-095500875.html,yahoo.com,1570442100,2019-10-07T09:55:00Z,0.81
257840,BMY,How Does Bristol-Myers Squibb’s Valuation Compare To Its Peers?,"Bristol-Myers Squibb’s market cap is much lower than some of the large pharmaceuticals companies, including J&J, Merck, and Pfizer. Despite garnering higher revenue growth, and adjusted net earnings margin in-line with peers, its current price to earnings mul…","Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/",https://www.forbes.com/sites/greatspeculations/2019/10/07/how-does-bristol-myers-squibbs-valuation-compare-to-its-peers/,forbes.com,1570440000,2019-10-07T09:20:00Z,0.1
453929,BMY,How Does Bristol-Myers Squibb’s Valuation Compare To Its Peers?,"Bristol-Myers Squibb’s market cap is much lower than some of the large pharmaceuticals companies, including J&J, Merck, and Pfizer. Despite garnering higher revenue growth, and adjusted net earnings margin in-line with peers, its current price to earnings mul…","Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/",https://www.forbes.com/sites/greatspeculations/2019/10/07/how-does-bristol-myers-squibbs-valuation-compare-to-its-peers/,Forbes.com,1532304,2019-10-07T09:20:00Z,0.1
453232,ABBV,"AbbVie-Allergan Merger - Don't Worry About Debt, AbbVie Is Still A Buy",Allergan released its merger prospectus which includes 5-year forward forecasts for it and AbbVie. Strong Humira sales before US loss of exclusivity in 2023 all,Gary Gambino,https://seekingalpha.com/article/4295290-abbvie-allergan-merger-worry-debt-abbvie-still-buy,Seekingalpha.com,1567900,2019-10-06T21:01:32Z,0.67
257532,ABBV,"AbbVie-Allergan Merger - Don't Worry About Debt, AbbVie Is Still A Buy",Allergan released its merger prospectus which includes 5-year forward forecasts for it and AbbVie. Strong Humira sales before US loss of exclusivity in 2023 all,Gary Gambino,https://seekingalpha.com/article/4295290-abbvie-allergan-merger-worry-debt-abbvie-still-buy,seekingalpha.com,1570395692,2019-10-06T21:01:32Z,0.67
257521,ZTS,"Heroes to America's Animals: Meet the Winners of the 2019 American Humane Hero Veterinarian and Hero Veterinary Nurse Awards™, Presented by Zoetis","LOS ANGELES, Oct. 6, 2019 /PRNewswire/ -- Heroic canines were not the only honorees Saturday night at the ninth annual American Humane Hero Dog Awards®. America's first national humane organization also honored a couple of human beings – with the American Hum…",,https://www.newswire.ca:443/news-releases/heroes-to-americas-animals-meet-the-winners-of-the-2019-american-humane-hero-veterinarian-and-hero-veterinary-nurse-awards-presented-by-zoetis-300932699.html,newswire.ca,1570377600,2019-10-06T16:00:00Z,0.97
453199,ZTS,"Heroes to America's Animals: Meet the Winners of the 2019 American Humane Hero Veterinarian and Hero Veterinary Nurse Awards™, Presented by Zoetis","LOS ANGELES, Oct. 6, 2019 /PRNewswire/ -- Heroic canines were not the only honorees Saturday night at the ninth annual American Humane Hero Dog Awards®. America's first national humane organization also honored a couple of human beings – with the American Hum…",,https://www.newswire.ca:443/news-releases/heroes-to-americas-animals-meet-the-winners-of-the-2019-american-humane-hero-veterinarian-and-hero-veterinary-nurse-awards-presented-by-zoetis-300932699.html,Newswire.ca,1567641,2019-10-06T16:00:00Z,0.97
520487,ZTS,"Top Analyst Upgrades and Downgrades: Ally, Altria, AT&T, Ford ...","Sep 10, 2019 ... Altria Group Inc. (NYSE: MO) was downgraded to Neutral from ... Groupon, 
Honeywell, Mastercard, Newmont Goldcorp, Roku, Zoetis and more.",Jon C. Ogg,https://247wallst.com/investing/2019/09/10/top-analyst-upgrades-and-downgrades-ally-altria-att-ford-micron-shopify-valero-wells-fargo-whiting-petroleum-zscaler-and-more/,247wallst.com,1570320000,2019-10-06T00:00:00Z,0.2
520486,ZTS,"Top Analyst Upgrades and Downgrades: Apple, Caterpillar, Costco ...","Sep 9, 2019 ... Groupon Inc. (NASDAQ: GRPN) was reiterated as Neutral with a ... Zoetis Inc. (
NYSE: ZTS) was started with a Buy rating and was added to the ...",Jon C. Ogg,https://247wallst.com/investing/2019/09/09/top-analyst-upgrades-and-downgrades-apple-caterpillar-costco-chipotle-ebay-groupon-honeywelll-mastercard-newmont-goldcorp-roku-zoetis-and-more/2/,247wallst.com,1570320000,2019-10-06T00:00:00Z,0.2
520488,ZTS,"AAPL | 24/7 Wall St. | Page 24","Apple Inc. (NASDAQ: AAPL) is set to unveil the next generation of iPhone in its ... 
Groupon, Honeywell, Mastercard, Newmont Goldcorp, Roku, Zoetis and More.",Chris Lange,https://247wallst.com/companies/aapl/page/24/?0601%3Ftag=aapl,247wallst.com,1570320000,2019-10-06T00:00:00Z,0
254923,ABBV,"Medical stocks on the move: AbbVie, Arrowhead Pharmaceuticals and Zynex",AbbVie has been rallying for the past month.,Harry Boxer,https://www.marketwatch.com/story/medical-stocks-on-the-move-abbvie-arrowhead-pharmaceuticals-and-zynex-2019-10-04,marketwatch.com,1570205508,2019-10-04T16:11:48Z,0
447327,ABBV,"Medical stocks on the move: AbbVie, Arrowhead Pharmaceuticals and Zynex",AbbVie has been rallying for the past month.,Harry Boxer,https://www.marketwatch.com/story/medical-stocks-on-the-move-abbvie-arrowhead-pharmaceuticals-and-zynex-2019-10-04,Marketwatch.com,1521590,2019-10-04T16:11:48Z,0
447385,ALLY,Ally Financial joins the zero commission bandwagon,"Ally Financial Inc.'s online brokerage and wealth management arm Ally Financial Inc. said Friday it was jumping on the bandwagon by cutting commissions to zero, from $4.95 per trade, starting Oct. 9. ""With continued advancements in technology making online tr…",Tomi Kilgore,https://www.marketwatch.com/story/ally-financial-joins-the-zero-commission-bandwagon-2019-10-04,Marketwatch.com,1567900,2019-10-04T15:58:02Z,0.4
254940,ALLY,Ally Financial joins the zero commission bandwagon,"Ally Financial Inc.'s online brokerage and wealth management arm Ally Financial Inc. said Friday it was jumping on the bandwagon by cutting commissions to zero, from $4.95 per trade, starting Oct. 9. ""With continued advancements in technology making online tr…",Tomi Kilgore,https://www.marketwatch.com/story/ally-financial-joins-the-zero-commission-bandwagon-2019-10-04,marketwatch.com,1570204682,2019-10-04T15:58:02Z,0.4
447389,ALLY,Ally Invest Joins the Zero Commissions Movement,"CHARLOTTE, N.C., Oct. 4, 2019 /PRNewswire/ -- Ally Invest, the online brokerage and wealth management arm of Ally Financial Inc. (NYSE: ALLY), today announced it is joining the online trading movement that is eliminating commissions on U.S. exchange-listed st…",,https://www.prnewswire.com/news-releases/ally-invest-joins-the-zero-commissions-movement-300931311.html,Prnewswire.com,1567900,2019-10-04T15:30:00Z,0.49
254942,ALLY,Ally Invest Joins the Zero Commissions Movement,"CHARLOTTE, N.C., Oct. 4, 2019 /PRNewswire/ -- Ally Invest, the online brokerage and wealth management arm of Ally Financial Inc. (NYSE: ALLY), today announced it is joining the online trading movement that is eliminating commissions on U.S. exchange-listed st…",,https://www.prnewswire.com/news-releases/ally-invest-joins-the-zero-commissions-movement-300931311.html,prnewswire.com,1570203000,2019-10-04T15:30:00Z,0.49
255261,JNJ,"Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY","J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.",Kinjel Shah,https://finance.yahoo.com/news/pharma-stock-roundup-jnjs-opioid-151103483.html,yahoo.com,1570201863,2019-10-04T15:11:03Z,0
255287,MRK,"Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY","J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.",Kinjel Shah,https://finance.yahoo.com/news/pharma-stock-roundup-jnjs-opioid-151103483.html,yahoo.com,1570201863,2019-10-04T15:11:03Z,0
447923,JNJ,"Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY","J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.",Kinjel Shah,https://finance.yahoo.com/news/pharma-stock-roundup-jnjs-opioid-151103483.html,Yahoo.com,1567900,2019-10-04T15:11:03Z,0
447954,MRK,"Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY","J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.",Kinjel Shah,https://finance.yahoo.com/news/pharma-stock-roundup-jnjs-opioid-151103483.html,Yahoo.com,1567900,2019-10-04T15:11:03Z,0
447393,ALLY,Ally Financial extends deal with Hendrick Motorsports through 2023,"Having yet to complete its first year, Ally Financial extends its sponsorship of the No. 48 car for three more years.",Dustin Long,https://nascar.nbcsports.com/2019/10/04/ally-financial-extends-deal-with-hendrick-motorsports-through-2023/,Nbcsports.com,1567900,2019-10-04T15:02:34Z,-0.05
447394,ALLY,"Johnson's sponsor stays on Hendrick 48 car through 2023",Jimmie Johnson will keep his primary sponsor Ally Financial for Hendrick 48 car for as long as he races,AP,https://www.foxsports.com/motor/story/johnson-s-sponsor-stays-on-hendrick-48-car-through-2023-100419,Fox Sports,1567900,2019-10-04T15:00:56Z,0
447396,ALLY,Johnson’s sponsor stays on Hendrick 48 car through 2023,"DOVER, Del. (AP) — Jimmie Johnson’s primary sponsor will stay on the Hendrick Motorsports No. 48 car through the 2023 season — with or without the seven-time NASCAR champion. Ally Financial extended its partnership with Hendrick and the 48 Chevrolet on Friday…",DAN GELSTON,https://www.seattletimes.com/sports/auto-racing/johnsons-sponsor-stays-on-hendrick-48-car-through-2023/,Seattletimes.com,1567900,2019-10-04T15:00:56Z,0.4
254944,ALLY,Johnson’s sponsor stays on Hendrick 48 car through 2023,"DOVER, Del. (AP) — Jimmie Johnson’s primary sponsor will stay on the Hendrick Motorsports No. 48 car through the 2023 season — with or without the seven-time NASCAR champion. Ally Financial extended its partnership with Hendrick and the 48 Chevrolet on Friday…",DAN GELSTON,https://www.seattletimes.com/sports/auto-racing/johnsons-sponsor-stays-on-hendrick-48-car-through-2023/,seattletimes.com,1570201256,2019-10-04T15:00:56Z,0.4
254945,ALLY,Ally Financial Extends Full-Season Primary Sponsorship Of Hendrick Motorsports,"CONCORD, N.C., Oct. 4, 2019 /PRNewswire/ -- Less than 12 months after it first raced into NASCAR, Ally Financial has extended its full-season primary sponsorship of Hendrick Motorsports and the No. 48 Chevrolet Camaro ZL1 team for three more years through the…",,https://prnmedia.prnewswire.com:443/news-releases/ally-financial-extends-full-season-primary-sponsorship-of-hendrick-motorsports-300931236.html,prnewswire.com,1570201200,2019-10-04T15:00:00Z,-0.18
447398,ALLY,Ally Financial Extends Full-Season Primary Sponsorship Of Hendrick Motorsports,"CONCORD, N.C., Oct. 4, 2019 /PRNewswire/ -- Less than 12 months after it first raced into NASCAR, Ally Financial has extended its full-season primary sponsorship of Hendrick Motorsports and the No. 48 Chevrolet Camaro ZL1 team for three more years through the…",,https://prnmedia.prnewswire.com:443/news-releases/ally-financial-extends-full-season-primary-sponsorship-of-hendrick-motorsports-300931236.html,Prnewswire.com,1567900,2019-10-04T15:00:00Z,-0.18
255265,JNJ,J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug,"J&J (JNJ) announces that the FDA has granted Breakthrough Therapy status to its PARP inhibitor, niraparib, for the treatment for advanced prostate cancer.",Zacks Equity Research,https://finance.yahoo.com/news/j-j-gets-breakthrough-therapy-143102443.html,yahoo.com,1570199462,2019-10-04T14:31:02Z,-0.8
447927,JNJ,J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug,"J&J (JNJ) announces that the FDA has granted Breakthrough Therapy status to its PARP inhibitor, niraparib, for the treatment for advanced prostate cancer.",Zacks Equity Research,https://finance.yahoo.com/news/j-j-gets-breakthrough-therapy-143102443.html,Yahoo.com,1549584,2019-10-04T14:31:02Z,-0.8
447329,ABBV,"Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report","AbbVie's Humira has been topping pharma's sales charts, but in a few years it'll be passed by Merck's Keytruda and several other meds, a GlobalData forecast shows. Also in the top 10 are Bristol and Pfizer's Eliquis, Celgene's Revlimid, and BMS' Opdivo.",Eric Sagonowsky,https://www.fiercepharma.com/pharma/pharma-s-top-drugs-2025-featuring-blockbusters-from-merck-bms-abbvie-and-more,Fiercepharma.com,1567900,2019-10-04T13:16:39Z,0.3
447933,JNJ,Johnson and Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis,"NEW BRUNSWICK, N.J., Oct. 4, 2019 -- (Healthcare Sales & Marketing Network) -- Johnson & Johnson (NYSE: JNJ) today announced it has committed to ensuring more than $500 million is dedicated to world class research & development and delivery programs over... B…",Johnson & Johnson,https://salesandmarketingnetwork.com/news_release_bs.html?ID=2045421,Salesandmarketingnetwork.com,1551312,2019-10-04T13:07:35Z,0.84
254925,ABBV,"The Zacks Analyst Blog Highlights: Cintas, Air Products, Walmart, Target and AbbVie","The Zacks Analyst Blog Highlights: Cintas, Air Products, Walmart, Target and AbbVie",Zacks Equity Research,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-cintas-123712648.html,yahoo.com,1570192632,2019-10-04T12:37:12Z,0
447330,ABBV,"The Zacks Analyst Blog Highlights: Cintas, Air Products, Walmart, Target and AbbVie","The Zacks Analyst Blog Highlights: Cintas, Air Products, Walmart, Target and AbbVie",Zacks Equity Research,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-cintas-123712648.html,Yahoo.com,1522627,2019-10-04T12:37:12Z,0
255276,JNJ,"JNJ pledges $500M, four-year investment to fight HIV, tuberculosis",Johnson &amp; Johnson (NYSE:JNJ) says it is committing $500M over the next four years to invest in research and development and delivery programs to help eliminate HIV and tuberculosis by 2030.JNJ say,SA Editor Carl Surran,https://seekingalpha.com/news/3503966-jnj-pledges-500m-four-year-investment-fight-hiv-tuberculosis,seekingalpha.com,1570192284,2019-10-04T12:31:24Z,0.1
447939,JNJ,"JNJ pledges $500M, four-year investment to fight HIV, tuberculosis",Johnson &amp; Johnson (NYSE:JNJ) says it is committing $500M over the next four years to invest in research and development and delivery programs to help eliminate HIV and tuberculosis by 2030.JNJ say,SA Editor Carl Surran,https://seekingalpha.com/news/3503966-jnj-pledges-500m-four-year-investment-fight-hiv-tuberculosis,Seekingalpha.com,1567900,2019-10-04T12:31:24Z,0.1
447938,LLY,"The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly","The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly",Zacks Equity Research,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-bank-123012339.html,Yahoo.com,1551830,2019-10-04T12:30:12Z,0
255275,LLY,"The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly","The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly",Zacks Equity Research,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-bank-123012339.html,yahoo.com,1570192212,2019-10-04T12:30:12Z,0
254491,JNJ,Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis,"NEW BRUNSWICK, N.J., Oct. 4, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced it has committed to ensuring more than $500 million is dedicated to world class research & development and delivery programs over the next four years to accelerate…",,https://www.prnewswire.com/news-releases/johnson--johnson-commits-500-million-investment-over-four-years-to-help-end-the-epidemics-of-hiv-and-tuberculosis-300931193.html,prnewswire.com,1570188600,2019-10-04T11:30:00Z,0.84
446478,JNJ,Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis,"NEW BRUNSWICK, N.J., Oct. 4, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced it has committed to ensuring more than $500 million is dedicated to world class research & development and delivery programs over the next four years to accelerate…",,https://www.prnewswire.com/news-releases/johnson--johnson-commits-500-million-investment-over-four-years-to-help-end-the-epidemics-of-hiv-and-tuberculosis-300931193.html,Prnewswire.com,1567900,2019-10-04T11:30:00Z,0.84
253676,ALLY,Ally Financial CMO Andrea Brimmer: Bringing programmatic in-house has saved us a lot of money,"Ally Financial is in the middle of implementing multi-touch attribution. The company previous took programmatic marketing in-house but it won't be bringing everything in-house, the company told Digiday at the ANAs. The post Ally Financial CMO Andrea Brimmer: …",Kristina Monllos,https://digiday.com/marketing/ally-financial-cmo-andrea-brimmer-bringing-programmatic-house-made-us-25-efficient/,digiday.com,1570161719,2019-10-04T04:01:59Z,0.23
444879,ALLY,Ally Financial CMO Andrea Brimmer: Bringing programmatic in-house has saved us a lot of money,"Ally Financial is in the middle of implementing multi-touch attribution. The company previous took programmatic marketing in-house but it won't be bringing everything in-house, the company told Digiday at the ANAs. The post Ally Financial CMO Andrea Brimmer: …",Kristina Monllos,https://digiday.com/marketing/ally-financial-cmo-andrea-brimmer-bringing-programmatic-house-made-us-25-efficient/,Digiday.com,1567900,2019-10-04T04:01:59Z,0.23
254001,PRGO,Perrigo® Hosts 175 West Michigan Students for Manufacturing Week Celebration,"ALLEGAN, Mich., Oct. 3, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of ""Quality Affordable Self-Care Products™"", opened its doors for more than 175 high school students Thursday as part of Michigan Manufacturing Week. Atten…",,https://prnmedia.prnewswire.com:443/news-releases/perrigo-hosts-175-west-michigan-students-for-manufacturing-week-celebration-300930992.html,prnewswire.com,1570137480,2019-10-03T21:18:00Z,0
445538,PRGO,Perrigo® Hosts 175 West Michigan Students for Manufacturing Week Celebration,"ALLEGAN, Mich., Oct. 3, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of ""Quality Affordable Self-Care Products™"", opened its doors for more than 175 high school students Thursday as part of Michigan Manufacturing Week. Atten…",,https://prnmedia.prnewswire.com:443/news-releases/perrigo-hosts-175-west-michigan-students-for-manufacturing-week-celebration-300930992.html,Prnewswire.com,1549411,2019-10-03T21:18:00Z,0
445230,JNJ,"J&J's Janssen gets breakthrough designation for niraparib in prostate cancer","The U.S. Food and Drug Administrations grants Johnson &amp; Johnson's (NYSE:JNJ) Janssen Pharmaceutical unit a breakthrough therapy designation for niraparib, an orally administered PARP inhibitor for",SA Editor Liz Kiesche,https://seekingalpha.com/news/3503876-j-and-js-janssen-gets-breakthrough-designation-niraparib-prostate-cancer,Seekingalpha.com,1540944,2019-10-03T20:27:36Z,0.15
253877,JNJ,"J&J's Janssen gets breakthrough designation for niraparib in prostate cancer","The U.S. Food and Drug Administrations grants Johnson &amp; Johnson's (NYSE:JNJ) Janssen Pharmaceutical unit a breakthrough therapy designation for niraparib, an orally administered PARP inhibitor for",SA Editor Liz Kiesche,https://seekingalpha.com/news/3503876-j-and-js-janssen-gets-breakthrough-designation-niraparib-prostate-cancer,seekingalpha.com,1570134456,2019-10-03T20:27:36Z,0.15
252737,LLY,Plaque Psoriasis Suffers May Have Better Option After Eli Lilly Study,Eli Lilly announced some good news for people suffering moderate to severe plaque psoriasis when it presented at the 5th Annual Maui Derm NP+PA Fall meeting.,247chrislange,https://247wallst.com/healthcare-business/2019/10/03/plaque-psoriasis-suffers-may-have-better-option-after-eli-lilly-study/,247wallst.com,1570119022,2019-10-03T16:10:22Z,-0.46
443345,LLY,Plaque Psoriasis Suffers May Have Better Option After Eli Lilly Study,Eli Lilly announced some good news for people suffering moderate to severe plaque psoriasis when it presented at the 5th Annual Maui Derm NP+PA Fall meeting.,247chrislange,https://247wallst.com/healthcare-business/2019/10/03/plaque-psoriasis-suffers-may-have-better-option-after-eli-lilly-study/,247wallst.com,1567900,2019-10-03T16:10:22Z,-0.46
252787,MRK,"Merck's Pediatric Filings for Dificid Get FDA's Priority Review","The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.",Zacks Equity Research,https://finance.yahoo.com/news/mercks-pediatric-filings-dificid-fdas-152203437.html,yahoo.com,1570116123,2019-10-03T15:22:03Z,0.59
443409,MRK,"Merck's Pediatric Filings for Dificid Get FDA's Priority Review","The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.",Zacks Equity Research,https://finance.yahoo.com/news/mercks-pediatric-filings-dificid-fdas-152203437.html,Yahoo.com,1540857,2019-10-03T15:22:03Z,0.59
443334,JNJ,"J&J Settles Ahead of Multi-District Opioid Trial, Stock Up",J&J (JNJ) reaches settlement agreement with Cuyahoga and Summit counties in Ohio concerning the lawsuits pending in MDL.,Zacks Equity Research,https://finance.yahoo.com/news/j-j-settles-ahead-multi-151603902.html,Yahoo.com,1567900,2019-10-03T15:16:03Z,0.42
252726,JNJ,"J&J Settles Ahead of Multi-District Opioid Trial, Stock Up",J&J (JNJ) reaches settlement agreement with Cuyahoga and Summit counties in Ohio concerning the lawsuits pending in MDL.,Zacks Equity Research,https://finance.yahoo.com/news/j-j-settles-ahead-multi-151603902.html,yahoo.com,1570115763,2019-10-03T15:16:03Z,0.42
442970,BMY,Bristol-Myers Squibb On Roll With Opdivo Results,"Opdivo had positive trial results for esophageal cancer, melanoma, and non-small cell lung cancer. This should reassure investors that sales will continue to ri",William Meyers,https://seekingalpha.com/article/4294793-bristol-myers-squibb-roll-opdivo-results,Seekingalpha.com,1548028,2019-10-03T14:12:28Z,-0.59
252493,BMY,Bristol-Myers Squibb On Roll With Opdivo Results,"Opdivo had positive trial results for esophageal cancer, melanoma, and non-small cell lung cancer. This should reassure investors that sales will continue to ri",William Meyers,https://seekingalpha.com/article/4294793-bristol-myers-squibb-roll-opdivo-results,seekingalpha.com,1570111948,2019-10-03T14:12:28Z,-0.59
252738,LLY,Why Lilly (LLY) Could Beat Earnings Estimates Again,Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,Zacks Equity Research,https://finance.yahoo.com/news/why-lilly-lly-could-beat-141002629.html,yahoo.com,1570111802,2019-10-03T14:10:02Z,0.66
443346,LLY,Why Lilly (LLY) Could Beat Earnings Estimates Again,Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,Zacks Equity Research,https://finance.yahoo.com/news/why-lilly-lly-could-beat-141002629.html,Yahoo.com,1567900,2019-10-03T14:10:02Z,0.66
252377,ABBV,2 Great Stocks You Can Buy on Sale,AbbVie and Amgen are two great stocks that are way too cheap right now.,newsfeedback@fool.com (George Budwell),https://www.fool.com/investing/2019/10/03/2-great-stocks-you-can-buy-on-sale.aspx,fool.com,1570111200,2019-10-03T14:00:00Z,0.85
442729,ABBV,2 Great Stocks You Can Buy on Sale,AbbVie and Amgen are two great stocks that are way too cheap right now.,newsfeedback@fool.com (George Budwell),https://www.fool.com/investing/2019/10/03/2-great-stocks-you-can-buy-on-sale.aspx,Fool.com,1567900,2019-10-03T14:00:00Z,0.85
443347,LLY,"Eli Lilly's Taltz tops J&J's Tremfya with 43% skin clearance in head-to-head tussle",Eli Lilly knows it has a tough fight ahead for psoriasis med Taltz with challengers from Novartis and Johnson & Johnson on the march. But in a head-to-head battle with one—J&J’s Tremfya—Taltz has taken the day in clearing patients’ skin.,Kyle Blankenship,https://www.fiercepharma.com/pharma/eli-lilly-s-taltz-busts-tremfya-43-skin-clearance-head-to-head-tussle,Fiercepharma.com,1567900,2019-10-03T13:46:30Z,-0.25
443348,LLY,Eli Lilly to voluntarily delist from Euronext Paris exchange,"Eli Lilly and Co. said Thursday it is voluntarily delisting from the Euronext Paris exchange, citing low trading volume, costs and administrative requirements. The stock will continue to trade on the New York Stock Exchange, its primary listing exchange. Shar…",Ciara Linnane,https://www.marketwatch.com/story/eli-lilly-to-voluntarily-delist-from-euronext-paris-exchange-2019-10-03-9913715,Marketwatch.com,1567900,2019-10-03T13:37:16Z,-0.27
252739,LLY,Eli Lilly to voluntarily delist from Euronext Paris exchange,"Eli Lilly and Co. said Thursday it is voluntarily delisting from the Euronext Paris exchange, citing low trading volume, costs and administrative requirements. The stock will continue to trade on the New York Stock Exchange, its primary listing exchange. Shar…",Ciara Linnane,https://www.marketwatch.com/story/eli-lilly-to-voluntarily-delist-from-euronext-paris-exchange-2019-10-03-9913715,marketwatch.com,1570109836,2019-10-03T13:37:16Z,-0.27
252735,JNJ,Dallas firm scores win against Johnson & Johnson with $40M verdict,"A Los Angeles jury last week handed a $40 million win to a California woman diagnosed with mesothelioma in the latest talcum powder trial brought against Johnson & Johnson. After six days of deliberation, the jury ruled that Johnson & Johnson (NYSE: JNJ) baby…",Natalie Posgate,https://www.bizjournals.com/dallas/news/2019/10/03/simon-greenstone-panatier.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_dallas+%28Dallas+Business+Journal%29,bizjournals.com,1570109442,2019-10-03T13:30:42Z,0.82
443343,JNJ,Dallas firm scores win against Johnson & Johnson with $40M verdict,"A Los Angeles jury last week handed a $40 million win to a California woman diagnosed with mesothelioma in the latest talcum powder trial brought against Johnson & Johnson. After six days of deliberation, the jury ruled that Johnson & Johnson (NYSE: JNJ) baby…",Natalie Posgate,https://www.bizjournals.com/dallas/news/2019/10/03/simon-greenstone-panatier.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_dallas+%28Dallas+Business+Journal%29,Bizjournals.com,1567900,2019-10-03T13:30:42Z,0.82
252740,LLY,Lilly Announces Voluntary Delisting from Euronext Paris,"INDIANAPOLIS, Oct. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has requested the delisting of its shares (ISIN US5324571083) (""Lilly Shares"") from Euronext Paris due to the very low trading volume, costs and administrativ…",,https://www.prnewswire.com/news-releases/lilly-announces-voluntary-delisting-from-euronext-paris-300930595.html,prnewswire.com,1570109100,2019-10-03T13:25:00Z,-0.05
443349,LLY,Lilly Announces Voluntary Delisting from Euronext Paris,"INDIANAPOLIS, Oct. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has requested the delisting of its shares (ISIN US5324571083) (""Lilly Shares"") from Euronext Paris due to the very low trading volume, costs and administrativ…",,https://www.prnewswire.com/news-releases/lilly-announces-voluntary-delisting-from-euronext-paris-300930595.html,Prnewswire.com,1567900,2019-10-03T13:25:00Z,-0.05
252363,ZTS,"Zoetis names Kristin Peck as CEO effective Jan 1, replacing Juan Ramon Alaix who is retiring","Zoetis Inc. said Thursday it has named Kristin Peck as chief executive effective Jan. 1, replacing Juan Ramon Alaix, who is retiring. Peck is currently executive vice president and group president responsible for U.S. operations, business development and stra…",Ciara Linnane,https://www.marketwatch.com/story/zoetis-names-kristin-peck-as-ceo-effective-jan-1-replacing-juan-ramon-alaix-who-is-retiring-2019-10-03,marketwatch.com,1570104010,2019-10-03T12:00:10Z,0.82
442709,ZTS,"Zoetis names Kristin Peck as CEO effective Jan 1, replacing Juan Ramon Alaix who is retiring","Zoetis Inc. said Thursday it has named Kristin Peck as chief executive effective Jan. 1, replacing Juan Ramon Alaix, who is retiring. Peck is currently executive vice president and group president responsible for U.S. operations, business development and stra…",Ciara Linnane,https://www.marketwatch.com/story/zoetis-names-kristin-peck-as-ceo-effective-jan-1-replacing-juan-ramon-alaix-who-is-retiring-2019-10-03,Marketwatch.com,1556755,2019-10-03T12:00:10Z,0.82
252050,PRGO,Perrigo Announces the Relaunch of the AB Rated Generic Version of Transderm Scop® 1.5 MG,"DUBLIN, Oct. 3, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the relaunch of the AB rated generic equivalent of Transderm Scop® (scopolamine 1.5 mg). Annual market sales of Transderm Scop® and therapeutic equivalents for the 12 …",,https://www.prnewswire.com/news-releases/perrigo-announces-the-relaunch-of-the-ab-rated-generic-version-of-transderm-scop-1-5-mg-300930535.html,prnewswire.com,1570104000,2019-10-03T12:00:00Z,0
442091,PRGO,Perrigo Announces the Relaunch of the AB Rated Generic Version of Transderm Scop® 1.5 MG,"DUBLIN, Oct. 3, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the relaunch of the AB rated generic equivalent of Transderm Scop® (scopolamine 1.5 mg). Annual market sales of Transderm Scop® and therapeutic equivalents for the 12 …",,https://www.prnewswire.com/news-releases/perrigo-announces-the-relaunch-of-the-ab-rated-generic-version-of-transderm-scop-1-5-mg-300930535.html,Prnewswire.com,1549324,2019-10-03T12:00:00Z,0
442710,ZTS,"New CEO at Zoetis effective January 1, 2020","Zoetis (NYSE:ZTS) announces that Kristin Peck will succeed Juan Ramón Alaix as Chief Executive Officer &#40;CEO&#41;, effective January 1, 2020, and join the Board of Directors, effective immediately",Mamta Mayani,https://seekingalpha.com/news/3503674-new-ceo-zoetis-effective-january-1-2020,Seekingalpha.com,1555632,2019-10-03T11:37:33Z,0.93
252364,ZTS,"New CEO at Zoetis effective January 1, 2020","Zoetis (NYSE:ZTS) announces that Kristin Peck will succeed Juan Ramón Alaix as Chief Executive Officer &#40;CEO&#41;, effective January 1, 2020, and join the Board of Directors, effective immediately",Mamta Mayani,https://seekingalpha.com/news/3503674-new-ceo-zoetis-effective-january-1-2020,seekingalpha.com,1570102653,2019-10-03T11:37:33Z,0.93
442711,ZTS,"Zoetis Names Kristin Peck to Succeed Juan Ramón Alaix as CEO on January 1, 2020","PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #CEO--Kristin Peck will succeed Juan Ramón Alaix as Chief Executive Officer of Zoetis, effective January 1, 2020.",,https://www.businesswire.com/news/home/20191003005420/en/Zoetis-Names-Kristin-Peck-Succeed-Juan-Ram%C3%B3n,Businesswire.com,1556668,2019-10-03T11:21:26Z,0.86
252365,ZTS,"Zoetis Names Kristin Peck to Succeed Juan Ramón Alaix as CEO on January 1, 2020","PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #CEO--Kristin Peck will succeed Juan Ramón Alaix as Chief Executive Officer of Zoetis, effective January 1, 2020.",,https://www.businesswire.com/news/home/20191003005420/en/Zoetis-Names-Kristin-Peck-Succeed-Juan-Ram%C3%B3n,businesswire.com,1570101686,2019-10-03T11:21:26Z,0.86
251846,LLY,New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis,"INDIANAPOLIS, Oct. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented detailed data at the 5th Annual Maui Derm NP+PA Fall meeting from the Phase 4 IXORA-R study, the first head-to-head (H2H) study between an IL-17A inhibitor and an IL-…",,https://www.prnewswire.com/news-releases/new-head-to-head-data-show-taltz-ixekizumab-superiority-versus-tremfya-guselkumab-in-people-with-moderate-to-severe-plaque-psoriasis-300929897.html,prnewswire.com,1570099500,2019-10-03T10:45:00Z,-0.13
441722,LLY,New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis,"INDIANAPOLIS, Oct. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented detailed data at the 5th Annual Maui Derm NP+PA Fall meeting from the Phase 4 IXORA-R study, the first head-to-head (H2H) study between an IL-17A inhibitor and an IL-…",,https://www.prnewswire.com/news-releases/new-head-to-head-data-show-taltz-ixekizumab-superiority-versus-tremfya-guselkumab-in-people-with-moderate-to-severe-plaque-psoriasis-300929897.html,Prnewswire.com,1567900,2019-10-03T10:45:00Z,-0.13
251708,BMY,Japan drug price reforms risk hurting investment: Bristol-Myers CEO,"TOKYO: Japan's ""overly restrictive"" drug pricing policies risk diverting foreign direct investment to China and other markets, the chief executive of Bristol-Myers Squibb said on Thursday. The Japanese government made reforms in 2018 that change how its natio…",CNA,https://www.channelnewsasia.com/news/asia/japan-drug-price-reforms-risk-hurting-investment--bristol-myers-ceo-11966832,channelnewsasia.com,1570095143,2019-10-03T09:32:23Z,-0.71
441491,BMY,Japan drug price reforms risk hurting investment: Bristol-Myers CEO,"TOKYO: Japan's ""overly restrictive"" drug pricing policies risk diverting foreign direct investment to China and other markets, the chief executive of Bristol-Myers Squibb said on Thursday. The Japanese government made reforms in 2018 that change how its natio…",CNA,https://www.channelnewsasia.com/news/asia/japan-drug-price-reforms-risk-hurting-investment--bristol-myers-ceo-11966832,Channelnewsasia.com,1532044,2019-10-03T09:32:23Z,-0.71
251131,LLY,Lilly Confirms Date and Conference Call for Third-Quarter 2019 Financial Results Announcement,"INDIANAPOLIS, Oct. 2, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2019 financial results on Wednesday, October 23, 2019. Lilly will also conduct a conference call on that day with the investment community and media t…",,https://www.prnewswire.com/news-releases/lilly-confirms-date-and-conference-call-for-third-quarter-2019-financial-results-announcement-300929993.html,prnewswire.com,1570048200,2019-10-02T20:30:00Z,0
440346,LLY,Lilly Confirms Date and Conference Call for Third-Quarter 2019 Financial Results Announcement,"INDIANAPOLIS, Oct. 2, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2019 financial results on Wednesday, October 23, 2019. Lilly will also conduct a conference call on that day with the investment community and media t…",,https://www.prnewswire.com/news-releases/lilly-confirms-date-and-conference-call-for-third-quarter-2019-financial-results-announcement-300929993.html,Prnewswire.com,1567900,2019-10-02T20:30:00Z,0
438389,JNJ,"Johnson & Johnson climbs after settling two opioid epidemic lawsuits, allowing it to avoid an upcoming federal trial (JNJ)",Associated Press Johnson & Johnson shares jumped as much as 3.6% on Wednesday after the company settled two Ohio opioid-crisis lawsuits for $20.4 million. The settlement allows J&J to avoid an October federal trial looking to hold numerous pharmaceutical comp…,"bwinck@businessinsider.com (Ben Winck), Ben Winck",https://www.businessinsider.com/johnson-and-johnson-stock-price-jumps-on-opioid-lawsuit-settlement-2019-10,Business Insider,1567900,2019-10-02T15:40:26Z,-0.53
250078,JNJ,"Johnson & Johnson climbs after settling two opioid epidemic lawsuits, allowing it to avoid an upcoming federal trial (JNJ)",Associated Press Johnson & Johnson shares jumped as much as 3.6% on Wednesday after the company settled two Ohio opioid-crisis lawsuits for $20.4 million. The settlement allows J&J to avoid an October federal trial looking to hold numerous pharmaceutical comp…,"bwinck@businessinsider.com (Ben Winck), Ben Winck",https://www.businessinsider.com/johnson-and-johnson-stock-price-jumps-on-opioid-lawsuit-settlement-2019-10,businessinsider.com,1570030826,2019-10-02T15:40:26Z,-0.53
438396,LLY,"Lilly, Bayer dodge whistleblower suits as judge follows DOJ's lead","Eli Lilly and Bayer are in the clear. A set of whistleblower lawsuits alleging drugmakers ran “white-coat marketing” schemes—by offering nursing and reimbursement services as kickbacks—generated buzz in the industry, but government prosecutors looked into the…",Eric Sagonowsky,https://www.fiercepharma.com/pharma/judge-dismisses-whistleblower-suits-against-lilly-bayer-after-government-opts-not-to-proceed,Fiercepharma.com,1567900,2019-10-02T15:14:20Z,0.13
437833,ABBV,"ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach","Just days after releasing a draft report suggesting that three JAK inhibitors for rheumatoid arthritis would be unlikely to be cost-effective if priced above AbbVie's best-selling Humira, the Institute for Clinical and Economic Review (ICER) has taken the unu…",Arlene Weintraub,https://www.fiercepharma.com/pharma/icer-pulls-report-blasting-marginal-ra-drugs-citing-need-to-re-think-its-approach,Fiercepharma.com,1529539,2019-10-02T13:47:36Z,-0.25
437837,ABBV,"The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square","The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square",Zacks Equity Research,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-abbvie-132001004.html,Yahoo.com,1533772,2019-10-02T13:20:01Z,0
249741,ABBV,"The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square","The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square",Zacks Equity Research,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-abbvie-132001004.html,yahoo.com,1570022401,2019-10-02T13:20:01Z,0
250083,LLY,Lilly Oncology Update at ESMO,The following slide deck was published by Eli Lilly and Company in conjunction with this event.,SA Transcripts,https://seekingalpha.com/article/4294544-lilly-oncology-update-esmo,seekingalpha.com,1570021363,2019-10-02T13:02:43Z,0
438397,LLY,Lilly Oncology Update at ESMO,The following slide deck was published by Eli Lilly and Company in conjunction with this event.,SA Transcripts,https://seekingalpha.com/article/4294544-lilly-oncology-update-esmo,Seekingalpha.com,1567900,2019-10-02T13:02:43Z,0
248632,JNJ,J&J agrees to settlement with two Ohio counties ahead of opioid trial,Johnson &amp; Johnson (NYSE:JNJ) says it will pay a $20.4M settlement with Cuyahoga and Summit counties in Ohio that accused it of contributing to the U.S. opioid addiction epidemic.JNJ says the deal,SA Editor Carl Surran,https://seekingalpha.com/news/3503212-j-and-j-agrees-settlement-two-ohio-counties-ahead-opioid-trial,seekingalpha.com,1569984641,2019-10-02T02:50:41Z,-0.2
435693,JNJ,J&J agrees to settlement with two Ohio counties ahead of opioid trial,Johnson &amp; Johnson (NYSE:JNJ) says it will pay a $20.4M settlement with Cuyahoga and Summit counties in Ohio that accused it of contributing to the U.S. opioid addiction epidemic.JNJ says the deal,SA Editor Carl Surran,https://seekingalpha.com/news/3503212-j-and-j-agrees-settlement-two-ohio-counties-ahead-opioid-trial,Seekingalpha.com,1430438,2019-10-02T02:50:41Z,-0.2
248634,JNJ,Johnson & Johnson Reaches Settlement Agreement with Two Ohio Counties Ahead of Upcoming Opioid Trial,"NEW BRUNSWICK, N.J., Oct. 1, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) and its Janssen Pharmaceutical Companies today announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties' claims with no adm…",,https://www.prnewswire.com/news-releases/johnson--johnson-reaches-settlement-agreement-with-two-ohio-counties-ahead-of-upcoming-opioid-trial-300929254.html,prnewswire.com,1569973560,2019-10-01T23:46:00Z,0.73
435696,JNJ,Johnson & Johnson Reaches Settlement Agreement with Two Ohio Counties Ahead of Upcoming Opioid Trial,"NEW BRUNSWICK, N.J., Oct. 1, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) and its Janssen Pharmaceutical Companies today announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties' claims with no adm…",,https://www.prnewswire.com/news-releases/johnson--johnson-reaches-settlement-agreement-with-two-ohio-counties-ahead-of-upcoming-opioid-trial-300929254.html,Prnewswire.com,1430352,2019-10-01T23:46:00Z,0.73
248660,MRK,Merck (MRK) Stock Moves -0.68%: What You Should Know,"Merck (MRK) closed the most recent trading day at $83.61, moving -0.68% from the previous trading session.",Zacks Equity Research,https://finance.yahoo.com/news/merck-mrk-stock-moves-0-214509695.html,yahoo.com,1569966309,2019-10-01T21:45:09Z,0
435734,MRK,Merck (MRK) Stock Moves -0.68%: What You Should Know,"Merck (MRK) closed the most recent trading day at $83.61, moving -0.68% from the previous trading session.",Zacks Equity Research,https://finance.yahoo.com/news/merck-mrk-stock-moves-0-214509695.html,Yahoo.com,1461110,2019-10-01T21:45:09Z,0
248425,ZTS,Call Traders Betting on More ZTS Stock Upside,"Call buying has been hot on ZTS, but call writers have focused on the October 125 call",Josh Selway,https://finance.yahoo.com/news/call-traders-betting-more-zts-172236861.html,yahoo.com,1569950556,2019-10-01T17:22:36Z,0.53
435332,ZTS,Call Traders Betting on More ZTS Stock Upside,"Call buying has been hot on ZTS, but call writers have focused on the October 125 call",Josh Selway,https://finance.yahoo.com/news/call-traders-betting-more-zts-172236861.html,Yahoo.com,1428278,2019-10-01T17:22:36Z,0.53
433487,BMY,Why Bristol-Myers (BMY) is Poised to Beat Earnings Estimates Again,Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,Zacks Equity Research,https://finance.yahoo.com/news/why-bristol-myers-bmy-poised-141002529.html,Yahoo.com,1515974,2019-10-01T14:10:02Z,0.75
247309,BMY,Why Bristol-Myers (BMY) is Poised to Beat Earnings Estimates Again,Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,Zacks Equity Research,https://finance.yahoo.com/news/why-bristol-myers-bmy-poised-141002529.html,yahoo.com,1569939002,2019-10-01T14:10:02Z,0.75
247209,ALLY,Ally Financial Announces Completion of Acquisition of Health Credit Services,"CHARLOTTE, N.C., Oct. 1, 2019 /PRNewswire/ -- Ally Financial Inc. (NYSE: ALLY) today announced that it has completed the acquisition of Health Credit Services, LLC (HCS), a technology-driven, patient financing company that partners with medical providers to o…",,https://www.prnewswire.com/news-releases/ally-financial-announces-completion-of-acquisition-of-health-credit-services-300928674.html,prnewswire.com,1569938400,2019-10-01T14:00:00Z,0.64
433288,ALLY,Ally Financial Announces Completion of Acquisition of Health Credit Services,"CHARLOTTE, N.C., Oct. 1, 2019 /PRNewswire/ -- Ally Financial Inc. (NYSE: ALLY) today announced that it has completed the acquisition of Health Credit Services, LLC (HCS), a technology-driven, patient financing company that partners with medical providers to o…",,https://www.prnewswire.com/news-releases/ally-financial-announces-completion-of-acquisition-of-health-credit-services-300928674.html,Prnewswire.com,1457568,2019-10-01T14:00:00Z,0.64
435334,ZTS,"Is Zoetis (ZTS) a Solid Growth Stock? 3 Reasons to Think "" Yes ""","Zoetis (ZTS) is well positioned to outperform the market, as it exhibits above-average growth in financials.",Zacks Equity Research,https://finance.yahoo.com/news/zoetis-zts-solid-growth-stock-124512999.html,Yahoo.com,1430179,2019-10-01T12:45:12Z,0.86
248427,ZTS,"Is Zoetis (ZTS) a Solid Growth Stock? 3 Reasons to Think "" Yes ""","Zoetis (ZTS) is well positioned to outperform the market, as it exhibits above-average growth in financials.",Zacks Equity Research,https://finance.yahoo.com/news/zoetis-zts-solid-growth-stock-124512999.html,yahoo.com,1569933912,2019-10-01T12:45:12Z,0.86
246704,JNJ,Dividend King: Johnson & Johnson Poised For Another Dividend Boost,"JNJ has a moderate long-term outlook that is strengthened by its robust business segments and strong management team. The company's large scale and broad scope","Arturo Neto, CFA",https://seekingalpha.com/article/4294306-dividend-king-johnson-and-johnson-poised-another-dividend-boost,seekingalpha.com,1569926700,2019-10-01T10:45:00Z,0.86